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Abstract 
Cognitive impairment is a major cause of disability for a large number of working-age 
adults living with chronic psychiatric and neurological conditions. Although well 
recognised in schizophrenia spectrum disorders and in neurological diseases such as 
multiple sclerosis (MS), cognitive impairment has historically received less attention in 
mood disorders. The relative prevalence of cognitive impairment in bipolar disorder (BD) 
and major depression compared with other conditions has not been clearly established, and 
the risk factors that drive cognitive variation within and across conditions are not well 
understood.  
The primary focus of this thesis was on BD, and the objectives were: (1) to investigate the 
prevalence of cognitive impairment in BD, compared with major depression, 
schizophrenia, MS and Parkinson’s disease (PD); and (2) to develop causal models to 
quantify and explain variation in cognitive function in BD and in other conditions. The 
methods encompassed a systematic literature review, a prevalence study using cross-
sectional data from the UK Biobank cohort, and a series of multivariable analyses of UK 
Biobank data using graphical methods, regression- and matching-based estimation, and 
mediation models.  
The systematic review indicated that between 5% and 58% of adults with euthymic BD 
showed cognitive impairment. Prevalence was lower in the mania/BD group identified 
within the UK Biobank cohort, at around 7-10%, which was similar to rates seen in the MS 
and PD groups within the cohort. When causal models of cognitive performance in the 
mania/BD group took account of multiple potential confounders, performance on a short-
term visuospatial memory test showed a small but reliable decrement. Mediation models 
provided evidence of indirect negative effects on cognitive performance via psychotropic 
medication, but not via cardiometabolic disease. A similar pattern of results was seen in the 
major depression group, though with smaller effect sizes.  
This thesis emphasises the importance of cognitive function as a fundamental phenotype in 
psychiatric and epidemiological research. There is scope to build on this work in future 
follow-up waves in UK Biobank, as well as in other UK and international cohort studies 
and through linkage with routine healthcare data. 
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Chapter 1 Introduction 
Cognitive impairment is a core feature of many different behavioural and brain disorders, 
contributing to the significant burden attributed to these conditions. In addition to rising 
dementia prevalence in the ageing population, cognitive dysfunction is a major cause of 
disability for a large number of working age adults living with chronic psychiatric and 
neurological conditions. Although well recognised in schizophrenia spectrum disorders and 
in neurological diseases such as multiple sclerosis (MS), cognitive impairment has 
historically received less attention in mood disorders. The relative prevalence of cognitive 
impairment in bipolar disorder (BD) and major depression compared with other conditions 
has not been clearly established, and the risk factors that drive cognitive variation within 
and across conditions are not well understood.  
This chapter summarises previous research findings regarding the nature and impact of 
cognitive impairment in chronic behavioural and brain disorders, and highlights important 
gaps in knowledge. The potential to use large population cohorts and routine healthcare 
data to address some of these gaps is considered, and the aims and structure of this thesis 
are outlined.  
1.1 Cognitive function and its assessment 
Cognitive function refers to a range of mental processes that enable humans to perceive 
and make sense of the world and other people, and to acquire and use knowledge and skills 
that facilitate independence and success in everyday life. General cognitive ability, or 
intelligence, has been conceptualised as an underlying level of intellectual capability that 
can be captured empirically as a unitary latent factor contributing to performance across 
diverse cognitive domains and tasks (Deary, 2013; Johnson, Bouchard, Krueger, McGue, 
& Gottesman, 2004). Such ability varies widely in the population and is substantially 
heritable (Plomin & Deary, 2015), and its development and decline over the life course has 
been the subject of much research. The distinct cognitive domains that reflect general 
intelligence include processing speed, memory, reasoning, language and spatial ability, and 
their neurological basis has been elucidated through structural and functional brain 
imaging studies (Deary, Penke, & Johnson, 2010). For example, magnetic resonance 
imaging (MRI) tractography has highlighted the importance of white matter tract integrity 
for speed of information processing across distributed networks involved in general 
cognitive performance (Penke et al., 2012). 
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Research on cognitive ability in the general population has primarily been situated within 
the fields of cognitive and differential psychology. Within neuropsychology, there has 
been a related but distinct emphasis on the effects of brain injury and illness on cognitive 
function. Neuropsychological research has focused on identifying patterns or profiles of 
cognitive dysfunction within and across different domains, and relating these to underlying 
neuropathology in clinical populations (Vakil, 2012). Neuropsychological assessments are 
typically structured around the core cognitive domains of processing speed, attention, 
memory, executive function (i.e. higher-order abilities such as planning, problem-solving 
and error monitoring), language and visuospatial performance (Burrell & Piguet, 2015; 
Goldstein & McNeil, 2013; Vakil, 2012). Overall assessment of general intelligence is also 
important, although often as a premorbid contextual factor against which current 
performance in each cognitive domain is interpreted (Schoenberg, Lange, Marsh, & 
Saklofske, 2011). Domain-specific deficits in cognitive performance have been 
documented following focal brain injuries (e.g. Stuss & Levine, 2002), and typical patterns 
of impairment across domains have been found to associate with clinical syndromes such 
as sub-types of dementia (Burrell & Piguet, 2015). The origins of modern clinical 
neuropsychology can be traced to work with brain injury survivors following the second 
world war and with neurosurgical patients in the mid-20th century, and the discipline has 
since developed to encompass assessment and intervention in a wide range of neurological, 
psychiatric and developmental conditions across the life course.   
Whether working in cognitive, differential or neuropsychology traditions, psychologists 
make use of a wide range of standardised psychometric tests to measure cognitive function. 
Intelligence tests yield an overall score called the intelligence quotient (IQ), and can also 
produce separate domain-focused and task-specific scores, e.g. the verbal, perceptual, 
working memory and processing speed scales of the Wechsler Adult Intelligence Scale 
(Wechsler, 2010). Multi-domain test batteries, such as the Kaplan-Baycrest Neurocognitive 
Assessment (Richards, Rewilak, Kaplan, Proulx, & Leach, 2000), are often used in clinical 
practice to examine the profile of strengths and weaknesses across different cognitive 
domains. Computerised cognitive batteries such as the Cambridge Neuropsychological 
Test Automated Battery (CANTAB; Cambridge Cognition, 2017) and the National 
Institutes of Health (NIH) Toolbox (Weintraub et al., 2013) are now widely used in 
research, especially where efficient administration and scoring is required at scale in large 
studies.   
14 
 
Separate tasks or batteries are also available for the assessment of each cognitive domain 
(although it should be noted that there are no pure tests of any specific domain, because of 
the multiple demands inherent in understanding and responding during any assessment). 
Processing speed is typically assessed using psychomotor tests such as the Trailmaking 
Test Part A (Tombaugh, 2004) and the Symbol Digit Modalities Test (A. Smith, 1982), and 
reaction time can be measured with high precision using computerised tasks (e.g. Deary, 
Liewald, & Nissan, 2011). Batteries such as the Wechsler Memory Scale (Wechsler, 2011) 
assess various aspects of memory function, including learning, recall and recognition, in 
visual and verbal modalities, while other memory tests focus in detail on one modality (e.g. 
California Verbal Learning Test; Delis, Kramer, Kaplan, & Ober, 2000). Higher order or 
‘executive’ functions, such as planning, problem-solving, attentional switching, abstract 
reasoning and response inhibition, are assessed by various batteries including the Delis-
Kaplan Executive Function System (Delis, Kaplan, & Kramer, 2001) and the Behavioural 
Assessment of the Dysexecutive Syndrome (Wilson, Emslie, Evans, Alderman, & Burgess, 
1996), or by standalone tasks such as the Trailmaking Test (Tombaugh, 2004), the Stroop 
task (Trenerry, Crosson, DeBoe, & Leber, 1989) and the Wisconsin Card Sorting Test 
(Grant & Berg, 1948). Separate tests are available for attention (e.g. Test of Everyday 
Attention; Robertson, Nimmo-Smith, Ward, & Ridgeway, 1994), language (e.g. 
Multilingual Aphasia Examination; Benton, Hamsher, & Sivan, 1994) and visuospatial 
function (e.g. Visual Object and Space Perception battery; Warrington & James, 1991). 
Tests have also been developed for social cognition skills, focusing on the ability to 
understand and behave appropriately in social situations (e.g. the Awareness of Social 
Inference Test; McDonald, Flanagan, & Rollins, 2002).  
These standardised tests have usually been validated against similar established tasks or 
relevant clinical criteria, and they are expected to demonstrate satisfactory reliability, 
quantified as the proportion of variance in test scores that is true variance rather than 
measurement error (Crawford, 2012). Most tests produce standardised scores, whereby raw 
scores are transformed to a standard distribution with reference to a representative sample. 
Scoring metrics in common use include z-scores (mean 0 and standard deviation 1), 
standard scores (mean 100 and standard deviation 15) and percentiles; standardisation 
typically takes into account age-group and sometimes gender and education level. There is 
no specific score threshold below which performance is deemed to be impaired: the 2nd 
percentile is used as a guide in many tests (e.g. <70 on the Wechsler scales), but less 
stringent thresholds such as the 7th percentile are also employed (Strauss, Sherman, & 
Spreen, 2006, Ch. 5). These thresholds can be used to classify an individual as impaired 
15 
 
relative to his or her peer group, but they do not take into account individual contextual 
factors (e.g. the person’s own premorbid level of ability). 
1.2 Cognitive impairment in psychiatric and neurological 
conditions 
Adults with chronic psychiatric and neurological disorders experience functional disability, 
reduced wellbeing and quality of life, and restricted social and economic participation. 
Cognitive impairment plays an important role in this. The overall detrimental impact of 
cognitive impairment on society has been termed the ‘cognitive footprint’ (Rossor & 
Knapp, 2015); this is conceptualised as a marker of the effect of cognitive impairment 
(from any cause) on such outcomes as education, employment, earnings and instrumental 
activities of daily living, which in turn influence national income distribution and 
economic growth. Because many neurological and mental health conditions have a young 
age of onset and a chronic course, and some are common in the population, their societal 
‘cognitive footprint’ may be substantial and long-lasting. The cognitive burden of these 
chronic conditions is of great public health importance: echoing previous discussions on 
the ‘mental wealth of nations’ (Beddington et al., 2008), it has been argued that 
interventions to prevent or manage associated cognitive impairment have the potential “to 
foster cognitive health and to preserve cognitive capital” (Rossor & Knapp, 2015, p. 1008) 
at both individual and societal levels. This thesis will focus on psychiatric and neurological 
conditions with an average age of onset below 65 years, and whose chronic course means 
that affected individuals may live with cognitive impairment for many years.  
1.2.1 Psychiatric conditions 
Psychiatric conditions that are commonly associated with persistent cognitive impairment 
include bipolar disorder, major depression and schizophrenia. Cognitive impairment is also 
a feature of attention deficit hyperactivity disorder, but this will not be considered further 
here because of its distinct classification status as a neurodevelopmental disorder.  
1.2.1.1 Mood disorders 
Mood disorders are very common in the population, and follow a chronic or recurrent 
course in many of those affected. BD is characterised by episodes of abnormally elevated 
or irritable mood, encompassing symptoms such as grandiosity, hyperactivity and 
talkativeness, with resultant functional impairment or need for treatment (Gajwani, 2017); 
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many people with BD also experience episodes of depressed mood. BD may be sub-
divided into type I and type II, with the latter denoting depressive and hypomanic episodes 
in the absence of frank mania (Gajwani, 2017). The core features of major depressive 
disorder are persistent low mood or loss of interest and pleasure (anhedonia), which are 
present for prolonged periods together with symptoms such as appetite or sleep 
disturbance, feelings of worthlessness, and loss of energy, causing functional impairment 
(D. F. MacKinnon, 2017). In the United Kingdom (UK), lifetime prevalence per 100,000 
population is estimated at up to 10,000 for major depression (NICE, 2011) and 
approximately 1,000 for BD (Fajutrao, Locklear, Priaulx, & Heyes, 2009).  
Research into cognitive impairment in mood disorders has increased in recent years, with 
studies investigating the pattern and persistence of cognitive dysfunction and its 
relationship to disorder subtype, severity and remission status. Several systematic reviews 
and meta-analyses have reported largely consistent findings in adults with BD. Impairment 
is typically found on tests of attention, working and episodic memory, processing speed 
and executive function, even in euthymia, with group differences of medium to large effect 
size compared with adults without a history of psychiatric illness (Arts, Jabben, 
Krabbendam, & van Os, 2008; Bortolato, Miskowiak, Koehler, Vieta, & Carvalho, 2015; 
Bostock, Kirkby, Garry, & Taylor, 2017; Bourne et al., 2013; Dickinson, Becerra, & 
Coombes, 2017; Mann-Wrobel, Carreno, & Dickinson, 2011; Raucher-Chene, Achim, 
Kaladjian, & Besche-Richard, 2017; Robinson et al., 2006). Meta-analyses of longitudinal 
studies in BD have found no evidence of accelerated cognitive decline over follow-up 
periods of up to five years (Bora & Ozerdem, 2017; Samamé, Martino, & Strejilevich, 
2014), although other meta-analytic evidence indicates that BD history increases the odds 
of dementia diagnosis in later life (Diniz et al., 2017). Estimates of the prevalence of 
cognitive impairment in BD have ranged from 14-70% (Burdick et al., 2014; Gualtieri & 
Morgan, 2008; Kessing, 1998; Martino et al., 2014; Reichenberg et al., 2009; Szmulewicz, 
Samame, Martino, & Strejilevich, 2015), varying according to the sample composition, test 
used, and threshold applied to define impairment. Cognitive impairment has been 
highlighted as a key determinant of instrumental, occupational and social outcomes and 
quality of life in BD (Baune & Malhi, 2015; Duarte, Becerra, & Cruise, 2016; Gitlin & 
Miklowitz, 2017; P. D. Harvey, Wingo, Burdick, & Baldessarini, 2010). The growing 
recognition of this impact has sparked increasing interest in developing pharmacological 
and behavioural interventions to prevent, reduce or manage cognitive impairment in BD 
patients (Kluwe-Schiavon et al., 2015; Miskowiak, Carvalho, Vieta, & Kessing, 2016; Solé 
et al., 2017). 
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Studies that have directly compared cognitive performance between BD and major 
depression have generally found similar patterns across cognitive domains, although 
typically at a less severe level in the groups with major depression (Szmulewicz et al., 
2017). The magnitude of differences between groups with remitted major depression and 
those with no psychiatric history is typically small, with greater deficits seen in late-onset 
depression patients (Bora, Harrison, Yucel, & Pantelis, 2013). Approximately one-third to 
one-half of patients with remitted major depression are estimated to show clinically 
significant levels of impairment (Rock, Roiser, Riedel, & Blackwell, 2014). As with BD 
patients, greater cognitive impairment in adults with major depression is associated with 
worse functional and psychosocial outcomes (Buist-Bouwman et al., 2008; Evans, Iverson, 
Yatham, & Lam, 2014), and the development of interventions for cognitive enhancement 
or remediation has been a key focus of recent research (Bortolato et al., 2016; Miskowiak, 
Ott, Petersen, & Kessing, 2016; Rosenblat, Kakar, & McIntyre, 2015; Salagre et al., 2017; 
Solé, Jimenez, Martinez-Aran, & Vieta, 2015). 
1.2.1.2 Schizophrenia 
Schizophrenia is a chronic and often highly disabling illness involving delusions, 
hallucinations, disordered thinking or speech, and so-called negative symptoms such as 
apathy and social withdrawal, together with lack of insight (Picchioni & Murray, 2007). 
The broader term ‘schizophrenia spectrum’ encompasses related conditions such as 
schizoaffective disorder (Bhati, 2013). The lifetime prevalence of schizophrenia is 
estimated to be approximately 400-1,000 per 100,000 (McGrath, Saha, Chant, & Welham, 
2008), of whom up to 80% are thought to have cognitive impairment (Keefe & Fenton, 
2007). Studies have consistently shown marked and persistent deficits in multiple cognitive 
domains (Fioravanti, Bianchi, & Cinti, 2012), with evidence of greater severity of 
impairment in patients with prominent negative symptoms (Bora, Akdede, & Alptekin, 
2017). Many studies have directly compared cognitive functioning in schizophrenia and 
BD; domain profiles tend to be similar, but impairment is typically more severe in 
schizophrenia, and is reported to be evident from a younger age, often pre-dating illness 
onset (Bora, 2016; Bortolato et al., 2015; Trotta, Murray, & MacCabe, 2015; Vohringer et 
al., 2013). Poor functional outcomes are strongly associated with persistent cognitive 
deficits (Lepage, Bodnar, & Bowie, 2014), especially problems with social cognition (Fett 
et al., 2011). Cognitive remediation interventions have been extensively studied in this 
population (Kluwe-Schiavon, Sanvicente-Vieira, Kristensen, & Grassi-Oliveira, 2013; 
18 
 
Revell, Neill, Harte, Khan, & Drake, 2015; Wykes, Huddy, Cellard, McGurk, & Czobor, 
2011).   
1.2.2 Chronic neurological conditions 
Many individuals in the working-age population are living with neurological disorders that 
affect cognitive functioning. It is of interest to compare the prevalence and pattern of 
cognitive impairment in mood disorders and schizophrenia with that in chronic 
neurological conditions, because they each contribute to the ‘cognitive footprint’ at the 
societal level, and they may share risk factors that contribute to cognitive outcome. The 
focus here will be on MS and Parkinson’s disease (PD), as their average age of onset is 
below 65 years and they share psychiatric phenotypic features with the disorders discussed 
above.  
1.2.2.1 Multiple sclerosis 
MS is a degenerative disease of the central nervous system, which is thought to be 
autoimmune in origin (Dendrou, Fugger, & Friese, 2015). It causes characteristic 
demyelinating lesions—primarily in the brain white matter and the spinal cord but also 
evident in cortical and subcortical grey matter—together with axonal damage and atrophy 
(Matthews et al., 2016). Clinically, this leads to symptoms including sensory and motor 
dysfunction, fatigue, pain and depression, which may follow a relapsing-remitting or 
progressive course (Kamm, Uitdehaag, & Polman, 2014). The lifetime prevalence of MS in 
the UK population is approximately 200 per 100,000 (MacDonald, Cockerell, Sander, & 
Shorvon, 2000). The typical cognitive profile involves prominent processing speed 
deficits, as well as impairment of attention, executive function, memory and visuospatial 
skills (Brito Ferreira, 2010; Guimaraes & Sa, 2012). Cognitive impairment severity is only 
partly explained by severity of structural brain changes (Bobholz & Rao, 2003). Prevalence 
of impairment has been estimated at 40-80%, depending on the threshold applied (Fischer 
et al., 2014; Patti et al., 2015; Rao, Leo, Bernardin, & Unverzagt, 1991). Over and above 
the impact of physical disability and illness duration, patients with cognitive impairment 
experience generally worse domestic, occupational and social outcomes (Rao, Leo, 
Ellington, et al., 1991). The evidence base for cognitive rehabilitation programmes in MS 
is mixed (Mitolo, Venneri, Wilkinson, & Sharrack, 2015), and more research is also 
needed regarding the potential efficacy of stimulant medications such as methylphenidate 
and L-amphetamine (Lovera & Kovner, 2012). There is some evidence that the disease 
modifying treatments interferon β-1a and natalizumab have a beneficial impact on 
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cognitive function in the short term, but long term evidence is lacking (Lovera & Kovner, 
2012). 
1.2.2.2 Parkinson’s disease 
PD is a progressive disease involving the degeneration of dopaminergic neurons in the 
substantia nigra pars compacta and the proliferation of α-synuclein inclusions, known as 
Lewy bodies, within the neuronal cell bodies. The resultant dopamine deficiency leads to a 
clinical picture of movement disorder, including slowing (bradykinesia), rigidity, resting 
tremor, postural instability and gait impairment (Kalia & Lang, 2015). Non-motor 
symptoms such as mood disturbance, apathy and sleep disorders are also common (Poewe, 
2008). The lifetime prevalence of PD is similar to that of MS, at around 200 per 100,000 
(MacDonald et al., 2000). Approximately 50-55% are estimated to experience cognitive 
impairment (Svenningsson, Westman, Ballard, & Aarsland, 2012), about half of whom 
meet criteria for dementia (Aarsland, Zaccai, & Brayne, 2005). Cognitive impairment is 
associated with increasing age, disease duration and disease severity (Litvan et al., 2011), 
and the domains affected typically include executive function, attention, processing speed 
and visuospatial skills. The severity of cognitive impairment has been found to be 
associated with measures of quality of life (A. J. Mitchell, Kemp, Benito-Leon, & Reuber, 
2010). There is some evidence for cognitive benefits from acetylcholinesterase inhibitors 
(Pagano et al., 2015), and modest benefits have also been reported from non-
pharmacological interventions such as cognitive training (Hindle, Petrelli, Clare, & Kalbe, 
2013; Leung et al., 2015). 
1.2.3 Limitations of current research evidence 
The literature on cognitive function in psychiatric and neurological conditions primarily 
documents average between-group score differences on cognitive tests, with prevalence of 
cognitive impairment reported much less frequently. Where prevalence estimates are 
available for a particular condition, these are difficult to synthesise, owing to heterogeneity 
in the populations studied (e.g. clinic- or community-based), in the tests used, and in the 
thresholds applied to define impairment. Systematic reviews of cognitive impairment 
prevalence are lacking, and there are also challenges in comparing prevalence estimates 
across different conditions, again because of heterogeneity in recruitment, assessment and 
impairment definitions. In order to quantify and understand the cognitive footprint of 
psychiatric and neurological conditions, it is essential that we obtain clearer estimates of 
cognitive impairment prevalence within and across these conditions; this will contribute to 
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a greater appreciation of the scale of clinical and service need within each clinical group, 
as well as highlighting the population-level impact of cognitive impairment associated with 
different conditions, some of which (e.g. major depression) are considerably more common 
than others.  
In studies that have investigated differences in cognitive test performance between groups, 
approaches to accounting for confounding influences have been inconsistent. Some studies 
have used groups that are matched on characteristics such as age and gender, while others 
have used statistical methods to adjust between-group difference estimates, or to measure 
the strength of association between cognitive performance and sociodemographic, clinical 
and lifestyle factors. The selection of variables used for matching and statistical adjustment 
has differed from study to study, and systematic distinctions have not been drawn between 
potential confounders (i.e. background factors that are not themselves a consequence of the 
clinical disorder) and other kinds of variables that may co-vary with clinical status and 
cognitive outcome in other ways (e.g. intermediate factors such as mood state or 
medication use). The collective inclusion of such variables without distinction in multiple 
regression analyses, for example, makes it difficult to interpret the coefficient estimates, 
and to move towards causal explanations for variation in cognitive function in psychiatric 
and neurological conditions. Such causal explanations require careful modelling of a range 
of potential confounding, mediating and moderating factors, acknowledging the 
complexity of their inter-relationships with the clinical disorder, the cognitive outcome, 
and each other. Although path analysis and mediation modelling are commonly used in 
psychological research (Gelfand, Mensinger, & Tenhave, 2009), the application of formal 
causal inference frameworks and related statistical techniques in psychiatric epidemiology 
is not yet widespread (Kendler, 2017). This endeavour requires large samples with data on 
a wide range of relevant variables, which is difficult to achieve in clinic-based studies. 
1.3 Population cohorts in cognitive and mental health 
research 
There is increasing interest in taking a ‘data science’ approach to mental health research 
(McIntosh et al., 2016), which has been facilitated by computational and statistical 
advances that permit analysis of high dimensional datasets. Relevant data sources include 
dedicated research cohorts as well as routine healthcare and administrative records 
(Stewart & Davis, 2016). A recent review by the UK Medical Research Council (MRC, 
2014) described 34 UK-led large population research cohorts, of which 21 contain data on 
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mental health together with direct measures of cognitive function. By far the largest of 
these is UK Biobank, which recruited more than 502,000 adults at baseline (Sudlow et al., 
2015). 
An obvious advantage of population cohorts is their typically large size, which means they 
are more likely to provide sufficient statistical power to conduct multivariable analyses 
with high precision. General population cohorts may also provide broader representation 
than those recruited from clinics, in that they will include individuals with a psychiatric or 
neurological history who are not necessarily in contact with specialist clinical services. 
Conversely, more severely affected individuals may be less likely to join population cohort 
studies. Other benefits of population cohorts include the breadth of data collected, which 
typically encompasses demographic, lifestyle, clinical, physiological and psychosocial 
measures, as well as the necessary resources and administrative capability for re-contact 
and linkage to other records and registries.  
The empirical studies in this thesis use data from the UK Biobank cohort. As described in 
detail in Chapter 3, UK Biobank collected mental health and cognitive data on an 
unprecedented scale, together with a broad range of other relevant measures including 
genotyping and linkage to hospital records. These permit comprehensive investigation of 
the complex relationship between psychiatric and neurological health and cognitive 
function. Initial analyses of cognitive function in the whole cohort and in clinical sub-
groups have previously been reported by our group (Cullen et al., 2015; Lyall et al., 2016), 
and this thesis develops this work by investigating prevalence and by applying a formal 
causal inference approach to understand patterns of cognitive performance.  
1.4 Thesis aims 
The aims of this thesis were to investigate the prevalence of cognitive impairment in 
psychiatric and neurological conditions, and to understand the risk factors that may explain 
variation in cognitive function in these conditions. The primary focus was on BD, as this 
disorder is relatively common in the population, and cognitive impairment is thought to be 
a major cause of chronic disability even in euthymia. Comparisons were also made with 
major depression, schizophrenia, MS and PD. 
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1.4.1 Research questions 
Two research questions were addressed, via a systematic literature review and a series of 
primary data analyses.  
1.4.1.1 What is the prevalence of cognitive impairment in BD, and in other 
psychiatric and neurological conditions? 
This question was investigated by (i) undertaking a systematic review of studies reporting 
the prevalence of cognitive impairment in euthymic BD and (ii) conducting an empirical 
study of baseline data from the UK Biobank cohort, to estimate the prevalence of cognitive 
impairment in BD, major depression, schizophrenia, MS and PD. 
1.4.1.2 What explains variation in cognitive function in BD and other 
conditions? 
This question was investigated by conducting a series of multivariable analyses of baseline 
UK Biobank data, using a causal inference framework to estimate the overall effect of BD 
and other disorders on cognitive function, and the magnitude of the effect that is 
transmitted through potentially modifiable intermediate factors. 
1.5 Overview of thesis structure 
Chapter 2 presents the systematic review of cognitive impairment prevalence in euthymic 
BD. Chapter 3 describes the UK Biobank resource, Chapter 4 outlines the ascertainment 
and characteristics of the psychiatric and neurological groups within this resource, and 
Chapter 5 reports the prevalence of cognitive impairment in those groups. An overview of 
causal inference methods, as applied to observational data, is given in Chapter 6. Chapter 7 
presents estimates of the overall effect of BD on cognitive performance and indirect effects 
through potentially modifiable intermediate factors, and Chapter 8 presents similar 
analyses for other psychiatric conditions. The key results, implications and future 
directions are discussed in Chapter 9. 
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Chapter 2 Systematic review of the prevalence of 
cognitive impairment in bipolar disorder 
This chapter focuses on cognitive impairment in bipolar disorder. As outlined in Chapter 1, 
it is particularly important to study BD because it is common and chronic, and risk factors 
for poor cognitive function in people with this condition are currently not well understood. 
This chapter describes a systematic review carried out to establish the prevalence of 
cognitive impairment in people in the euthymic phase of BD, and to identify factors which 
may be associated with cognitive impairment.1  
2.1 Background 
Adults with BD show impairment in cognitive domains including attention, memory, 
processing speed and executive function, even when in remitted or euthymic phases (Arts 
et al., 2008; Bortolato et al., 2015; Bostock et al., 2017; Bourne et al., 2013; Dickinson et 
al., 2017; Mann-Wrobel et al., 2011; Raucher-Chene et al., 2017; Robinson et al., 2006). 
Although group-level differences of medium to large effect size have been consistently 
reported, the proportion of adults with BD who have clinically relevant levels of cognitive 
impairment has not yet been clearly established. There are a number of reasons why it 
would be beneficial to establish the prevalence of cognitive impairment in the BD 
population. From a clinical point of view, cognitive impairment is a major contributor to 
the overall burden of disability in mood disorders, and is a target in its own right for 
therapeutic intervention. Service planning would be helped by clearer information about 
the numbers and characteristics of those who are likely to need more health or social care 
input to manage the disabling effects of cognitive impairment. From a research 
perspective, shifting our focus to identifying subgroups with cognitive impairment will 
facilitate efforts to understand why some people with BD experience significant problems 
with cognitive function while others remain unimpaired. This, in turn, may help to identify 
particular risk factors for clinically significant cognitive impairment. 
                                                 
1 The work described in this chapter has been published in Cullen, B., Ward, J., Graham, N. A., 
Deary, I. J., Pell, J. P., Smith, D. J., & Evans, J. J. (2016). Prevalence and correlates of 
cognitive impairment in euthymic adults with bipolar disorder: A systematic review. Journal of 
Affective Disorders, 205, 165-181. doi:10.1016/j.jad.2016.06.063 
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2.1.1 Objectives 
The objectives of the review were: (1) to determine the prevalence of cognitive impairment 
in euthymic adults with a history of BD; and (2) to describe sociodemographic, clinical and 
other factors that are associated with cognitive impairment in BD. 
2.1.2 Scope of review 
The population of interest was community-dwelling adults with a history of BD (the 
exposure), who were euthymic at the time of assessment. The outcome of interest was 
cognitive impairment, measured using standardised tests; presence or absence of 
impairment was defined with reference to published test norms or scores obtained by a 
comparison group without BD. Since the aim was to determine prevalence, only cross-
sectional results were considered (cross-sectional studies, or baseline results from cohort 
studies or trials).  
2.2 Methods 
The review was conducted according to a structured protocol which followed Preferred 
Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 
guidance (Moher et al., 2015). The protocol was registered on the International Prospective 
Register of Systematic Reviews (PROSPERO) database on 16 March 2015 (reference 
number CRD42015017558; see Appendix A). Reporting is in accordance with PRISMA 
and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines 
(Moher, Liberati, Tetzlaff, & Altman, 2009; Stroup et al., 2000).  
2.2.1 Eligibility criteria 
The following inclusion criteria were applied during the search and screening process: 
original research published in peer-reviewed journals from 1994 onwards (the year that the 
Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] and International 
Classification of Diseases [ICD-10] diagnostic classifications came into use); articles 
published in English; studies of community-dwelling adults (not hospital in-patients) aged 
18 to 70 years inclusive (to minimise the additional contribution of age-related cognitive 
decline); cross-sectional studies or baseline results from cohort studies or trials; clinical 
samples must have been recruited consecutively from clinics or via a method that ensured 
eligible individuals in the target population had an equal chance of being approached (so 
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that prevalence estimates would be based on representative samples); primary diagnosis of 
BD; euthymic at time of assessment; assessed using at least one direct, standardised, 
objective cognitive measure. Articles were excluded if samples were selected on the basis 
of presence/absence of cognitive impairment (known or suspected). 
2.2.2 Concepts and definitions 
The following definitions were applied for each construct: 
2.2.2.1 Bipolar disorder 
History of bipolar disorder type I, II or not otherwise specified, meeting defined criteria 
(e.g. DSM or ICD). 
2.2.2.2 Euthymia  
Not meeting defined criteria for a depressive or manic episode at time of cognitive 
assessment; or as otherwise defined by the study authors based on an appropriate clinical 
measure. 
2.2.2.3 Cognitive impairment  
Evidence of impaired performance on one or more objective cognitive tests. Impairment 
was defined as the fail range on a pass/fail test, or as otherwise defined by the study 
authors with reference to the score distribution of an unexposed (“healthy”) comparison 
group (e.g. from published test norms, or an appropriate comparison group recruited to the 
study). Results based on any threshold that was less strict than 1 standard deviation (SD) 
below the comparison mean were not considered. 
2.2.2.4 Prevalence 
Assessments must have been conducted at a single time point, yielding a point prevalence 
estimate of cognitive impairment, reported as the proportion of the sample falling below 
the cut-off for impairment. 
2.2.2.5 Correlates 
Any sociodemographic, clinical or other factor that was reported by the authors to be 
statistically associated with the presence or severity of cognitive impairment.  
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2.2.3 Search strategy 
2.2.3.1 Information sources 
The following electronic databases were searched on 24 February 2015: Web of Science 
(Thomson Reuters), including Science Citation Index Expanded, Social Sciences Citation 
Index, Arts & Humanities Citation Index, Current Contents Connect, Data Citation Index, 
MEDLINE and SciELO Citation Index; PubMed (NCBI), including MEDLINE, PubMed 
Central and in-process/ahead-of-print citations; EBSCOhost (EBSCO), including CINAHL 
and PsycINFO. Additional articles published up to the search date were sought via: the 
‘cited by’ function within individual electronic records of relevant articles; hand searching 
of reference lists of relevant articles and recent review papers; and email contact with study 
authors.  
2.2.3.2 Process for study identification and selection 
A detailed search strategy was developed and tailored for each electronic database. 
Controlled vocabulary and free text variations were used, including synonyms, 
abbreviations and spelling variants. Appendix B shows the search strategy as implemented 
in Web of Science. Search outputs were managed using EndNote software 
(http://endnote.com/).  
Duplicate records were removed, and study titles and/or abstracts were screened for 
relevance by B.C. Screening was carried out with reference to a detailed checklist of 
eligibility criteria; this was piloted by B.C. and a second researcher independently against a 
sample of initial search results, and refined as required (see Appendix C for the final 
checklist). The sensitivity of the search strategy was checked by testing whether key papers 
that were known to be relevant were detected by the search. Reproducibility was assessed 
by the second researcher, who independently ran the search in one electronic database 
(Web of Science) and screened the first 200 titles and/or abstracts for relevance. 
Agreement was 93% (100% following consensus discussion). Full text was obtained for all 
potentially relevant papers that remained. These were assessed by B.C. using the eligibility 
checklist, with the second researcher independently assessing the first 100 papers for 
comparison. Agreement was 95% (100% following consensus discussion). Reasons for 
exclusion were documented. 
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2.2.4 Data extraction 
A spreadsheet template was used for extracting data from included papers, having been 
piloted by B.C. and a second researcher independently. The list of data fields is given in 
Appendix D. Data extraction was carried out by B.C., following which the second 
researcher compared four randomly-chosen data extraction records against the source 
papers to check for accuracy and completeness; no discrepancies were identified. Where 
authors appeared to have collected data that could be used to report the prevalence of 
impairment, but had not reported the prevalence explicitly in the paper (e.g. articles only 
reporting group mean differences), the authors were contacted via email to request 
prevalence results using an appropriate cut-off of their choice. 
2.2.5 Assessment of risk of bias 
2.2.5.1 Risk of bias within studies 
Each included study was assessed for risk of bias using a critical appraisal tool for 
systematic reviews addressing questions of prevalence (Munn, Moola, Riitano, & Lisy, 
2014). Reporting bias was assessed using the STROBE checklist for cross-sectional studies 
(von Elm et al., 2007). B.C. and a second researcher independently rated randomly-chosen 
articles for comparison, followed by consensus discussion. Initial rating concordance was 
83-95% across four articles, and 93% when one further article was independently assessed 
following the consensus discussion exercise. Subsequent ratings were made by B.C. only. 
These assessments were considered in the synthesis and discussion, in order to comment 
on the quality of the literature in this field and to aid interpretation of the results. 
2.2.5.2 Risk of bias across studies 
Funnel plots were generated using the metafunnel package in Stata software version 13 
(StataCorp, 2013) to allow visual inspection of the relationship between the magnitude and 
precision of the prevalence estimates. These are scatter plots depicting a measure of study 
size (e.g. sample size or standard error of the effect estimate) on the vertical axis against 
the study’s effect estimate on the horizontal axis. Larger (more precise) studies are 
expected to have effect estimates close to the centre on the horizontal axis, and smaller 
studies are expected to have effect estimates scattered symmetrically about the centre. 
Asymmetry in this characteristic inverted funnel shape indicates “small study bias”, for 
example resulting from publication bias (Egger, Smith, Schneider, & Minder, 1997).  
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2.2.6 Data synthesis 
Where one study population was analysed in two or more eligible articles, the article 
reporting the largest sample was included in the data synthesis. Additional articles were 
only included if they contributed unique relevant information (e.g. additional cognitive 
measures). A narrative synthesis was conducted, alongside summary tables of extracted 
data, and forest plots of impairment prevalence estimates and 95% confidence intervals 
(CI) by cognitive domain. Forest plots were generated using the metan package in Stata 
v13. Sociodemographic, clinical and other variables that were reported to be associated 
with cognitive impairment were summarised, and consistency in these findings was 
compared across studies. Only variables that were potential risk factors for cognitive 
impairment were included; variables that were viewed as consequences of that impairment 
(e.g. occupational status, instrumental functioning) were not considered, on the basis that 
they are not potential causal, mediating or moderating factors in explaining the association 
between BD status and cognitive impairment. 
2.3 Results  
2.3.1 Article selection 
Figure 2.1 shows a PRISMA flow diagram of the article selection process. Titles and/or 
abstracts of 5,412 records were screened for eligibility, followed by full text evaluation of 
658 papers. Forty-six articles were deemed eligible. The most common reasons for 
exclusion were lack of evidence of consecutive sample recruitment, inclusion of in-patients 
in study samples, and inclusion of non-euthymic participants. Examples of acceptable 
sample recruitment methods in the eligible articles were systematic invitation of: 
consecutively attending eligible patients at out-patient clinics; all eligible patients on a 
database of open records at a specific clinical service; all eligible persons identified via 
national registers during a specific period. Of the 46 eligible articles, 16 were omitted from 
the data synthesis (see list in Appendix E): 11 reported on overlapping samples without 
contributing relevant additional information, and for a further five, results directly 
addressing either of the two research questions of this review were unavailable. 
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Figure 2.1 - PRISMA flow diagram showing results of literature search and screening 
 
The possible reasons for exclusion are explained in the eligibility checklist in Appendix C. 
 
2.3.2 Characteristics of included studies 
Key characteristics of the 30 included articles are summarised in Table 2.1. The majority 
included BD-I samples only (Altshuler et al., 2004; Arslan, Tiryaki, & Ozkorumak, 2014; 
Cavanagh, Van Beck, Muir, & Blackwood, 2002; Cheung, Halari, Cheng, Leung, & 
Young, 2013; Doganavsargil-Baysal et al., 2013; Fakhry, El Ghonemy, & Salem, 2013; 
Ferrier, Stanton, Kelly, & Scott, 1999; Frangou, Donaldson, Hadjulis, Landau, & 
Goldstein, 2005; Goswami et al., 2009; Ibrahim, Rahman, & Shah, 2009; Jamrozinski, 
Gruber, Kemmer, Falkai, & Scherk, 2009; Juselius, Kieseppa, Kaprio, Lonnqvist, & 
Tuulio-Henriksson, 2009; Kieseppa et al., 2005; Lopera-Vasquez, Bell, & López-
Jaramillo, 2011; Lopez-Jaramillo et al., 2010; Normala et al., 2010; Osher, Dobron, 
Belmaker, Bersudsky, & Dwolatzky, 2011; Pirkola et al., 2005). A further eight articles 
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reported on mixed BD samples (Barrera, Vazquez, Tannenhaus, Lolich, & Herbst, 2013; 
Daban et al., 2012; Elshahawi et al., 2011; Martino et al., 2014; Martino et al., 2008; Mur, 
Portella, Martinez-Aran, Pifarre, & Vieta, 2007; Sánchez-Morla et al., 2009; van der Werf-
Eldering, Burger, Holthausen, Aleman, & Nolen, 2010) and four articles included separate 
BD-I and BD-II samples (Martino, Igoa, Marengo, Scapola, & Strejilevich, 2011a; 
Martino, Strejilevich, Fassi, Marengo, & Igoa, 2011b; Martino, Strejilevich, Torralva, & 
Manes, 2011c; Sparding et al., 2015). Three articles reported on samples recruited from 
population registers of twin births and hospital discharges (Juselius et al., 2009; Kieseppa 
et al., 2005; Pirkola et al., 2005) and the rest recruited from specialist psychiatry clinics. 
Definitions of euthymia differed across studies; many used the Hamilton Rating Scale for 
Depression (HRSD) and the Young Mania Rating Scale (YMRS), but score thresholds 
varied. Most studies excluded participants with major psychiatric, neurological or medical 
comorbidity or learning disability, and many also excluded those with recent substance 
misuse or electroconvulsive therapy.  
Ratings of methodological and reporting bias are shown in Appendix F and Appendix G, 
respectively. Although all the studies aimed to recruit representative participants using 
consecutive or random methods, nine of 30 articles included samples which were 
unrepresentative of the BD population with regard to gender balance, and two did not 
report gender composition. Most articles did not report numbers of patients initially 
considered or deemed eligible, or information about comparability of eligible patients who 
did and did not participate; there was evidence of adequate coverage of the intended 
population in only four articles. Sample sizes were generally small. All articles reported on 
objective cognitive measures, but 13 did not report sufficient information to allow 
appraisal of measurement reliability (e.g. qualifications and training of assessors; inter-
rater reliability data). Most did not report adequate consideration of sources of bias or 
imprecision in their procedures or interpretation.  
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Table 2.1 - Characteristics of the included articles 
 
Author 
Year 
Country Sample n BD sample 
type 
BD definition 
Euthymia definition Exclusion criteria 
  BD HC    
Altshuler 
2004  
USA 40 22 BD-I 
DSM-III-R 
HRSD <6 and YMRS <7 for 3 consecutive 
months 
Head injury with LOC >1 hour; learning disability; migraine; liver function 
abnormalities; alcoholic dementia; abuse of alcohol in past 6 months; history of 
cocaine abuse/dependence; diabetes; hypertension; seizure disorder; any other 
neurologic illness; left-handedness; ECT in past 2 years; other current DSM-III-
R Axis I disorder 
Arslan 
2014  
Turkey 30 32 BD-I 
DSM-IV 
HRSD <7 and MADRS <12 and YMRS ≤12 DSM Axis I comorbidities; mental retardation; hearing/visual loss interfering 
with clinical interview; alcohol/substance abuse in past 6 months; any disease 
affecting CNS; head trauma with LOC 
Barrera 
2013  
Argentina 12 12 BD-I or BD-II 
Not stated 
HRSD (17 items) <7 and YMRS <8  Significant medical diseases; neurological disorders; mental deficiency; drug 
abuse 
Cavanagh 
2002  
UK 20 20 BD-I 
DSM-IV 
HRSD ≤7 and MMS ≤2 Significant physical or neurological illness; stroke or head trauma; significant 
alcohol and/or drug misuse; ECT in past 6 months; comorbid psychiatric 
disorder; neurodegenerative disorder; learning disability; endocrine abnormalities 
Cheung 
2013  
China 
(Hong 
Kong) 
52 52 BD-I 
ICD-10 and 
DSM-IV 
HRSD (21 items) <7 and YMRS <7 on two 
occasions 4 weeks apart 
Mental retardation; change in psychotropic medication in past 4 weeks; DSM-IV 
alcohol/substance abuse in past 12 months; head injury with LOC; neurological 
disorder; history of psychiatric illness other than BD-I; significant physical 
health problem which could affect cognition 
Daban 
2012  
France 53 60 BD 
DSM-III-R 
MADRS <6 and BR-MRS <5  History of severe head trauma; learning difficulties; neurological disorder; 
current alcohol/drug abuse 
Doganavsargil-
Baysal 
2013  
Turkey 54 18 BD-I 
DSM-IV-TR 
HRSD ≤7 and YMRS ≤5 Comorbid psychiatric or neurological disorders; IQ score <80; infectious or 
autoimmune diseases; on anti-inflammatory or antibiotic medication; 
biochemical values not within normal range 
Elshahawi 
2011  
Egypt 50 50 BD-I or BD-II; 
history of ≥3 
affective 
episodes 
ICD-10 
HRSD <8 and YMRS <6 Comorbid psychiatric disorder; ECT in past 3 months; neurological disorder; 
mental retardation; substance abuse; organic cause of cognitive impairment 
Fakhry 
2013  
UAE 30 (recent 
manic 
episode)  
30 (recent 
depressive 
episode) 
30 BD-I; history of 
≤3 affective 
episodes; illness 
duration <5 
years 
DSM-IV 
MES and MAS <6; free from symptoms for 
at least 8 weeks and not fulfilling DSM-IV 
criteria for an affective episode 
Comorbid psychiatric disorders; ECT in past 6 months; lithium-receiving 
patients in a trial  
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Author 
Year 
Country Sample n BD sample 
type 
BD definition 
Euthymia definition Exclusion criteria 
  BD HC    
Ferrier 
1999  
UK 21 (‘good’ 
outcome) 
20 (‘poor’ 
outcome) 
20 BD-I; at least 5 
years illness 
duration 
DSM-IV 
HRSD ≤8 and MSS <20 Dementing disorder; learning disability; history of substance misuse, 
cerebrovascular disease, neurodegenerative disorders, head injury with 
concussion, clinical epilepsy, systemic illness with known cerebral 
consequences, severe hypertension, severe hepatic or renal disorder, or endocrine 
disorders other than corrected hypothyroidism 
Frangou 
2005  
UK 44 44 BD-I 
DSM-IV 
Syndromal remission: not meeting DSM-IV 
criteria for a mood episode for at least 3 
months; no change in medication type/dose 
over the same period. Symptomatic 
remission: HRSD and MRS-SADS <10 
None  
Goswami 
2009  
India 22 (on 
medication) 
22 (not on 
medication) 
NA BD-I 
DSM-IV 
HRSD <8 and MSS <20 on two occasions 4 
weeks apart 
Other DSM Axis I or II diagnoses; cardiorespiratory, gastrointestinal, 
neurological and endocrine disorders (other than corrected hypothyroidism); 
substance misuse/dependency disorders; other medications e.g. anticholinergics, 
hypnotics or steroids 
Ibrahima 
2009  
Malaysia 40 40 BD-I 
DSM-IV 
No active manic or depressive symptoms as 
reflected by YMRS and HRSD scores 
Overtly disturbed/aggressive; severe mental retardation; dementia; significant 
CNS disease; head injury; comorbid psychiatric disorders; substance 
abuse/dependence; use of anticholinergics or benzodiazepines 
Jamrozinski 
2009  
Germany 40 40 BD-I 
DSM-IV 
MADRS ≤10 and YMRS ≤12 Other medical disorders 
Juseliusb 
2009  
Finland 26 114 BD-I 
DSM-IV (past 
diagnosis using 
ICD-8 or DSM-
III-R) 
In remission according to DSM-IV criteria Other psychotic disorders; neurological disorders; brain injury; current alcohol 
dependence 
Kieseppäb 
2005  
Finland 26 114 BD-I 
DSM-IV (past 
diagnosis using 
ICD-8 or DSM-
III-R) 
In full symptom remission according to 
DSM-IV criteria 
Other psychotic disorders; neurological disorders; brain injury; current alcohol 
dependence 
Lopera-
Vásquez 
2011  
Colombia 40 (on 
medication) 
31 (not on 
medication) 
28 BD-I 
DSM-IV 
ZSDS <8 and YMRS <6 Illicit substances or benzodiazepines in past 4 weeks; other psychiatric or 
neurological disorders; mental retardation; any treatment with ECT 
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Author 
Year 
Country Sample n BD sample 
type 
BD definition 
Euthymia definition Exclusion criteria 
  BD HC    
López-
Jaramillo 
2010  
Colombia 24 (1 manic 
episode)  
27 (2 manic 
episodes)  
47 (≥3 manic 
episodes) 
66 BD-I 
DSM-IV 
HRSD <8 and YMRS <6 Illicit substances or benzodiazepines in past 4 weeks; other psychiatric or 
neurological disorders that could affect cognition; mental retardation; any 
treatment with ECT; physical/sensory limitations that could affect performance 
Martinoc 
2008  
Argentina 50 30 BD-I or BD-II 
DSM-IV 
HRSD ≤8 and YMRS ≤6 for at least 6 weeks Substance abuse; mental retardation; neurological disease; any clinical condition 
that could affect cognitive performance 
Martinoc 
2011a  
Argentina 48 (BD-I)  
39 (BD-II) 
39 BD-I; BD-II 
DSM-IV 
HRSD ≤8 and YMRS ≤6 for at least 8 weeks Substance abuse; mental retardation; neurological disease; any clinical condition 
that could affect cognitive performance 
Martinoc 
2011b  
Argentina 45 (BD-I)  
36 (BD-II) 
34 BD-I; BD-II 
DSM-IV 
HRSD ≤8 and YMRS ≤6 for at least 8 weeks Substance abuse; mental retardation; neurological disease; any clinical condition 
that could affect cognitive performance 
Martinoc 
2011c  
Argentina 48 (BD-I)  
37 (BD-II) 
34 BD-I; BD-II 
DSM-IV 
HRSD ≤8 and YMRS ≤6 for at least 8 weeks Substance abuse; mental retardation; neurological disease; any clinical condition 
that could affect cognitive performance 
Martinoc 
2014  
Argentina 100 40 BD-I or BD-II 
DSM-IV 
HRSD ≤9 and YMRS ≤8 for at least 8 weeks Substance abuse; mental retardation; neurological disease; any clinical condition 
that could affect cognitive performance 
Mur 
2007  
Spain 44 46 BD-I or BD-II 
DSM-IV 
HRSD (17-item) <8 and YMRS <6 for at 
least 3 months; on same treatment regimen 
and clinically stable for 3 months 
Significant physical or neurologic illness; substance abuse/dependence in the 
past year; ECT in the past year; any mood-stabilising medication other than 
lithium 
Normalaa 
2010  
Malaysia 40 40 BD-I 
DSM-IV 
No active manic or depressive symptoms as 
reflected by YMRS and HRSD scores 
Overtly disturbed/aggressive; severe mental retardation; dementia; significant 
CNS disease; head injury; comorbid psychiatric disorders; substance 
abuse/dependence; use of anticholinergics or benzodiazepines 
Osher 
2011  
Israel 51 495 BD-I 
DSM-IV 
Consensus judgement by two clinicians based 
on full history and evidence of stability for at 
least three monthsd 
Serious physical illness or substance abuse  
Pirkolab 
2005  
Finland 22 100 BD-I 
DSM-III-R or 
DSM-IV 
Not stated Schizoaffective disorder; psychotic disorder other than BD-I; neurological 
disease; clinically significant head injury; mental retardation 
Sánchez-Morla 
2009  
Spain 73 67 BD 
DSM-IV 
HRSD <7 and YMRS <6 for 3 consecutive 
monthly evaluations 
Neurological or medical diseases that can affect cognition; mental retardation; 
history of alcohol or other substance abuse/dependence in past 2 years; ECT in 
past 2 years; history of head injury with LOC 
Sparding 
2015  
Sweden 64 (BD-I)  
44 (BD-II) 
86 BD-I; BD-II 
DSM-IV 
MADRS and YMRS <14 None stated 
van der Werf-
Eldering 
2010  
The 
Netherlands 
46 75 BD-I, BD-II or 
BD-NOS 
DSM-IV 
IDS-SR <14 and YMRS <8 Mental retardation; systemic or neurological disease which could affect 
cognition; alcohol use disorder currently needing treatment in a specialised 
setting 
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BD, bipolar disorder; BD-I, bipolar disorder type I; BD-II, bipolar disorder type II; BD-NOS, bipolar disorder not otherwise specified; BR-MRS, Bech–Rafaelsen Mania Rating Scale; CNS, central nervous 
system; DSM, Diagnostic and Statistical Manual of Mental Disorders; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders third edition revised; DSM-IV, Diagnostic and Statistical Manual 
of Mental Disorders fourth edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders fourth edition text revision; ECT, electroconvulsive therapy; HC, healthy comparison; HRSD, 
Hamilton Rating Scale for Depression; ICD-8, International Classification of Diseases eighth revision; ICD-10, International Classification of Diseases tenth revision; IDS-SR, Inventory of Depressive 
Symptomatology - Self Rating; IQ, intelligence quotient; LOC, loss of consciousness; MADRS, Montgomery–Åsberg Depression Rating Scale; MAS, Bech–Rafaelsen Mania Scale; MES, Bech–Rafaelsen 
Melancholia Scale; MRS-SADS, Mania Rating Scale from the Schedule for Affective Disorders and Schizophrenia (Change Version); MSS, Bech’s modification of Beigel’s Mania State Rating Scale; NA, 
not applicable; YMRS, Young Mania Rating Scale; ZSDS, Zung Self-Rated Depression Scale. 
a. Studies contain overlapping samples. 
b. Studies contain overlapping samples. 
c. Studies contain overlapping samples. 
d. Information provided by author. 
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2.3.3 Prevalence of cognitive impairment 
Prevalence was available for 15 articles, reporting on 16 BD samples. Tables 2.2 and 2.3 
show prevalence results in BD-I only and mixed BD samples, respectively. Characteristics 
of these samples are provided in supplementary tables within Appendix H. Prevalence was 
available for one study with separate BD-I and BD-II samples (Appendix I).  
Studies applied a variety of impairment thresholds: some were simple pass/fail cut-offs, 
and others were based on score distributions from published test norms or from a healthy 
comparison group. Distribution-based thresholds ranged from 1 SD to 2 SD below the 
comparison mean, with the most common being 1.5 SD (approximately 7th percentile), 
1.64 SD (approximately 5th percentile) and 2 SD (approximately 2nd percentile). At every 
threshold and on almost all cognitive measures, the prevalence of impairment in BD 
samples was higher than in the comparison group. Heterogeneity in prevalence across 
studies did not clearly relate to study quality/risk of bias. Studies differed in whether they 
used comparison group score distributions or published norms as the reference for 
impairment, but there was no clear relationship between choice of reference and magnitude 
of impairment prevalence. For example, on the same tests at the same thresholds, Mur et 
al. (2007) used published norms and reported lower prevalence estimates than Juselius et 
al. (2009), who used their own comparison group. On the other hand, Cheung et al. (2013) 
used published norms and reported some of the highest prevalence estimates across several 
cognitive domains. Prevalence of impairment did not differ consistently between BD-I 
only (Table 2.2) and mixed BD samples (Table 2.3), although direct comparison is difficult 
owing to the variation in measures and thresholds used. In the only study where BD-I and 
BD-II samples could be directly compared (Sparding et al., 2015) (results given in 
Appendix I), prevalence was higher in the BD-I participants on several measures, but there 
was considerable overlap in estimates between the two samples.  
Prevalence of cognitive impairment was further considered according to cognitive domain. 
Results within domains are presented graphically using forest plots, but pooled estimates 
are not reported because of the wide variation in cognitive tests used and in cut-offs 
applied to define presence of impairment. The classification of tests by domain was guided 
by the classifications used by the authors of the original articles. Where tests were thought 
to cross multiple domains, this is indicated in Tables 2.2 and 2.3. 
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Table 2.2 - Prevalence of cognitive impairment in BD-I samples 
 
Author 
Year 
Sample na Cognitive measure Impairment 
definition 
Impairment prevalence  
n (%) 
d 
 BD HC   BD HC  
Altshuler 
2004  
40 22 WCST categories (executive) Score 0 to 3 (42%) (0%) -0.98 
  CVLT total recall 1-5 (verbal 
memory) 
1.75 SD from 
published 
normative meanb 
(22%) (0%) -0.99 
Cavanagh 
2002c  
20 20 Stroop Color-Word Test 
(executive) 
1.64 SD from HC 
mean 
7 (36.8%) (5%)d -0.61 
   Letter fluency (executive)  2 (10%) (5%)d -0.31 
   BADS Six Elements (executive)  1 (5.3%) (5%)d -0.31 
   CVLT trial 1 (verbal memory)  7 (35%) (5%)d -1.24 
   CVLT total recall 1-5 (verbal 
memory) 
 5 (25%) (5%)d -1.06 
   CVLT delayed recall (verbal 
memory) 
 8 (42.1%) (5%)d -0.96 
   CVLT delayed recognition total 
(verbal memory) 
 4 (21.1%) (5%)d -0.62 
   CVLT delayed recognition 
minus false positives (verbal 
memory) 
 4 (21.1%) (5%)d -0.66 
   Stroop Color-Word Test 
(executive) 
2 SD from HC 
mean 
7 (36.8%) (2.275%)d -0.61 
   Letter fluency (executive)  2 (10%) (2.275%)d -0.31 
   BADS Six Elements (executive)  1 (5.3%) (2.275%)d -0.31 
   CVLT trial 1 (verbal memory)  2 (10%) (2.275%)d -1.24 
   CVLT total recall 1-5 (verbal 
memory) 
 4 (20%) (2.275%)d -1.06 
   CVLT delayed recall (verbal 
memory) 
 5 (26.3%) (2.275%)d -0.96 
   CVLT delayed recognition total 
(verbal memory) 
 4 (21.1%) (2.275%)d -0.62 
   CVLT delayed recognition 
minus false positives (verbal 
memory) 
 4 (21.1%) (2.275%)d -0.66 
Cheung 
2013  
52 52 CNS-VS neurocognition 
(overall) 
5th percentile of 
published norm 
(46.2%) (0.0%) -1.64 
   CNS-VS executive function  (53.8%) (0.0%) -1.69 
   CNS-VS cognitive flexibility  (57.7%) (0.0%) -1.66 
   CNS-VS complex attention  (51.9%) (1.9%) -1.36 
   CNS-VS processing speed  (26.9%) (0.0%) -1.21 
   CNS-VS psychomotor speed  (30.8%) (1.9%) -1.15 
   CNS-VS reaction time  (44.2%) (13.5%) -0.90 
   CNS-VS memory composite  (30.8%) (5.8%) -0.80 
   CNS-VS verbal memory  (28.8%) (5.8%) -0.71 
   CNS-VS visual memory  (11.5%) (3.8%) -0.65 
   1 SD from published normative 
mean on ≥2 index scores 
 (61.5%) (1.9%) NA 
   2 SD from published normative 
mean on ≥2 index scores 
 (40.4%) (0.0%) NA 
Fakhry 
2013  
S1: recent 
manic 
episode 
30 30 MMSE (global) Score <25 23 (76.7%) 0 (0%) -4.62 
  MTS (global) Score <27 18 (60%) 0 (0%) -2.10 
  CDT (executive/visuospatial) Score <6 0 (0%) 0 (0%) -3.31 
Fakhry 
2013  
S2: recent 
depressive 
episode 
30 30 MMSE (global) Score <25 6 (20%) 0 (0%) -2.74 
  MTS (global) Score <27 5 (16.7%) 0 (0%) -0.84 
  CDT (executive/visuospatial) Score <6 0 (0%) 0 (0%) -2.89 
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Author 
Year 
Sample na Cognitive measure Impairment 
definition 
Impairment prevalence  
n (%) 
d 
 BD HC   BD HC  
Ibrahim 
2009e & 
Normala 
2010e  
40 40 Category fluency 
(executive/language) 
Score ≤30 3 (7.5%) 0 (0%)c -1.01 
  TMT part A (speed/attention)c >40/45/50 
secondsf 
19 (47.5%) 11 (27.5%) -0.52 
   TMT part B (executive)c >90/100/135 
secondsf 
25 (62.5%) 13 (32.5%) -0.81 
   Digit span forward (attention)c Span <5 3 (7.5%) 1 (2.5%) -0.97 
   Digit span backward (working 
memory)c 
Span <4 18 (15.0%) 5 (12.5%) -1.10 
   RAVLT trial 1 (verbal memory) Score <7 31 (77.5%) 13 (32.5%) NR 
   RAVLT trial 5 (verbal memory) Score <12 23 (57.5%) 1 (2.5%) NR 
   RAVLT trials 1 to 5 (verbal 
memory) 
Score increment 
<5 
16 (40%) 3 (7.5%) NR 
   RAVLT list B (verbal memory) Score <7 37 (92.5%) 14 (35%) NR 
Juselius 
2009  
26g 114 WCST categories (executive) 1.5 SD from HC 
mean 
12 (50%) (6.68%)d -0.78 
  WCST perseverative 
(executive) 
13 (54%) (6.68%)d -1.74 
   Stroop interference (executive)  15 (68%) (6.68%)d -3.58 
   TMT B minus A (executive)  10 (42%) (6.68%)d -0.33 
   Letter fluency 
(executive/language) 
 15 (63%) (6.68%)d -1.75 
   Category fluency 
(executive/language) 
 18 (78%) (6.68%)d -3.40 
Osher 
2011c  
51 495 Mindstreams global cognition 1.5 SD from HC 
mean 
25 (49.0%) (6.68%)d -1.19 
  Mindstreams executive function 13 (25.5%) (6.68%)d -0.83 
   Mindstreams attention  20 (39.2%) (6.68%)d -1.04 
   Mindstreams information 
processing speed 
 15 (29.4%) (6.68%)d -0.91 
   Mindstreams memory  22 (43.1%) (6.68%)d -0.96 
   Mindstreams verbal function  11 (21.6%) (6.68%)d -0.51 
   Mindstreams visual-spatial  16 (31.4%) (6.68%)d -0.67 
   Mindstreams motor skills  12 (23.5%) (6.68%)d -0.58 
BADS, Behavioural Assessment of the Dysexecutive Syndrome; BD, bipolar disorder; BD-I, bipolar disorder type I; 
CDT, Clock Drawing Test; CNS-VS, Central Nervous System Vital Signs computerised battery; CVLT, California 
Verbal Learning Test; HC, healthy comparison; MMSE, Mini-mental State Examination; MTS, Mental Test Score; NA, 
not applicable; NR, unable to calculate as mean and SD not reported in article; RAVLT, Rey Auditory Verbal Learning 
Test; SD, standard deviation; TMT, Trailmaking Test; WCST, Wisconsin Card Sorting Test. 
d is the standardised mean difference between BD and HC groups, calculated from unadjusted results in the article; 
negative values indicate worse performance in BD group. 
a. Sample characteristics are reported in Supplementary Table H.1 (Appendix H) 
b. T-score <32; impairment definition not explicit in article but inferred from bar graph of results. 
c. Prevalence data provided by author. 
d. By definition, according to impairment threshold applied. 
e. Same sample; RAVLT reported in Ibrahim 2009 and other tests reported in Normala 2010. 
f. Age groups 18-39, 40-49 and 50-59, respectively. 
g. Sample denominator for prevalence results ranges from 22 to 24. 
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Table 2.3 - Prevalence of cognitive impairment in mixed BD samples 
 
Author  
Year 
Sample na 
 
Cognitive measure Impairment 
definition 
Impairment prevalence  
n (%) 
d 
 BD HC   BD HC  
Barrera 
2013b  
12 12 Reading the Mind in the Eyes test 
(theory of mind) 
Score <21 6 (50%) 2 (16.7%) -0.61 
   Faux Pas Recognition Test 
cognitive items (theory of mind) 
Score <0.75 7 (58.3%) 4 (33.3%) -0.77 
Daban 
2012  
53 60 WAIS-III Digit Symbol Coding 
(processing speed) 
1.64 SD from 
HC mean 
(30.2%) (5%)c -0.89 
Martino 
2014  
100 40 Various tests (executive, 
attention/working memory, verbal 
memory, naming) 
1.5 SD from 
published 
normative 
mean in ≥1 
cognitive 
domain  
(70%) (27.5%) NA 
    2 SD from 
published 
normative 
mean in ≥2 
cognitive 
domains  
(30%) (7.5%) NA 
Mur 
2007b  
44 46 TMT part B (executive) 1.5 SD from 
published 
normative 
mean 
0 (0%) 0 (0%) -0.72 
   Letter fluency 
(executive/language) 
6 (13.6%) 0 (0%) -0.71 
   WCST categories (executive)  18 (40.9%) 7 (15.2%) -0.87 
   WCST perseverative (executive)  15 (34.1%) 5 (10.9%) -0.49 
   Stroop inhibition (executive)  11 (25.0%) 1 (2.2%) -1.30 
   Digit span (attention/working 
memory) 
 3 (6.8%) 0 (0%) NR 
   TMT part A (speed/attention)  0 (0%) 0 (0%) -0.28 
   CVLT trial 1 (verbal memory)  11 (25.0%) 7 (15.2%) 0.19 
   CVLT total words (verbal 
memory) 
 17 (38.6%) 6 (13.0%) 0.01 
   CVLT immediate recall (verbal 
memory) 
 13 (29.5%) 4 (8.7%) 0.12 
   CVLT delayed recall (verbal 
memory) 
 12 (27.3%) 6 (13.0%) -0.33 
   RCFT immediate (visual 
memory) 
 13 (29.5%) 0 (0%) -0.52 
   RCFT delayed (visual memory)  16 (36.4%) 4 (8.7%) -0.55 
Sánchez-
Morla 
2009  
73 67 Executive composite z-score 1.64 SD from 
HC mean 
33 (45.2%) (5%)c -1.80 
  Sustained attention composite z-
score 
10 (13.7%) (5%)c -0.65 
   Verbal memory composite z-
score 
 21 (28.8%) (5%)c -1.18 
   Visual memory composite z-score  24 (32.9%) (5%)c -1.10 
   WCST % conceptual level 
response (executive) 
 (19.2%) (5%)c -1.02 
   WCST % perseverative errors 
(executive) 
 (19.2%) (5%)c -1.01 
   Stroop interference (executive)  (35.6%) (5%)c -0.98 
   TMT part B (executive)  (32.9%) (5%)c -0.97 
   Letter fluency 
(executive/language) 
 (16.4%) (5%)c -1.00 
   Animal fluency 
(executive/language) 
 (24.7%) (5%)c -0.89 
   Tower of Hanoi no. of 
movements (executive) 
 (19.0%) (5%)c -0.64 
   Digit span backward (working 
memory) 
 (11.0%) (5%)c -0.53 
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Author  
Year 
Sample na 
 
Cognitive measure Impairment 
definition 
Impairment prevalence  
n (%) 
d 
 BD HC   BD HC  
   CPT hits (attention)   (9.6%) (5%)c -0.52 
   CPT sensitivity A (attention)  (9.6%) (5%)c -0.58 
   CPT reaction time 
(attention/speed) 
 (23.3%) (5%)c -0.72 
   CVLT total recall 1-5 (verbal 
memory) 
 (19.2%) (5%)c -0.97 
   CVLT short free-recall (verbal 
memory) 
 (27.4%) (5%)c -0.96 
   CVLT long free-recall (verbal 
memory) 
 (15.1%) (5%)c -0.97 
   CVLT short cued-recall (verbal 
memory) 
 (20.5%) (5%)c -1.11 
   CVLT long cued-recall (verbal 
memory) 
 (23.3%) (5%)c -0.97 
   CVLT recognition 
discriminability (verbal memory) 
 (8.2%) (5%)c -0.67 
   CVLT semantic strategies trial A 
(verbal memory) 
 (41.1%) (5%)c -0.82 
   RCFT copy (visuospatial)  (16.4%) (5%)c -0.51 
   RCFT short-term (visual 
memory) 
 (31.5%) (5%)c -0.98 
   RCFT long-term (visual memory)  (32.9%) (5%)c -1.01 
van der 
Werf-
Eldering 
2010  
46 75 Various tests (executive, 
attention/working memory, 
reaction time, verbal and visual 
memory) 
2 SD from HC 
mean in ≥1 
cognitive 
domain 
6 (13%) (2.275%)c NA 
BD, bipolar disorder; BD-I, bipolar disorder type I; CPT, Continuous Performance Test; CVLT, California Verbal 
Learning Test; HC, healthy comparison; NA, not applicable; NR, unable to calculate as mean and SD not reported in 
article; RCFT, Rey Complex Figure Test; SD, standard deviation; TMT, Trailmaking Test; WAIS-III, Wechsler Adult 
Intelligence Scale third edition; WCST, Wisconsin Card Sorting Test. 
d is the standardised mean difference between BD and HC groups, calculated from unadjusted results in the article; 
negative values indicate worse performance in BD group. 
a. Sample characteristics are reported in Supplementary Table H.2 (Appendix H). 
b. Prevalence data provided by author. 
c. By definition, according to impairment threshold applied.
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2.3.3.1 Executive function, reasoning and social cognition 
Figure 2.2 shows the prevalence of impairment in studies that used a normative 
distribution-based threshold for impairment. Additional score-based threshold results from 
three studies (Altshuler et al., 2004; Barrera et al., 2013; Normala et al., 2010) are reported 
in Tables 2.2 and 2.3. Measures that are likely to be significantly influenced by 
performance speed are considered separately from those that are not, to minimise the 
overlap between underlying processing speed ability and instrumental executive function. 
The former category included timed fluency measures, Stroop test, Trailmaking test, and 
composite scores primarily influenced by these. The latter category included Tower tests, 
non-time-dependent aspects of fluency tasks (e.g. category switching accuracy), reasoning 
tests, Wisconsin Card Sorting test, BADS Six Elements task, and composite scores 
primarily influenced by these. These timed/non-timed distinctions are not absolute: some 
tasks in the latter category have time limits imposed during administration, although speed 
of responding per se is not the key determinant of performance success. 
Figure 2.2 shows that impairment prevalence tended to be slightly higher on speed-
sensitive tasks (lower panel) than on those that depend less on speed (upper panel), though 
this pattern was not evident in all studies. The estimates did not follow a clear gradient 
according to the different threshold strata: for example, the estimates from Cavanagh et al. 
(2002) were the same at the 5th and 2nd percentile levels. This may be a consequence of the 
small sample size, or may indicate that impaired individuals were strongly clustered at the 
extreme low end of the score distribution, such that less strict thresholds made little 
difference to the absolute numbers considered impaired. The estimates from Juselius et al. 
(2009) were somewhat higher than expected in the context of the other studies. This may 
be related to study size and quality, but it should also be noted that this study included 
several twin pairs who were concordant for BD. BD-II-only results are not shown in Figure 
2.2, but the supplementary table in Appendix I indicates that fewer BD-II participants were 
impaired, in comparison with BD-I participants, on most executive function measures in 
Sparding et al. (2015). Only one study provided prevalence data for social cognition tasks 
(Barrera et al., 2013): in a small mixed BD sample (n = 12), prevalence of impairment on 
emotional and cognitive theory of mind measures was higher compared with the healthy 
comparison sample (Table 2.3).  
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Figure 2.2 - Executive function impairment prevalence across different thresholds 
 
BADS, Behavioural Assessment of the Dysexecutive Syndrome; BD, bipolar disorder; BD-I, 
bipolar disorder type I; CI, confidence interval; CNS-VS, Central Nervous System Vital Signs 
computerised battery; TMT, Trailmaking Test; WAIS-III, Wechsler Adult Intelligence Scale 
third edition; WCST, Wisconsin Card Sorting Test. Results include mixed BD and BD-I 
(b) 
(a) 
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samples. Some studies reported results for several cognitive scores, and so there is sample 
overlap across rows. CI estimates are based on standard errors calculated as follows: 
((prevalence*(100-prevalence))/n). Results are stratified by impairment threshold 
(percentile), in descending order from least to most strict. Panel (a) shows executive 
measures whose scores do not have a prominent timed/speed contribution, and panel (b) 
shows executive measures whose scores are influenced by speed.  
 
2.3.3.2 Attention and working memory 
Figure 2.3 shows the prevalence of impairment in five studies, of similar quality, that 
reported attention/working memory measures. Estimates were generally higher than in the 
healthy comparison population, and this was most striking on the CNS-VS complex 
attention score reported by Cheung et al. (2013) and the Mindstreams attention score from 
Osher et al. (2011). These scores are composites of several demanding tasks, more akin to 
the executive measures presented in Figure 2.2. Additional measures from Normala et al. 
(2010) are reported in Table 2.2, showing a slightly elevated percentage of BD participants 
with reduced forward and backward digit span. The study by Sparding et al. (2015) allows 
comparison between BD-I and BD-II samples on two attention/working memory measures, 
indicating that the proportions with impairment were similar (Appendix I). 
 
Figure 2.3 - Attention/working memory impairment prevalence across different thresholds 
 
BD, bipolar disorder; BD-I, bipolar disorder type I; CI, confidence interval; CNS-VS, Central 
Nervous System Vital Signs computerised battery; CPT, Continuous Performance Test; 
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WAIS-III, Wechsler Adult Intelligence Scale third edition. Results include mixed BD and BD-I 
samples. Some studies reported results for several cognitive scores, and so there is sample 
overlap across rows. CI estimates are based on standard errors calculated as follows:          
((prevalence*(100-prevalence))/n). Results are stratified by impairment threshold 
(percentile), in descending order from least to most strict.  
 
2.3.3.3 Speed and reaction time 
Figure 2.4 shows that the prevalence of impairment on speed and reaction time measures 
was similar across different impairment thresholds. However, Daban et al. (2012) reported 
that 30.2% were impaired on the WAIS-III Digit Symbol Coding task at the 5th percentile 
threshold, whereas Sparding et al. (2015) reported 19% impairment prevalence on the same 
task at the less strict threshold of 11th percentile. Daban et al. assessed a mixed BD sample 
but did not report subtypes or illness characteristics, making it difficult to infer reasons for 
the disparity with Sparding et al.’s BD-I sample. It was also evident from the Sparding et 
al. study that fewer BD-II participants were impaired on these tasks; in the case of WAIS-
III Digit-Symbol Coding, the proportion impaired (11%) was in line with the normative 
score distribution (supplementary table in Appendix I). 
 
Figure 2.4 - Speed/reaction time impairment prevalence across different thresholds 
 
BD, bipolar disorder; BD-I, bipolar disorder type I; CI, confidence interval; CNS-VS, Central 
Nervous System Vital Signs computerised battery; CPT, Continuous Performance Test; 
TMT, Trailmaking Test; WAIS-III, Wechsler Adult Intelligence Scale third edition. Results 
include mixed BD and BD-I samples. Some studies reported results for several cognitive 
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scores, and so there is sample overlap across rows. CI estimates are based on standard 
errors calculated as follows: ((prevalence*(100-prevalence))/n). Results are stratified by 
impairment threshold (percentile), in descending order from least to most strict.  
 
2.3.3.4 Memory 
Figure 2.5 shows impairment prevalence results for verbal memory (upper panel) and 
visual memory (lower panel). Additional score-based threshold results from Ibrahim et al. 
(2009) are shown in Table 2.2. Two studies of similar quality that reported composite 
verbal and visual measures separately (Cheung et al., 2013; Sánchez-Morla et al., 2009) 
showed contradictory findings regarding relative prevalence of impairment: both studies 
reported that 28.8% were impaired on verbal memory at the 5th percentile threshold, but 
the proportions impaired on visual memory were 11.5% in Cheung et al. (2013) versus 
32.9% in Sánchez-Morla et al. (2009). The proportions impaired on overall memory 
composite measures were 43.1% at the 7th percentile threshold (Osher et al., 2011) and 
30.8% at the 5th percentile (Cheung et al., 2013).  
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Figure 2.5 - Verbal and visual memory impairment prevalence across different thresholds 
 
BD, bipolar disorder; BD-I, bipolar disorder type I; CI, confidence interval; CNS-VS, Central 
Nervous System Vital Signs computerised battery; CVLT, California Verbal Learning Test; 
RCFT, Rey Complex Figure Test; WAIS-III, Wechsler Adult Intelligence Scale third edition. 
Results include mixed BD and BD-I samples. Some studies reported results for several 
cognitive scores, and so there is sample overlap across rows. CI estimates are based on 
standard errors calculated as follows: ((prevalence*(100-prevalence))/n). Results are 
stratified by impairment threshold (percentile), in descending order from least to most strict. 
Panel (a) shows verbal memory measures and panel (b) shows visual memory measures. 
(b) 
(a) 
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The California Verbal Learning Test (CVLT) was the most common of the verbal memory 
measures, used in four studies with different thresholds. Results from Cavanagh et al. 
(2002) and Altshuler et al. (2004) indicated a threshold-related gradient, with fewer 
participants falling below the stricter 2nd percentile level for CVLT learning and recall, 
though not for recognition performance. Sánchez-Morla et al. (2009) reported lower 
impairment prevalence than Cavanagh et al. using the same 5th percentile threshold for the 
same CVLT measures (total trials 1 to 5, and long delay recall). This may be explained by 
the larger sample size and mix of BD-I and BD-II participants in the former study. No 
verbal memory results were available for BD-II separately.  
Visual memory results were available from four studies of similar quality. Three (Mur et 
al., 2007; Sánchez-Morla et al., 2009; Sparding et al., 2015) used the Rey Complex Figure 
Test (RCFT) at different impairment thresholds; prevalence on this test was lowest in 
Sparding et al. (2015) despite the less strict threshold and more severe clinical 
characteristics of their sample. Prevalence of visual memory impairment was similar 
between BD-I and BD-II samples in that study (Appendix I).  
2.3.3.5 Visuospatial function 
Three studies (Osher et al., 2011; Sánchez-Morla et al., 2009; Sparding et al., 2015) 
reported visuospatial measures (Tables 2.2 and 2.3, and Appendix I). Impairment 
prevalence was lower for visuospatial tasks than for other cognitive domains, though still 
somewhat higher than would be expected from the normative distribution. Prevalence was 
highest on the WAIS-III Block Design task—reported as 40% by Sparding et al. (2015) at 
the 11th percentile threshold—which may reflect the executive and speed components that 
contribute to success on this task. Prevalence was similarly high among BD-II participants 
on this task (Sparding et al., 2015).  
2.3.3.6 Any domain, multi-domain and global impairment 
Fakhry et al. (2013) used the Mini-mental State Examination (MMSE), Mental Test Score 
(MTS) and Clock Drawing Test (CDT)—typically used as global measures in dementia 
settings—to assess BD-I participants, grouped by the polarity of their most recent illness 
episode. Table 2.2 shows that the proportions falling below the impairment cut-off were 
markedly higher in the group whose most recent episode was manic. No BD participant 
scored below the cut-off on the CDT, however.  
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Osher et al. (2011) reported that 49% of their BD-I sample fell below the 7th percentile (1.5 
SD) on the global cognition measure of the Mindstreams computerised battery. Also in 
BD-I, 46.2% of the Cheung et al. (2013) sample were below the 5th percentile on the CNS-
VS overall measure of neurocognition. Furthermore, 61.5% were at least 1 SD below the 
normative mean on at least two CNS-VS index scores, and 40.4% met the stricter criterion 
of being at least 2 SD below the normative mean on at least two index scores.  
Two studies reported overall results from mixed BD samples. Van der Werf-Eldering et al. 
(2010) found that 6 of 46 participants (13%) were at least 2 SD above the healthy 
comparison mean (where higher scores indicated worse performance) in at least one 
cognitive domain. The sample of 46 was a euthymic sub-group from a larger study, for 
whom demographic and clinical characteristics were not available. It is therefore unclear 
why the proportion impaired was relatively low in this study. Martino et al. (2014) 
assessed a larger sample (n = 100), and reported that 70% were impaired using “soft” 
criteria (1.5 SD below the normative mean in at least one cognitive domain) and 30% were 
impaired using “hard” criteria (at least 2 SD below the normative mean on at least two 
domains).  
2.3.4 Risk of bias across studies 
Figure 2.6 shows funnel plots of the relationship between the prevalence estimates and 
their precision (standard error), presented separately by cognitive domain, for studies 
reporting measures at the 5th percentile impairment threshold. Visual inspection suggested 
a degree of asymmetry for measures of verbal memory, and to a lesser extent for speed-
sensitive measures (both within the executive domain and on specific tests of 
speed/reaction time). Relatively fewer estimates in the lower left quadrant of these plots 
may indicate publication bias, or reflect other factors such as different sample 
characteristics or assessment methods in the smaller/less precise studies. The small number 
of independent measures meant it was not possible to apply statistical tests of asymmetry. 
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Figure 2.6 - Funnel plots with pseudo 95% confidence limits 
 
SE, standard error. Plots show cognitive impairment prevalence estimates and standard 
errors by cognitive domain, using results reported at the 5th percentile impairment 
threshold. Standard errors were calculated as follows: ((prevalence*(100-prevalence))/n). 
Some studies contributed more than one data point to the plot; data points are labelled by 
study. 
 
2.3.5 Factors associated with cognitive impairment 
Twenty-eight articles provided information regarding the relationship between various 
sociodemographic, clinical or other variables, and the presence or severity of cognitive 
impairment. Articles were not always clear about which associations had been tested 
statistically, and they varied in the extent to which they adjusted for other potential 
confounders. Appendix J shows an overview of the types of variables that were 
49 
 
investigated, with reportedly significant findings highlighted across studies. This synthesis 
is presented qualitatively rather than quantitatively, owing to the wide variety of ways in 
which differences or associations were reported across studies.  
Associations with demographic variables and premorbid ability were often not 
investigated. In some cases this was because key background factors had been frequency-
matched in a between-group study design, or had been adjusted for when calculating 
standardised cognitive scores. Other analyses included these background factors as 
covariates (e.g. in multiple regression), without reporting results for these covariates 
separately. For the remainder, greater cognitive impairment was associated with older age, 
lower education and lower premorbid ability in some studies, but others reported no 
statistically significant findings. 
Illness characteristics—such as duration since onset, number of affective episodes and 
hospitalisations, history of psychotic symptoms, and residual depressive or manic 
symptoms—were more frequently investigated. Where statistically significant results were 
reported, they indicated that more severe illness characteristics were associated with worse 
cognitive function. An exception was history of psychotic symptoms, for which one study 
reported both positive and negative associations. Several studies investigated associations 
with psychotropic medication, with mixed findings. The most frequently reported 
association was between antipsychotic medication and worse cognition, although some 
studies reported null findings. By contrast, mood stabilisers (lithium or anticonvulsants) 
were less frequently associated with impairment.  
Although two studies examined history of alcohol/substance use disorder, none 
investigated the relationship between frequency/amount of alcohol or recreational drug 
consumption and cognitive impairment. No study examined associations with smoking or 
other cardiovascular risk factors that may be relevant to cognitive impairment. 
2.4 Discussion 
2.4.1 Summary of findings 
The aims of the review presented in this chapter were to determine the prevalence of 
cognitive impairment in euthymic adults with BD, and to ascertain which clinical, 
sociodemographic or other factors were associated with cognitive impairment in this 
population. Thirty articles contributed to the findings, of which 15 provided prevalence 
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data. Impairment prevalence was similar between BD-I only and mixed BD samples. One 
study with separate results for BD-I and BD-II participants indicated that impairment was 
more common in those with BD-I, though considerable overlap was apparent. Examination 
of impairment proportions across different cognitive domains indicated wide variation both 
within and between domains. For example, taking the 5th percentile threshold as the 
reference, impairment prevalence ranges were as follows: non-speed-sensitive executive 
function 5.3% to 57.7%; speed-sensitive executive function 10.0% to 36.8%; 
attention/working memory 9.6% to 51.9%; speed/reaction time 23.3% to 44.2%; verbal 
memory 8.2% to 42.1%; visual memory 11.5% to 32.9%. Generally small sample sizes 
resulted in wide CIs for most estimates. A recent review of neuropsychological function in 
BD (Szmulewicz et al., 2015) highlighted impairment prevalence as an issue of particular 
interest, and reported estimates between 30% and 57% from six studies. Four of these 
studies were not eligible for the present review, either because participants were not 
euthymic or because the recruitment method did not meet our criteria. The fact that the 
lower bounds of the prevalence estimates reported in the present review are below the 
previous estimate of 30% can be understood in light of our exclusion of non-euthymic 
participants and samples recruited by convenience, either of which may bias prevalence 
estimates upwards.  
There was some evidence that more severe or longstanding illness was associated with 
greater cognitive impairment. Several studies reported an association with antipsychotic 
medication but less so with other types of psychotropic medication; it should be noted, 
however, that medication associations are likely to be confounded by illness severity as 
well as treatment adherence and responsiveness. A previous individual participant data 
meta-analysis of 2,876 euthymic patients with BD (Bourne et al., 2013) also reported 
statistically significant associations between cognitive performance and some illness 
severity indices (e.g. number of manic episodes and total hospitalisations), and reported an 
association on a verbal memory test for antipsychotic medication only, but not lithium, 
antidepressants or anticonvulsants.  
2.4.2 Limitations of included studies 
Valid prevalence estimates depend on representative samples, but representativeness was 
questionable in many of the studies included here. Although all appear to have used an 
appropriate recruitment method (e.g. consecutive or random sampling), details were scant 
in published papers regarding exact recruitment processes and numbers considered at each 
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stage. Exclusion on the basis of comorbidity such as substance misuse was common, but 
numbers excluded were rarely reported. Definitions of euthymia varied; even when these 
were based on common measures (e.g. HRSD and YMRS), cut-off scores differed across 
studies. A wide range of cognitive tests was used, and even within specific tests, many 
different scores were reported (e.g. various CVLT sub-scores). This made direct 
comparison across studies difficult. The use of different thresholds to define cognitive 
impairment also limited synthesis at the outcome level. Most studies focused on the 
cognitive domains of executive function, memory and attention, with other areas of 
function such as visuospatial ability and language studied rarely if at all. Articles were 
sometimes unclear regarding which demographic, clinical or other variables were 
statistically analysed in conjunction with the cognitive measures.  
2.4.3 Limitations of review 
Recommended practices in systematic review methodology were followed, but 
reproducibility of screening, data extraction and bias appraisal processes was checked for 
only a proportion of records. Judgements about study eligibility relied solely on 
information contained in the articles, and authors were not contacted to request missing 
information during the selection process. A large number of articles were excluded on the 
sample recruitment criterion, in some cases because this information was not contained in 
the article; it is possible that some of these did in fact employ an appropriate sampling 
procedure. The requirement for information within the article indicating an acceptable 
recruitment procedure meant that several articles included in previous reviews of cognitive 
function in BD are not included here, including some that reported prevalence estimates. 
Despite repeated attempts to obtain additional prevalence results from authors of eligible 
articles, prevalence data were available for only 15 articles. In particular, there was little 
information regarding impairment prevalence in BD-II samples. Heterogeneity of cognitive 
measures and thresholds meant that it was not feasible to meta-analyse the prevalence 
estimates obtained, or to conduct statistical tests of funnel plot asymmetry, and so the 
results are limited to graphical and narrative synthesis only. This was organised by 
cognitive domain, though it is acknowledged that many tests make multiple cognitive 
demands across domains. Regarding the second review question, variation in the way that 
correlates were analysed across studies meant it was not possible to comment on the nature 
of any inter-relationships between the potential risk factors reported here. Risk of bias was 
considered carefully, but it should be noted that the appraisal tool used was developed for 
questions of prevalence, whereas many of the studies included here were not originally 
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designed to investigate prevalence. The literature search results were restricted to English-
language publications only, although studies from a wide range of international settings 
were found.  
2.4.4 Conclusions and implications 
The review presented in this chapter is the first to systematically examine the prevalence of 
cognitive impairment in euthymic bipolar disorder. It complements and extends the 
findings of previous reviews, which have focused on the magnitude of between-group 
differences on cognitive measures. Although group differences are important for 
understanding the nature and extent of cognitive impairment in this population, quantifying 
the number who have clinically relevant cognitive impairment is essential if we wish to 
identify risk factors for a cognitively impaired subtype of euthymic BD, and to target 
clinical resources towards neuropsychological rehabilitation and support for those who 
need it most. Despite the heterogeneity demonstrated in this chapter, some tentative 
conclusions can be drawn. Cognitive impairment affects patients across the BD spectrum; 
impairment appears to be more common in BD-I but there is considerable overlap with 
BD-II. It is also evident that even at the lower ends of the prevalence ranges reported here, 
the proportion of patients whose affective illness is in remission but who continue to show 
cognitive impairment substantially exceeds the expected proportion in the general 
population. With BD diagnosis typically being made in early adulthood, this means that the 
excess burden of cognitive impairment will affect this population over several decades. 
This ‘cognitive footprint’ effect (Rossor & Knapp, 2015) is considered further in Chapter 
5.  
2.5 Next steps 
The review presented here has highlighted the challenges of synthesising prevalence 
estimates from studies with heterogeneous methods. By using the UK Biobank data 
resource, there is potential to estimate prevalence reliably in a large community-based BD 
sample who have been assessed in a standardised way, and to directly compare estimates 
between BD and other clinical groups within the cohort. Chapter 3 describes the UK 
Biobank resource in detail, and Chapter 4 describes how self-reported and linked health 
records data were used to identify groups within the cohort with a history of the conditions 
of interest. Chapter 5 reports the results of the prevalence analyses across these groups.  
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Chapter 3 Description of the UK Biobank 
resource 
This chapter describes the recruitment, cohort composition and relevant data available in 
the UK Biobank resource. Detailed information about the resource is publicly accessible at 
http://www.ukbiobank.ac.uk/. 
UK Biobank is a general population-based prospective cohort study, established with the 
aim of elucidating the genetic and non-genetic determinants of diseases of middle and old 
age (Sudlow et al., 2015). It has received funding from the Wellcome Trust, Medical 
Research Council, UK Government Department of Health, Scottish Government, 
Northwest Regional Development Agency, Welsh Assembly Government, British Heart 
Foundation and Diabetes UK. Data are made available, upon application, to bona fide 
researchers for health-related research that is in the public interest. The studies reported in 
this thesis were conducted under approved application 11332 (Appendix K). UK Biobank 
has approval from the National Health Service (NHS) National Research Ethics Service as 
a research tissue bank (reference 16/NW/0274 and 11/NW/0382; see Appendix L), and 
separate project-specific ethical approval is not required by researchers using data released 
by UK Biobank. For administrative completeness, however, the proposal for this thesis 
was approved by the College of Medical, Veterinary and Life Sciences Ethics Committee 
at the University of Glasgow (reference 200150023; Appendix M), and was acknowledged 
by the NHS Greater Glasgow & Clyde Research and Development Department (reference 
GN14NE132; Appendix N).  
3.1 Cohort composition 
3.1.1 Population and recruitment 
UK Biobank aimed to recruit 500,000 participants, in order to achieve adequate statistical 
power to reliably detect odds ratios of 1.3 to 1.5 for the main effects of different exposures 
on risk of disease over a follow-up period of 10-20 years (Sudlow et al., 2015). Adults 
aged 40 to 69 years who were registered with the NHS and living within 25 miles of a 
study assessment centre were invited by post to participate in UK Biobank. No exclusion 
criteria were applied. The age range was chosen so that participants would be expected to 
experience incident disease outcomes in the early years of follow-up, while allowing 
baseline assessment of exposures with minimal influence of incipient disease (Sudlow et 
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al., 2015). Twenty-two assessment centres were in operation across England, Scotland and 
Wales at different times between 2006 and 2010. Figure 3.1 shows the invitation and 
appointment process, which was managed centrally using national NHS records. Invitation 
mailings were stratified according to age, gender and postcode area (as a measure of social 
deprivation). Approximately 9 million invitations were issued to achieve the eventual 
cohort size of ~502,000, indicating an overall response rate of around 5.6% (Manolio et al., 
2012). 
 
Figure 3.1 - UK Biobank invitation and appointment process 
 
A schematic representation of the invitation and appointment process is shown. Image 
taken from the UK Biobank protocol UKBB-PROT-09-06, dated 21 March 2007. 
 
3.1.2 Cohort characteristics 
Available data as at 3rd November 2016 (n = 502,639)2 indicated that participant ages 
ranged from 37 to 73 years, with the majority (n = 500,205; 99.5%) being between 40 and 
69 years as per the recruitment strategy (M = 56.5; SD = 8.1). More women than men took 
                                                 
2 The number with available baseline data changes slightly over time due to participant 
withdrawals. 
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part (n = 273,465; 54.4%). The majority self-reported white ethnicity (white British n = 
442,698, 88.1%; white Irish n = 13,213, 2.6%; white other n = 16,911, 3.4%), followed by 
Asian/Asian British (n = 9,882; 2.0%), black/black British (n = 8,065; 1.6%) and mixed 
ethnic background (n = 2,958; 0.6%). Most were in paid employment or were self-
employed (n = 287,231; 57.1%), with 177,485 (35.3%) retired and 20,386 (4.1%) unable to 
work due to sickness or disability. Almost one-third reported having a university or college 
degree (n = 161,208; 32.1%).  
A recent comparison of the UK Biobank cohort with UK Biobank invitees who did not 
participate, and with findings from nationally representative surveys, confirmed that the 
cohort is not representative with regard to gender and deprivation; the proportion reporting 
white ethnicity is representative of the 2001 UK census but is higher than that reported in 
the 2011 census (Fry et al., 2017). Another study (Hill, Hagenaars, et al., 2016), focusing 
on the subset of the cohort that was included in the first release of genomic data, compared 
the distribution of deprivation scores with the distribution in England and Wales in the 
2001 census; this showed that the most deprived areas were not represented in the UK 
Biobank sample, but the shape of the distribution was otherwise similar. It has been argued 
that measures of association within the study population may still be valid (Collins, 2012), 
but caution must be exercised when non-representativeness is due to self-selection, because 
spurious associations may arise when the characteristics under study have themselves 
influenced selection into the cohort (Ebrahim & Smith, 2013; Swanson, 2012). This issue, 
known as collider stratification bias (Greenland, Pearl, & Robins, 1999; Munafò, Tilling, 
Taylor, Evans, & Smith, 2017), is considered in more detail in later chapters.  
3.2 Assessment procedures 
Participants attended baseline assessment visits lasting about two hours at UK Biobank 
assessment centres between 2006 and 2010. Written consent was provided, following 
which participants completed computerised touchscreen questionnaires and cognitive 
assessments, then underwent a verbal interview and physical measures with a trained staff 
member. They also provided urine and blood samples for biomarker and genomic analysis. 
The assessment process was standardised, as depicted in Figure 3.2.  
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Figure 3.2 - Layout of UK Biobank assessment centre 
 
Each assessment centre was laid out approximately as shown, allowing standardised 
participant flow between stations. Image taken from 
http://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=Clinic_layout  
 
Approximately 20,000 participants attended a repeat visit in 2012-2013, at which the same 
assessments were re-administered. Imaging visits commenced in 2014, with the aim of 
collecting MRI scans of brain, heart and abdomen from up to 100,000 participants. 
Additional web-based data collection has been undertaken since 2013, including 
questionnaires about diet, work environment and lifetime mental health experiences. 
Additional cognitive data have also been collected via web-based assessment, and physical 
activity has been measured using wrist-worn accelerometers supplied and returned by post. 
Data linkage has been established between UK Biobank and NHS medical records, cancer 
registers and death registers, providing information about medical history pre-dating 
recruitment to UK Biobank as well as incident outcomes and mortality on an ongoing 
basis.  
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The studies reported in this thesis primarily used data from the baseline assessment visit, 
together with linked NHS records and web-based mental health data. Relevant measures 
and data sources are described below. 
3.3 Sociodemographic data  
Age was calculated from assessment date minus date of birth, and truncated to whole 
years. Gender, ethnic group and country of origin were self-reported via the computerised 
touchscreen interface. The Townsend deprivation index (Townsend, 1987) was calculated 
for the participant’s postcode of residence immediately prior to the baseline assessment 
date. This score combines data from census output areas (approximately 125 households 
per area in England/Wales and 50 households per area in Scotland) regarding 
unemployment, car ownership, home ownership and household overcrowding, to produce a 
standardised score, where higher values indicate greater relative deprivation. Information 
about occupation, income, household factors and car ownership was also self-reported in 
the touchscreen questionnaire. Participants were asked to report which educational 
qualifications they held (if any), from a list encompassing college/university degree, higher 
and intermediate secondary school qualifications, and vocational qualifications.  
3.4 Lifestyle and physical measures 
The touchscreen questionnaire recorded information on current and past smoking habits, 
from which variables were derived by UK Biobank to code for current, former and never 
smokers. Current frequency of alcohol consumption was recorded using categories from 
‘never’ to ‘daily/almost daily’, and those responding ‘never’ were asked about previous 
consumption. Touchscreen questions also recorded self-reported estimates of typical 
dietary intake and physical activity levels, as well as typical sleep patterns. Physical 
measures were performed by trained staff, and included blood pressure, height, waist and 
hip circumference, weight, and body mass index (BMI).  
3.5 Medical history and mental wellbeing 
Information regarding medical and psychiatric history and medications was primarily self-
reported, via touchscreen questions and an interview conducted by a trained staff member 
at baseline. Additional self-reported data regarding lifetime mental health-related 
experiences were collected several years later via an online questionnaire. Hospital 
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admissions data were available for most participants from linked NHS records. These 
sources of information are described below.  
3.5.1 Self-reported information 
3.5.1.1 Self-reported diagnoses, medications and family history 
Touchscreen questions asked about diagnoses within certain pre-specified categories, e.g. 
cardiovascular disease. All participants were later asked during the interview whether they 
had ever been told by a doctor that they had any serious illness or disability, and they were 
asked to name all current regular prescribed medications (doses and formulations were not 
recorded). Responses were recorded by the interviewer and were subsequently assigned 
unique codes. Diagnoses and medications of interest for the studies in this thesis were 
manually coded, as described in the relevant chapters. The touchscreen questionnaire also 
asked about history of specific illnesses in parents and siblings, including cancers, 
cardiovascular disease, dementia, Parkinson’s disease and severe depression. 
3.5.1.2 Baseline mental health questionnaire 
Additional self-reported information about mental health was elicited as part of the 
touchscreen questionnaire. Some of the questions were added in the final two years of the 
baseline phase, and so data are not available for all participants. Neuroticism was assessed 
using 12 yes/no items from the Eysenck Personality Questionnaire Revised short form 
(Eysenck, Eysenck, & Barrett, 1985), summed to produce a total score from 0 to 12, where 
higher scores indicate greater neuroticism. Four questions were administered regarding 
frequency of depressive symptoms in the past two weeks: depressed mood or hopelessness; 
lack of interest or pleasure; tenseness or restlessness; and tiredness or low energy. These 
were based on items from the Patient Health Questionnaire (PHQ; Kroenke, Spitzer, & 
Williams, 2001). Participants self-rated each symptom on a four-point scale from ‘not at 
all’ to ‘nearly every day’, summed to produce an overall score ranging from 0 to 12, with 
higher scores indicating more frequent depressive symptoms.  
Past experiences of depressive and manic symptoms, and medical help-seeking for mental 
health, were assessed using touchscreen questions agreed by an expert group and informed 
by the Structured Clinical Interview for DSM-IV Axis I disorders (First, Spitzer, Gibbon, 
& Williams, 2002). Responses to these items have been used to classify UK Biobank 
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participants according to probable lifetime features of mania/BD and major depression (D. 
J. Smith et al., 2013).  
3.5.1.3 Web-based mental health questionnaire 
A web-based mental health questionnaire was disseminated to all participants in 2016. This 
included a range of items taken from standardised instruments, to assess lifetime and 
current experiences relating to depression, mania, anxiety, psychotic-like phenomena, self-
harm, post-traumatic stress and substance use. The questionnaire and the results from the 
first data release (n = 157,366) are described in detail in Davis et al. (2018). This 
questionnaire also asked about adverse or traumatic experiences in adulthood and in 
childhood. The childhood items were taken from the brief Childhood Trauma 
Questionnaire (Bernstein et al., 2003). Participants were asked how frequently certain 
statements, reflecting abuse or neglect, applied to them while they were growing up 
(‘never true’ to ‘very often true’): that they felt loved; were hit resulting in bruises or 
marks; felt hated within their family; were molested sexually; and had someone to take 
them to the doctor if needed.  
3.5.2 Linked NHS records 
NHS records were obtained by UK Biobank from the Health and Social Care Information 
Centre (HSCIC) in England, the Information and Statistics Division (ISD) of NHS 
Scotland and the Secure Anonymised Information Linkage (SAIL) system in Wales, and 
were linked centrally to UK Biobank data using participant identifiers. A mixture of exact 
and probabilistic matching was used 
(http://biobank.ctsu.ox.ac.uk/~bbdatan/matching_algorithms_documentation_v1.pdf). Data 
were available from in-patient and day case admissions to NHS hospitals from the mid-
1990s onwards (dates varied by country). Records from England (Hospital Episode 
Statistics; HES) and Wales (Patient Episode Database for Wales; PEDW) included both 
acute and psychiatric hospitals. Records from Scotland were from the Scottish Morbidity 
Record - General Acute Inpatient and Day Case dataset (SMR01), which does not cover 
psychiatric hospitals.  
3.5.3 Adjudicated diagnoses 
UK Biobank analysts developed algorithms to classify likely history of certain medical 
conditions, using data from the baseline assessments (self-reported medical conditions, 
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operations and medications), linked hospital records (diagnoses and procedures) and death 
registers. These were developed by the UK Biobank Outcome Adjudication Group, with 
the aim of maximising the positive predictive value of the classification. To date, 
algorithmic classifications are available for myocardial infarction and stroke. Details of the 
algorithms can be found at http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=42. 
3.6 Cognitive assessment  
A short cognitive assessment battery was administered during assessment centre visits, as 
described below.  
3.6.1 Materials and procedure 
Brief cognitive tests were administered via touchscreen, during the first stage of the 
assessment centre visit. The tests were designed specifically for UK Biobank but share 
some characteristics with other established tests of cognitive function. Two tests were 
included in the protocol throughout the UK Biobank baseline phase (reaction time and 
visuospatial memory), two tests were introduced in the final two years of recruitment 
(reasoning and prospective memory), and one test was introduced in the final two years 
and then subsequently removed for reasons of time (numeric memory). Sample size 
therefore varies across tests. The total time to complete all five tests was approximately 15 
minutes. 
3.6.1.1 Reasoning test 
Thirteen questions were presented sequentially via touchscreen on a self-paced basis with 
an overall time limit of two minutes. Responses were selected from a multiple-choice 
array. Any questions not attempted during the two-minute time limit were scored as zero. 
The items included both verbal and numerical reasoning tasks. An example of a verbal 
item is “Bud is to flower as child is to? (Select from: Grow / Develop / Improve / Adult / 
Old / Do not know / Prefer not to answer)”, and an example of a numerical item is 
“150…137…125…114…104… What comes next? (Select from: 96 / 95 / 94 / 93 / 92 / Do 
not know / Prefer not to answer)”. The score for analysis was an unweighted total ranging 
from 0 to 13, with higher scores indicating better performance.  
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3.6.1.2 Reaction time test 
Participants were asked to press a button with their dominant hand as quickly as possible 
each time a matching pair of symbols was presented on the computer screen. This type of 
‘Go/No-Go’ reaction time paradigm was described by Donders (1868/1969), cited in 
Gomez, Ratcliff, and Perea (2007). Five practice trials were administered, followed by 
seven test trials. An example of a non-matching trial is shown in Figure 3.3. The score for 
analysis was the mean time (in milliseconds) taken to press the button, derived from the 
four trials on which a matching pair occurred. Higher scores indicate slower (i.e. worse) 
performance. 
  
Figure 3.3 - Reaction time test in UK Biobank 
 
The touchscreen and response button are shown in the left panel. The right panel shows a 
screenshot of a non-matching trial. Images taken from the UK Biobank manual v1.1, dated 
19th March 2013. 
 
3.6.1.3 Numeric memory test 
A string of numbers was presented on-screen and, after a brief delay, participants were 
asked to enter it from memory, in reverse order, via a touchscreen numeric keypad (see 
Figure 3.4). Each string was presented on the screen for 2000ms, plus an additional 500ms 
multiplied by the string length. A delay of 3000ms occurred between clearing the screen 
and activating the response keypad. All participants began with a string length of two, and 
successive strings increased by one, up to a maximum string length of 12. The test was 
discontinued after five successive incorrect responses at a string length of two, or after two 
successive incorrect responses at string lengths of three or more. The score for analysis 
was the maximum string length recalled correctly, with higher scores indicating better 
performance. 
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Figure 3.4 - Numeric memory test in UK Biobank 
 
Screenshot of the first trial of the numeric memory test. The touchscreen keypad activated 
after the number was cleared from the screen. Image taken from 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=10 
 
3.6.1.4 Visuospatial memory test 
In the ‘pairs matching’ test, symbol cards were presented on-screen in a random array. 
Participants were asked to memorise the position of as many matching pairs as possible. 
The cards were then turned face down on the screen and participants were asked to touch 
as many matching pairs as possible in the fewest tries (see Figure 3.5). Two trials of this 
task were administered, one with three pairs of symbols and one with six pairs; the 
presentation times for memorisation were 3000ms and 5000ms seconds respectively. No 
time limit was applied during the recall phase. The score for analysis was the number of 
errors made while attempting to select the pairs, with a higher score indicating worse 
performance.  
  
Figure 3.5 - Visuospatial memory (‘pairs matching’) test in UK Biobank 
 
The left panel shows a three-pair array during the memorisation phase. The right panel 
shows the cards face down, ready for the participant to respond. Images taken from the UK 
Biobank manual v1.2, dated 17th December 2013. 
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3.6.1.5 Prospective memory test 
The following instruction appeared on the touchscreen: “At the end of the games we will 
show you four coloured symbols and ask you to touch the blue square. However, to test 
your memory, we want you to actually touch the orange circle instead”. After a delay 
during which participants completed the other cognitive tasks described above, a screen 
appeared showing four coloured shapes with the instruction to touch the blue square 
(Figure 3.6). If the participant touched the orange circle, their response was recorded as 
‘correct on first attempt’. If they touched the blue square, they were given a prompt on-
screen to try to recall what the original instruction was, and were asked to respond again. If 
they correctly selected the orange circle after receiving this prompt, their response was 
recorded as ‘correct on second attempt’. All other responses (including no response) were 
recorded on the system as incorrect.  
  
Figure 3.6 - Prospective memory test in UK Biobank 
 
The left panel shows the instruction screen, and the right panel shows the response screen 
presented after a filled delay. Images taken from UK Biobank manual v1.1, dated 28th 
February 2012. 
 
3.6.2 Psychometric characteristics 
The cognitive tests were developed specifically by UK Biobank to be brief and feasible for 
self-administration at scale using a touchscreen. Pilot testing for feasibility purposes was 
conducted before the main baseline phase commenced, which resulted in some original 
tasks being removed and others being shortened. UK Biobank did not publish information 
about the psychometric properties of the pilot or main phase tests, but the data that are 
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available to researchers from the pilot, baseline and repeat assessment visits enable some 
limited examination of score stability and covariance structure. 
3.6.2.1 Validity 
Although the UK Biobank cognitive tests share some face validity with existing tests of 
cognitive function, there are some points of difference worth noting. The reasoning test is 
referred to in all UK Biobank documentation as a ‘fluid intelligence’ test, but performance 
does not appear to decline with age as would be expected on a fluid ability task, and it is 
likely that successful performance on some of the items would be influenced by 
crystallised abilities (Hagenaars et al., 2016). For this reason, it is referred to simply as a 
reasoning test throughout this thesis. In the numeric memory test, the digit strings were 
presented on-screen in their entirety, rather than one digit at a time. This means that the 
apparent demand of recalling the string in reverse order will have been lessened if 
participants chose to read the numbers in reverse when they were first presented, thus 
turning the task into a forward rather than reverse span test. The ‘pairs matching’ test of 
visuospatial memory differed from existing computerised visual paired associate learning 
tests (such as the CANTAB Paired Associate Learning test; 
www.cambridgecognition.com) by presenting the full array of symbol pairs on screen 
simultaneously, rather than a series of individual symbols whose spatial location must be 
memorised and recalled. The prospective memory test required memorisation and 
execution of an instruction after a filled delay, in common with other tests of this type, but 
it also required the participant to inhibit a competing response (to touch the blue square). 
These idiosyncrasies in the bespoke UK Biobank cognitive tests must be considered when 
interpreting patterns of performance observed in the data.  
The validity of the tests can also be considered in terms of their covariance structure, 
which indicates to what extent they are measuring shared or unique underlying abilities. 
Lyall and colleagues (2016) reported a principal components analysis of the reasoning, 
reaction time, numeric memory and visuospatial memory scores, whose first unrotated 
principal component accounted for 39.9% of the variance. When only reasoning, reaction 
time and visuospatial memory were included, the first component accounted for 44.4% of 
the variance. All individual tests had moderate to high loadings on the first unrotated 
principal component in each model (loadings ranged from |0.49| to |0.77| in the four-test 
model). The overall results indicated a one-factor solution, but the magnitude of variance 
explained was lower than that reported in other cohorts with more detailed cognitive 
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assessments, e.g. approximately 50% in the Lothian Birth Cohort-1936 (Lyall et al., 2013). 
It would therefore be informative to analyse the UK Biobank cognitive tasks separately as 
well as, or instead of, constructing a composite score or using the observed data to estimate 
a latent general factor of cognitive function.  
3.6.2.2 Reliability 
Lyall and colleagues (2016) reported that test-retest reliability between the UK Biobank 
baseline and the first repeat visit (mean interval = 4.33 years, SD = 0.93), excluding 
participants with diseases affecting brain function at baseline, varied across tests. Intraclass 
correlation (ICC) coefficients were 0.65 for reasoning, 0.57 for reaction time and 0.16 for 
visuospatial memory (numeric memory was not administered at the repeat visit), and 
Cohen’s kappa for prospective memory was 0.36, with 97.9% of participants scoring 
correctly at both time points. Additional data were available from the pilot phase of UK 
Biobank for the visuospatial memory test, when participants were administered a six-pair 
trial twice in immediate succession: the ICC was again low at 0.17.  
Internal consistency can be examined for tests containing multiple items or multiple trials. 
In UK Biobank, only the reasoning and reaction time tests could be examined in this way. 
Hagenaars and colleagues (2016) reported Cronbach’s alpha coefficients in a subsample of 
the cohort who were included in a genetic analysis. Alpha was 0.85 for the four ‘Go’ trials 
on the reaction time test. Although this is considered acceptable (Streiner, 2003), other 
computerised reaction time tests such as the Deary-Liewald task (Deary et al., 2011) have 
yielded alpha coefficients >0.90 across greater numbers of trials (20 trials for simple 
reaction time and 40 for four-choice reaction time). Cronbach’s alpha was 0.62 for the 13 
items on the UK Biobank reasoning test (Hagenaars et al., 2016), which is lower than 
values reported (range 0.87 to 0.98) for subtests of a ‘gold standard’ intelligence test, the 
Wechsler Adult Intelligence Scale Fourth Edition (Wechsler, 2010). Cronbach’s alpha 
coefficients for reasoning and reaction time tests in cohort subgroups analysed in the 
present thesis are reported in the relevant chapters.  
Test reliability has important implications for both bias and power in statistical analyses. 
Random measurement error in independent variables causes bias towards the null in 
regression slope estimates (Hutcheon, Chiolero, & Hanley, 2010). Random measurement 
error in the dependent variable does not bias the slope estimate, but does increase its 
standard error. This latter problem can be addressed by using larger study samples. 
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Increasing the sample size does not mitigate the problem of bias arising from unreliably-
measured independent variables, instead simply producing slope estimates that are more 
precisely wrong (Hutcheon et al., 2010). In the studies reported in this thesis, the cognitive 
test scores were the dependent variables in all the analyses.  
3.7 Genetic data 
Participants provided a blood sample at the baseline assessment, and genotyping was 
carried out centrally by UK Biobank. An interim genotypic dataset covering approximately 
150,000 participants was made available to researchers in mid-2015, and the full cohort 
dataset was released in mid-2017.  
3.7.1 Genotyping procedure 
Full details of the genotyping, imputation and quality control processes used by UK 
Biobank are publicly available at http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100314 
and in Bycroft et al. (2017). Direct genotyping was performed using two custom 
Affymetrix arrays: approximately 50,000 participants were genotyped on the UK BiLEVE 
Axiom array, which was designed for the BiLEVE study of lung function (a partner study 
of UK Biobank), and the remainder were genotyped using the UK Biobank Axiom array. 
The two arrays are very similar, with over 95% common marker content. The arrays 
included more than 800,000 single nucleotide polymorphisms (SNP), chosen because of 
known or likely associations with a wide range of diseases and health-related phenotypes, 
as well as to provide good genome-wide coverage for imputation purposes in European 
populations across common (>5%) and low (1-5%) minor allele frequency (MAF) ranges. 
Each SNP marker encodes variation in the population at a single base pair locus in the 
DNA sequence, and the MAF value indicates the proportion of the population carrying the 
second most common of the possible alleles at that SNP location.  
The directly genotyped data were imputed by UK Biobank to reference panels from the 
Haplotype Reference Consortium (http://www.haplotype-reference-consortium.org/site) 
and the UK10K project and the 1000 Genomes Project (Phase 3)3. Imputation allows 
unobserved genotypes to be inferred on the basis of known clusters of genotypes in the 
population: a set of SNPs inherited together is termed a haplotype, and observed data from 
                                                 
3 Only the Haplotype Reference Consortium imputed data were available at the time the studies in 
this thesis were conducted, due to quality control problems with the UK10K and 1000 Genomes 
imputations.  
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a subset of that haplotype can be mapped to a population reference panel to reconstruct the 
genotype of the unobserved alleles.  
A dataset including approximately 40 million markers was made available to researchers. 
The quality of imputation at each SNP was indicated in the form of an information score 
between 0 and 1, where 1 indicates that there is no uncertainty in the imputed genotype and 
0 means that there is complete uncertainty. Data were provided regarding pair-wise 
relatedness of individuals within the cohort, mismatch between reported and genetic sex, 
and probable white British genetic ancestry. Principal components analysis was conducted 
by UK Biobank to identify ancestral population structure within the cohort (Price et al., 
2006); spurious associations arising from population stratification may occur if study 
samples include groups of individuals who differ systematically in both genetic ancestry 
and the phenotype of interest (Turner et al., 2011). Data were also provided regarding the 
MAF of each SNP, and Hardy-Weinberg test results; significant deviations from Hardy-
Weinberg equilibrium—the expected ratios of homozygous and heterozygous genotypes in 
the population—may indicate genotyping errors or population structure effects (Turner et 
al., 2011). These additional variables can be used to exclude SNPs or individual 
participants from analysis, or to adjust analyses for confounding due to population 
stratification.  
3.7.2 Polygenic scores 
For the studies in this thesis, the genotypic data were used to construct polygenic scores 
derived from previous genome-wide association studies (GWAS) of phenotypes of interest. 
A polygenic approach was used because psychological and cognitive traits are likely to be 
explained at the population level by multiple genetic variants, each exerting small effects. 
This approach is also well suited to the genotypic data available in UK Biobank, which 
comprise a very large number of SNPs across the genome, thus providing rich information 
for use in dimensional scores. 
The polygenic scoring method was developed in recent years as it became clear from 
GWAS of complex traits that groups of markers, which individually did not reach a 
genome-wide statistical significance threshold, could collectively explain a meaningful 
proportion of phenotypic variation (Dudbridge, 2013). There are several ways of 
constructing polygenic scores. In their simplest form, genotypes across a small set of SNPs 
identified via previous research as being of interest can be summed to create an aggregate 
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score, which may be weighted by the strength of their association with the target 
phenotype (Plomin & Simpson, 2013). Increasingly, however, researchers are making use 
of GWAS results to construct genome-wide polygenic scores (GPS), which use 
information from all available SNPs, thresholded at various statistical significance levels. 
Using this method, summary statistics (directional effect sizes and p values) for every 
marker included in a GWAS of a given phenotype, regardless of whether they achieved 
genome-wide statistical significance, are used to create a weighted polygenic score in an 
independent sample (Dudbridge, 2013). The use of GPS is becoming increasingly common 
in mental health and cognitive research (Plomin & Deary, 2015; Wray et al., 2014), where 
the phenotypes of interest are assumed to have a polygenic architecture. Polygenic scoring 
has also been used to investigate pleiotropy, whereby a given polygenic profile score may 
be associated with multiple phenotypes (Hagenaars et al., 2016). 
It has been pointed out that additive polygenicity is not the only possible explanation for 
the findings of GWAS and polygenic scoring analyses of complex phenotypes (K. J. 
Mitchell, 2012), and that the influence of diverse rare variants (which are not generally 
captured by SNP-based GWAS methods) with large effects is likely to be important at the 
extreme ends of the distribution of cognitive ability in the population (Le Hellard & Steen, 
2014). Nevertheless, polygenic scores based on common SNPs remain a useful way to 
measure background population variation in large studies, and are employed in this thesis 
for that reason. GPS were calculated using a bespoke script for R (https://www.r-
project.org/) and PLINK (https://www.cog-genomics.org/plink2) software. Details of the 
summary statistics and scoring specifications employed are provided in the relevant 
chapters.  
3.8 Summary 
UK Biobank is a rich resource containing genetic, environmental, sociodemographic, 
lifestyle, medical and cognitive data for over half a million adults in Britain. It provides 
valuable opportunities to investigate the prevalence of cognitive impairment and variation 
in cognitive performance in groups with a history of psychiatric or neurological conditions, 
taking into account potential confounders measured in a standard way. The assessment 
visit process necessitated by the very large scale of the cohort means that some baseline 
measures, including the cognitive assessments, were briefer and hence less reliable than 
those typically used in smaller clinic-based studies. Factors that may have influenced the 
likelihood of responding to the study invitation must be considered, especially where these 
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relate to the exposures and outcomes under study, and similar considerations are important 
when making assumptions about missing data mechanisms. These benefits and limitations 
of the UK Biobank data resource were taken into account when planning, analysing and 
interpreting the studies reported in subsequent chapters.  
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Chapter 4 Identifying psychiatric and 
neurological groups in UK Biobank 
This chapter describes the process of identifying exposure groups of interest in UK 
Biobank. Multiple information sources were used to identify participants with a pre-
baseline history of mood disorder, schizophrenia, MS or PD, and those with no psychiatric 
or neurological history. The characteristics of the groups identified using the different 
information sources were compared, in order to inform decisions regarding which exposure 
group definitions would be used in subsequent studies. 
4.1 Information sources 
Three information sources were available, each with different levels of coverage of the 
cohort: self-reported diagnoses, linked NHS records and a touchscreen mood 
questionnaire. The web-based mental health questionnaire administered in 2016 was not 
used to ascertain the exposure groups, because this post-dated the cognitive assessment 
which was the outcome under study in this thesis. The current depressive symptom score 
(from the PHQ items) and data regarding current medications did not contribute to any of 
the exposure group classifications. 
4.1.1 Self-reported diagnoses 
All participants were asked to report lifetime history of medical or psychiatric diagnoses 
made by a doctor, using touchscreen questions supplemented by a staff interview. 
Responses were coded into categories by UK Biobank analysts. This information source 
covered the whole cohort, and contributed to the ascertainment of all the exposures of 
interest. 
4.1.2 Linked NHS records 
Medical history was available from hospital records, retrieved by UK Biobank from NHS 
data providers across the UK and linked centrally to UK Biobank data using participant 
identifiers. Records covered hospital admissions (in-patient and day case only) starting in 
the mid-1990s (dates varied by country). The data analysed were ICD-10 diagnostic codes 
from any position in the record. Only data prior to the UK Biobank assessment date were 
used, to identify past diagnoses. Hospital records from England and Wales included both 
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acute and psychiatric hospitals, but records from Scotland covered acute hospitals only, at 
the time the present research was conducted. Participants in Scotland (7.1% of the whole 
cohort) were therefore coded as ‘missing’ when ascertaining the psychiatric exposures 
using this information source, but they contributed data when ascertaining the MS and PD 
exposures. Linked NHS records were sought by UK Biobank for the full cohort; 
participants with no linked hospital record are assumed to have had no in-patient or day 
case admission during the available period.  
4.1.3 Touchscreen mood questionnaire 
The touchscreen mood questionnaire4 covering lifetime history of mood symptoms and 
medical help-seeking for mental health was described in Chapter 3. This was added to the 
assessment schedule in the last two years of baseline recruitment, and data are therefore 
only available for participants assessed in that period (approximately one-third of the 
cohort). The questions covered depression and mania symptoms only, and so these data 
contributed to the ascertainment of the mood disorder exposures but not schizophrenia, MS 
or PD.  
4.2 Ascertaining exposures of interest 
Table 4.1 shows which exposures of interest were potentially ascertainable from the three 
information sources. 
Table 4.1 - Information sources for each exposure 
 
 Mania/ 
bipolar 
Major depression Schizophrenia Multiple 
sclerosis 
Parkinson’s 
disease 
  Any 
depression 
Severe 
recurrent 
Mild-moderate 
recurrent 
Single 
episode 
   
Self-reported 
diagnoses 
 
All 
 
All 
 
 
 
 
 
 
 
All 
 
All 
 
All 
NHS hospital 
records 
 
England  
& Wales 
 
England  
& Wales 
 
England  
& Wales 
 
England  
& Wales 
 
England  
& Wales 
 
England  
& Wales 
 
All 
 
All 
Touchscreen 
mood 
questionnaire 
 
Last 2 
years 
 
Last 2  
years 
 
Last 2 
years 
 
Last 2  
years 
 
Last 2  
years 
   
 
                                                 
4 For the remainder of this thesis, ‘touchscreen mood questionnaire’ refers to the questions about 
lifetime mood disorder symptoms only; the four PHQ questions are referred to separately as the 
‘current depressive symptom score’. 
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Each exposure group, and a comparison group with none of the exposures, were 
ascertained as described below. Participants who did not meet the criteria for any of the 
exposed or unexposed groups were not further considered. 
4.2.1 Mood disorders 
The mood disorder exposures (mania/BD and major depression) were classified 
hierarchically into mutually exclusive groups within each information source. Using the 
self-reported diagnosis data, the hierarchy order was: mania/BD (‘mania/bipolar/manic 
depression’); any depression (‘depression’ or ‘post-natal depression’). Using the hospital 
ICD-10 codes, the order was: mania/BD (F30x or F31x); severe recurrent major depression 
(F33.2 or F33.3); mild-moderate recurrent major depression (all other F33 codes); single 
episode of major depression (F32x). Using the touchscreen mood questionnaire data, the 
hierarchy was as described by D. J. Smith et al. (2013): mania/BD (BD-I and BD-II 
combined); severe recurrent major depression; mild-moderate recurrent major depression; 
single episode of major depression (see Appendix O for information about the item 
responses contributing to these classifications). To permit comparison between the self-
reported diagnosis classification and the other two information sources, all categories of 
major depression derived from the ICD-10 codes and the touchscreen mood questionnaire 
were also combined into an overall ‘any depression’ category. Owing to the limited detail 
in the self-reported diagnosis data and the touchscreen mood questionnaire with regard to 
bipolar features, no distinction was made between single manic episode, bipolar disorder 
type I and bipolar disorder type II; the term ‘mania/BD’ is therefore used throughout.  
4.2.2 Schizophrenia 
Participants were classified by self-report of ‘schizophrenia’ and by hospital ICD-10 codes 
in the F20x category. The touchscreen mood questionnaire did not cover data relevant to 
this exposure.  
4.2.3 Multiple sclerosis 
Participants were classified by self-report of ‘multiple sclerosis’ and by hospital ICD-10 
code G35.  
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4.2.4 Parkinson’s disease 
Participants were classified by self-report of ‘Parkinson’s disease’ and by hospital ICD-10 
code G20. 
4.2.5 Unexposed comparison group 
A single comparison group was constructed as a common reference for all of the exposure 
groups. Participants in this group were considered to be unexposed with regard to the 
conditions of interest, as well as any other psychiatric condition or any condition affecting 
brain function. This group met all of the following criteria: provided data on the 
touchscreen mood questionnaire and were not classified in the mania/BD or major 
depression groups; no hospital ICD-10 code of any psychiatric or brain condition (as listed 
in Appendix P); no self-reported diagnosis of any psychiatric or brain condition (as listed 
in Appendix Q). Two versions of this group were constructed, ‘broad’ and ‘narrow’. Using 
the broad definition, sub-threshold mood symptoms were permitted on the touchscreen 
mood questionnaire; using the narrow definition, such symptoms were not permitted. 
Medical conditions other than those listed in the appendices were not excluded.  
4.3 Comparison of group characteristics by each 
ascertainment method 
Sociodemographic, lifestyle, medication and psychological measures were summarised and 
compared descriptively within each exposure group, by information source. Details of the 
medications coded in each class (psychotropics; MS disease modifying treatments; 
medications used in PD) are given in Appendix R. Exposed participants were also grouped 
into two further categories, representing ‘broad’ and ‘narrow’ exposure classifications. The 
broad classification required participants to have met the exposure criteria by at least one 
information source, and the narrow classification required them to have met the exposure 
criteria by at least two information sources.  
The mania/BD and major depression exposure groups were mutually exclusive within each 
information source, but participant overlap was otherwise possible between the various 
exposed groups. Within each exposed group, no exclusions were applied regarding other 
psychiatric, neurological or medical comorbidities. No statistical tests were conducted for 
the data in the tables that follow, because of the potential participant overlap across 
information sources and definitions.  
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4.3.1 Mood disorders 
4.3.1.1 Mania/BD 
Table 4.2 shows the characteristics of the mania/BD exposure group as identified by each 
information source, and grouped by broad and narrow definitions. The most striking 
difference was in the use of psychotropic medication, which was much less common in the 
group identified via the touchscreen mood questionnaire.  
4.3.1.2 Major depression 
Table 4.3 shows the characteristics of the ‘any depression’ group, by ascertainment source 
and broad versus narrow definitions. This indicates that participants identified through 
hospital records were more likely to live in areas of greater deprivation, were less likely to 
have a degree, and were more likely to be current smokers and former alcohol drinkers. 
Participants identified through the touchscreen mood questionnaire were much less likely 
to be on psychotropic medication, and had lower neuroticism and current depressive 
symptom scores. Additional tables for the severe recurrent, mild-moderate recurrent and 
single episode depression groups are given in Appendix S.  
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Table 4.2 - Mania/bipolar disorder group characteristics 
 
 Information source Definition 
 Self-reported 
diagnosis 
NHS hospital 
records 
Touchscreen 
mood 
questionnaire 
Broad Narrow 
n  1,412 688 1,615 3,020 607 
Age, M (SD) 55.4 (7.9) 54.8 (8.0) 54.5 (8.1) 54.9 (8.0) 54.8 (8.0) 
Female, n (%)a 788 (55.8) 412 (59.9) 790 (48.9) 1,589 (52.6) 345 (56.8) 
Ethnic group, n (%)a 
White  
Asian/Asian British 
Black/black British 
Other 
 
1,333 (95.1) 
18 (1.3) 
22 (1.6) 
29 (2.1) 
 
619 (91.6) 
6 (0.9) 
23 (3.4) 
28 (4.1) 
 
1,422 (88.8) 
66 (4.1) 
53 (3.3) 
61 (3.8) 
 
2,727 (91.2) 
84 (2.8) 
84 (2.8) 
94 (3.1) 
 
563 (93.4) 
6 (1.0) 
13 (2.2) 
21 (3.5) 
Townsend quintileb, n (%)a 
Qu1 (least deprived)  
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
179 (12.7) 
189 (13.4) 
233 (16.5) 
300 (21.3) 
509 (36.1) 
 
82 (11.9) 
90 (13.1) 
101 (14.7) 
128 (18.6) 
286 (41.6) 
 
174 (10.8) 
209 (13.0) 
269 (16.7) 
402 (24.9) 
560 (34.7) 
 
356 (11.8) 
405 (13.4) 
492 (16.3) 
676 (22.4) 
1,088 (36.1) 
 
71 (11.7) 
78 (12.9) 
99 (16.3) 
133 (22.0) 
225 (37.1) 
Has a degree, n (%)a 585 (41.9) 237 (35.4) 578 (36.0) 1,117 (37.5) 250 (41.5) 
Smoking status, n (%)a 
Never  
Former 
Current 
 
612 (43.6) 
468 (33.4) 
323 (23.0) 
 
287 (42.6) 
204 (30.3) 
183 (27.2) 
 
683 (42.5) 
577 (35.9) 
347 (21.6) 
 
1,281 (42.8) 
1,024 (34.2) 
689 (23.0) 
 
262 (43.5) 
196 (32.6) 
144 (23.9) 
Alcohol frequency, n (%)a 
Daily/almost daily  
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
256 (18.2) 
236 (16.8) 
279 (19.9) 
161 (11.5) 
235 (16.7) 
162 (11.5) 
75 (5.3) 
 
86 (12.8) 
97 (14.4) 
151 (22.4) 
78 (11.6) 
113 (16.8) 
91 (13.5) 
58 (8.6) 
 
326 (20.3) 
267 (16.6) 
353 (21.9) 
201 (12.5) 
244 (15.2) 
129 (8.0) 
90 (5.6) 
 
561 (18.7) 
492 (16.4) 
641 (21.4) 
355 (11.8) 
473 (15.8) 
296 (9.9) 
180 (6.0) 
 
99 (16.4) 
92 (15.3) 
126 (20.9) 
75 (12.4) 
99 (16.4) 
74 (12.3) 
38 (6.3) 
Any psychotropic  
medication, n (%)a 
 
1,212 (86.3) 
 
562 (82.9) 
 
514 (32.3) 
 
1,663 (55.8) 
 
542 (89.7) 
Lithium, n (%)a 458 (33.5) 190 (28.6) 86 (5.4) 501 (17.1) 209 (35.3) 
Other mood stabiliser, n (%)a 451 (32.7) 266 (39.8) 130 (8.2) 531 (18.0) 267 (44.7) 
SSRI antidepressant, n (%)a 322 (23.5) 98 (14.7) 203 (12.8) 508 (17.3) 102 (17.2) 
Other antidepressant, n (%)a 270 (19.8) 146 (22.0) 165 (10.4) 428 (14.6) 128 (21.7) 
Traditional antipsychotics,  
n (%)a 
 
101 (7.4) 
 
48 (7.3) 
 
27 (1.7) 
 
131 (4.5) 
 
39 (6.6) 
Second generation  
antipsychotics, n (%)a 
 
387 (28.2) 
 
225 (33.7) 
 
100 (6.3) 
 
470 (16.0) 
 
205 (34.5) 
Neuroticism score, M (SD) 7.3 (3.6) 6.8 (3.7) 6.6 (3.6) 6.8 (3.6) 7.1 (3.6) 
Current depressive symptom  
score, M (SD) 
 
3.6 (3.3) 
 
3.4 (3.3) 
 
3.6 (3.2) 
 
3.6 (3.3) 
 
3.4 (3.2) 
M, mean; Qu, quintile; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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Table 4.3 - 'Any depression' group characteristics 
 
 Information source Definition 
 Self-reported 
diagnosis 
NHS hospital 
records 
Touchscreen 
mood 
questionnaire 
Broad Narrow 
n  28,366 4,279 31,844 56,425 7,583 
Age, M (SD) 55.4 (7.8) 55.6 (8.0) 55.7 (8.0) 55.6 (7.9) 55.1 (7.9) 
Female, n (%)a 18,744 (66.1) 2,520 (58.9) 20,510 (64.4) 36,574 (64.8) 4,923 (64.9) 
Ethnic group, n (%)a 
White  
Asian/Asian British 
Black/black British 
Other 
 
27,125 (96.2) 
376 (1.3) 
240 (0.9) 
467 (1.7) 
 
4,021 (94.7) 
80 (1.9) 
58 (1.4) 
87 (2.1) 
 
29,981 (94.5) 
586 (1.9) 
542 (1.7) 
624 (2.0) 
 
53,515 (95.3) 
887 (1.6) 
718 (1.3) 
1,026 (1.8) 
 
7,171 (94.8) 
144 (1.9) 
108 (1.4) 
140 (1.9) 
Townsend quintileb, n (%)a  
Qu1 (least deprived)  
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
4,571 (16.1) 
4,942 (17.5) 
5,229 (18.5) 
5,882 (20.8) 
7,692 (27.2) 
 
475 (11.1) 
596 (14.0) 
643 (15.1) 
910 (21.3) 
1,648 (38.6) 
 
4,896 (15.4) 
5,911 (18.6) 
6,440 (20.3) 
7,357 (23.2) 
7,175 (22.6) 
 
8,872 (15.8) 
10,071 (17.9) 
10,836 (19.2) 
12,380 (22.0) 
14,165 (25.2) 
 
1,015 (13.4) 
1,304 (17.2) 
1,388 (18.4) 
1,663 (22.0) 
2,194 (29.0) 
Has a degree, n (%)a 8,431 (30.1) 928 (22.3) 11,308 (35.7) 18,188 (32.6) 2,344 (31.2) 
Smoking status, n (%)a 
Never  
Former 
Current 
 
13,652 (48.4) 
9,788 (34.7) 
4,780 (16.9) 
 
1,811 (42.7) 
1,384 (32.6) 
1,047 (24.7) 
 
15,975 (50.3) 
11,721 (36.9) 
4,074 (12.8) 
 
27,577 (49.1) 
20,210 (36.0) 
8,402 (15.0) 
 
3,611 (47.8) 
2,559 (33.8) 
1,392 (18.4) 
Alcohol frequency, n (%)a 
Daily/almost daily  
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
5,270 (18.7) 
5,066 (17.9) 
6,295 (22.3) 
3,493 (12.4) 
4,459 (15.8) 
2,172 (7.7) 
1,488 (5.3) 
 
687 (16.2) 
571 (13.5) 
862 (20.4) 
482 (11.4) 
773 (18.3) 
569 (13.4) 
291 (6.9) 
 
6,285 (19.8) 
6,726 (21.1) 
7,660 (24.1) 
4,057 (12.8) 
4,220 (13.3) 
1,631 (5.1) 
1,242 (3.9) 
 
10,801 (19.2) 
11,020 (19.6) 
13,097 (23.3) 
7,031 (12.5) 
8,153 (14.5) 
3,609 (6.4) 
2,557 (4.5) 
 
1,361 (18.0) 
1,281 (17.0) 
1,634 (21.6) 
938 (12.4) 
1,207 (16.0) 
699 (9.3) 
435 (5.8) 
Any psychotropic  
medication, n (%)a 
 
20,062 (72.0) 
 
2,663 (63.4) 
 
6,502 (20.7) 
 
23,280 (42.0) 
 
5,530 (73.5) 
Lithium, n (%)a 290 (1.1) 116 (2.9) 100 (0.3) 373 (0.7) 117 (1.6) 
Other mood stabiliser,  
n (%)a 
 
460 (1.7) 
 
234 (5.7) 
 
305 (1.0) 
 
768 (1.4) 
 
196 (2.7) 
SSRI antidepressant, n (%)a 14,211 (51.5) 1,423 (34.4) 3,919 (12.5) 15,529 (28.2) 3,792 (50.8) 
Other antidepressant, n (%)a 5,879 (21.6) 1,098 (26.7) 2,177 (7.0) 7,239 (13.2) 1,737 (23.5) 
Neuroticism score, M (SD) 7.5 (3.2) 7.5 (3.3) 5.7 (3.3) 6.4 (3.4) 7.4 (3.2) 
Current depressive  
symptom score, M (SD) 
 
4.0 (3.2) 
 
4.5 (3.5) 
 
2.4 (2.6) 
 
3.1 (3.0) 
 
4.0 (3.4) 
M, mean; Qu, quintile; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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4.3.2 Schizophrenia 
Table 4.4 shows that the schizophrenia group characteristics were similar regardless of 
ascertainment source. Some differences were evident in the proportions taking 
psychotropic medication, which were slightly higher in the group ascertained via self-
reported diagnosis. The proportion with black or black British ethnicity was higher in the 
group ascertained through hospital records.  
4.3.3 Multiple sclerosis 
Table 4.5 shows the characteristics of the MS groups. Differences were seen in deprivation 
and education measures only, with the group ascertained via hospital records being 
somewhat more likely to live in areas of greater deprivation and less likely to have a 
degree.  
4.3.4 Parkinson’s disease 
Similar to the MS groups, Table 4.6 shows that participants with PD ascertained via 
hospital records were somewhat more likely to live in areas of greater deprivation and less 
likely to have a degree. 
4.3.5 Unexposed comparison group 
Table 4.7 indicates that the characteristics of the unexposed comparison group were 
virtually identical regardless of whether the broad (subthreshold mood symptoms 
permitted) or narrow (no subthreshold symptoms) definitions were used.  
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Table 4.4 - Schizophrenia group characteristics 
 
 Information source Definition 
 Self-reported 
diagnosis 
NHS hospital 
records 
Broad Narrow 
n  619 490 850 259 
Age, M (SD) 53.8 (8.1) 53.4 (8.1) 53.9 (8.1) 52.6 (8.2) 
Female, n (%)a 201 (32.5) 166 (33.9) 293 (34.5) 74 (28.6) 
Ethnic group, n (%)a 
White  
Asian/Asian British 
Black/black British 
Other 
 
537 (88.3) 
16 (2.6) 
29 (4.8) 
26 (4.3) 
 
403 (84.7) 
16 (3.4) 
37 (7.8) 
20 (4.2) 
 
719 (86.7) 
24 (2.9) 
49 (5.9) 
37 (4.5) 
  
221 (86.7) 
8 (3.1) 
17 (6.7) 
9 (3.5) 
Townsend quintileb, n (%)a  
Qu1 (least deprived)  
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
24 (3.9) 
32 (5.2) 
49 (8.0) 
120 (19.5) 
391 (63.5) 
 
17 (3.5) 
27 (5.5) 
45 (9.2) 
89 (18.2) 
311 (63.6) 
 
33 (3.9) 
48 (5.7) 
75 (8.9) 
165 (19.5) 
526 (62.1) 
 
8 (3.1) 
11 (4.3) 
19 (7.4) 
44 (17.1) 
176 (68.2) 
Has a degree, n (%)a 158 (26.4) 116 (24.7) 212 (25.9) 65 (25.3) 
Smoking status, n (%)a 
Never  
Former 
Current 
 
223 (36.4) 
173 (28.2) 
217 (35.4) 
 
165 (34.7) 
138 (29.0) 
173 (36.3) 
 
299 (35.9) 
237 (28.4) 
298 (35.7) 
 
89 (34.9) 
74 (29.0) 
92 (36.1) 
Alcohol frequency, n (%)a 
Daily/almost daily  
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
96 (15.6) 
63 (10.3) 
120 (19.5) 
54 (8.8) 
122 (19.9) 
103 (16.8) 
56 (9.1) 
 
63 (13.1) 
45 (9.4) 
94 (19.6) 
47 (9.8) 
86 (17.9) 
94 (19.6) 
51 (10.6) 
 
125 (14.9) 
84 (10.0) 
161 (19.2) 
79 (9.4) 
157 (18.8) 
151 (18.0) 
80 (9.6) 
 
34 (13.2) 
24 (9.3) 
53 (20.6) 
22 (8.6) 
51 (19.8) 
46 (17.9) 
27 (10.5) 
Any psychotropic medication,  
n (%)a 
 
528 (87.9) 
 
391 (81.8) 
 
688 (83.2) 
 
231 (91.7) 
Traditional antipsychotics, n (%)a 153 (26.4) 83 (18.2) 174 (21.9) 62 (25.6) 
Second generation antipsychotics,  
n (%)a 
 
346 (58.7) 
 
262 (56.1) 
 
439 (54.4) 
 
169 (67.9) 
Neuroticism score, M (SD) 6.8 (3.6) 6.9 (3.6) 6.8 (3.6) 6.9 (3.5) 
Current depressive symptom score,  
M (SD) 
 
3.5 (3.1) 
 
3.9 (3.4) 
 
3.7 (3.3) 
 
3.9 (3.3) 
M, mean; Qu, quintile; SD, standard deviation. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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Table 4.5 - Multiple sclerosis group characteristics 
 
 Information source Definition 
 Self-reported 
diagnosis 
NHS hospital 
records 
Broad Narrow 
n  1,777 1,059 1,905 931 
Age, M (SD) 55.3 (7.5) 55.3 (7.5) 55.4 (7.5) 55.3 (7.5) 
Female, n (%)a 1,300 (73.2) 765 (72.2) 1,400 (73.5) 665 (71.4) 
Ethnic group, n (%)a 
White  
Asian/Asian British 
Black/black British 
Other 
 
1,734 (98.2) 
5 (0.3) 
9 (0.5) 
18 (1.0) 
 
1,024 (97.4) 
4 (0.4) 
7 (0.7) 
16 (1.5) 
 
1,859 (98.2) 
5 (0.3) 
11 (0.6) 
19 (1.0) 
 
899 (97.4) 
4 (0.4) 
5 (0.5) 
15 (1.6) 
Townsend quintileb, n (%)a  
Qu1 (least deprived)  
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
353 (19.9) 
366 (20.6) 
370 (20.9) 
349 (19.7) 
335 (18.9) 
 
210 (19.9) 
189 (17.9) 
209 (19.8) 
211 (20.0) 
238 (22.5) 
 
382 (20.1) 
382 (20.1) 
389 (20.5) 
373 (19.6) 
375 (19.7) 
 
181 (19.5) 
173 (18.6) 
190 (20.5) 
187 (20.1) 
198 (21.3) 
Has a degree, n (%)a 602 (34.6) 318 (30.8) 642 (34.4) 278 (30.7) 
Smoking status, n (%)a 
Never  
Former 
Current 
 
828 (47.1) 
651 (37.0) 
281 (16.0) 
 
488 (46.6) 
376 (35.9) 
184 (17.6) 
 
897 (47.5) 
690 (36.6) 
301 (15.9) 
 
419 (45.5) 
337 (36.6) 
164 (17.8) 
Alcohol frequency, n (%)a 
Daily/almost daily  
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
349 (19.7) 
321 (18.1) 
425 (24.0) 
217 (12.2) 
271 (15.3) 
113 (6.4) 
77 (4.3) 
 
188 (17.8) 
170 (16.1) 
236 (22.4) 
135 (12.8) 
182 (17.3) 
86 (8.2) 
57 (5.4) 
 
368 (19.4) 
342 (18.0) 
447 (23.5) 
232 (12.2) 
295 (15.5) 
128 (6.7) 
88 (4.6) 
 
169 (18.2) 
149 (16.1) 
214 (23.1) 
120 (12.9) 
158 (17.0) 
71 (7.7) 
46 (5.0) 
MS disease-modifying medication,  
n (%)a 
 
171 (10.5) 
 
124 (13.0) 
 
175 (10.0) 
 
120 (14.3) 
Neuroticism score, M (SD) 4.5 (3.4) 4.6 (3.3) 4.6 (3.4) 4.5 (3.3) 
Current depressive symptom score,  
M (SD) 
 
2.6 (2.4) 
 
2.9 (2.5) 
 
2.6 (2.4) 
 
2.9 (2.5) 
M, mean; MS, multiple sclerosis; Qu, quintile; SD, standard deviation. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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Table 4.6 - Parkinson's disease group characteristics 
 
 Information source Definition 
 Self-reported 
diagnosis 
NHS hospital 
records 
Broad Narrow 
n  858 381 916 323 
Age, M (SD) 62.3 (5.4) 62.3 (5.6) 62.2 (5.6) 62.5 (5.2) 
Female, n (%)a 318 (37.1) 159 (41.7) 346 (37.8) 131 (40.6) 
Ethnic group, n (%)a 
White  
Asian/Asian British 
Black/black British 
Other 
 
824 (96.6) 
12 (1.4) 
7 (0.8) 
10 (1.2) 
 
362 (95.5) 
9 (2.4) 
2 (0.5) 
6 (1.6) 
 
876 (96.3) 
15 (1.7) 
8 (0.9) 
11 (1.2) 
 
310 (96.3) 
6 (1.9) 
1 (0.3) 
5 (1.6) 
Townsend quintileb, n (%)a  
Qu1 (least deprived)  
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
214 (25.0) 
176 (20.5) 
164 (19.1) 
157 (18.3) 
146 (17.0) 
 
88 (23.2) 
78 (20.6) 
72 (19.0) 
63 (16.6) 
78 (20.6) 
 
222 (24.3) 
188 (20.6) 
177 (19.4) 
167 (18.3) 
160 (17.5) 
 
80 (24.8) 
66 (20.5) 
59 (18.3) 
53 (16.5) 
64 (19.9) 
Has a degree, n (%)a 269 (32.0) 95 (25.5) 276 (30.8) 88 (27.8) 
Smoking status, n (%)a 
Never  
Former 
Current 
 
526 (61.8) 
273 (32.1) 
52 (6.1) 
 
230 (61.7) 
118 (31.6) 
25 (6.7) 
 
555 (61.3) 
293 (32.3) 
58 (6.4) 
 
201 (63.2) 
98 (30.8) 
19 (6.0) 
Alcohol frequency, n (%)a 
Daily/almost daily  
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
170 (19.9) 
158 (18.5) 
209 (24.4) 
79 (9.2) 
115 (13.5) 
73 (8.5) 
51 (6.0) 
 
70 (18.5) 
59 (15.6) 
87 (23.0) 
39 (10.3) 
64 (16.9) 
33 (8.7) 
27 (7.1) 
 
178 (19.5) 
167 (18.3) 
221 (24.2) 
86 (9.4) 
124 (13.6) 
79 (8.7) 
57 (6.3) 
 
62 (19.3) 
50 (15.5) 
75 (23.3) 
32 (9.9) 
55 (17.1) 
27 (8.4) 
21 (6.5) 
PD medication, n (%)a 711 (88.3) 310 (84.9) 721 (84.0) 300 (96.2) 
Neuroticism score, M (SD) 4.0 (3.3) 4.4 (3.4) 4.1 (3.3) 4.4 (3.4) 
Current depressive symptom score,  
M (SD) 
 
2.3 (2.4) 
 
2.6 (2.5) 
 
2.3 (2.4) 
 
2.6 (2.5) 
M, mean; PD, Parkinson’s disease; Qu, quintile; SD, standard deviation. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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Table 4.7 - Unexposed comparison group characteristics 
 
 Definition 
 Broad Narrow 
n  104,410 80,505 
Age, M (SD) 57.0 (8.2) 57.3 (8.1) 
Female, n (%)a 52,210 (50.0) 39,928 (49.6) 
Ethnic group, n (%)a 
White  
Asian/Asian British 
Black/black British 
Other 
 
94,798 (91.1) 
3,643 (3.5) 
3,121 (3.0) 
2,450 (2.4) 
 
73,177 (91.3) 
2,832 (3.5) 
2,369 (3.0) 
1,818 (2.3) 
Townsend quintileb, n (%)a  
Qu1 (least deprived)  
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
18,130 (17.4) 
21,340 (20.5) 
21,782 (20.9) 
23,337 (22.4) 
19,664 (18.9) 
 
14,303 (17.8) 
16,682 (20.8) 
16,879 (21.0) 
17,712 (22.0) 
14,803 (18.4) 
Has a degree, n (%)a 36,082 (34.9) 27,012 (33.9) 
Smoking status, n (%)a 
Never  
Former 
Current 
 
60,061 (57.7) 
35,126 (33.8) 
8,851 (8.5) 
 
46,841 (58.4) 
26,913 (33.6) 
6,440 (8.0) 
Alcohol frequency, n (%)a 
Daily/almost daily  
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
22,026 (21.1) 
24,920 (23.9) 
26,928 (25.8) 
11,266 (10.8) 
11,449 (11.0) 
2,783 (2.7) 
4,963 (4.8) 
 
17,070 (21.2) 
19,356 (24.1) 
20,728 (25.8) 
8,428 (10.5) 
8,821 (11.0) 
2,118 (2.6) 
3,924 (4.9) 
Any psychotropic medication, n (%)a 1,424 (1.4) 1,072 (1.4) 
Neuroticism score, M (SD) 3.3 (2.9) 3.2 (2.9) 
Current depressive symptom score, M (SD) 1.1 (1.6) 1.1 (1.5) 
M, mean; Qu, quintile; SD, standard deviation. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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4.4 Overlap between ascertainment methods 
The extent of overlap between participants ascertained via each information source was 
examined, as depicted in the Venn diagrams below. For the mood disorder group 
calculations, only participants with complete data on the touchscreen mood questionnaire 
were included, in order that the base population would be comparable between methods. 
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Figure 4.1 - Overlap between mania/bipolar disorder ascertainment sources 
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Figure 4.2 - Overlap between 'any depression' ascertainment sources 
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Figure 4.3 - Overlap between schizophrenia ascertainment sources 
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Figure 4.4 - Overlap between multiple sclerosis ascertainment sources 
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Figure 4.5 - Overlap between Parkinson's disease ascertainment sources 
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4.5 Discussion 
There were marked differences in the numbers meeting the criteria for each exposure of 
interest, according to the three information sources available. For the mood disorder 
exposures, a much greater number were identified via the touchscreen mood questionnaire 
than via self-reported diagnoses or hospital records. This may indicate that the mood 
questionnaire was sensitive to milder illness history or that it misclassified people without 
true mood disorder, although it has previously been shown that the characteristics of the 
groups classified by this method are in line with what would be expected with regard to 
gender distribution, socioeconomic status, self-reported health rating, current depressive 
symptoms and smoking (D. J. Smith et al., 2013). Fewer participants reported having been 
diagnosed with mood disorder by a doctor, which may be unsurprising given that bipolar 
disorder and major depression diagnoses are under-recorded in primary care (Rait et al., 
2009; D. J. Smith et al., 2011).  
There were also disparities between the numbers of participants with self-reported and 
hospital records of each diagnosis, which may be largely explained by the fact that the 
records covered in-patient and day case admissions only, and did not extend further back 
than the mid-1990s. These disparities were smaller for the MS and PD groups, possibly 
because of the greater likelihood of a hospital admission for these disorders. It should be 
noted that a substantial minority of participants with a relevant diagnosis in the hospital 
records did not disclose this in the UK Biobank interview. This may have been because of 
participant preferences (for example, privacy concerns), or because the hospital record 
ICD-10 diagnosis did not reflect their understanding, perception or recall of their medical 
history at the time of the baseline assessment. The group classifications reported here 
accepted any instance of a relevant ICD-10 code at any time in the available records, and it 
is possible that revised diagnoses or clerical errors in the records may have contributed to 
discrepancies with the self-reported data (Davis, Sudlow, & Hotopf, 2016).  
None of the three information sources can be said to be a ‘gold standard’: the self-reported 
diagnoses and the questionnaire responses are liable to under- and over-reporting, and the 
hospital records are time-limited, with ICD-10 codes that are subject to clinical revision or 
clerical error. A pragmatic approach is to use more than one classification method to define 
the exposures, as illustrated above with the broad and narrow definitions. The numbers in 
the broad and narrow groups for each exposure were again markedly different, for the 
same reasons as discussed above. There were also differences in their characteristics, 
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driven by the fact that many participants meeting the narrow definition will have had a 
hospital admission, possibly indicating a more severe illness course.  
Despite the evident differences across each information source and the broad versus 
narrow definitions, certain characteristics support the validity of the distinctions between 
each exposure group, for example: women were over-represented in the depression and 
MS groups and under-represented in the schizophrenia and PD groups; the PD group was 
older than the other groups; the proportion with white ethnicity was lowest in the 
schizophrenia group and highest in the MS group; greater levels of deprivation were 
common in the mood disorder and schizophrenia groups but not those with MS or PD; 
smoking was most common in the mania/BD and schizophrenia groups and least common 
in PD. These patterns are in line with previous epidemiological evidence in these disorders 
(Andrade et al., 2003; de Leon & Diaz, 2005; Fajutrao et al., 2009; Gajwani, 2017; Kalia & 
Lang, 2015; Kamm et al., 2014; Kirkbride et al., 2012; MacDonald et al., 2000; D. F. 
MacKinnon, 2017; McGrath et al., 2008; Merikangas et al., 2011; Picchioni & Murray, 
2007). Patterns of medication usage also supported the exposure group classifications.  
4.6 Next steps 
In consideration of the above findings, it was decided that the broad and narrow exposure 
group definitions would be used in the studies in this thesis. The broadly defined group 
was the primary group for analysis, and secondary analyses were conducted in the narrow 
group where relevant. The broadly and narrowly defined unexposed comparison groups 
were very similar, and so only the broadly defined group was analysed. Although 
subgroups with single episode, mild-moderate and severe recurrent depression were 
identifiable (Appendix S), the UK Biobank self-reported diagnosis data did not permit 
these distinctions, and the numbers in the narrowly defined versions of these subgroups 
were very small. For these reasons, only the ‘any depression’ exposure was used in the 
studies reported in this thesis. Reporting of all studies follows STROBE guidelines (von 
Elm et al., 2007). 
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Chapter 5 Prevalence of cognitive impairment in 
psychiatric and neurological groups in UK 
Biobank 
This chapter reports on the prevalence of cognitive impairment in UK Biobank participants 
with a history of mania/BD, in comparison with those who have a history of major 
depression, schizophrenia, multiple sclerosis or Parkinson’s disease. This is the first study 
to directly compare prevalence of cognitive impairment across these conditions, using 
consistent assessment methods and a single unexposed comparison group, and illustrates 
the power of using a large population cohort such as UK Biobank to investigate the 
‘cognitive footprint’ of chronic psychiatric and neurological conditions.5 
5.1 Background 
As outlined in Chapter 1, cognitive impairment is a commonly reported feature of mood 
disorders, which persists between illness episodes and contributes substantially to ongoing 
disability. Estimates of cognitive impairment prevalence in euthymic adults with a history 
of mood disorder vary considerably, depending on the measures used and the definition of 
impairment. The systematic review in Chapter 2 showed that the prevalence in BD ranges 
from 5% to 58%, and in major depressive disorder it has been estimated at one-third to 
one-half (Rock et al., 2014). Cognitive impairment has been studied more extensively in 
schizophrenia; it is reportedly evident in the majority of patients—possibly as many as 
80%—and has been proposed as a core diagnostic criterion (Kahn & Keefe, 2013; Keefe, 
2008; Keefe & Fenton, 2007). The prevalence of cognitive impairment in mental health 
disorders may be compared with that in chronic neurological conditions: studies in MS 
have reported prevalence of 40-80% (Fischer et al., 2014; Patti et al., 2015; Rao, Leo, 
Bernardin, et al., 1991), and in PD the prevalence has been estimated at 50-55% 
(Svenningsson et al., 2012).  
The comparative burden of cognitive impairment across disorders must be considered with 
reference to the relative prevalence of the disorders themselves. As noted in Chapter 1, 
lifetime prevalence in the UK per 100,000 population is estimated at up to 10,000 for 
                                                 
5 The work described in this chapter has been published in Cullen, B., Smith, D. J., Deary, I. J., 
Evans, J. J., & Pell, J. P. (2017). The ‘cognitive footprint’ of psychiatric and neurological 
conditions: Cross-sectional study in the UK Biobank cohort. Acta Psychiatrica Scandinavica, 
135, 593-605. doi:10.1111/acps.12733 
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major depression (NICE, 2011) and approximately 1,000 for BD (Fajutrao et al., 2009), 
compared with 400-1,000 for schizophrenia (McGrath et al., 2008), and 200 for both MS 
and PD (MacDonald et al., 2000). Despite the generally greater research focus on cognitive 
function in schizophrenia and neurological disorders, it is clear that the higher prevalence 
of mood disorders in the population means that the absolute number with associated 
cognitive impairment is likely to be substantial and of significant public health importance.  
Previous studies of cognitive function in various psychiatric and neurological conditions 
are difficult to compare directly, because of variations in source populations, methods of 
recruitment, assessment tools, impairment definitions, composition of normative 
comparison groups, and adjustment for potential confounders. The UK Biobank cohort 
presents an opportunity to overcome these limitations. The aim of this cross-sectional 
analysis was to quantify the prevalence of cognitive impairment in adults with a history of 
mood disorder, schizophrenia, MS or PD, in the UK Biobank cohort.  
5.2 Methods 
5.2.1 Participants 
Data from the full UK Biobank cohort at baseline (n = 502,642) were used.  
5.2.2 Materials and procedure 
Details of demographic, lifestyle and psychological assessment procedures were given in 
Chapter 3. The key sociodemographic variables for the present analyses were age, gender 
and educational attainment (dichotomised according to whether or not participants held a 
university/college degree), and additional measures were also reported to characterise the 
sample descriptively.   
5.2.3 Exposed and unexposed groups 
The exposures of interest were mania/BD, major depression (single or recurrent episodes), 
schizophrenia, MS and PD. Exposure status for each condition was classified using both 
broad and narrow definitions, as described in Chapter 4. A single unexposed comparison 
group was analysed, as described in Chapter 4 (broad definition). Participants who did not 
meet the criteria for any of the exposed or unexposed groups were not further analysed.  
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5.2.4 Cognitive impairment 
Details of the cognitive assessment were given in Chapter 3. The measures analysed were: 
reasoning (total correct out of 13 items); reaction time (mean time in milliseconds to press 
a button in response to matching cards); numeric memory (longest numeric string recalled 
in reverse); visuospatial memory (‘pairs matching’ test: total errors when recalling the 
positions of matching cards); and prospective memory (successfully carrying out an 
instruction after a filled delay).  
Performance on each of the five tests was classified as impaired or unimpaired. For all 
measures except prospective memory, the score distribution in the unexposed comparison 
group was converted into percentile ranks, and the raw score corresponding to the 5th 
percentile (or 95th, on tests where higher scores represented worse performance) was 
identified as the cut-off for impairment. If that raw score spanned more than one percentile 
rank, the nearest percentile rank with a raw score that uniquely divided the sample into 
impaired and unimpaired groups was used instead. Participants in the exposed groups were 
then classified as impaired according to that cut-off score, i.e. having a score that was 
equal to or worse than the lowest-performing 5% (or nearest feasible proportion) of the 
unexposed group. Since prospective memory was a categorical measure, impairment in all 
groups was defined as being incorrect on the first attempt. 
5.2.5 Minimisation of bias 
As described in Chapter 3, all assessments were administered according to a standard 
operating procedure, and administration and scoring of cognitive measures and 
questionnaires was automated. Bias in the ascertainment of the exposure groups was 
minimised by using the same sources of information (self-reported diagnoses and hospital 
records) for all exposures. Additional questionnaire-based data were, however, only 
available for the mania/BD and major depression exposures. Participants in Scotland were 
coded as missing for the mental health exposures, since their hospital records covered 
acute hospital admissions only; any mental health diagnoses in those records would be less 
likely to be in the primary position compared with participants in England and Wales, 
therefore possibly reflecting a different clinical presentation or comorbidity status in those 
participants. A single unexposed comparison group was used as the reference for all 
exposure groups, so that impairment prevalence ratios could be directly compared. 
89 
 
5.2.6 Data analysis 
Statistical analyses were carried out using Stata software version 13 (StataCorp, 2013). 
Demographic, lifestyle and psychological measures were summarised descriptively to 
characterise the exposed and unexposed groups. Townsend deprivation index scores were 
categorised into quintiles based on frequency in the whole cohort. The reliability (internal 
consistency) of the cognitive tests in each group was examined using Cronbach’s alpha 
where possible.  
The prevalence of impairment on the five cognitive tests was calculated in each group, 
reported as a percentage with 95% CI based on the standard error calculated as 
. The ratio of prevalence in each exposed group versus the 
unexposed reference group was calculated, together with 95% CI, using the epitab 
functions in Stata v13. Crude results are reported, along with directly standardised results, 
which were computed using weights derived from the unexposed comparison group. In 
direct standardisation, sample sizes within each stratum of an external reference group 
(here, the unexposed comparison group) are used as weights to adjust the stratum-specific 
prevalence ratios in the exposed group: the prevalence ratio in each stratum of the exposed 
group is multiplied by the sample size of that stratum in the reference group, and the 
resulting products are then summed and divided by the total sample size of the reference 
group, to produce a standardised prevalence ratio for the whole exposed group. The 
purpose of standardisation was to control for demographic differences between the 
exposed and unexposed groups that might confound the crude results. Stratification was by 
age group (<60 versus ≥60 years; chosen to be close to the sample median of 58) and 
gender. Statistical interactions between exposure status and age group and between 
exposure status and gender were tested using robust Poisson regression models (Chen, Shi, 
Qian, & Azen, 2014) including a product term.  
The population attributable prevalence of cognitive impairment (number of cases of 
cognitive impairment, per 100,000 total population, that are attributable to the exposure) 
was derived from 2x2 tables constructed for each exposure separately. The prevalence of 
each exposure within these tables was based on the lifetime estimates cited in section 5.1 
above. The population attributable prevalence of cognitive impairment was calculated as 
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the total number of cases of cognitive impairment per 100,000 population multiplied by the 
population attributable fraction (PAF), where PAF was . 
5.2.7 Sensitivity analyses 
5.2.7.1 Comorbidity 
Because the exposed groups may have had other comorbid psychiatric or neurological 
conditions in addition to the exposure of interest, which might increase the cognitive 
impairment prevalence relative to the unexposed comparison group, sensitivity analyses 
were conducted to examine the effect on the crude results of restricting the analyses to 
participants with no known comorbidities. Psychiatric and neurological comorbidities were 
identified from self-reported diagnoses and hospital records, as listed in Appendices P and 
Q.  
5.2.7.2 Educational attainment 
Sensitivity analyses were also conducted to examine the effect on the standardised results 
of accounting for educational attainment. Educational attainment is a potential confounder 
of cognitive performance that differed across the exposure groups in the present study. 
However, because the typical age of onset of each exposure of interest varies considerably 
(e.g. young adulthood in schizophrenia versus late middle age in PD), it may be that 
educational attainment is a consequence of exposure in the groups with younger onset, but 
a confounder in exposure groups with older onset. Stratifying on a variable that is a 
consequence of the exposure and outcome may cause ‘collider bias’, affecting the estimate 
of their association (Greenland et al., 1999). The age- and gender-stratified standardised 
analyses were therefore repeated with additional stratification on education (degree versus 
no degree), for comparison. Further to these analyses, missing data checks were also 
conducted: since there were some missing data on the education variable (but not on age or 
gender), a comparison was made between the crude results using all available data and the 
crude results in only those participants who had complete education data.  
5.2.7.3 Information bias 
It is possible that the additional information source (touchscreen mood questionnaire) by 
which participants could be classified as exposed for the mood disorders, in the absence of 
an equivalent information source for the other exposures of interest, might have led to 
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differential misclassification bias. Alternative versions of the mood disorder exposure 
groups were therefore constructed, only using data from the other two information sources 
(self-reported diagnoses and linked hospital records), and the analyses were repeated for 
comparison. Secondly, because hospital records data from Scotland were included when 
ascertaining the MS and PD groups but not the psychiatric exposures, the characteristics of 
the MS and PD groups identified via hospital records were examined including and 
excluding data from Scotland, for comparison. Lastly, because the proportion of missing 
data on the cognitive measures differed across the exposure groups, the characteristics of 
those with and without missing data were examined: age, gender, education and 
comorbidity status were compared within the broadly-defined exposure groups between 
participants who did and did not have missing data on each cognitive test.  
5.3 Results 
5.3.1 Characteristics of the exposed and unexposed groups 
Table 5.1 shows the characteristics of each group on key demographic factors and the five 
cognitive measures. Additional group characteristics are provided in Appendix T. The total 
number in the cohort who did not meet the criteria for any of the exposed groups or the 
unexposed comparison group was 336,662; a large number were excluded from the 
unexposed group because they were recruited prior to the addition of the touchscreen mood 
questionnaire to the baseline assessment protocol. The proportion of missing data varied 
across measures, but tended to be higher in the exposed groups (particularly those with 
schizophrenia), compared with the unexposed comparison group. Cronbach’s alpha is 
reported in Table 5.1 for the reasoning and reaction time tests in each group; it was not 
possible to calculate this for the other three cognitive tests, as they did not include multiple 
items. Alpha was higher for reaction time than for reasoning, but coefficients did not differ 
notably across groups.  
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Table 5.1 - Characteristics of the exposed and unexposed groups 
 
 Unexposed 
comparison 
Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
n  104,410 3,020 607 56,425 7,583 850 259 1,905 931 916 323 
Age (years)a 
Mean (SD) 
 
57.0 (8.2) 
 
54.9 (8.0) 
 
54.8 (8.0) 
 
55.6 (7.9) 
 
55.1 (7.9) 
 
53.9 (8.1) 
 
52.6 (8.2) 
 
55.4 (7.5) 
 
55.3 (7.5) 
 
62.2 (5.6) 
 
62.5 (5.2) 
Gendera 
n (%) female 
 
52,210 (50.0) 
 
1,589 (52.6) 
 
345 (56.8) 
 
36,574 (64.8) 
 
4,923 (64.9) 
 
293 (34.5) 
 
74 (28.6) 
 
1,400 (73.5) 
 
665 (71.4) 
 
346 (37.8) 
 
131 (40.6) 
Has a degree  
n (%) missing 
n (%)b 
 
1,033 (1.0) 
36,082 (34.9) 
 
40 (1.3) 
1,117 (37.5) 
 
4 (0.7) 
250 (41.5) 
 
582 (1.0) 
18,188 (32.6) 
 
59 (0.8) 
2,344 (31.2) 
 
31 (3.7) 
212 (25.9) 
 
10 (3.9) 
65 (25.3) 
 
39 (2.0) 
642 (34.4) 
 
26 (2.8) 
278 (30.7) 
 
20 (2.2) 
276 (30.8) 
 
6 (1.9) 
88 (27.8) 
No known 
comorbiditya,c  
n (%) 
 
 
- 
 
 
2,018 (66.8) 
 
 
338 (55.7) 
 
 
43,289 (76.7) 
 
 
4,842 (63.9) 
 
 
30 (3.5) 
 
 
8 (3.1) 
 
 
279 (14.7) 
 
 
116 (12.5) 
 
 
172 (18.8) 
 
 
65 (20.1) 
Reasoning 
score 
n (%) missingd 
Mean (SD) 
Cronbach’s α 
 
 
1,595 (1.6) 
6.0 (2.2) 
0.70 
 
 
40 (2.1) 
5.7 (2.2) 
0.71 
 
 
7 (2.2) 
6.0 (2.4) 
0.73 
 
 
485 (1.4) 
6.0 (2.1) 
0.69 
 
 
97 (1.6) 
5.9 (2.2) 
0.69 
 
 
17 (5.8) 
4.8 (2.1) 
0.70 
 
 
5 (5.5) 
4.7 (2.0) 
0.65 
 
 
17 (2.9) 
5.9 (2.0) 
0.66 
 
 
10 (3.6) 
5.7 (2.0) 
0.64 
 
 
6 (2.1) 
5.8 (2.2) 
0.70 
 
 
2 (1.7) 
5.7 (2.2) 
0.71 
Reaction time 
(ms)  
n (%) missing 
Mdn  
(Q1, Q3) 
Cronbach’s α 
 
 
1,107 (1.1) 
543 
(484, 621) 
0.82 
 
 
65 (2.2) 
558 
(492, 640) 
0.83 
 
 
14 (2.3) 
571 
(500, 664) 
0.85 
 
 
652 (1.2) 
543 
(484, 621) 
0.82 
 
 
99 (1.3) 
551 
(488, 633) 
0.83 
 
 
52 (6.1) 
601 
(520, 688) 
0.87 
 
 
16 (6.2) 
583 
(521, 668) 
0.85 
 
 
39 (2.1) 
590 
(512, 694) 
0.84 
 
 
25 (2.7) 
594 
(516, 716) 
0.85 
 
 
19 (2.1) 
571 
(512, 644) 
0.82 
 
 
7 (2.2) 
578 
(516, 653) 
0.83 
Numeric 
memory score 
n (%) missingd 
Mean (SD) 
 
 
749 (2.4) 
6.7 (1.3) 
 
 
22 (4.2) 
6.5 (1.5) 
 
 
2 (2.6) 
6.5 (1.3) 
 
 
301 (2.7) 
6.7 (1.3) 
 
 
59 (3.3) 
6.6 (1.4) 
 
 
9 (12.5) 
5.9 (1.5) 
 
 
5 (20.0) 
5.9 (1.3) 
 
 
9 (4.5) 
6.6 (1.3) 
 
 
8 (7.2) 
6.4 (1.3) 
 
 
3 (3.1) 
6.5 (1.4) 
 
 
2 (5.4) 
6.4 (1.5) 
Visuospatial 
memory errors 
n (%) missing 
Mdn (Q1, Q3) 
 
 
0 (0.0) 
3 (2, 5) 
 
 
14 (0.5) 
4 (2, 6) 
 
 
1 (0.2) 
4 (2, 7) 
 
 
117 (0.2) 
3 (2, 6) 
 
 
12 (0.2) 
4 (2, 6) 
 
 
17 (2.0) 
4 (2, 7) 
 
 
3 (1.2) 
4 (2, 6) 
 
 
18 (0.9) 
3 (2, 6) 
 
 
11 (1.2) 
3 (2, 6) 
 
 
9 (1.0) 
4 (2, 6) 
 
 
2 (0.6) 
4 (2, 7) 
Prospective 
memorya,d 
n (%)a correct 
 
 
80,192 (77.2) 
 
 
1,391 (71.0) 
 
 
219 (65.4) 
 
 
28,148 (77.7) 
 
 
4,724 (75.4) 
 
 
180 (55.4) 
 
 
58 (56.3) 
 
 
446 (73.4) 
 
 
206 (70.8) 
 
 
217 (70.9) 
 
 
79 (63.7) 
Mdn, median; Q, quartile; SD, standard deviation. 
a. No missing data. 
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b. Missing excluded from denominator. 
c. Not known to have any other psychiatric or neurological condition in addition to the exposure. By definition, no member of the unexposed comparison group had any primary or comorbid psychiatric or 
neurological condition.  
d. Missing data refers only to the period when this measure was included in the battery. 
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5.3.2 Prevalence of cognitive impairment across groups 
On the reaction time, numeric memory and visuospatial memory tests, the cognitive 
impairment threshold corresponded to the worst-performing 5% of the unexposed group. 
Owing to the restricted raw score range on the reasoning test, the same raw score spanned 
the 5th to 11th percentile range and so the 4th percentile score was instead used to divide the 
sample; the impairment threshold therefore corresponded to the worst-performing 4% of 
the unexposed group. Prospective memory was a pass/fail test; the proportion of the 
unexposed group with an incorrect score was 22.8%.  
Table 5.2 shows the prevalence of impairment in each exposed group, along with 
prevalence ratios relative to the unexposed group. Standardised estimates are not reported 
for some groups, because of insufficient data in some strata.  
The crude estimates (Table 5.2) indicated that cognitive impairment prevalence was higher 
in mania/BD than in the unexposed comparison group, with prevalence ratios in the 
broadly-defined group ranging from 1.27 (95% CI 1.18, 1.36) to 1.97 (95% CI 1.52, 2.56). 
Prevalence in major depression was closer to the comparison group level, with crude ratios 
in the broadly-defined group ranging from 0.98 (95% CI 0.96, 1.00) to 1.09 (95% CI 1.04, 
1.14). Crude impairment prevalence was higher in MS and PD groups than in the 
comparison group for reaction time (2.87 [95% CI 2.56, 3.22] and 1.34 [95% CI 1.05, 
1.72] respectively in the broadly-defined groups), visuospatial memory (1.42 [95% CI 
1.19, 1.69] and 1.89 [95% CI 1.52, 2.35]) and prospective memory (1.17 [95% CI 1.02, 
1.33] and 1.27 [95% CI 1.07, 1.52]). Crude impairment prevalence was highest in 
schizophrenia on all tests (prevalence ratios in the broadly-defined group ranged from 1.95 
[95% CI 1.73, 2.21] to 3.95 [95% CI 2.43, 6.43]) except reaction time, for which 
prevalence was highest in MS. 
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Table 5.2 - Prevalence of cognitive impairment across groups 
 
Impairment 
threshold 
 Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
Reasoning 
≤ unexposed 4th 
percentile score 
(Unexposed prevalence 
4.16%) 
n 1,866 318 35,211 6,052 274 86 572 272 283 115 
Crude P %  
95% CI 
Crude PR  
95% CI 
7.13 
5.96, 8.30 
1.71* 
1.45, 2.02 
6.29 
3.62, 8.96 
1.51 
0.99, 2.31 
4.22 
4.01, 4.43 
1.02 
0.96, 1.08 
5.24 
4.68, 5.80 
1.26* 
1.13, 1.41 
10.95 
7.25, 14.65 
2.63* 
1.88, 3.70 
6.98 
1.59, 12.37 
1.68 
0.78, 3.63 
2.80 
1.45, 4.15 
0.67 
0.41, 1.09 
1.84 
0.24, 3.44 
0.44 
0.19, 1.05 
4.95 
2.42, 7.48 
1.19 
0.71, 1.98 
6.96 
2.31, 11.61 
1.67 
0.86, 3.27 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
7.20 
6.02, 8.37 
1.73* 
1.45, 2.05 
6.49 
3.78, 9.20 
1.56* 
1.01, 2.42 
4.33 
4.11, 4.54 
1.04a 
0.98, 1.10 
5.41 
4.84, 5.98 
1.30* 
1.16, 1.47 
10.61 
6.96, 14.25 
2.55* 
1.75, 3.71 
-b 
- 
- 
- 
3.20 
1.76, 4.65 
0.77 
0.43, 1.37 
-b 
- 
- 
- 
5.91 
3.16, 8.65 
1.42 
0.70, 2.89 
9.24 
3.94, 14.53 
2.22* 
1.02, 4.83 
Reaction time 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.98%) 
n 2,955 593 55,773 7,484 798 243 1,866 906 897 316 
Crude P %  
95% CI 
Crude PR  
95% CI 
6.73 
5.83, 7.63 
1.35* 
1.18, 1.55 
7.59 
5.46, 9.72 
1.52* 
1.15, 2.02 
5.31 
5.12, 5.50 
1.07* 
1.02, 1.11 
6.55 
5.99, 7.11 
1.32* 
1.20, 1.44 
12.91 
10.58, 15.24 
2.59* 
2.16, 3.11 
10.70 
6.81, 14.59 
2.15* 
1.49, 3.09 
14.31 
12.72, 15.90 
2.87* 
2.56, 3.22 
17.77 
15.28, 20.26 
3.57* 
3.10, 4.12 
6.69 
5.05, 8.33 
1.34* 
1.05, 1.72 
7.28 
4.42, 10.14 
1.46 
0.99, 2.17 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
7.27 
6.33, 8.21 
1.46* 
1.27, 1.68 
8.12 
5.92, 10.32 
1.63* 
1.22, 2.19 
5.58 
5.39, 5.77 
1.12*c 
1.07, 1.17 
7.02 
6.44, 7.60 
1.41*d 
1.29, 1.55 
13.70 
11.31, 16.08 
2.75* 
2.25, 3.37 
12.10 
8.00, 16.20 
2.43* 
1.60, 3.69 
15.19 
13.56, 16.82 
3.05*e 
2.68, 3.48 
18.82 
16.28, 21.37 
3.78*f 
3.22, 4.43 
6.27 
4.69, 7.86 
1.26 
0.92, 1.71 
5.68 
3.13, 8.23 
1.14 
0.71, 1.83 
Numeric memory 
≤ unexposed 5th 
percentile score 
(Unexposed prevalence 
5.22%) 
n 505 75 10,808 1,746 63 20 193 103 94 35 
Crude P %  
95% CI 
Crude PR  
95% CI 
10.30 
7.65, 12.95 
1.97* 
1.52, 2.56 
5.33 
0.25, 10.41 
1.02 
0.39, 2.65 
5.65 
5.21, 6.09 
1.08 
0.99, 1.19 
7.67 
6.42, 8.92 
1.47* 
1.24, 1.74 
20.63 
10.64, 30.62 
3.95* 
2.43, 6.43 
15.00 
0.00, 30.65 
2.87* 
1.01, 8.17 
6.74 
3.20, 10.28 
1.29 
0.76, 2.19 
8.74 
3.29, 14.19 
1.67 
0.90, 3.13 
8.51 
2.87, 14.15 
1.63 
0.84, 3.17 
14.29 
2.70, 25.88 
2.74* 
1.21, 6.17 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
10.39 
7.73, 13.05 
1.99* 
1.51, 2.62 
-b 
- 
- 
- 
5.74 
5.30, 6.18 
1.10 
0.99, 1.21 
7.78 
6.52, 9.03 
1.49* 
1.24, 1.79 
20.46 
10.50, 30.42 
3.92* 
2.34, 6.57 
-b 
- 
- 
- 
7.41 
3.72, 11.11 
1.42 
0.72, 2.82 
-b 
- 
- 
- 
12.68 
5.96, 19.41 
2.43*g 
1.19, 4.97 
18.69 
5.77, 31.60 
3.58*h 
1.60, 8.03 
Visuospatial memory 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.38%) 
n 3,006 606 56,308 7,571 833 256 1,887 920 907 321 
Crude P %  
95% CI 
Crude PR  
95% CI 
6.35 
5.48, 7.22 
1.45* 
1.26, 1.67 
8.58 
6.35, 10.81 
1.96* 
1.51, 2.55 
4.76 
4.58, 4.94 
1.09* 
1.04, 1.14 
5.15 
4.65, 5.65 
1.18* 
1.06, 1.30 
9.12 
7.16, 11.08 
2.08* 
1.68, 2.59 
7.81 
4.52, 11.10 
1.78* 
1.17, 2.72 
6.20 
5.11, 7.29 
1.42* 
1.19, 1.69 
7.28 
5.60, 8.96 
1.66* 
1.32, 2.10 
8.27 
6.48, 10.06 
1.89* 
1.52, 2.35 
8.10 
5.12, 11.08 
1.85* 
1.28, 2.68 
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Impairment 
threshold 
 Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
6.57 
5.68, 7.46 
1.50* 
1.30, 1.73 
8.98 
6.70, 11.26 
2.05* 
1.57, 2.69 
5.12 
4.94, 5.31 
1.17* 
1.12, 1.23 
5.65 
5.13, 6.17 
1.29* 
1.16, 1.44 
9.68 
7.67, 11.69 
2.21* 
1.75, 2.79 
8.58 
5.15, 12.02 
1.96* 
1.20, 3.18 
6.57 
5.45, 7.69 
1.50* 
1.22, 1.84 
8.02 
6.26, 9.77 
1.83* 
1.41, 2.37 
6.66 
5.04, 8.28 
1.52* 
1.16, 1.99 
7.36 
4.50, 10.21 
1.68* 
1.05, 2.68 
Prospective memory 
Incorrect score 
(Unexposed prevalence 
22.82%) 
n 1,959 335 36,237 6,267 325 103 608 291 306 124 
Crude P %  
95% CI 
Crude PR  
95% CI 
28.99 
26.98, 31.00 
1.27* 
1.18, 1.36 
34.63 
29.53, 39.73 
1.52* 
1.31, 1.76 
22.32 
21.89, 22.75 
0.98 
0.96, 1.00 
24.62 
23.55, 25.69 
1.08* 
1.03, 1.13 
44.62 
39.22, 50.02 
1.95* 
1.73, 2.21 
43.69 
34.11, 53.27 
1.91* 
1.54, 2.38 
26.64 
23.13, 30.15 
1.17* 
1.02, 1.33 
29.21 
23.99, 34.43 
1.28* 
1.07, 1.53 
29.08 
23.99, 34.17 
1.27* 
1.07, 1.52 
36.29 
27.83, 44.75 
1.59* 
1.26, 2.01 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
29.67 
27.64, 31.69 
1.30*i 
1.20, 1.39 
35.37 
30.25, 40.49 
1.55* 
1.34, 1.80 
22.82 
22.39, 23.25 
1.00j 
0.98, 1.02 
25.56 
24.48, 26.64 
1.12*k 
1.07, 1.17 
45.87 
40.45, 51.29 
2.01* 
1.76, 2.28 
43.13 
33.57, 52.69 
1.89* 
1.47, 2.42 
26.24 
22.75, 29.74 
1.15 
0.99, 1.34 
29.67 
24.42, 34.91 
1.30* 
1.07, 1.59 
27.84 
22.82, 32.86 
1.22 
0.98, 1.54 
34.46 
26.09, 42.82 
1.51* 
1.13, 2.01 
CI, confidence interval; P, prevalence; PR, prevalence ratio. 
Standardised estimates are directly standardised by age and gender with reference to the unexposed comparison group. 
* p < 0.05 
a. Significant interaction with gender: women PR = 0.95 (CI 0.88, 1.02); men PR = 1.14 (CI 1.04, 1.25). 
b. Estimates not reported because at least 1 of 4 strata contained no exposed participants with cognitive impairment. 
c. Significant interaction with gender: women PR = 1.05 (CI 0.99, 1.11); men PR = 1.21 (CI 1.13, 1.30). 
d. Significant interaction with gender: women PR = 1.29 (CI 1.15, 1.45); men PR = 1.56 (CI 1.34, 1.82). 
e. Significant interaction with age and gender: <60 years PR = 4.31 (CI 3.65, 5.08); ≥60 years PR = 2.38 (CI 1.94, 2.90); women PR = 2.55 (CI 2.21, 2.93); men PR = 3.69 (CI 2.99, 4.55). 
f. Significant interaction with age and gender: <60 years PR = 5.85 (CI 4.84, 7.08); ≥60 years PR = 2.66 (CI 2.04, 3.47); women PR = 3.00 (CI 2.50, 3.60); men PR = 4.76 (CI 3.72, 6.08). 
g. Significant interaction with age: <60 years PR = 4.85 (CI 2.11, 11.17); ≥60 years PR = 0.72 (CI 0.24, 2.19). 
h. Significant interaction with age: <60 years PR = 6.66 (CI 2.54, 17.50); ≥60 years PR = 1.40 (CI 0.36, 5.51). 
i. Significant interaction with age: <60 years PR = 1.43 (CI 1.31, 1.56); ≥60 years PR = 1.19 (CI 1.06, 1.33). 
j. Significant interaction with gender: women PR = 0.96 (CI 0.93, 0.99); men PR = 1.04 (CI 1.00, 1.08). 
k. Significant interaction with gender: women PR = 1.06 (CI 0.99, 1.12); men PR = 1.19 (CI 1.10, 1.28). 
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Following direct standardisation with reference to the unexposed group weights for age 
group and gender, estimates increased in the mania/BD and major depression groups on all 
measures (Table 5.2). Some estimates increased and some decreased in the schizophrenia 
groups, although the general pattern was similar to the crude results. In the MS groups, all 
estimates but one increased, and in PD, reasoning and numeric memory estimates 
increased but other estimates decreased. Within the mania/BD, MS and PD groups, 
interaction tests indicated that impairment prevalence was significantly lower in the older 
age group on some measures. Significant interactions with gender were found in major 
depression and MS on some measures, showing lower impairment prevalence in women. 
Figure 5.1 shows the standardised absolute prevalence and Figure 5.2 shows the 
standardised prevalence ratios on all measures in the broadly-defined exposure groups. 
When the highest standardised impairment prevalence estimates from Table 5.2 were 
applied to population prevalence estimates for each exposure (cited in section 5.1), the 
population attributable lifetime prevalence of cognitive impairment per 100,000 population 
was approximately 256 (95% CI 130, 381) for major depression, 151 (95% CI 52, 251) for 
schizophrenia, 45 (95% CI 23, 68) for mania/BD, 27 (95% CI 22, 32) for MS and 26 (95% 
CI 1, 52) for PD (Appendix U).  
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Figure 5.1 - Standardised prevalence estimates for cognitive impairment 
 
Estimates are prevalence (%), directly standardised by age and gender with reference to the 
unexposed comparison group. Point estimates and 95% confidence intervals are shown. 
Exposure groups are broadly defined (classified as exposed by at least one ascertainment 
method). Panels show: (a) Reasoning; (b) Reaction time; (c) Numeric memory; (d) 
Visuospatial memory; (e) Prospective memory. 
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Figure 5.2 - Standardised prevalence ratios for cognitive impairment 
 
Estimates are prevalence ratios compared with the unexposed group, directly standardised 
by age and gender. Point estimates and 95% confidence intervals are shown. Dashed line 
represents the null (no difference relative to unexposed group). Exposure groups are 
broadly defined (classified as exposed by at least one ascertainment method). Panels show: 
(a) Reasoning; (b) Reaction time; (c) Numeric memory; (d) Visuospatial memory; (e) 
Prospective memory. 
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5.3.3 Sensitivity analyses 
5.3.3.1 Comorbidity 
When the crude estimates were re-calculated in participants with no known comorbidities, 
the prevalence ratios attenuated towards the null (see Table V.1 in Appendix V). In all the 
groups except major depression, the estimates generally remained higher compared with 
the unexposed group, although very small sample sizes in some groups (e.g. schizophrenia 
and PD) reduced the statistical power or prevented valid analysis. A somewhat different 
pattern was seen in the major depression group: some estimates in the broadly-defined 
group reversed such that impairment prevalence became significantly lower compared with 
the unexposed group, and most estimates in the narrowly-defined group were no longer 
significantly different from the unexposed group.  
5.3.3.2 Educational attainment 
Table V.2 in Appendix V shows standardised results taking account of educational 
attainment as well as age group and gender. Results are not reported for some groups 
owing to sparse data across strata. Compared with results standardised for age and gender 
only (Table 5.2), some estimates were higher and some were lower in all exposed groups. 
The magnitude of difference in either direction was generally small, and the overall pattern 
of results remained similar. Educational attainment was lower in the schizophrenia and PD 
groups compared with the unexposed group, but there was no clear indication of collider 
bias in the former: inclusion of education in the standardised analyses reduced rather than 
inflated the prevalence estimates on most measures. Comparison of crude results between 
the full sample (Table 5.2) and those with complete education data (Table V.3 in Appendix 
V) did not indicate an effect of missing data. 
5.3.3.3 Information bias 
The analyses were also repeated using alternative versions of the mania/BD and major 
depression groups, formed without reference to the touchscreen mood disorders 
questionnaire data. The results showed that almost all estimates were higher in these 
alternative groups, and all were significantly higher than in the unexposed group. The 
crude and standardised results for these groups are presented in Table V.4 in Appendix V. 
103 
 
The characteristics of the MS and PD groups identified via hospital records were very 
similar regardless of whether data from Scotland were included (Table V.5 in Appendix 
V).  
Comparison of participant characteristics between those with and without missing data on 
the cognitive measures showed that participants with missing data across each exposed 
group were generally older, less likely to have a degree, and more likely to have 
comorbidities (Tables V.6a  to V.6d in Appendix V; no participants had missing data on 
the prospective memory test). Unexposed comparison participants with missing cognitive 
data were also older and less likely to have a degree. Men were over-represented in the 
missing data groups for major depression, schizophrenia and MS, but were under-
represented in the missing data group for mania/BD. The missing data mechanism was 
likely to be ‘not-at-random’, assuming that participants with worse cognitive function 
would be more likely to discontinue the tests. The impairment prevalence estimates 
reported in this chapter are therefore likely to be biased downward, compared with true 
prevalence in the UK Biobank cohort and in the general population. 
5.4 Discussion 
In this community-based population in middle to early old age, standardised prevalence of 
cognitive impairment was higher in people with a history of psychiatric or neurological 
conditions than in those with no such history. Across the exposure groups studied, 
standardised prevalence was highest on most measures in participants with schizophrenia 
and lowest in those with major depression. Mania/BD was the second most impaired 
exposure group on three of the five measures (reasoning, numeric memory and prospective 
memory), and sensitivity analyses showed that impairment in this group was higher still 
when exposure information sources were strictly equivalent with the other groups. 
Reaction time impairment was most prevalent in the MS group, which is in line with 
previous research showing particular problems with processing speed in MS and other 
white matter disorders (Prins et al., 2005; Rao, Leo, Bernardin, et al., 1991; Rao et al., 
2014). Although the increased prevalence (compared with the unexposed group) of 
cognitive impairment in major depression was relatively small, lifetime prevalence of 
major depression is approximately ten times that of BD and schizophrenia and fifty times 
that of MS and PD, which meant that the population attributable prevalence of cognitive 
impairment was highest overall for this group. Sensitivity analyses suggested that 
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comorbidities may be contributing to the increased likelihood of cognitive impairment in 
major depression. 
This is the first study to directly compare prevalence of cognitive impairment across these 
conditions, using consistent assessment methods and a single unexposed comparison 
group. Multiple sources of information were used to classify exposure status, and 
impairment status was defined with reference to a very large normative group. Direct 
standardisation permitted like-for-like comparisons across the exposure groups, and 
sensitivity analyses were conducted to examine possible sources of bias and confounding. 
The overall pattern of findings was consistent regardless of exposure group definitions 
(broad or narrow) and adjustment for key demographic characteristics.  
The prevalence of cognitive impairment in all groups was lower than expected. This may 
indicate that people living with psychiatric and neurological conditions in the general 
population are less impaired than the patient population represented in clinical studies. 
Alternatively, the low prevalence of impairment may reflect selection bias in UK Biobank, 
such that invitees may have been more motivated to join a medical research study if they 
had prior experience of health problems, and may have been more willing or able to take 
part if they had better cognitive function and/or less severe disorder. This represents 
collider bias (Greenland et al., 1999), whereby exposed status and (lower) probability of 
impaired outcome together influenced study participation. This would introduce bias, by 
attenuating or reversing any true positive association of exposure with impaired outcome. 
Similarly, the greater proportion of missing cognitive data in the exposed groups, and the 
finding that missingness was itself associated with older age, lower educational attainment 
and comorbidities, suggests that selection into the analysed sample was biased towards 
more cognitively able participants.  
The prevalence of impairment was higher when the mood disorder exposure groups were 
based on self-reported doctor diagnosis and/or hospital records, without reference to the 
touchscreen questionnaire data on lifetime mood disorder experiences (Table V.4); the 
results in Table 5.2 can therefore be taken as a lower bound of true prevalence. It may be 
that the questionnaire data misclassified participants as exposed (differentially so for less 
cognitively impaired participants), or, alternatively, there might be a large number of 
people living with undiagnosed mood disorders in the general population, whose true 
prevalence of cognitive impairment is lower than previous studies have suggested.  
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With regard to demographic factors, the finding that cognitive impairment was less 
common in women compared with men in the MS group on some measures may reflect 
generally less severe disease course in women (Bergamaschi, 2007). A similar finding for 
women in the major depression group was unexpected in light of a recent meta-analysis, 
which found no such association (Bora et al., 2013). Impairment was also less common in 
older compared with younger participants within the mania/BD, MS and PD groups. Given 
the consistent association between older age and greater cognitive impairment in the 
general population, this finding is likely to indicate survivor bias in these exposed groups. 
A number of study limitations need to be considered. Unlike previous studies in these 
conditions, clinician-confirmed diagnoses were not available, and linked health records 
covered in-patient and day case admissions only. Psychiatric hospital data were 
unavailable for participants in Scotland, although these comprised only 7% of the whole 
cohort. Information regarding exposure status relied substantially on self-reported 
diagnoses or responses to questionnaire items. Nevertheless, descriptive data regarding 
sociodemographic factors, psychological measures and medication use supported the 
distinctions between the groups. The cross-sectional nature of the study and the limitations 
of the available clinical information also meant that the onset times and durations of 
exposures and outcomes were not known; exposure-outcome associations may not be 
causal, and it is possible that cognitive impairment may precede clinical onset of some 
disorders (e.g. schizophrenia). The UK Biobank cohort is not representative of the UK 
population in many respects, and the exposure groups that were identified within it are 
likely to differ from psychiatric and neurological samples in other studies and in clinical 
practice, with regard to sociodemographic characteristics, illness severity and motivational 
factors. It is not known whether the degree of non-representativeness differed across the 
exposure groups, however. If it did not, then between-group comparisons remain valid. 
Within the mood disorder groups, it was not possible to distinguish reliably between 
subtypes of bipolar presentations and single versus recurrent depression, thus limiting the 
comparability of the findings to previous clinical studies. Current depressive symptoms 
were reported, but status with regard to clinical euthymia was not known. The population 
attributable prevalence calculations were based on the standardised results presented in 
Table 5.2, in which comorbidities were permitted in the exposed groups but not in the 
unexposed comparison group; this does not reflect the composition of the general 
population, and the attributable estimates would only be considered valid if the results 
reflected a causal effect of the exposures on cognitive outcome.  
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The limitations of the cognitive tests were discussed in Chapter 3. It should also be noted 
that the impairment threshold in the present analyses differed slightly across the five tests, 
because of variation in the reference score distributions. It is possible that the relatively 
low impairment prevalence on these cognitive tests compared with previous clinical 
studies reflects insensitivity of the brief measures, or differential reliability across exposure 
groups, but variation in performance across groups was detectable whilst internal 
consistency was similar. Despite the very large size of the cohort, sample sizes were 
modest on some cognitive measures and data were sparse across strata in the narrowly-
defined exposure groups, which limited the standardised analyses. No information was 
available regarding the impact of cognitive impairment on instrumental functioning: it is 
possible that the impact of impairment on disability and participation is not well captured 
by the 5th percentile impairment threshold used here, given that the range of severity below 
this threshold may differ across disorders, and other people will experience instrumental 
dysfunction even when measured cognitive performance remains above the 5th percentile 
threshold.  
5.5 Conclusion 
In directly comparative analyses in this large general population cohort, cognitive 
impairment was most common in participants with schizophrenia and least common in 
those with major depression, although the much higher population prevalence of major 
depression means that the overall burden of cognitive impairment attributable to this 
disorder is likely to be considerable. Cognitive impairment in mania/BD has previously 
received less research and clinical attention than impairment in schizophrenia and 
neurological disorders, but direct comparisons in the present study indicated that 
impairment prevalence in mania/BD was similar to that in MS and PD, both of which are 
much less common in the population. Study limitations included self-reported data and 
selection bias.  
5.6 Next steps 
The analyses presented in this chapter aimed to quantify the prevalence of cognitive 
impairment in order to permit direct comparisons across disorders of interest. Although 
potential confounding influences of age, gender and education were taken into account, 
more complex analyses are required to investigate the multitude of other social, clinical, 
lifestyle and genetic factors that are likely to contribute to cognitive risk and resilience in 
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these disorders. Understanding such variation is the second key aim of this thesis. Chapter 
6 describes graphical and statistical methods for causal inference in the context of 
observational studies. Chapters 7 and 8 report the results of multivariate models to explain 
the effect of psychiatric exposures on cognitive impairment, and the role of intermediate 
risk factors.  
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Chapter 6 Causal inference with observational 
data 
The axiom that correlation does not imply causation is ingrained in scientific research. 
Most prudent researchers in the biomedical and social sciences are wary of making causal 
claims, especially in observational studies. Although this caution is well-founded, it 
illustrates the mismatch between a key rationale or motivation for conducting research—to 
explain phenomena—and the reality of the reported findings, which are often more 
descriptive than explanatory. Dissatisfaction with this mismatch, along with advances in 
statistical methods and computing power, have stimulated a different approach to data 
analysis that makes causal inference an explicit goal. Proponents of this approach 
encourage researchers to stop “retreating into the associational haven” and instead “to take 
the causal bull by the horns” (Hernán, 2005, p. 620). This chapter summarises the causal 
definitions on which this framework rests, the reasons why statistical associations arise in 
data, and the circumstances under which such associations may justify a causal 
interpretation. Methods for identifying and estimating total causal effects are outlined, 
together with approaches for effect decomposition within the causal framework, and 
threats to internal and external validity are considered. Although the causal inference 
framework has been applied to a variety of study designs including randomised controlled 
trials (e.g. Emsley, Dunn, & White, 2010; Kaufman, Kaufman, & Poole, 2003) and 
longitudinal repeated measures designs (e.g. Daniel, Cousens, De Stavola, Kenward, & 
Sterne, 2013), this chapter focuses primarily on causal inference in cross-sectional 
observational research.  
6.1 Conceptualisations of causality 
Many different conceptualisations and definitions of causality have been proposed by 
thinkers and researchers in a diverse range of fields, from philosophy to artificial 
intelligence. The ‘sufficient-component’ model (Rothman, 1976) has gained widespread 
acceptance in epidemiology, and underpins other key epidemiological concepts such as 
interaction and attributable risk. Under this model, a sufficient cause is defined as “a 
minimal set of conditions and events that are sufficient for the outcome to occur” 
(Rothman, Greenland, Poole, & Lash, 2008, p. 6). This set of conditions or events 
comprises multiple components, some of which are unknown, and the outcome will not 
occur unless all the components are present. Conversely, blocking or removing one or 
109 
 
more components will prevent the sufficient cause from acting to produce the outcome. For 
any given outcome, many different sufficient causes can be conceptualised, any one of 
which will produce the outcome in a particular individual. If there is a component that is 
part of all such sufficient causes, that component is considered a (universally) necessary 
cause.  
A key characteristic of all causal components is that they are contrasted with a specified 
alternative or referent. Tobacco smoking is considered a component cause of lung cancer, 
for example. Smoking might be specified as smoking 20 cigarettes per day for 40 years, 
and the specified referent would differ from this with regard to the number of cigarettes (or 
other tobacco product), and/or the duration of smoking. This type of contrast is intrinsic to 
the definition of causality that underpins the sufficient-component model: “a cause of a 
disease occurrence is an event, condition, or characteristic that preceded the disease onset 
and that, had the event, condition, or characteristic been different in a specified way, the 
disease either would not have occurred at all or would not have occurred until some later 
time” (Rothman et al., 2008, p. 6, italics added). The italicised phrases show that this 
definition of causality rests on counterfactuals, i.e. conditional statements containing 
antecedents (if-clauses) that are contrary to fact. The counterfactual view of causality has a 
long history in experimental research, statistics and economics, and within epidemiology it 
is primarily identified with the ‘potential outcomes’ framework of Rubin (1974), 
influenced by earlier research by Neyman (1990[1923]). Researchers working in this 
framework express causality in terms of potential outcomes under contrasting conditions. 
Using potential outcomes notation, where X is a binary exposure (or treatment) and Y is an 
outcome, Y(1) denotes the outcome if X were set (possibly contrary to fact) to 1, and Y(0) 
denotes the outcome if X were set (possibly contrary to fact) to 0. If the expected values 
(E[Y]) of these potential outcomes in the population are not equal, i.e.  
E[Y(1)] ≠ E[Y(0)] 
then X is said to have a causal effect on Y.   
An alternative notation system to express causal relationships is through graphs. This 
approach is primarily identified with Pearl (Pearl, 2009; Pearl et al., 2016). Pearl and 
colleagues defined causality informally as follows: “A variable X is a cause of a variable Y 
if Y in any way relies on X for its value…[We] think of causation as a form of listening; X 
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is a cause of Y if Y listens to X and decides its value in response to what it hears” (Pearl et 
al., 2016, p. 5). This simple situation is depicted graphically in Figure 6.1 below.  
 
 
 
Figure 6.1 - Directed acyclic graph showing a causal effect of X on Y 
 
Figure 6.1 is a directed acyclic graph (DAG), which encodes a structural causal model 
(SCM). Box 6.1 (overleaf) briefly summarises rules for the construction and interpretation 
of DAGs and SCMs. Despite the notational differences between graphical/SCM and 
potential outcomes representations of causal effects, these two frameworks have been 
shown to be logically equivalent (Pearl, 2009, Ch. 7). 
6.2 Sources of statistical association in data 
Aside from the play of chance, there are three key reasons why associations are observed 
between variables: causation, confounding, and collider conditioning (Elwert, 2013). These 
can be shown graphically in DAGs, thus demonstrating the correspondence between the 
causal relations depicted in the DAG and the probabilistic relations observed in the data. 
6.2.1 Causation 
As noted above, causation means that one variable relies for its value on another. This will 
induce a statistical association between measurements of those variables. Interpreting the 
direction of causation from an observed association requires background knowledge, for 
example regarding temporal order. Causal relations between variables are depicted 
graphically as chains (Figure 6.2 below). Variables at either end of a causal chain are likely 
to be unconditionally associated6 with each other, assuming (for example) that positive and 
negative causal effects at intermediate points along the chain do not exactly cancel each 
other out. If X and Y are two variables in a causal chain, the association between them can 
be broken by conditioning on an intermediate variable or set of variables, M. This means 
that X and Y are conditionally independent given M (provided that there is no other open 
path between X and Y except through M).  
                                                 
6 i.e. marginally associated, in a crude analysis 
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Box 6.1 - Directed acyclic graphs 
Directed acyclic graphs (DAG) are graphical tools that are employed by researchers to visually represent 
qualitative causal assumptions (Elwert, 2013). The structural nature of these assumptions permits the 
detection of implied patterns of dependency and independency among variables, which can then be 
tested with data. The structural relations encoded by the DAG are also used to detect whether causal 
effects of interest (e.g. the total causal effect of one variable on another) are identified, with or without 
conditioning on other variables. 
Each node in a DAG represents a variable, and each single-headed arrow represents a putative 
causal effect flowing from the node that emits the arrow (the parent) to the node that receives it (the 
child). The presence of an arrow represents the weak assumption of a causal relationship for at least one 
member of the population; the absence of an arrow between two nodes represents the strong 
assumption of no causal relationship for any member of the population. A node that only emits arrows is 
exogenous, and a node that receives any arrow is endogenous. A sequence of nodes connected by 
arrows (regardless of the direction of the arrowheads) is a path. If the sequence can be traced in one 
direction along the arrowheads, then the path is a directed path. Cyclical or reciprocal paths are not 
permitted in a DAG, but the same variable at different points in time can be shown as separate nodes.  
For a DAG to be considered a causal DAG, every common parent of every pair of nodes must be 
depicted, whether they are measured in the dataset or not. Unmeasured variables can be depicted as 
hollow or light-coloured nodes, as shown in Figure B.1 below.  
 
                      
 
Figure B.1   Panel (a) shows a DAG with one exogenous variable (Z) and two endogenous variables (X and Y). X is caused by Z, and Y 
is caused by X and Z. Panel (b) adds an exogenous node U, which is unmeasured. An alternative notation is to replace node U and 
its emitted arrows with a dashed bi-directed arc           between Z and Y. 
 
DAGs visually encode structural causal models (SCM), which provide a general framework for 
describing causal relations among variables. An SCM comprises a set of exogenous and endogenous 
variables, and a set of functions f that assigns each endogenous variable a value based on the values of 
the other variables in the model (Pearl et al., 2016). In this way, causality under the SCM is defined as 
follows: “A variable X is a direct cause of a variable Y if X appears in the function that assigns Y’s value. X 
is a cause of Y if it is a direct cause of Y, or any cause of Y” (Pearl et al., 2016, p. 26). Figure B.2 below 
shows a DAG whose corresponding functions can be expressed in the most general case as: 
     
 
 
 
Figure B.2   This DAG is shown ‘under magnification’ to include independent unmeasured nodes, representing unknown or random 
contributors to the observed variables. These unmeasured factors are assumed to be independent of each other and of all other 
nodes in the graph, and so are usually not shown for reasons of clarity. Only factors that influence two or more nodes must be 
depicted in a causal DAG.  
 
SCMs are non-parametric, which means that no assumptions are made about the distribution of 
the variables (e.g. continuous, discrete) or the functional form of the relationships between them (linear 
or non-linear). The possibility of interaction or effect modification is therefore accommodated within 
DAGs as a matter of course, without requiring additional graphical notation. 
Researchers who are accustomed to linear structural equation models (SEM) will note the visual 
similarity between DAGs and path diagrams used in SEM; DAGs can in fact be interpreted as non-
parametric structural equation models (NPSEM; Elwert, 2013), of which linear SEM is a special case. 
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Figure 6.2 - Causal chains 
 
In DAGs (a) to (c), X and Y are likely to be unconditionally associated. In DAG (d), X and Y 
are independent, conditional on M.  
 
6.2.2 Confounding 
Two variables may be unconditionally associated in a dataset if they share a common 
cause. This spurious association is the result of confounding bias, shown graphically by 
forks (Figure 6.3 below). Conditioning on the common cause (via statistical adjustment, 
stratification or sample restriction) will block the portion of the observed association that is 
spurious. If there is no other path between two variables X and Y apart from via common 
cause C, then X and Y are independent conditional on C.  
 
                               
 
Figure 6.3 - Confounding 
 
DAG (a) shows a causal effect of X on Y, and a confounding effect of their common cause, 
C. In DAG (b), X and Y are independent conditional on C, because the only path between 
them is the ‘back-door’ path via C, which is blocked. 
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The criteria typically used to identify confounding of an exposure-outcome association 
(McNamee, 2003) are that the putative confounding variable: must be a cause of the 
outcome (or a surrogate measure of a cause) in unexposed people; must be correlated with 
the exposure in the study population; and must not be on the causal pathway between the 
exposure and the outcome (or more generally, must not be affected by the exposure). The 
use of DAGs offers a structural method to detect confounding. The advantage of this 
approach is that it allows multiple possible confounders to be considered jointly, enabling 
the identification of crucial variables that must be taken into account when estimating the 
true effect of an exposure on an outcome. This method can be used when planning data 
collection or data analysis, to detect those variables that must be measured and those that 
need not be. This is achieved by applying the ‘d-separation’ criterion (see Box 6.2 below)  
to the DAG, either by hand or (for larger graphs) using an automated algorithm such as 
DAGitty (Textor, van der Zander, Gilthorpe, Liskiewicz, & Ellison, 2016). Importantly, 
examining variables jointly in terms of d-separation demonstrates that it is not always 
necessary to include all common causes in an analysis, because the potential confounding 
influence of one variable may already be blocked by another. This knowledge is 
particularly helpful when some common causes are unmeasured, or when measurement is 
difficult or expensive. Box 6.2 provides further information about d-separation and 
conditional independence in DAGs. The use of graphical methods to determine if causal 
effects are identified is described in section 6.4 below.    
6.2.3 Collider conditioning 
A shared outcome of two variables is referred to as a collider. This is shown graphically as 
a node where two arrowheads meet (Figure 6.4 below), i.e. an inverted fork (Elwert, 2013). 
Two variables, X and Y, are unconditionally independent given their shared outcome, S 
(assuming there are no other open paths between them), because the structural position of S 
as a collider prevents any association from flowing between X and Y. Importantly, 
however, conditioning on S, or on a descendant of S, unblocks the path between X and Y, 
thus inducing a spurious association within at least one stratum of S. This is collider 
conditioning (or collider stratification) bias, also known as Berkson’s bias or selection 
bias7 (Westreich, 2012). It is often illustrated with reference to restricted sampling 
situations, e.g.: sporting and musical talent may be independent in the population, but data 
                                                 
7 The term ‘selection bias’ is sometimes used in the literature to refer to non-random selection into 
treatment groups (i.e. confounding). In this thesis, ‘selection bias’ is used to denote non-random 
selection into a sample or an analysis, rather than selection into treatment/exposure groups.  
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gathered from scholarship students in a school that selects for these characteristics will 
indicate a spurious negative association. In the general population, knowing that someone 
lacks sporting prowess would not give any clues about their musical ability, but having 
additional information about scholarship status induces an inverse association such that 
lack of sporting talent increases the likelihood of musical excellence.  
 
                               
 
Figure 6.4 - Collider conditioning 
 
In DAG (a), X and Y are unconditionally independent, because the path between them is 
blocked by their shared outcome S, which is a collider node. In DAG (b), conditioning on S 
(e.g. through sample selection) induces a spurious association between X and Y in at least 
one stratum of S.  
  
Collider conditioning bias is recognised as a problem in a variety of research situations, not 
just with regard to sample selection at the study outset but also when there are missing data 
issues more generally (Westreich, 2012). For example, if loss to follow-up or patterns of 
missing assessment data are a result of the exposure and outcome of interest in the study, 
collider conditioning bias may affect the measured associations in the analysis sample. The 
potential impact on genetic association studies has also been highlighted (Munafò et al., 
2017; Yaghootkar et al., 2017). Box 6.2 describes how the DAG d-separation criterion 
seeks to avoid collider conditioning bias whilst blocking confounding bias.  
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6.3 Assumptions necessary for valid causal inference 
Within the potential outcomes framework, a number of assumptions have been set out as 
prerequisites for valid causal inference. Further assumptions are required when working 
with DAGs. These core assumptions are summarised here. Where additional assumptions 
apply to the identifiability of particular causal effects (e.g. indirect effects), these are noted 
in sections 6.4 and 6.5 below. 
Box 6.2 - D-separation and conditional independence in DAGs 
Elwert (2013, p. 252) notes that “All associations between variables in a DAG are transmitted along 
paths. Not all paths, however, transmit association”. If two nodes X and Y are linked by any open path 
then they are d-connected (d stands for directional), and if all paths between them are blocked then 
they are d-separated. A path can be blocked by a single node; it is not necessary to block all the nodes on 
the path. In this way, a variable that meets the standard definition of a confounder (McNamee, 2003) 
will not necessarily exert a confounding influence in an analysis, provided all biasing paths are blocked by 
other variables.  
Pearl’s d-separation criterion (Pearl, 1986; Pearl, Glymour, & Jewell, 2016) determines whether 
each pair of nodes in a DAG is d-separated or d-connected along every possible path, regardless of the 
size or complexity of the DAG. This is determined entirely from the structure of the graph, rather than 
from measured data. The criterion for deciding whether X is d-separated from Y, given a covariate set Z, 
can be expressed as follows (Pearl et al., 2016, Ch.2): 
 A path is blocked by a set of nodes Z if and only if 
1. The path contains a chain or a fork such that the middle node is in Z (i.e. it is conditioned 
on), or 
2. The path contains a collider (inverted fork) such that the collider node is not in Z, and no 
descendant of the collider node is in Z (i.e. no conditioning on colliders or their 
descendants). 
By applying this criterion, it is possible to generate a list of unconditional and conditional independencies 
implied by a DAG. For example, the DAGitty web algorithm (Textor, Hardt, & Knuppel, 2011) indicates 
that the following independencies are implied by the DAG below (where ⊥ denotes ‘independent of’ and 
| denotes ‘conditional on’): 
 
  
 
Figure B.3 DAG created in the DAGitty web tool, along with its testable implied independencies.  
 
The DAGitty algorithm only generates lists of testable independencies, ignoring any unmeasured nodes 
(e.g. U, shown in light grey above). The predicted independencies can be tested empirically using 
measured data, as an indicator of local model fit. Observed associations that depart from the null may 
indicate misspecification in certain parts of the model, or other issues such as measurement error. The 
predicted conditional independencies derived from a DAG are equivalent to vanishing partial correlations 
in linear path diagrams (Pearl, 1998). 
A ⊥ C 
C ⊥ X | A, B
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6.3.1 Conditional exchangeability 
At the heart of the potential outcomes framework is the idea of comparing outcomes under 
mutually exclusive conditions: being exposed (or treated) versus being unexposed (or 
untreated). The ‘fundamental problem’ of causal inference (Holland, 1986) is that these 
outcomes cannot be observed simultaneously in the same individual; they necessitate 
imagining alternative possible worlds. The closest practicable way of realising and 
comparing potential outcomes is through randomised controlled trials (RCT), in which the 
treated and untreated participants experience the counterfactual conditions. The validity of 
RCTs rests on the comparability of the treatment and control groups at the point of 
randomisation: their potential outcomes are taken to be equivalent prior to treatment, 
because the distribution of confounding factors is the same in both groups (assuming 
adequate sample size and an effective randomisation scheme). In this way, the two groups 
are considered exchangeable by design at the point of assignment to treatment (X = 1) or 
control (X = 0), and their potential outcomes Y (prior to treatment) are unconditionally 
independent of their treatment assignment. This is expressed in counterfactual notation as 
[Y(1), Y(0)] ⊥ X 
When working with observational data in the causal inference framework, the goal is to 
achieve conditional exchangeability8 between the exposed (treated) and unexposed 
(untreated) groups, such that their potential outcomes are independent of their exposure 
status, conditional on a set of observed pre-exposure covariates, Z: 
[Y(1), Y(0)] ⊥ X | Z 
Furthermore, an assumption of positivity must hold, which means that there must be some 
exposed and some unexposed individuals in each stratum of Z in the population (Westreich 
& Cole, 2010).  
The conditional exchangeability assumption is not empirically verifiable, because the 
counterfactual outcomes for each individual are unobservable, and many pre-exposure 
characteristics will be unmeasured. Data analysis methods aimed at justifying this 
assumption are described in section 6.4 below. 
                                                 
8 Conditional exchangeability is known by other terms such as ignorable treatment assignment, 
selection on observables, exogeneity, and no unmeasured confounding given the measured 
variables (Guo & Fraser, 2010, Ch.2; Hernán & Robins, 2006). 
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6.3.2 Stable unit treatment value assumption (SUTVA) 
This assumption was set out by Rubin (1986), and is necessary for valid causal inference in 
both RCTs and observational studies (Hernán & Robins, 2006). SUTVA encompasses two 
elements. The first element is known as consistency: for individuals who actually receive 
exposure level x, actual outcome Y is the same as potential outcome Y(x). In studies where 
there may be more than one version of the same exposure/treatment (i.e. X = 1 differs in 
some uncontrolled way across individuals, for example in a therapy trial with multiple 
therapists or an unstandardised treatment programme), the consistency assumption may not 
hold. In practice, the consistency assumption necessitates a causal contrast between well-
defined exposure/treatment conditions (Hernán & Taubman, 2008). The second element is 
known as no interference: one individual’s outcome is not influenced by the exposure 
status of another individual. Together, the elements of SUTVA assume that each individual 
has only one potential outcome under each exposure condition (Schwartz, Gatto, & 
Campbell, 2012). If SUTVA is violated, the causal effect cannot be predicted consistently. 
6.3.3 Graphical model assumptions 
Two additional assumptions apply when working with DAGs, to enable the structure of the 
DAG to be linked with probability statements about the variables (Glymour, 2006).  
6.3.3.1 Causal Markov assumption 
The causal Markov assumption underpins the d-separation criterion stated in Box 6.2 
above. DAGs are Markovian or semi-Markovian (also known as recursive). In such 
models, each variable is independent of all its non-descendants in the graph, conditional on 
its parents (Pearl, 1998). This property means that all conditional independencies implied 
by the graph will be detected using the d-separation criterion.  
6.3.3.2 Faithfulness 
Under faithfulness, it is assumed that positive and negative causal effects never exactly 
cancel each other out (Glymour, 2006). If a positive causal effect of X on Y along one path 
were exactly offset by a negative causal effect of X on Y along a different path, the net 
statistical association would be zero; this would be unfaithful to the causal relation. It is 
assumed in practice that this will not occur.  
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6.4 Total causal effects 
The total causal effect of X on Y, under the assumptions outlined above (conditional 
exchangeability and SUTVA), can be given as 
E[Y(1)] − E[Y(0)] 
which denotes the average causal effect9 expressed as a marginal mean difference, for 
binary X and continuous Y data. This effect is of interest when one wishes to quantify an 
overall causal relationship, through all intermediate causal pathways, unbiased by 
confounding or selection issues. The aim is to establish whether a causal effect is likely to 
exist. Further research can then be undertaken to understand the mechanism by which the 
causal effect is transmitted; this is considered in section 6.5 below.  
6.4.1 Identification 
The decision as to whether the total causal effect is identified (i.e. estimable with the 
available data) in an observational study rests on the structural causal model developed by 
the researcher. DAGs are especially useful here, because they require the researcher to 
explicitly show his or her assumptions regarding the exposure-outcome relationship in the 
context of multiple covariates, in light of background knowledge in the field. D-separation-
based methods are then used to determine an appropriate set of covariates to justify the 
conditional exchangeability assumption.  
The core method by which total causal effects are identified from DAGs is called the 
‘back-door’ criterion. It takes this name because its purpose is to block non-causal paths 
between the exposure (X) and the outcome (Y), and these paths begin with an arrowhead 
pointing to the exposure (X←). The back-door criterion can be expressed as follows 
(Elwert, 2013; Pearl et al., 2016, Ch. 3): a set of observed variables Z (which may be 
empty) satisfies the back-door criterion relative to (X, Y) if no node in Z is a descendant of 
X, and Z blocks every path between X and Y that contains an arrow into X. Therefore, 
conditioning on the set Z will block all spurious paths between X and Y, while leaving all 
directed (causal) paths open, and without creating any new spurious paths (Pearl et al., 
2016, Ch. 3). 
                                                 
9 This is known in much of the literature as the average treatment effect (ATE), which represents 
the average effect, at the population level, of moving everyone from untreated to treated status 
(Austin, 2011). 
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If there is a set Z that satisfies this criterion, then the total causal effect of X on Y is non-
parametrically identified. The smallest possible set Z that satisfies the back-door criterion 
is referred to as a minimally sufficient set (Elwert, 2013). There may be more than one 
minimally sufficient set; the estimate of the total causal effect should be the same 
regardless of which minimally sufficient set is conditioned on, if the model is correctly 
specified. 
An alternative approach called the ‘front-door’ criterion (Pearl et al., 2016, Ch. 3) may 
allow a total causal effect to be identified in models where the back-door criterion is not 
met. This approach entails “piecing together a total causal effect from its constituent parts 
through repeated application of the back-door criterion” (Elwert, 2013, p. 261). This would 
be possible in a situation where X and Y were d-connected along a back-door path by an 
unmeasured confounder, but all causal paths from X to Y were intercepted by a set of 
measured intermediate variables Z, and the causal paths from X to Z and from Z to Y are 
identified.   
Instrumental variables offer an additional method for identifying total causal effects. A 
variable Z is an instrumental variable (‘instrument’ or IV) for the total causal effect10 of X 
on Y if: Z affects X; Z affects Y only through X; and Z is independent of the X-Y 
confounders (Glymour & Greenland, 2008). Although used for many decades in other 
fields such as econometrics, IV approaches have become well-known only more recently 
in epidemiology. This is partly through the popularity of Mendelian randomisation, which 
uses genotypic data as instruments for health-related exposures (Lawlor, Harbord, Sterne, 
Timpson, & Smith, 2008). Instrumental variables can be readily detected from the structure 
of a DAG, and this is automated in the DAGitty program (Textor et al., 2016). 
6.4.2 Estimation 
Once a causal effect has been structurally identified, there are many different methods for 
estimating this using the data. The most common approaches will be outlined here. 
                                                 
10 The total causal effect identified in this way is known as the local average treatment effect 
(LATE) or the complier average causal effect (CACE), because it is interpreted as the causal 
effect among those participants for whom the instrument Z actually affects the value of the 
exposure/treatment X (Angrist, Imbens, & Rubin, 1996).  
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6.4.2.1 Multiple regression 
Multiple regression can be used to estimate total causal effects using observational data, 
adjusting for all necessary covariates determined by the identification process. Most 
statistical analysis packages accommodate a wide range of linear and generalised 
regression models, thus permitting flexibility in modelling different types of outcome 
variable distributions and non-linear functions. Provided the assumptions necessary for 
causal inference can be justified, the coefficient of the exposure variable is interpreted as a 
causal effect, conditional on the covariates. The coefficients of the covariates do not have a 
causal interpretation; erroneous interpretation of these coefficients has been termed the 
‘Table 2 fallacy’ (Westreich & Greenland, 2013). It should also be noted that the use of 
multiple regression to estimate a causal effect is distinct from its use for prediction 
purposes: a prediction score can be developed from multiple regression model coefficients, 
reflecting the predictive power of certain risk factors, but this does not require, or imply, a 
causal interpretation (Hernán & Robins, 2017, Ch. 3). 
6.4.2.2 Propensity score-based methods 
These methods aim to use a measure of exposure propensity to achieve conditional 
exchangeability (predicated on the assumptions already discussed above). Various 
estimators are readily available in commonly used statistics packages, including Stata and 
R. 
Rather than using the exposure and covariate data to model the outcome directly, these 
estimators first model the probability (propensity) of belonging to the exposed group 
(Austin, 2011; Garrido et al., 2014). Exposure status is entered as the dependent variable in 
a logit or probit regression model, with the observed covariates entered as the regressors, 
including interaction terms as required. The fitted probability values from this model form 
a propensity score, which is then used to match or weight the exposure groups when 
modelling the outcome. The aim is to achieve conditional balance in the distribution of the 
observed covariates between the two groups; this can be checked using balance diagnostic 
procedures, although of course the influence of unmeasured confounding factors cannot be 
tested empirically. It has been suggested that all measured pre-exposure variables can be 
entered into this model (Austin, 2011). Somewhat counter-intuitively, simulation studies 
have indicated that including covariates that are thought to affect the outcome but not the 
exposure can improve the propensity model fit, possibly because such variables can show 
chance associations with the exposure in a measured dataset (Brookhart et al., 2006). The 
121 
 
chosen set of variables should also satisfy the back-door criterion for the total causal effect 
of the exposure on the outcome (Pearl et al., 2016, Ch. 3). Finding the best specification of 
the propensity model can be aided by data-driven or machine learning methods such as 
generalised boosted modelling (McCaffrey, Ridgeway, & Morral, 2004), although it should 
be noted that machine learning classifiers that aim to maximise exposure classification 
accuracy will not necessarily produce optimal covariate balance in a particular dataset.  
A benefit of the propensity score is that it is a single measure based jointly on all the 
covariates, thus avoiding the problem of dimensionality that arises when attempting to 
stratify or match directly on multiple covariates (Guo & Fraser, 2010, Ch. 5). A further 
advantage is that imbalance can be directly ‘diagnosed’ in the propensity model, whereas 
misspecification of a multiple regression model for the outcome is harder to detect. It has 
also been noted that the process of modelling exposure propensity separately before 
modelling the outcome is analogous to the stages of an RCT, where design factors are dealt 
with before the outcome is analysed (Austin, 2011), thus providing a principled way of 
approaching the analysis.  
Propensity score-based estimators typically employ either matching or weighting 
procedures. Propensity score matching (PSM) involves deriving matched sets of exposed 
and unexposed participants whose propensity scores are similar. This can be done on a 
one-to-one or one-to-many basis, with or without replacement, and the researcher can 
define the acceptable limits of similarity of the propensity scores (Austin, 2011). A 
potential drawback is that this entails excluding participants who cannot be adequately 
matched, thus reducing the sample size and restricting the region of common support in the 
analysed data (Guo & Fraser, 2010, Ch. 5). An alternative approach is inverse probability 
weighting (IPW): a participant’s analysis weight is calculated as the reciprocal of the 
probability of the exposure status that was actually observed, which equates to 
 for the exposed participants and  for those in the unexposed 
group, and this weight is then applied to a regression model of the outcome on exposure 
status. This method allows the whole sample to be analysed, but results may be sensitive to 
extreme weights (Austin, 2011).  
PSM and IPW both focus on specifying a model for exposure status rather than a model for 
the outcome. Related methods that include separate models for both the exposure and the 
outcome are also available. These are known as doubly robust estimators, because the 
122 
 
result will be unbiased and consistent as long as either the exposure model or the outcome 
model is correctly specified; it is not necessary for both to be correctly specified (Bang & 
Robins, 2005). A propensity model for the exposure is specified as described above, and a 
model for the outcome is separately specified, including covariates that overlap with the 
propensity model regressors if appropriate. Estimators of this type include IPW with 
regression adjustment and augmented IPW (Cattaneo, Drukker, & Holland, 2013). 
Targeted maximum likelihood estimation (TMLE) can also be used, with the option of 
incorporating machine learning methods to optimise specification (Schuler & Rose, 2017).  
6.4.2.3 IV estimation 
If the total causal effect has been identified using the instrumental variables approach, this 
can be estimated using IV models such as two-stage least squares (Wooldridge, 2016, Ch. 
15); this essentially entails regressing the exposure variable on the IV(s), obtaining the 
fitted values, and then regressing the outcome variable on the fitted values. This can be 
implemented in one step, for example using ivregress in Stata. Additional IV 
estimation methods have been developed specifically for Mendelian randomisation studies, 
where there may be problems with weak instruments or pleiotropy (Bowden, Smith, & 
Burgess, 2015; Bowden, Smith, Haycock, & Burgess, 2016; Burgess, Small, & Thompson, 
2015).  
6.5 Decomposition into direct and indirect effects 
The practice of partitioning total effects into direct and indirect effects (Figure 6.5) has a 
long history in psychology and the social sciences. Many researchers in these fields are 
familiar with regression-based techniques for quantifying mediation, and extensions into 
larger path analyses, usually within the framework of the so-called Baron-Kenny approach 
(Baron & Kenny, 1986) and linear structural equation modelling (SEM; e.g. Kline, 2016).  
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Figure 6.5 - Simple mediation model 
 
DAG showing a direct causal effect of X on Y, and an indirect causal effect through a 
mediator, M. The total effect of X on Y is the effect through all paths together. 
 
Effect decomposition has historically received less attention in epidemiology, although 
recent years have seen an increasing interest in the goal of opening the ‘black box’ of 
causality to understand the pathways by which causes lead to outcomes (Hafeman & 
Schwartz, 2009); it is argued that this can help to strengthen confidence in the total effect 
estimates, as well as highlighting intermediate factors that are relevant for intervention 
planning. 
This increase in interest has sparked greater attention to methods for causal mediation 
analysis within the potential outcomes framework. In particular, the assumptions required 
for estimates in a mediation model to have a causal interpretation have come under detailed 
scrutiny. A key issue that has been highlighted is that even if exchangeability can be 
assumed with respect to exposure status, the association between the mediator and the 
outcome may still be confounded. This is true even in an RCT, because although the 
exposure (treatment) is randomised, the mediator usually is not (D. P. MacKinnon & 
Pirlott, 2015; VanderWeele, 2016b). There is reportedly less awareness of the problem of 
mediator-outcome confounding among practitioners working in the Baron-Kenny or SEM 
frameworks (Pearl, 2014), and it has been suggested that this is partly because this issue 
was not discussed in the classic paper of Baron and Kenny (1986), despite having been 
clearly highlighted in an earlier paper by Judd and Kenny (1981). This has been a key 
focus for causal mediation researchers within epidemiology, and will be discussed further 
below in the context of effect identification. Conversely, the opportunity to incorporate 
measurement error through latent variables in causal mediation models has been 
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highlighted by experts working in the SEM tradition (Muthén & Asparouhov, 2015), and 
the importance of this for valid causal inference warrants greater attention.  
The intrinsic links between the graphical and counterfactual frameworks and linear SEM 
path models have been demonstrated in detail (De Stavola, Daniel, Ploubidis, & Micali, 
2015; Pearl, 2012, 2014). One difference of emphasis, however, concerns the 
conceptualisation of the direct and indirect effects. In the Baron-Kenny approach, these are 
stated in terms of products or differences of linear regression coefficients (outlined in the 
context of estimation in section 6.5.2 below). Within the counterfactual approach, non-
parametric definitions have been put forward for two different types of direct effects, and 
one indirect effect (Pearl, 2014). These definitions rest on the comparison of two 
hypothetical worlds, in which the values of the exposure and/or the mediator differ. In the 
examples below, X is a binary exposure, Y is a continuous outcome, and M is a binary or 
continuous mediator. Note that with respect to one particular mediator M, the term ‘direct 
effect’ refers to the portion of the total effect that does not go through M (although it may 
go through other mediators), and the ‘indirect effect’ refers to the portion of the total effect 
that goes only through M. 
The controlled direct effect (CDE) of X on Y when M is controlled at m, expressed as a 
marginal mean difference, is: 
CDE(m) = E[Y(1, m)] – E[Y(0, m)] 
Here, X is set to 1 in one hypothetical world, and set to 0 in the other, but M is set to the 
same fixed value m in both worlds. By fixing M at m, the CDE represents the direct effect 
of X only, unmediated by M. The complementary concept of a controlled indirect effect is 
undefined, however, because the CDE will change according to the value that M is set to, 
yet the total effect stays constant (i.e. it is not possible to subtract the CDE from the total 
effect to obtain a controlled indirect effect). Instead, a natural direct effect (NDE) has been 
defined, which does have a complementary natural indirect effect, together summing to the 
total effect. The NDE compares one world in which X is set to 1, and another world in 
which X is set to 0. But in both worlds, M is set to M(0), i.e. the value that M would 
naturally take had X been set to 0: 
NDE = E[Y(1, M(0))] – E[Y(0, M(0))] 
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For the natural indirect effect (NIE), X is set to 1 in both worlds. In one world, M is set to 
the value it would naturally take when X is 1, but in the other world, M is set to the value it 
would have naturally taken had X been 0: 
NIE = E[Y(1, M(1))] – E[Y(1, M(0))] 
If the indirect effect is of primary interest in a research study, specific identification 
assumptions must be met, and these are outlined below.  
6.5.1 Identification 
The following extended assumptions apply to the identification of natural direct and 
indirect effects (De Stavola et al., 2015; Pearl, 2014): the no interference assumption 
extends to the effect of X on M and of M on Y; the consistency assumption is generalised to 
all potential outcomes for M and Y; and the conditional exchangeability assumption 
requires all back-door paths between X and M and between M and Y to be blocked, as well 
as those between X and Y.  
If the structural model indicates that the mediator of interest is itself affected by another 
mediator, this is termed intermediate confounding (De Stavola et al., 2015), as shown in 
Figure 6.6 below.  
 
 
 
Figure 6.6 - Intermediate confounding 
 
In this DAG, M1 and M2 are both mediators of the causal effect of X on Y. M1 also affects M2, 
which means that M1 is an intermediate confounder: M1 lies on an open back-door path from 
M2 to Y.  
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This situation imposes additional identification challenges for the natural direct and 
indirect effects. If M2 is the mediator of interest in Figure 6.6, then M1 must be conditioned 
on, because it is a confounder of the causal relationship between M2 and Y. M1 is also 
affected by X, however, which normally suggests it should not be conditioned on. In this 
situation, it is possible to condition on the intermediate confounder M1 if a further 
parametric assumption is made that there is no interaction between X and M2 at an 
individual level (De Stavola et al., 2015; Robins & Greenland, 1992). Alternatively, an 
assumption can be made that, conditional on other relevant confounders, the CDE does not 
vary according to the value of M2 when X = 0 (Petersen, Sinisi, & van der Laan, 2006). It 
has been suggested that these estimands be considered ‘randomised interventional analogs’ 
of the NDE and the NIE (VanderWeele, Vansteelandt, & Robins, 2014): rather than setting 
the values of the mediator to what they would have been for each individual under a 
particular level of the exposure, the effect is instead defined with the mediator set to a 
random value from the distribution of mediator values among all those at a particular level 
of exposure.  
6.5.2 Estimation 
6.5.2.1 General methods 
As with total causal effects, several options are available for estimating direct and indirect 
effects. The most general method is based on G-computation (Robins, 1986), a technique 
equivalent to standardisation to the total population, which was originally introduced as a 
way of estimating the effects of time-varying exposures. As implemented in the Stata 
command gformula (Daniel, De Stavola, & Cousens, 2011), this is extended to generate 
estimates of the CDE, NDE, NIE and total effects, in flexible models that accommodate 
continuous and binary outcome variables. The gformula command also estimates 
models with intermediate confounding. The command paramed (Emsley & Liu, 2013) is 
also available in Stata, although it does not accommodate models with intermediate 
confounding. Other estimators mentioned earlier, such as IPW and doubly robust 
approaches, can be used in mediation analysis (De Stavola et al., 2015; Linden & Karlson, 
2013). 
6.5.2.2 Linear regression methods 
SEM and Baron-Kenny framework mediation models are based on linear regression 
estimation. The core feature of this approach to mediation, as developed by Baron and 
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Kenny (1986), is that the relationship between total, direct and indirect effects is expressed 
in terms of products or differences of linear regression coefficients. Figure 6.7 below 
shows a simple mediation model with structural parameters labelled α, β and γ.  
 
 
 
Figure 6.7 - Linear mediation model 
 
This is the linear case of a basic DAG for mediation. The structural parameters labelled on 
each path correspond to linear regression estimates, assuming independent error terms 
and no interaction. 
 
Provided that the aforementioned causal inference assumptions hold, in addition to 
assuming linearity, independent errors and no interaction, the causal effects are identified. 
The equations for the three variables are: 
    
The total causal effect τ is: 
 
This decomposes into the direct effect, β, and the indirect effect, αγ. The total effect τ can 
be estimated by regressing Y on X. Then, Y is regressed on X and M to obtain the 
coefficient of X conditional on M (the direct effect, β), and this is subtracted from the total 
effect to quantify the indirect effect mediated through M (αγ). Alternatively, M can be 
regressed on X to obtain coefficient α, and Y can be regressed on M conditional on X to 
give γ. These can be multiplied to give the indirect effect, then subtracted from τ to give 
the direct effect β.  
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If all the assumptions hold, τ corresponds to the counterfactually-defined total causal 
effect, β corresponds to both the NDE and the CDE(m), and αγ corresponds to the NIE 
(Pearl, 2014).  
Linear regression-based mediation models can be estimated with specific packages such as 
PROCESS for SPSS and SAS software (Hayes, 2013). More extensive path diagrams or 
structural models with latent variables can be estimated using SEM programs, including 
Stata’s sem command or standalone programs such as Mplus (Muthén, Muthén, & 
Asparouhov, 2016). These allow a system of equations to be estimated simultaneously, 
following which specific directed path coefficients within the model can be multiplied and 
summed to derive any desired indirect effect estimates. Strong assumptions are necessary 
for the results of such a procedure to have a causal interpretation, because the no-
confounding requirement applies to every path in the model. An advantage of the SEM 
estimation method is that, assuming all assumptions hold, the issue of multiple mediators 
and intermediate confounding is easily accommodated in the simultaneous estimation 
process (De Stavola et al., 2015).  
6.6 Validity and generalisability 
As has been evident in this chapter so far, valid causal inference is heavily dependent on a 
range of testable and untestable assumptions. Care must be taken to consider these at all 
stages of study planning and analysis, and sensitivity analyses for key threats to validity 
should be undertaken where possible. This section summarises some of these 
considerations.  
6.6.1 Model misspecification and residual confounding 
Uncertainty regarding temporal order is a particular problem in cross-sectional studies, and 
in many longitudinal studies, unless the study cohort was recruited long before the relevant 
exposure period. Despite the availability of data-driven estimation methods and balance 
‘diagnostics’, misspecification is not generally amenable to empirical evaluation, primarily 
because the role of unmeasured covariates is unknown. It is important that researchers 
spend time developing comprehensive graphical models, including plausible alternative 
specifications. The final analysed models can also be examined for structural equivalence 
with other models that are compatible with the data. A range of fixed and probabilistic 
methods for quantitative bias analysis are now available, allowing researchers to explore 
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the magnitude of residual bias that would negate the observed results (Lash, Fox, & Fink, 
2009; Rosenbaum, 2002). 
6.6.2 Selection bias and missing data 
The non-random nature of recruitment into most observational studies means that collider 
conditioning bias is likely to be widespread, particularly with regard to the psychiatric and 
cognitive characteristics that are the subject of this thesis. Patterns of missing data among 
the participants will also be subject to this problem, leading to biased selection into the 
analysis sample. Methods are available to determine the probable direction of bias in light 
of the presumed missingness mechanism (Daniel, Kenward, Cousens, & De Stavola, 
2012), and quantitative bias analysis approaches can also be applied (Lash et al., 2009), 
although these may require additional data (e.g. regarding invitees who declined or 
participants who dropped out). Weighting and/or imputation methods may be appropriate, 
if missingness mechanism assumptions are met, and some statistical programs offer 
optimised estimation methods such as full information maximum likelihood as an 
alternative to complete case analysis.  
6.6.3 Measurement error, misclassification and power 
The potential effect of measurement error and misclassification depends on whether it 
arises randomly or systematically, and whether it is differential or non-differential with 
respect to the outcome. VanderWeele and Hernán (2012) have developed ‘signed DAGs’ 
to facilitate a qualitative appraisal of the likely presence and direction of true causal effects 
in the context of different error scenarios. Lash et al. (2009) again provide quantitative 
options to estimate the effect of different levels of classification accuracy on the results 
estimates. The biasing impact of measurement error in a mediator can be appraised with 
regard to the direct and indirect effect estimates (VanderWeele, Valeri, & Ogburn, 2012), 
and measurement error can be incorporated directly in SEM analysis through the use of 
latent variables. The implications of random measurement error for study power should 
also be considered.  
6.6.4 Generalisability 
Related to the issue of sample selection bias are questions regarding the extent to which 
study results are generalisable (or transportable) to the source population or to populations 
elsewhere. A range of weighting and imputation-based methods can be used to estimate the 
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magnitude of bias in study estimates compared with the reference population, provided that 
data are available for comparison (Gorman et al., 2017; Stuart, Cole, Bradshaw, & Leaf, 
2011; Westreich, Edwards, Lesko, Stuart, & Cole, 2017). It is also important to gather 
information about the population prevalence of the various component causes that act in 
concert with identified exposures, as this will influence the extent to which the exposure 
expresses its effects in a given population (Keyes & Galea, 2017). 
6.7 Criticisms of the causal inference approach 
The causal inference approach is relatively new in epidemiology, and it has generated 
some strong criticism (Broadbent, Vandenbroucke, & Pearce, 2016; Krieger & Smith, 
2016a, 2016b; Vandenbroucke, Broadbent, & Pearce, 2016), together with an equally 
robust defence from its proponents (Blakely, Lynch, & Bentley, 2016; Daniel, De Stavola, 
& Vansteelandt, 2016; VanderWeele, 2016a; VanderWeele, Hernán, Tchetgen, & Robins, 
2016).  
One of the criticisms expressed is that causal inference methods require unfeasibly strong 
assumptions. Conversely, it has been pointed out that many of the same assumptions 
simply remain hidden in other types of analysis, and that causal inference methodologists 
helpfully direct much of their efforts to determining when such assumptions can be relaxed 
and what kinds of sensitivity analyses should be done (Daniel et al., 2016). In the words of 
Pearl and Bareinboim (2014, p. 580), “…assumptions are self-destructive in their honesty. 
The more explicit the assumption, the more criticism it invites, for it tends to trigger a 
richer space of alternative scenarios in which the assumption may fail. Researchers prefer 
therefore to … make assumptions in private”. The approach taken in this thesis is to aim 
for transparency regarding the assumptions that are made.  
The assumption that has sparked the most debate in this regard is that exposures or 
treatments should be well-defined (Hernán, 2016; Kaufman, 2016; Schwartz, Gatto, & 
Campbell, 2016; Vandenbroucke et al., 2016). In its strongest form, this entails taking the 
position that there is “no causation without manipulation” (Holland, 1986) in 
epidemiological research, i.e. that causal effects cannot be attributed to any factor that is 
not amenable to intervention. The position of current practitioners appears to be more 
nuanced than this (VanderWeele, 2016a), with a distinction being drawn between a broad 
definition of a cause, and a somewhat narrower focus on what sorts of counterfactuals can 
reasonably be given a numerical estimate in an analysis. Nevertheless, key figures in the 
131 
 
field such as Hernán have argued cogently for the importance of well-defined 
exposures/interventions for underpinning the core assumptions of causal inference methods 
(Hernán, 2005, 2016; Hernán & Taubman, 2008).  
A second point of debate has been the relative merits of DAGs to aid causal inference 
(Krieger & Smith, 2016b). As already noted above, it is important that time is taken to 
develop comprehensive DAGs that appropriately reflect expert knowledge in the field, and 
to acknowledge plausible alternative specifications. Concerns centre on the possibility that 
users of DAGs will become blinkered by the diagram, and hence will make reactive model 
alterations that are data-driven rather than guided by theory or knowledge. This concern 
appears to be partly based on misunderstandings about what automated tools such as 
DAGitty actually do; the identification algorithms are entirely driven by the graph structure 
(i.e. the researcher’s beliefs), without involving any measured data at all, but it is not clear 
if this is fully appreciated by some critics11 (Krieger & Smith, 2016a). 
A broader issue that has been raised is that causal inference methods are but one of many 
complementary strategies for getting closer to the truth of causation. Critics have reminded 
users that causal inference in a broad sense relies on triangulation across different research 
methods with their own particular strengths and unique sources of bias (Lawlor, Tilling, & 
Smith, 2016). The benefits of ‘inference to the best explanation’ have also been 
highlighted, as a guide for moving away from overly deductive thinking and towards a 
more open-ended process of evaluating a causal explanation in the context of other 
plausible explanations (Krieger & Smith, 2016b). Thus the results of any one study—
within the causal inference framework or not—must be interpreted cautiously without 
losing sight of the wider context.  
6.8 Overview of analyses in UK Biobank 
Chapters 7 and 8 describe the application of causal inference methods to understand the 
effects of psychiatric conditions on cognitive function, and the role of intermediate risk 
factors in explaining any such effect. These methods were applied to cross-sectional 
observational data in the UK Biobank cohort, and the benefits and limitations of this 
framework were considered in light of the available data and the plausibility of the 
                                                 
11 The cited paper states critically that DAGitty offers automation for “selection of instrumental 
variables from the data provided”, and that “The use of instruments that are data-derived, rather 
than from subject-specific knowledge, is likely to lead to highly misleading findings, given the 
impact of measurement characteristics on such selection”. 
132 
 
assumptions required for valid causal inference. Graphical models were developed, which 
informed methods to estimate total causal effects, and direct and indirect effects where 
these were identified. Multiple estimators were used for comparison, and sensitivity 
analyses were conducted where possible with respect to key threats to validity.  
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Chapter 7 Explaining variation in cognitive 
function in bipolar disorder 
The study presented in this chapter aimed to estimate the total causal effect of bipolar 
disorder on cognitive function, and to decompose any such effect into direct and indirect 
effects through potentially modifiable intermediate factors. A graphical model was first 
developed, based on previous literature and assumptions regarding confounding influences 
and intermediate causal pathways. This was then applied to baseline data from UK 
Biobank. Following initial evaluation of the fit of the graphical model to these data, the 
total effect was identified and estimated using a range of regression- and matching-based 
methods. Decomposition of the total effect into direct and indirect effects was then 
conducted, where possible. The results were interpreted in light of the assumptions 
outlined in Chapter 6.  
7.1 Methods 
7.1.1 Participants 
Cross-sectional data from the full cohort at baseline (n = 502,618) were used. Of these, 
participants were retained for analysis if they had sufficient data to classify their exposure 
status (see below) and had data on at least one cognitive outcome measure. Adjusted 
analyses were restricted to participants of white British genetic ancestry, as explained in 
more detail below; the unadjusted analyses were not restricted by ethnic group. The sample 
size available for analysis is detailed in section 7.2.1. 
7.1.2 Exposure status 
The illness exposure of interest was mania or bipolar disorder (mania/BD), classified using 
the broad definition given in Chapter 4 (i.e. met criteria for mania or bipolar disorder 
according to self-reported diagnosis, or touchscreen mood questionnaire algorithm, or pre-
baseline hospital records; participants were classified as exposed if they met the criteria in 
at least one information source, even if other information sources were missing). The 
unexposed comparison group comprised participants who had complete self-reported and 
touchscreen mood questionnaire data indicating that they did not meet criteria for 
mania/BD or major depression, and whose pre-baseline hospital records had no primary or 
secondary diagnosis of mania/BD or major depression. Major depression was excluded in 
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addition to mania/BD here because the latter superseded the former in the hierarchical 
exposure definition, and it was therefore considered that major depression was already 
excluded, in effect, from the exposed group. Furthermore, because misclassification is 
common between mania/BD and schizophrenia spectrum disorders (Bromet et al., 2011; 
Laursen, Agerbo, & Pedersen, 2009), participants with a self-reported diagnosis or hospital 
record of schizophrenia (as defined in Chapter 4) were excluded from the exposed and 
unexposed groups. Participants who did not meet the above criteria for either the exposed 
or unexposed groups were not further analysed.  
7.1.3 Cognitive outcome measures 
The cognitive measures analysed were reasoning, reaction time, numeric memory, 
visuospatial memory and prospective memory, as described in Chapter 3. These data were 
provided by UK Biobank as raw scores, and for the purposes of the present analysis were 
standardised within five-year age strata, using all available data in the cohort at baseline. 
Five-year bands were deemed appropriate in light of the typical rate of age-related change 
in cognitive performance in middle to older adulthood (Strauss et al., 2006, Ch. 2), and this 
is similar to the strata sizes used across this age range in ‘gold standard’ cognitive batteries 
such as the Wechsler scales (Wechsler, 2010, 2011). To address skew in the raw data 
distributions, the scores were first transformed into percentiles and then into z-scores 
(mean 0 and standard deviation 1). The scores for analysis therefore represent the number 
of standard deviations above or below the mean score within each five-year age stratum. 
The scores for reaction time and visuospatial memory were reflected so that higher scores 
represent better performance, in line with the other tests. It was not possible to standardise 
the prospective memory data in this way because responses were dichotomous (correct 
response at the first attempt or not), and so the raw data were used in the analyses 
involving this test.  
7.1.4 Covariates  
A range of background measures and potential intermediate factors were considered in the 
analyses, and their putative relationships with mania/BD, cognitive performance and each 
other were depicted in a directed acyclic graph (see sections 7.1.5.1 and 7.2.2 below).  
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7.1.4.1 Sociodemographic measures 
Age was truncated to whole years, and was centred at 55 (approximating the cohort mean 
age at baseline) in the analyses. Gender was self-reported as male or female. Ethnic 
background was self-reported as white, Asian/Asian British, black/black British, Chinese, 
mixed or other. Participants who had self-reported a white British background were further 
grouped by similarity of genetic ancestry based on a principal components analysis of the 
genotypic data (http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=22006). Participants self-
reported their birth country, and these were grouped according to whether or not English 
was an official/first language (UK, Isle of Man, Channel Islands, Gibraltar, Ireland, 
Australia, New Zealand, USA, Canada, Anguilla, Antigua & Barbuda, Aruba, Bahamas, 
Barbados, Bermuda). Self-reported data regarding participants’ highest educational 
qualification were dichotomised as university/college degree or not. Neighbourhood 
deprivation level was recorded by UK Biobank prior to baseline using the Townsend Index 
(Townsend, 1987), and this was converted into quintiles in the whole cohort.  
7.1.4.2 Local environment 
The population density of each area of residence was classified categorically by UK 
Biobank, by combining participants’ residential postcodes with data generated from the 
2001 census, using the GeoConvert tool provided by the UK Data Service Census Support 
(http://geoconvert.mimas.ac.uk/). Proximity to the nearest major road (traffic intensity 
>5,000 motor vehicles per 24 hours) was calculated by UK Biobank as the inverse distance 
(1/m) from the baseline address, using data for the year 2008 provided by the Department 
for Transport, and was converted to quintiles in the whole cohort. Neighbourhood air 
pollution data from a land use regression model and satellite-derived estimates (Vienneau 
et al., 2013) were linked by UK Biobank to participants’ baseline addresses; particulate 
matter of up to 10μm diameter (PM10) and nitrogen dioxide (NO2) were measured as 
annual average values in μg/m3 (for the years 2007 and 2005 respectively) and were 
converted to quintiles in the whole cohort. Other air pollution data were also available but 
these were measured in later years, thus post-dating the cognitive assessment date for most 
participants, and so were not analysed. 
7.1.4.3 Lifestyle and physical measures 
Tobacco smoking status (current, former or never) was classified by UK Biobank using 
self-reported data. Self-reported frequency of alcohol consumption was categorised as 
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daily/almost daily, 3-4 times per week, 1-2 times per week, 1-3 times per month, special 
occasions only, former drinker, or never drinker. Sleeplessness/insomnia was self-reported 
as never/rarely, sometimes, or usually; if participants were unsure how to respond to this 
item, they were prompted to answer in relation to the past four weeks. Physical activity 
(walking, moderate and vigorous) in a typical week was recorded using self-reported items 
from the International Physical Activity Questionnaire short form (Booth, 2000), from 
which a single measure of total physical activity in metabolic equivalent of task (MET) 
hours per week was derived; this was converted into quintiles in the whole cohort. Body 
mass index (BMI; kg/m2) was calculated from measures of height and weight taken by UK 
Biobank staff, and was categorised as underweight (<18.5), normal (18.5 to 24.9), 
overweight (25.0 to 29.9), obese class I (30.0 to 34.9), obese class II (35.0 to 39.9), and 
obese class III (≥40.0).  
7.1.4.4 Medical and family history  
Participants were asked to self-report any illnesses previously diagnosed by a doctor, 
during the touchscreen questionnaire and verbal interview. These data were also combined 
with hospital records by UK Biobank analysts to generate ‘adjudicated’ classifications of 
myocardial infarction (http://biobank.ctsu.ox.ac.uk/crystal/docs/alg_outcome_mi.pdf) or 
stroke (http://biobank.ctsu.ox.ac.uk/crystal/docs/alg_outcome_stroke.pdf). For the present 
analysis, a dichotomous indicator was created for history of any cardiometabolic disease 
(self-reported diagnosis of angina, hypertension or non-gestational diabetes, or adjudicated 
diagnosis of myocardial infarction or stroke, pre-dating the baseline assessment). A 
dichotomous indicator was also created for history of any neurological or psychiatric 
condition (apart from mood disorder or schizophrenia) in the self-reported or hospital 
records data; the conditions included were as described in Chapter 4. Family history of 
certain illnesses in biological parents and siblings was queried during the touchscreen 
questionnaire, and for the present analysis dichotomous indicators were generated for 
history of psychiatric or neurological conditions (dementia, PD or severe depression, coded 
separately) in any parent or sibling. Participants also self-reported whether their mothers 
had smoked regularly around the time of their birth.  
7.1.4.5 Mental health and psychotropic medication 
In addition to the self-reported and hospital records data regarding psychiatric diagnoses, 
participants also provided self-reported information at baseline about depressive symptoms 
in the past two weeks (scored 0 to 12) and current psychotropic medications (dichotomous 
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indicator for any mood stabiliser, antidepressant, antipsychotic, sedative or hypnotic), as 
detailed in Chapters 3 and 4. Additional self-reported information was elicited using the 
web-based mental health questionnaire, which was administered in 2016. Information 
about the number of episodes of depressed mood or anhedonia experienced across the 
lifetime was collected both at baseline assessment and in the web-based questionnaire; for 
the present analysis this was coded ordinally (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, >10 and ‘too 
many to count’) using the baseline data if available, or the web-based data if the baseline 
data were missing. These data were available for participants regardless of their mood 
disorder exposure status (i.e. participants may have reported one or more such episodes 
without necessarily meeting the criteria for mood disorder). It was not possible to 
distinguish how many depression episodes preceded the baseline assessment date, in 
participants who only had web-based data. Participants were also asked five questions 
from the brief Childhood Trauma Questionnaire (Bernstein et al., 2003) within the web-
based mental health questionnaire, representing examples of abuse (physical, emotional, 
sexual) and neglect (physical, emotional). Ordinal responses on each of the five questions 
were dichotomised using thresholds extrapolated from previous research (Walker et al., 
1999), and an overall dichotomous indicator was created to represent above-threshold 
responses on one or more of the five items.  
7.1.4.6 Genome-wide polygenic scores 
Genome-wide polygenic scores (GPS) were generated from published genome-wide 
association study (GWAS) results, as described in Chapter 3. A GPS was generated from 
summary statistics from a large GWAS of years of education (Okbay et al., 2016); to 
minimise sample overlap with UK Biobank participants, the GWAS authors provided 
summary statistics from analyses that did not include UK cohorts (participants from the 
23andMe data resource were also omitted due to data-sharing restrictions). Years of 
education was used here as a proxy for general cognitive ability because, at the time the 
present analysis was conducted, results were unavailable from any similarly-sized GWAS 
of general cognitive ability that did not involve UK Biobank participants. Education and 
cognitive ability have a genetic correlation of ~0.8 (Hill et al., 2018), and current evidence 
suggests that a GPS based on the very large available GWAS of education has greater 
predictive power for observed cognitive ability than does a GPS based on smaller GWAS 
of cognitive ability itself (Plomin & von Stumm, 2018). A GPS was also generated for 
bipolar disorder, using summary statistics from the Psychiatric Genomics Consortium 
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(Sklar et al., 2011); this GWAS included UK cohorts and participant overlap is therefore 
possible with UK Biobank.  
Both GPS were generated from all available SNPs in the UK Biobank cohort, applying the 
following quality control criteria: information score >0.8; Hardy-Weinberg equilibrium 
test p >1x10-6; minor allele frequency >0.01; linkage disequilibrium clumping R2 <0.1 
using a 250kb window. GPS were created at various thresholds based on the p values in the 
source GWAS (5x10-8 to 0.9), and the optimum GPS was chosen based on the magnitude 
of the variance explained (R2) in the relevant phenotype measures in the UK Biobank data. 
These analyses were conducted in unrelated UK Biobank participants of white British 
genetic ancestry, after standard quality control exclusions for sex mismatch, sex 
chromosome aneuploidy, and outlying values of heterozygosity and missingness 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=22027). Each GPS was first regressed on 
variables indicating the genotyping array and batch, UK Biobank assessment centre, and 
the first 20 genetic principal components. The residuals from these models were then used 
as the independent variable in models to predict the relevant UK Biobank phenotype.  
Appendix W shows the R2 at each p threshold, and the regression coefficient or odds ratio 
for the association between deciles of the optimum GPS and the relevant phenotypes. In 
each case, the optimum GPS had a p threshold of 0.5. The R2 for the association between 
the optimum education/cognition GPS and having a degree in the UK Biobank cohort was 
0.018, and was 0.013 for the raw reasoning test score. These results are similar to those 
previously reported in independent samples, e.g. R2 = 0.02 for both educational attainment 
(de Zeeuw et al., 2014; Krapohl & Plomin, 2016) and general cognitive ability (Krapohl et 
al., 2016). They are notably lower, however, than more recent analyses which made use of 
the full Okbay et al. GWAS results including UK participants (Selzam et al., 2017), in 
which the R2 for educational attainment at age 16 was 0.091 and for general cognitive 
ability was 0.036. The R2 for the association between the optimum bipolar GPS and the 
broadly-defined mania/BD phenotype in the UK Biobank cohort was 0.01. This is lower 
than the variance explained in other independent samples, e.g. R2 = 0.024 in Aminoff et al. 
(2015), although results may not be directly comparable due to different methods of 
calculating pseudo R2 in logistic regression models.  
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7.1.5 Data analysis 
7.1.5.1 Graphical model 
A DAG was constructed to represent causal assumptions about the relationship between 
lifetime history of mania/BD and cognitive performance, in the context of possible 
confounding factors and intermediate pathways. This was done before any data were 
analysed. The nodes in the DAG and the assumed directional relationships between them 
were determined from previous systematic reviews of cognitive function in BD (Arts et al., 
2008; Bora, Yucel, & Pantelis, 2009; Bora, Yucel, Pantelis, & Berk, 2011; Bourne et al., 
2013; Camelo, Velasques, Ribeiro, Netto, & Cheniaux, 2013; Lee et al., 2014; Mann-
Wrobel et al., 2011; Robinson et al., 2006; Samamé, Martino, & Strejilevich, 2015) and the 
systematic review reported in Chapter 2, as well as general background knowledge and 
assumptions regarding other shared causes that were necessary to depict in order for the 
DAG to have a causal interpretation (as explained in Chapter 6). This included nodes 
depicting constructs that were not measured in the UK Biobank dataset (e.g. premorbid 
intellectual ability). The structure of the DAG also took into account the cross-sectional 
nature of the planned data analysis, in that nodes were labelled to represent past states 
where necessary. The DAG was reviewed by the thesis supervisors, to reach consensus 
about the likely structure and direction of relationships. If the putative direction of a 
relationship was unclear, multiple versions of the DAG were generated prior to data 
analysis, to represent alternative plausible specifications.  
The DAG was drawn using DAGitty software (Textor et al., 2016), which automatically 
generated a list of all the testable independencies implied by its structure (ignoring any 
nodes that were tagged as being unmeasured). These were then tested in the dataset, by 
calculating partial correlation coefficients between each pair of nodes that were predicted 
to be independent, adjusting for other covariates if this was specified in the prediction. For 
example, a predicted conditional independency generated by DAGitty such as  
age ⊥ physical_environment | deprivation educational_attainment 
would be tested by calculating the partial correlation coefficient between age and a 
measure of the local physical environment, adjusted for the Townsend deprivation score 
and having a degree. These calculations were done using correlation or regression models, 
depending on the need to adjust for covariates (see section 7.2.2 below, and Appendix X). 
For simplicity, only continuous or dichotomous measures were used in the initial 
140 
 
calculations. Where a node had more than one relevant available measure (e.g. 
physical_environment measured by population density or road proximity), the measure 
with the largest sample size was used, in order to minimise missing data bias. Where the 
results indicated lack of independence (i.e. partial correlation coefficient >|0.1|; Kline, 
2016, p. 240), follow-up regression models were conducted to obtain further detail. 
Modifications to the structure of the DAG were then considered, if appropriate, via 
discussion with the thesis supervisors.  
7.1.5.2 Total causal effects 
The total causal effect of lifetime history of mania/BD on cognitive performance was 
firstly identified in the DAG using the back-door criterion, as implemented automatically 
in DAGitty. If the algorithm was able to find at least one minimum sufficient set of 
measured nodes in the DAG that met the back-door criterion, this information was then 
used to plan regression- and matching-based analyses to estimate the effect in the UK 
Biobank dataset. This was estimated separately for each of the five cognitive outcome 
measures, to allow for the possibility of task-specific variation in the results. For the 
purpose of comparison, estimation was conducted in several ways:  
 Unadjusted regression model in all available participants;  
 Unadjusted regression model only in participants who had complete data on all 
covariates that were to be used in the adjusted models;  
 Multiple regression model adjusted for the minimum sufficient covariate set 
identified by DAGitty; 
 Multiple regression model adjusted for the minimum sufficient set plus all other 
measured common antecedents of exposure and outcome;  
 Multiple regression model adjusted for a propensity score created by regressing the 
mania/BD exposure on background covariates;  
 Matched analyses (1:1 and 1:3) using the propensity score to form matched 
participant sets;  
 Weighted regression model using inverse probability weights (IPW) derived from 
the propensity score;  
 Doubly robust models (IPW-weighted regression with additional covariate 
adjustment or augmented weighting).  
Where models included age as a covariate, age squared was also entered, to account for 
possible curvilinear relationships. The propensity score model was specified in three ways, 
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and the score that resulted in the best covariate balance (evaluated by comparing 
descriptive statistics for each covariate between the propensity score-matched samples) 
was taken forward into the total effects analyses listed above. This decision was based 
solely on covariate balance, without reference to the cognitive outcome data. The first 
propensity score model regressed the mania/BD exposure status variable on all ancestors of 
the exposure and all ancestors of the outcome that were not descended from the exposure 
(Brookhart et al., 2006). The second propensity score model used the same predictor 
variables as the first, but also included all pairwise interaction terms. The third approach 
used boosted regression modelling (a machine learning method) to find the optimum 
prediction specification (Friedman, 2001), again using the same predictor variables as the 
other two models. The propensity score was also converted to an inverse probability 
weight, which was rescaled to sum to 1 (Garrido et al., 2014).  
All analyses were conducted using Stata v15 (StataCorp, 2017). The propensity scores 
were estimated using psmatch2 and boost, and covariate balance was checked using 
pstest and pbalchk. The total effects models were estimated using regress or 
logistic, psmatch2 and teffects, and results were reported as beta coefficients or 
average treatment effects (ATE) with 95% confidence intervals (CI) calculated from robust 
standard errors. For the logistic regression models (prospective memory outcome 
measure), adjrr was used to convert the OR estimates into risk differences, which are 
comparable to the ATE estimates for the other cognitive measures. The matched models 
were performed with replacement and used a caliper set at 0.2 SD of the logit of the 
propensity score (Austin, 2011).  
7.1.5.3 Direct and indirect effects 
The DAG was used to assess whether indirect effects via various intermediates of interest 
could be identified. As outlined in Chapter 6, this required all back-door paths between the 
exposure and the intermediate and between the intermediate and the outcome to be 
blocked, as well as those between the exposure and the outcome. Where this requirement 
was satisfied (i.e. covariate adjustment sets could be found), G-computation was used to 
estimate the natural direct and indirect effects. This was implemented using the Stata 
package gformula, because gformula permits effect decomposition in the presence of 
intermediate confounding. The covariate adjustment sets in these models were the 
minimum sufficient adjustment sets to block all back-door paths, as determined by 
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DAGitty. All outcome and intermediate confounder variables were entered in continuous 
or binary form, as required by gformula. 
7.1.6 Sensitivity analyses 
7.1.6.1 Conditional exchangeability  
The assumption of conditional exchangeability implies that, within a matched pair of 
participants, each participant had equal odds of being exposed (‘treated’) and unexposed. 
Covariate balance checks allow this to be verified with respect to measured background 
factors, but cannot confirm that matched pairs are balanced (i.e. exchangeable) for 
unmeasured or unknown background variables. Sensitivity of treatment effect estimates or 
their p values to different potential magnitudes of departure from exchangeability can be 
evaluated quantitatively using ‘bounds’ methods developed by Rosenbaum (2002). 
Potential deviations from exchangeability are summarised in a parameter referred to as 
gamma (where Γ = 1 represents equal odds), and the value of gamma at which the effect 
estimate or p value crosses the null is ascertained using permutation methods. This was 
conducted following the propensity score matched models, using the Stata package 
rbounds12.  
7.1.6.2 Missing data 
Because the estimation methods used here involved adjustment and/or propensity score 
estimation for a large number of covariates, results were potentially sensitive to selection 
bias or reduced power, arising from missing data. Multiple imputation with chained 
equations was implemented using the ice package in Stata, and the regression models for 
total effects were repeated on the imputed datasets (25 imputations) using the mi 
estimate function. The cognitive outcome variables were included in the imputation 
model specification (White, Royston, & Wood, 2011), but their original (unimputed) 
values were analysed in the outcome models. A chained equations imputation option was 
also implemented in gformula, to allow a comparison of the results of the effect 
decomposition models using raw versus imputed mediator and covariate data. These 
methods assume missingness at random (MAR), which will be discussed further below. 
                                                 
12 The rbounds package conducts sensitivity analyses on the ‘average treatment effect in the 
treated’ (ATT), rather than on the overall ATE. The ATT represents the average effect of 
treatment/exposure on outcome within the group that actually received the treatment/exposure. 
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7.1.6.3 Exposure misclassification  
The effect of different hypothetical levels of mania/BD exposure misclassification on 
cognitive outcome was assessed using the Stata package episens. The outcome was 
dichotomised as impaired (z-score ≤ -1.645, i.e. 5th percentile) or not. The range of 
assumed sensitivity and specificity values for correct mania/BD classification was entered 
as a trapezoidal function, by specifying minimum and maximum values around a narrower 
range of equally probable values (e.g. minimum 0.7 and maximum 1.0, around a peak 
interval of 0.8 to 0.9). Differential misclassification was assumed, on the grounds that 
cognitively impaired participants would be more likely to be misclassified on the self-
reported mania/BD exposure data.  
7.1.6.4 Equivalent models 
The final DAG that was used as the basis for the total effects and mediation models was 
analysed structurally in the dagitty R package, to determine the number of alternative 
ways it could be drawn while retaining the same predicted conditional independencies. 
This ascertains whether there are other specifications of the model that would be 
statistically indistinguishable from the version that was analysed, i.e. an ‘equivalence class’ 
(Textor et al., 2016). 
7.2 Results 
7.2.1 Characteristics of the sample 
Figure 7.1 shows a flowchart of exclusions leading to the final analysis sample, which 
comprised 2,709 participants with mania/BD and 105,284 comparison participants. A large 
number of participants were excluded due to missing data in at least one exposure 
information source, which meant they could not be classified in the comparison group. 
Where genotyping data indicated relatedness (third degree or closer), one member of each 
related set was chosen at random for analysis. Ethnic ancestry exclusions were applied 
only in the adjusted models (see below).  
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Figure 7.1 - Mania/bipolar disorder analysis sample flowchart 
 
Table 7.1 summarises the cognitive outcome data and Table 7.2 summarises the covariate 
data, for the mania/BD and comparison groups separately. Descriptive results are also 
provided separately for the subset of participants who had complete data on the covariates 
that were used in the maximally-adjusted total effects models.  
Table 7.1 indicates that all the cognitive test scores appeared lower on average in the 
mania/BD group. Scores appeared higher on average in both groups among the participants 
with complete covariate data. Missing cognitive data was most common on the 
visuospatial memory test (5.8% and 2.8% in the mania/BD and comparison groups, 
respectively), and was more common in the mania/BD group on all tests. Reliability 
(Cronbach’s alpha) was higher for reaction time than for reasoning, although both were in 
the acceptable range. Reliability was similar between the mania/BD and comparison 
groups, apart from on the reaction time task in the complete covariate data sub-sample, 
where alpha was lower in the mania/BD group (0.72) than in the comparison group (0.82).  
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Table 7.1 - Summary of cognitive outcome measures in the mania/bipolar and comparison 
groups 
 
 All available data Complete covariate dataa 
 Mania/BD Comparison Mania/BD Comparison 
n  2,709 105,284 504 26,997 
Reasoning z-score 
n (%) missingb 
Mean (SD) 
Cronbach’s α 
 
31 (1.8) 
-0.35 (1.01) 
0.71 
 
1,627 (1.6) 
-0.20 (0.97) 
0.70 
 
1 (0.3) 
0.05 (0.96) 
0.70 
 
89 (0.3) 
0.12 (0.92) 
0.68 
Reaction time z-score  
n (%) missing 
Mean (SD)  
Cronbach’s α 
 
51 (1.9) 
-0.19 (1.01) 
0.82 
 
1,167 (1.1) 
-0.03 (0.98) 
0.82 
 
1 (0.2) 
0.03 (0.94) 
0.72 
 
72 (0.3) 
0.07 (0.96) 
0.82 
Numeric memory z-score 
n (%) missingb 
Mean (SD) 
 
18 (3.9) 
-0.52 (1.00) 
 
755 (2.4) 
-0.35 (0.94) 
 
0 (0.0) 
-0.23 (1.08) 
 
51 (0.7) 
-0.16 (0.93) 
Visuospatial memory z-score 
n (%) missing 
Mean (SD) 
 
157 (5.8) 
0.07 (1.07) 
 
2,896 (2.8) 
0.26 (1.05) 
 
10 (1.2) 
0.20 (1.09) 
 
212 (0.8) 
0.37 (1.03) 
Prospective memoryb,c 
n (%) correct 
 
1,264 (72.1) 
 
80,502 (76.9) 
 
286 (80.3) 
 
23,112 (85.7) 
BD, bipolar disorder; GPS, genome-wide polygenic score; SD, standard deviation. 
a. Participants with complete data on all the covariates that were entered into the maximally-adjusted total effects models 
(age, gender, white British genetic ancestry, English-speaking country of birth, degree, comorbid neurological/psychiatric 
condition, family history of dementia, family history of Parkinson’s disease, family history of severe depression, maternal 
smoking around birth, childhood trauma, education/cognition GPS, bipolar disorder GPS). 
b. Missing data refers only to the period when this measure was included in the battery. 
c. No missing data. 
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Table 7.2 shows a similar pattern with regard to missing data, with the exception of the 
number of depressed episodes, on which relatively fewer mania/BD than comparison 
participants had missing responses. Owing to the low response rate on the web-based 
mental health questionnaire (n = 157,366; 31.3% of the whole cohort), the proportion of 
missing data was highest for the childhood trauma variable. Missingness was also common 
on the family medical history, maternal smoking, current depressive symptoms and 
physical activity variables. Table 7.2 indicates that the mania/BD group was younger on 
average than the comparison group, and had a higher proportion of women and of degree-
holders. The participants with mania/BD also appeared to be more likely to live in urban 
and more deprived areas, and to be current smokers and former drinkers. The proportions 
with frequent sleeplessness, obesity, cardiometabolic disease, comorbid 
neurological/psychiatric conditions, family history of severe depression, current 
psychotropic medication, and history of childhood trauma were higher in the mania/BD 
group, and this group also reported more depressed episodes and a higher current 
depressive symptom score on average. The distribution of the education/cognition GPS 
score appeared to be somewhat different between the mania/BD and comparison groups, 
with both low (decile 1) and high (decile 10) GPS values being slightly over-represented in 
the mania/BD group. The distribution of the bipolar GPS score was skewed towards higher 
values in the mania/BD group. The subset of participants with complete covariate data 
appeared different from the full analysis sample, being on average younger, more highly 
educated and from less deprived areas, for example. 
 
147 
 
Table 7.2 - Summary of covariates in the mania/bipolar and comparison groups 
 
 All available data Complete covariate dataa 
 Mania/BD Comparison Mania/BD Comparison 
n  2,709 105,284 504 26,997 
Sociodemographic      
Age (years)b 
Mean (SD) 
 
55.0 (8.1) 
 
57.0 (8.2) 
 
54.3 (7.5) 
 
56.3 (7.9) 
Genderb 
n (%) female 
 
1,437 (53.1) 
 
52,730 (50.1) 
 
277 (55.0) 
 
14,414 (53.4) 
Ethnic group 
n (%) missing 
White, n (%)c 
Asian/Asian British 
Black/Black British 
Chinese 
Mixed & other background 
 
18 (0.7) 
2,457 (91.3) 
74 (2.8) 
78 (2.9) 
4 (0.2) 
78 (2.9) 
 
411 (0.4) 
95,463 (91.0) 
3,697 (3.5) 
3,182 (3.0) 
474 (0.5) 
2,057 (2.0) 
 
0 (0.0) 
479 (95.0) 
16 (3.2) 
2 (0.4) 
1 (0.2) 
6 (1.2) 
 
73 (0.3) 
25,708 (95.5) 
459 (1.7) 
322 (1.2) 
99 (0.4) 
336 (1.3) 
White British genetic ancestry 
n (%) missing 
n (%)c 
 
104 (3.8) 
1,968 (75.6) 
 
3,419 (3.3) 
81,183 (79.7) 
 
0 (0.0) 
394 (78.2) 
 
0 (0.0) 
22,606 (83.7) 
English-speaking country of birth 
n (%) missing 
n (%)c 
 
6 (0.2) 
2,432 (90.0) 
 
149 (0.1) 
93,802 (89.2) 
 
0 (0.0) 
462 (91.7) 
 
0 (0.0) 
24,993 (92.6) 
Has a degree  
n (%) missing 
n (%)c 
 
29 (1.1) 
1,034 (38.6) 
 
1,045 (1.0) 
36,797 (35.3) 
 
0 (0.0) 
265 (52.6) 
 
0 (0.0) 
13,210 (48.9) 
Townsend quintiled 
n (%) missing 
Qu1 (least deprived), n (%)c 
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
3 (0.1) 
334 (12.3) 
361 (13.3) 
461 (17.0) 
607 (22.4) 
943 (34.9) 
 
162 (0.2) 
18,097 (17.2) 
21,344 (20.3) 
21,794 (20.7) 
23,685 (22.5) 
20,202 (19.2) 
 
0 (0.0) 
78 (15.5) 
70 (13.9) 
93 (18.5) 
124 (24.6) 
139 (27.6) 
 
34 (0.1) 
5,162 (19.1) 
5,846 (21.7) 
5,924 (22.0) 
6,094 (22.6) 
3,937 (14.6) 
Local environment     
Home area population densitye 
n (%) missing 
England/Wales urban, n (%)c 
England/Wales town 
England/Wales village 
England/Wales hamlet/isolated 
Scotland large urban 
Scotland other urban 
Scotland small town 
Scotland rural 
 
38 (1.4) 
2,311 (86.5) 
129 (4.8) 
88 (3.3) 
45 (1.7) 
80 (3.0) 
11 (0.4) 
5 (0.2) 
2 (0.1) 
 
968 (0.9) 
90,610 (86.9) 
6,603 (6.3) 
4,967 (4.8) 
2,136 (2.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
5 (1.0) 
433 (86.8) 
25 (5.0) 
20 (4.0) 
10 (2.0) 
9 (1.8) 
1 (0.2) 
1 (0.2) 
0 (0.00 
 
271 (1.0) 
22,766 (85.2) 
1,776 (6.7) 
1,533 (5.7) 
651 (2.4) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
Proximity to major road (1/m) 
n (%) missing 
Mean (SD) 
 
65 (2.4) 
0.006 (0.021) 
 
1,299 (1.2) 
0.006 (0.013) 
 
9 (1.8) 
0.006 (0.010) 
 
348 (1.3) 
0.005 (0.011) 
Particulate matter ≤10μm (μg/m3) 
n (%) missing 
Mean (SD) 
 
72 (2.7) 
22.9 (3.1) 
 
1,679 (1.6) 
22.8 (3.0) 
 
11 (2.2) 
23.2 (3.2) 
 
437 (1.6) 
22.8 (3.2) 
Nitrogen dioxide (μg/m3) 
n (%) missing 
Mean (SD) 
 
65 (2.4) 
32.9 (11.0) 
 
1,299 (1.2) 
31.9 (10.6) 
 
9 (1.8) 
33.1 (11.7) 
 
348 (1.3) 
31.8 (11.0) 
Lifestyle and physical      
Smoking status 
n (%) missing 
Never, n (%)c 
Former 
Current 
 
15 (0.6) 
1,185 (44.0) 
922 (34.2) 
587 (21.8) 
 
380 (0.4) 
60,305 (57.5) 
35,436 (33.8) 
9,163 (8.7) 
 
1 (0.2) 
251 (49.9) 
175 (34.8) 
77 (15.3) 
 
47 (0.2) 
16,428 (61.0) 
8,885 (33.0) 
1,637 (6.1) 
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 All available data Complete covariate dataa 
 Mania/BD Comparison Mania/BD Comparison 
Alcohol frequency 
n (%) missing 
Daily/almost daily, n (%)c 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
12 (0.4) 
497 (18.4) 
451 (16.7) 
583 (21.6) 
312 (11.6) 
432 (16.0) 
261 (9.7) 
161 (6.0) 
 
80 (0.1) 
22,179 (21.1) 
24,718 (23.5) 
26,774 (25.5) 
11,397 (10.8) 
11,824 (11.2) 
3,186 (3.0) 
5,126 (4.9) 
 
1 (0.2) 
112 (22.3) 
98 (19.5) 
114 (22.7) 
63 (12.5) 
66 (13.1) 
36 (7.2) 
14 (2.8) 
 
4 (0.01) 
6,514 (24.1) 
7,176 (26.6) 
6,627 (24.6) 
2,872 (10.6) 
2,387 (8.8) 
620 (2.3) 
797 (3.0) 
Sleeplessness 
n (%) missing 
Never/rarely, n (%)c 
Sometimes 
Usually 
 
2 (0.1) 
535 (19.8) 
1,199 (44.3) 
973 (35.9) 
 
79 (0.1) 
29,205 (27.8) 
50,293 (47.8) 
25,707 (24.4) 
 
0 (0.0) 
113 (22.4) 
211 (41.9) 
180 (35.7) 
 
14 (0.1) 
8, 019 (29.7) 
12,802 (47.4) 
6,162 (22.8) 
Physical activity (MET h/week) 
n (%) missing 
Median (Q1, Q3)  
 
256 (9.5) 
25.6 (11.6, 56.7) 
 
6,861 (6.5) 
29.8 (13.7, 60.1) 
 
31 (6.2) 
27.5 (12.3, 54.9) 
 
1,054 (3.9) 
29.1 (14.2, 55.7) 
Body mass index 
n (%) missing 
Underweight, n (%)c 
Normal 
Overweight 
Obese class I 
Obese class II 
Obese class III 
 
27 (1.0) 
16 (0.6) 
719 (26.8) 
1,043 (38.9) 
610 (22.7) 
205 (7.6) 
89 (3.3) 
 
741 (0.7) 
514 (0.5) 
34,893 (33.4) 
44,979 (43.0) 
17,804 (17.0) 
4,729 (4.5) 
1,624 (1.6) 
 
1 (0.2) 
3 (0.6) 
174 (34.6) 
210 (41.8) 
87 (17.3) 
20 (4.0) 
9 (1.8) 
 
90 (0.3) 
156 (0.6) 
10,751 (40.0) 
11,104 (41.3) 
3,750 (13.9) 
860 (3.2) 
286 (1.1) 
Medical and family history     
Cardiometabolic disease 
n (%) missing 
n (%)c 
 
11 (0.4) 
986 (36.6) 
 
178 (0.2) 
32,120 (30.6) 
 
0 (0.0) 
140 (27.8) 
 
22 (0.1) 
6,310 (23.4) 
Comorbid neurological or 
psychiatric conditionf 
n (%) 
 
 
814 (30.1) 
 
 
9,430 (9.0) 
 
 
120 (23.8) 
 
 
2,093 (7.8) 
Family history of dementia 
n (%) missing 
n (%)c 
 
473 (17.5) 
384 (17.2) 
 
14,799 (14.1) 
15,755 (17.4) 
 
0 (0.0) 
83 (16.5) 
 
0 (0.0) 
4,661 (17.3) 
Family history of Parkinson’s 
disease 
n (%) missing 
n (%)c 
 
 
589 (21.8) 
107 (5.1) 
 
 
16,406 (15.6) 
4,250 (4.8) 
 
 
0 (0.0) 
18 (3.6) 
 
 
0 (0.0) 
1,276 (4.7) 
Family history of severe 
depression 
n (%) missing 
n (%)c 
 
 
466 (17.2) 
874 (39.0) 
 
 
15,655 (14.9) 
10,503 (11.7) 
 
 
0 (0.0) 
170 (33.7) 
 
 
0 (0.0) 
3,086 (11.4) 
Maternal smoking around birth 
n (%) missing 
n (%)c 
 
390 (14.4) 
716 (30.9) 
 
13,420 (12.7) 
24,807 (27.0) 
 
0 (0.0) 
151 (30.0) 
 
0 (0.0) 
7,065 (26.2) 
Mental health      
Current depressive symptoms 
n (%) missing 
Mean (SD)  
 
265 (9.8) 
3.5 (3.2) 
 
8,758 (8.3) 
1.2 (1.7) 
 
27 (5.4) 
2.8 (2.9) 
 
1,223 (4.5) 
1.0 (1.4) 
Any psychotropic medication 
n (%) missing 
n (%)c 
 
38 (1.4) 
1,457 (54.6) 
 
1,247 (1.2) 
2,647 (2.5) 
 
5 (1.0) 
221 (44.3) 
 
286 (1.1) 
503 (1.9) 
Number of depressed episodes 
n (%) missing 
Median (Q1, Q3) 
 
127 (4.7) 
1 (0, 6) 
 
6,573 (6.2) 
0 (0, 1) 
 
23 (4.6) 
4 (2, 11) 
 
1,448 (5.4) 
0 (0, 1) 
Any childhood traumag 
n (%) missing 
n (%)c 
 
1,976 (72.9) 
476 (64.9) 
 
68,715 (65.3) 
16,015 (43.8) 
 
0 (0.0) 
317 (62.9) 
 
0 (0.0) 
11,240 (41.6) 
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 All available data Complete covariate dataa 
 Mania/BD Comparison Mania/BD Comparison 
Genome-wide polygenic scores     
Education/cognition GPS deciled 
n (%) missing 
D1 (lowest), n (%)c 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
104 (3.8) 
291 (11.2) 
259 (9.9) 
281 (10.8) 
234 (9.0) 
245 (9.4) 
244 (9.4) 
251 (9.6) 
257 (9.9) 
246 (9.4) 
297 (11.4) 
 
3,419 (3.3) 
10,156 (10.0) 
10,188 (10.0) 
10,166 (10.0) 
10,213 (10.0) 
10,202 (10.0) 
10,203 (10.0) 
10,196 (10.0) 
10,190 (10.0) 
10,201 (10.0) 
10,150 (10.0) 
 
0 (0.0) 
36 (7.14) 
57 (11.3) 
51 (10.1) 
55 (10.9) 
51 (10.1) 
48 (9.5) 
42 (8.3) 
45 (8.9) 
54 (10.7) 
65 (12.9) 
 
0 (0.0) 
2,262 (8.4) 
2,439 (9.0) 
2,497 (9.3) 
2,619 (9.7) 
2,599 (9.6) 
2,666 (9.9) 
2,822 (10.5) 
2,878 (10.7) 
3,014 (11.2) 
3,201 (11.9) 
Bipolar disorder GPS deciled 
n (%) missing 
D1 (lowest), n (%)c 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
104 (3.8) 
199 (7.6) 
225 (8.6) 
232 (8.9) 
228 (8.8) 
228 (8.8) 
264 (10.1) 
274 (10.5) 
262 (10.1) 
306 (11.8) 
387 (14.9) 
 
3,419 (3.3) 
10,248 (10.1) 
10,222 (10.0) 
10,215 (10.0) 
10,219 (10.0) 
10,219 (10.0) 
10,183 (10.0) 
10,173 (10.0) 
10,185 (10.0) 
10,141 (10.0) 
10,060 (9.9) 
 
0 (0.0) 
39 (7.7) 
45 (8.9) 
47 (9.3) 
47 (9.3) 
36 (7.1) 
46 (9.1) 
49 (9.7) 
48 (9.5) 
63 (12.5) 
84 (16.7) 
 
0 (0.0) 
2,773 (10.3) 
2,698 (10.0) 
2,696 (10.0) 
2,654 (9.8) 
2,707 (10.0) 
2,638 (9.8) 
2,707 (10.0) 
2,706 (10.0) 
2,717 (10.1) 
2,701 (10.0) 
BD, bipolar disorder; D, decile; GPS, genome-wide polygenic score; MET, metabolic equivalent of task; Q, quartile; Qu, 
quintile; SD, standard deviation. 
a. Participants with complete data on all the covariates that were entered into the maximally-adjusted total effects models 
(age, gender, white British genetic ancestry, English-speaking country of birth, degree, comorbid neurological/psychiatric 
condition, family history of dementia, family history of Parkinson’s disease, family history of severe depression, maternal 
smoking around birth, childhood trauma, education/cognition GPS, bipolar disorder GPS). 
b. No missing data. 
c. Missing excluded from denominator. 
d. Based on data distribution in the whole UK Biobank cohort. 
e. Scottish psychiatric hospital records were unavailable, which meant no Scotland-based participants could be classified 
in the comparison group; therefore all locations for comparison participants are in England/Wales.  
f. Apart from mood disorder or schizophrenia; not possible to distinguish between missing data and self-report of no 
condition, therefore both classified as No. 
g. From the web-based questionnaire, which was completed by 157,366 (31.3%) of the cohort.  
150 
 
 
7.2.2 Evaluation of the graphical model 
The original DAG is shown in Figure 7.2, and Appendix Y explains the correspondence 
between each node and the available measures in UK Biobank, along with the rationale for 
the key assumptions made about the relationships between the nodes. This DAG postulated 
that educational attainment was a causal antecedent of mania/BD status, but a plausible 
alternative specification would show the arrow in reverse such that mania/BD causally 
influences educational attainment (for example, if illness onset occurs at a young age). The 
different predicted independencies implied by both specifications were tested. The results 
indicated poorer fit in the second specification, with a greater proportion of the partial 
correlation coefficients being above |0.1|. The first specification also showed poor fit 
involving certain nodes, particularly current psychotropic medication use. The reasons for 
poor fit (e.g. model misspecification, measurement error, selection bias) cannot be 
discerned from the data alone, but consideration was given to whether the graph should be 
modified by adding new nodes or paths.  
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Figure 7.2 - Original directed acyclic graph for the effect of mania/bipolar disorder on cognitive outcome 
 
Cardiomet, cardiometabolic disease; cog, cognitive; curr, current; edu, educational; eng_speak, English speaking birth country; famhx, family history; 
geno, genotype; hx, history; par, parental; PD, Parkinson’s disease; phys, physical; pre_IQ, premorbid intelligence; psych_meds, psychotropic 
medications; SES, socioeconomic status. Node labels and meanings are explained in detail in Appendix Y. Green node is the exposure and blue node is 
the outcome. Light nodes represent unmeasured constructs and darker nodes represent measured constructs.
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It was deemed plausible that paths should be added between educational attainment and 
current psychotropic medication, and between gender and current psychotropic medication 
(reflecting possible influences of, for example, knowledge or attitudes on likelihood of 
seeking or accepting treatment). A new node was also added, representing other psychiatric 
or neurological conditions (apart from mood disorder or schizophrenia); this was in line 
with the results reported in Chapter 5, which had indicated different patterns of cognitive 
impairment in participants with and without psychiatric or neurological comorbidities. The 
implied independencies of this modified DAG were then tested, firstly with educational 
attainment specified as a causal antecedent of both mania/BD and other 
psychiatric/neurological conditions (Figure 7.3), and then with educational attainment 
specified as a causal consequence of both. 
The best fit was observed in the first version of the modified DAG, in which educational 
attainment was specified as a causal antecedent of both mania/BD and other 
psychiatric/neurological conditions (see Appendix X). Twenty percent (28 of 138) of the 
partial correlation coefficients remained above |0.1|, but most of these were below |0.2| and 
the largest coefficient was |0.43|. The largest coefficients again involved the current 
psychotropic medication node. When evaluated further, however, regression models 
indicated wide variance in the estimated associations between the pairs of nodes, including 
the null in most instances (Appendix X). No further modifications were made to the DAG; 
it was decided that the diagram broadly reflected the evidence-based assumptions drawn 
from the literature and expert knowledge, and additional data-driven modifications may 
have been misleading if they were in fact influenced by issues such as measurement error 
rather than model misspecification. The model depicted in Figure 7.3 was used to plan the 
causal effect models reported below.  
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Figure 7.3 - Modified directed acyclic graph for the effect of mania/bipolar disorder on cognitive outcome 
 
Cardiomet, cardiometabolic disease; cog, cognitive; curr, current; edu, educational; eng_speak, English speaking birth country; famhx, family history; 
geno, genotype; hx, history; other_neupsy, other neurological/psychiatric condition; par, parental; PD, Parkinson’s disease; phys, physical; pre_IQ, 
premorbid intelligence; psych_meds, psychotropic medications; SES, socioeconomic status. Node labels and meanings are explained in detail in Appendix 
Y. Green node is the exposure and blue node is the outcome. Light nodes represent unmeasured constructs and darker nodes represent measured 
constructs. This graph and the underlying code are publicly accessible online at dagitty.net/mSTG_SM
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7.2.3 Total causal effects 
Applying d-separation criteria to the DAG indicated that the minimum sufficient 
adjustment set for the total effect of mania/BD on cognitive performance comprised 
gender, educational attainment, English-speaking birth country, ethnicity, 
education/cognition GPS, bipolar disorder GPS, family history of dementia, family history 
of PD, maternal smoking around birth, childhood trauma, and other 
psychiatric/neurological conditions. The extended adjustment set encompassed additional 
measured nodes that were antecedents of the exposure, namely age and family history of 
depression. This extended adjustment set was also used as the predictor set for the 
propensity score model. Ethnicity was accounted for in all the multivariable analyses and 
in the propensity score estimation by restricting these to participants of white British 
genetic ancestry. The GPS scores were residualised as described in section 7.1.4.6 above, 
and were entered as deciles, based on the distribution in the full analysis sample.  
The best propensity score model, in terms of covariate balance, was the first model with no 
interaction terms. This was used in all the outcome models that involved propensity score 
adjustment or matching, and was used as the basis for the inverse probability weights. 
Table 7.3 shows the degree of covariate balance, as illustrated within the matched samples 
used in the reaction time analyses reported below.  
Figures 7.4 to 7.8 show the results of all the total effects models for each of the five 
cognitive scores. Only the visuospatial memory test (and, more equivocally, the 
prospective memory test) indicated a detrimental effect of mania/BD that remained evident 
in the multivariable models. The effect sizes were small: the mania/BD group scored 
approximately 0.2 SD lower than the unexposed comparison group on the visuospatial 
memory test, and the proportion of the mania/BD group succeeding on the prospective 
memory task was lower by approximately 5 percentage points (approximately 82% in the 
mania/BD group versus 87% in the unexposed group). The visuospatial and prospective 
memory estimates showed little change between the unadjusted and adjusted/matched 
models, whereas the estimates for the other three cognitive measures generally attenuated 
towards the null.  
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Table 7.3 - Summary of covariates in matched mania/bipolar and comparison groups 
 
 Mania/BD Comparison 
 Mean (SD) 
Age (years) 54.9 (7.4) 55.1 (7.4) 
 % 
Female gender 52.9 52.0 
English-speaking country of birth 97.7 98.3 
Has a degree  52.4 55.2 
Comorbid neurological or psychiatric condition 25.2 25.1 
Family history of dementia 18.6 17.5 
Family history of Parkinson’s disease 3.6 4.3 
Family history of severe depression 34.6 36.2 
Maternal smoking around birth 33.1 34.5 
Any childhood trauma 60.8 60.2 
Education/cognition GPS 
D1 (lowest) 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
7.5 
9.9 
10.2 
10.7 
10.4 
9.2 
8.7 
8.7 
11.5 
13.2 
 
7.1 
8.6 
8.0 
12.3 
9.9 
10.3 
7.8 
10.0 
11.1 
14.9 
Bipolar disorder GPS 
D1 (lowest) 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
7.8 
9.7 
7.6 
9.7 
7.1 
8.9 
10.2 
9.4 
11.5 
18.1 
 
6.6 
10.3 
8.5 
9.3 
7.8 
9.9 
10.2 
9.5 
11.4 
16.5 
BD, bipolar disorder; D, decile; GPS, genome-wide polygenic score; SD, standard deviation. 
These results are from the propensity-score matched samples used in the 1:3 matched model for the total effect of 
mania/BD on reaction time (mania/BD n = 392; comparison n = 1,081). 
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Figure 7.4 - Total causal effect of mania/bipolar disorder on reasoning 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 7.5 - Total causal effect of mania/bipolar disorder on reaction time 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 7.6 - Total causal effect of mania/bipolar disorder on numeric memory 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 7.7 - Total causal effect of mania/bipolar disorder on visuospatial memory 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 7.8 - Total causal effect of mania/bipolar disorder on prospective memory 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are 
proportions and can be interpreted as risk differences. No estimates are provided from 
propensity-score matched models as it was not possible to express these as risk 
differences. 
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7.2.4 Direct and indirect effects 
Structural analysis of the DAG indicated that direct and indirect effects could be 
decomposed for two potentially modifiable intermediate variables: cardiometabolic disease 
and psychotropic medication. Effects via other intermediate nodes of interest (e.g. current 
depressive symptoms) could not be identified, because no covariate adjustment set could 
be found for the relevant exposure-mediator and/or mediator-outcome paths.  
Mediation analyses were conducted to quantify the proportion of the total causal effect of 
mania/BD on each cognitive outcome that was transmitted via (1) cardiometabolic disease 
and (2) psychotropic medication. In both sets of analyses, the indirect pathways were 
affected by intermediate confounding (i.e. the mediator-outcome path was confounded by 
at least one node that descended from mania/BD), and so the analyses were conducted 
under the identifying assumption of no interaction between mania/BD and either 
cardiometabolic disease or psychotropic medication (De Stavola et al., 2015). This 
assumption was checked by conducting a regression model of each cognitive outcome on 
mania/BD exposure status, the mediator and all the covariates, including a product term for 
mania/BD * mediator; there was no evidence of interaction in any of the models (see Table 
Z.1 in Appendix Z). The mediation model estimates are interpreted as ‘randomised 
interventional analogs’ of the natural direct and indirect effects (VanderWeele et al., 2014), 
as noted in Chapter 6. 
7.2.4.1 Cardiometabolic disease 
Table 7.4 shows the direct and indirect effect estimates via cardiometabolic disease (binary 
indicator of any of the following: self-reported diagnosis of angina, hypertension or non-
gestational diabetes, or adjudicated diagnosis of myocardial infarction or stroke). The 
model covariates were age, gender, educational attainment, English-speaking birth country, 
education/cognition GPS, bipolar disorder GPS, family history of dementia, family history 
of PD, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, population density, road proximity, air pollution (PM10 and NO2), 
BMI, alcohol frequency, smoking status, physical activity, and psychotropic medication. 
The analyses were restricted to participants of white British genetic ancestry, and the 
residualised GPS scores were entered as deciles. There was no evidence of substantive 
indirect effects via cardiometabolic disease in any of the models.  
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Table 7.4 - Mediation of the effect of mania/bipolar disorder on cognitive outcome via 
cardiometabolic disease 
 
 n Estimate 95% CIa 
Reasoningb  21,043   
TCE  -0.049 -0.157, 0.059 
CDE  -0.048 -0.156, 0.061 
NDE  -0.045 -0.153, 0.063 
NIE  -0.004 -0.020, 0.013 
Reaction timeb  21,213   
TCE  0.014 -0.082, 0.111 
CDE  0.034 -0.063, 0.132 
NDE  0.007 -0.090, 0.103 
NIE  0.008 -0.011, 0.026 
Numeric memoryb  6,396   
TCE  0.047 -0.213, 0.306 
CDE  0.021 -0.237, 0.280 
NDE  0.023 -0.235, 0.281 
NIE  0.024 -0.008, 0.055 
Visuospatial memoryb  21,124   
TCE  -0.166 -0.285, -0.047 
CDE  -0.160 -0.277, -0.044 
NDE  -0.164 -0.282, -0.046 
NIE  -0.002 -0.022, 0.017 
Prospective memoryc  21,139   
TCE  -0.033 -0.078, 0.012 
CDE  -0.038 -0.083, 0.006 
NDE  -0.038 -0.083, 0.007 
NIE  0.005 -0.002, 0.012 
CDE, controlled direct effect when cardiometabolic disease = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; NO2, nitrogen dioxide; PM10, particulate matter of up to 
10μm diameter; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for age, gender, educational 
attainment, English-speaking birth country, education/cognition GPS, bipolar disorder GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, population density, road proximity, air pollution (PM10 and NO2), body mass index, alcohol 
frequency, smoking status, physical activity, and psychotropic medication. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
 
7.2.4.2 Psychotropic medication 
Table 7.5 shows the direct and indirect effect estimates via psychotropic medication 
(binary variable for any mood stabiliser, antidepressant, antipsychotic, sedative or 
hypnotic). The model covariates were gender, educational attainment, English-speaking 
birth country, education/cognition GPS, bipolar disorder GPS, family history of dementia, 
family history of PD, maternal smoking around birth, childhood trauma, other 
psychiatric/neurological conditions, deprivation, and lifetime number of episodes of 
depressed mood/anhedonia. The analyses were restricted to participants of white British 
genetic ancestry, and the residualised GPS scores were entered as deciles. 
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There was evidence that the previously noted detrimental effect of mania/BD on 
visuospatial memory was indirectly transmitted via psychotropic medication: of the 
estimated total effect of -0.19 SD units (95% CI -0.31, -0.08), approximately one quarter 
was mediated via psychotropic medication (-0.05; 95% CI -0.09, -0.01). Indirect effects 
were also evident in the reasoning, reaction time and prospective memory models, 
although the total effects estimates in these models did not show reliable decrements for 
mania/BD.  
Table 7.5 - Mediation of the effect of mania/bipolar disorder on cognitive outcome via 
psychotropic medication 
 
 n Estimate 95% CIa 
Reasoningb  21,339   
TCE  -0.065 -0.176, 0.047 
CDE  0.016 -0.098, 0.130 
NDE  -0.015 -0.130, 0.099 
NIE  -0.049 -0.077, -0.021 
Reaction timeb  21,518   
TCE  -0.005 -0.103, 0.094 
CDE  0.073 -0.036, 0.182 
NDE  0.036 -0.072, 0.144 
NIE  -0.040 -0.075, -0.005 
Numeric memoryb  6,547   
TCE  0.033 -0.203, 0.270 
CDE  0.058 -0.181, 0.296 
NDE  0.075 -0.163, 0.312 
NIE  -0.041 -0.097, 0.015 
Visuospatial memoryb  21,424   
TCE  -0.194 -0.311, -0.077 
CDE  -0.098 -0.220, 0.024 
NDE  -0.140 -0.263, -0.018 
NIE  -0.054 -0.094, -0.013 
Prospective memoryc  21,436   
TCE  -0.037 -0.082, 0.009 
CDE  -0.028 -0.072, 0.016 
NDE  -0.018 -0.062, 0.026 
NIE  -0.019 -0.030, -0.007 
CDE, controlled direct effect when psychotropic medication = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for gender, educational 
attainment, English-speaking birth country, education/cognition GPS, bipolar disorder GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, and lifetime number of episodes of depressed mood/anhedonia. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
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7.2.5 Sensitivity analyses 
7.2.5.1 Conditional exchangeability 
Rosenbaum bounds were calculated to check the sensitivity of the visuospatial memory 
total effects result to departures from exchangeability. The estimated effect crossed the null 
at a gamma value of 1.2, which corresponds to the probability of being in the exposed 
group being approximately 0.45 or 0.55, rather than 0.5 as would be the case if the groups 
were truly exchangeable. This indicates that the results would not be robust to an 
unmeasured confounder with even a weak association with group membership.   
7.2.5.2 Missing data 
There was evidence of missing data bias on several of the outcome measures: much of the 
attenuation towards the null seen in Figures 7.4 to 7.6 above occurred prior to any 
multivariable adjustment/matching, simply by restricting the sample to participants with 
complete covariate data. When the multiple linear regression models for total causal effects 
were repeated after multiple imputation of the covariate values, the results showed less 
attenuation (Figure 7.9 below). The effect size estimates in these reasoning, reaction time 
and numeric memory models were of small magnitude (point estimates approximately -
0.10 to -0.15). The estimates in the visuospatial memory models remained similar 
regardless of which estimation method was used (approximate point estimate -0.19).  
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Figure 7.9 - Comparison of missing data approaches in mania/bipolar disorder total effects 
analyses 
 
CI, confidence interval; MICE, multiple imputation with chained equations. Panels show: (a) 
reasoning, (b) reaction time, (c) numeric memory and (d) visuospatial memory. Prospective 
memory not shown as it was not possible to calculate risk differences. 
 
When the mediation models were repeated with imputation of missing mediator and 
covariate values, the proportion of the total effect transmitted indirectly via 
cardiometabolic disease remained negligible (Table Z.2 in Appendix Z), whereas there was 
evidence of indirect effects via psychotropic medication for all the cognitive outcomes 
(Table Z.3 in Appendix Z). 
7.2.5.3 Exposure misclassification  
The results of the probabilistic analysis using episens indicated that the total effects 
estimate for visuospatial memory is likely to be sensitive to exposure misclassification. 
When dichotomised into impaired and unimpaired outcome categories, and assuming no 
exposure misclassification, the unadjusted relative risk of impairment was 1.70 in the 
mania/BD group (95% CI 1.45, 2.01). Assuming lower sensitivity to true mania/BD status 
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among the cognitively impaired (sensitivity range 0.6 to 0.9) versus unimpaired 
participants (sensitivity range 0.7 to 1.0), the relative risk was estimated as 1.81 (0.22, 
11.44).  
7.2.5.4 Equivalent models 
DAGitty determined that there were six other DAGs that were equivalent to the DAG 
shown in Figure 7.3 above. In each of these, path directions involving the ancestral history 
or parental genotype nodes were reversed (see Appendix AA). None of these alternative 
configurations was causally plausible, owing to temporal order constraints (e.g. it is not 
possible for parental genotype to be causally influenced by offspring genotype). DAGitty 
also generated minimum sufficient covariate adjustment sets for the equivalent DAGs, for 
the total effect of mania/BD on cognitive outcome. The same minimum adjustment set was 
valid for the analysed DAG and for the six equivalent DAGs. This indicates that the 
multivariable analyses reported above remain valid, regardless of which model within the 
equivalence class is correct. 
7.3 Discussion 
The total causal effect of mania/BD on cognitive performance in the UK Biobank cohort 
was small, and was principally evident on a test of short-term visuospatial memory. There 
was evidence of an indirect causal pathway through psychotropic medication, but not 
through cardiometabolic disease. The effect estimates are likely to be sensitive to even low 
levels of residual confounding, and to misclassification of mania/BD exposure status. 
Widespread missingness in the covariates limited the interpretation of the multivariable 
analyses. 
The finding of a specific effect of mania/BD on short-term visuospatial memory was 
unexpected. This result was robust to covariate adjustment and missingness, and was 
estimated consistently regardless of the regression or matching approach used. Previous 
meta-analyses have also reported decrements on visual memory tests in adults with BD 
(Arts et al., 2008; Bora et al., 2009; Bora et al., 2011; Mann-Wrobel et al., 2011), although 
with exceptions: one review of first episode BD patients reported no group differences in 
this domain (Lee et al., 2014). The magnitude of reported effects has been in the medium 
to large range in previous studies (standardised mean differences -0.5 to -0.8), in contrast 
with the small effect evident here (approximately -0.2). This may reflect the larger sample 
size or milder clinical status of the mania/BD group in UK Biobank, compared with clinic-
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based samples in previous studies. Deficits in other cognitive domains have also been 
evident in the literature; for example, group differences in speed/reaction time have been 
consistently reported, but no such difference was found here. There were indications, 
however, that the estimates in the present analyses were biased toward the null as a result 
of missing covariate data. The UK Biobank baseline cognitive assessment did not cover 
other key domains that have been highlighted in previous research, such as verbal memory, 
and so a comprehensive cross-domain comparison cannot be made.  
Despite evidence of elevated rates of cardiometabolic disease in adults with BD (e.g. 
Fiedorowicz, He, & Merikangas, 2011)—including in UK Biobank (Martin et al., 2016; 
see also Table 7.2)—and negative associations between cardiometabolic disease and 
cognitive function (e.g. Qiu & Fratiglioni, 2015), a mediating effect of cardiometabolic 
disease on cognitive performance was not found in the present analyses. This may be 
because of statistical adjustment for closely related sociodemographic and lifestyle 
covariates (e.g. BMI, smoking), or it may be related to misclassification in the self-
reported cardiometabolic disease data, or the relatively young age of the sample compared 
with previous studies of cardiometabolic disease and cognitive function.  
There was clearer evidence of mediation through psychotropic medication. Previous 
studies of cognitive function in BD have highlighted antipsychotic medication, in 
particular, as a risk factor for cognitive impairment (Altshuler et al., 2004; Balanzá-
Martínez et al., 2010; Frangou et al., 2005; Jamrozinski et al., 2009; Kieseppa et al., 2005). 
It is important to consider the possibility of confounding by indication: adults with 
mania/BD who are on particular psychotropic medications may have had a phenotypically 
different or more severe disease course than those who are not on these medications, and 
this may not have been adequately controlled for in the present analyses. It should also be 
noted that the residual dependencies in the DAG (pair-wise correlations >|0.10|; see section 
7.2.2 above and Appendix X) involved the psychotropic medication node, which may 
indicate measurement error or model misspecification, leading to uncontrolled influences 
of measured or unmeasured background confounders in the analyses involving this 
variable. It is therefore important that the possible causal role of psychotropic medication 
is evaluated carefully in future research; where possible, future studies should also analyse 
different psychotropic classes separately, and should consider opposing directions of effect 
whereby the potential positive cognitive effects of medication-related affective remission 
are contrasted against the potential adverse effects of the medications themselves.  
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The strengths of the present research include the large sample size, with the number of 
mania/BD participants in this single sample (n = 2,709) approaching that of a recent 
individual participant data meta-analysis (n = 2,876) of 31 studies (Bourne et al., 2013). A 
wide range of potential confounders were considered, each measured in a standard way. 
Multiple planned analyses were conducted, comparing different estimation approaches 
within a formal causal inference framework. The model specification was carefully 
evaluated using statistical and graphical methods, to compare the fit of alternative models 
and to consider the implications of structurally equivalent graphs for the plausibility of the 
analysed model.  
As outlined in previous chapters, a number of limitations must be considered when 
interpreting the results of cognitive research in UK Biobank. The cohort is not 
representative of the general population in some respects (Fry et al., 2017), and this may 
lead to collider bias if both exposure and outcome status influenced participation and/or 
missing data rates. In the present analyses, it is plausible that milder mental health 
problems and better cognitive function would increase the likelihood of joining UK 
Biobank and contributing complete data, which would mean that any true negative 
relationship between mental illness and cognitive function would be attenuated or reversed. 
The sensitivity analyses showed that when the impact of missingness was reduced through 
multiple imputation, the degree of attenuation in the group differences was lessened in the 
multivariable models, with decrements (albeit very small) now evident in the mania/BD 
group on multiple cognitive outcomes. These analyses relied on an assumption of 
missingness at random, however, which is likely to be implausible for at least some of the 
variables, e.g. past mental state.  
Measurement error and misclassification also present challenges for UK Biobank research. 
The sensitivity analyses reported here indicated that plausible degrees of exposure 
misclassification would attenuate the visuospatial memory result toward the null. A stricter 
definition of the mania/BD exposure (e.g. the narrow definition described in Chapter 4) 
may produce higher estimates of impairment. Conversely, retaining participants with major 
depression in the unexposed group would likely reduce the average group differences in 
cognitive performance. The suboptimal reliability of the cognitive outcome measures 
(Lyall et al., 2016) will have reduced the statistical power, although this is unlikely to have 
affected the visuospatial memory and reaction time analyses, as these measures were 
available for the whole cohort. It is possible to address measurement error by using latent 
variables; for example, a single latent cognitive outcome variable could have been entered 
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into the analyses, with the measured test scores as indicators. This was not done, however, 
because it was of interest to investigate whether domain- or test-specific deficits were 
evident in the mania/BD group, and any such differentiation would have been masked in a 
latent global variable. It is also possible to use test-retest reliability data to adjust single-
indicator measures; repeat data are available in UK Biobank (n ~ 20,000) for most of the 
exposure, outcome and covariate measures, but these were collected up to 7 years post-
baseline, and so may not provide an accurate indication of test-retest reliability in the 
absence of true change. The validity of some of the covariate measures is open to question, 
e.g. the information regarding the number of past depressive episodes could not be clearly 
separated into pre- and post-baseline periods for participants with web-based questionnaire 
data only, and the GPS that was intended to measure genetic aspects of cognitive function 
was based on a GWAS of education rather than cognitive ability per se (although these 
phenotypes have a very high genetic correlation). A further limitation was the absence of 
data regarding the number of past episodes of mania; combining such information with the 
data on past depressive episodes would have strengthened the validity of the past mental 
health measure.  
Other limitations of the UK Biobank data used in these analyses include their cross-
sectional nature, particularly the absence of information about premorbid cognitive 
function that would support the assumptions made here regarding the temporal order of the 
mania/BD exposure and the cognitive outcomes. There were also constraints on which 
intermediate variables could be examined in mediation analyses; for example, current 
depressive symptoms could not be analysed in this way, owing to an open back-door path 
involving the unmeasured ‘brain_health’ node, but this can be addressed in future analyses 
as the number of participants with neuroimaging data increases. This and other issues—
e.g. the transportability of UK Biobank results to external populations—will be considered 
further in Chapter 9. Chapter 8 continues the present research by applying the same causal 
inference framework to cognitive performance in major depression and schizophrenia 
groups in UK Biobank. 
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Chapter 8 Explaining variation in cognitive 
function in other psychiatric conditions 
The studies presented in this chapter aimed to estimate the total causal effects of major 
depression and schizophrenia on cognitive function, and to decompose these into direct 
and indirect effects through potentially modifiable intermediate factors. The analyses were 
conducted using baseline data from the UK Biobank cohort, and followed the same 
procedures as were described in Chapter 7. The major depression analyses and their results 
are presented first, followed by the schizophrenia analyses, and both are discussed together 
at the end of the chapter. Owing to the absence of data regarding past illness course for UK 
Biobank participants with neurological conditions, no causal analyses for cognitive 
outcome in MS or PD were undertaken in this thesis. 
8.1 Major depression 
8.1.1 Methods 
8.1.1.1 Participants 
Participants were retained for analysis if they had sufficient data to classify their exposure 
status and had data on at least one cognitive outcome measure. Adjusted analyses were 
restricted to participants of white British genetic ancestry; the unadjusted analyses were not 
restricted by ethnic group. The sample size available for analysis is detailed in section 
8.1.2.1. 
8.1.1.2 Exposure status 
The illness exposure of interest was major depression, classified using the broad definition 
given in Chapter 4 (i.e. met criteria for single or multiple episodes of major depression 
according to self-reported diagnosis, or touchscreen mood questionnaire algorithm, or pre-
baseline hospital records; participants were classified as exposed if they met the criteria in 
at least one information source, even if other information sources were missing). The 
unexposed comparison group comprised participants who had complete self-reported and 
touchscreen mood questionnaire data indicating that they did not meet the criteria for 
major depression or mania/BD, and whose pre-baseline hospital records had no primary or 
secondary diagnoses of major depression or mania/BD. Participants with a self-reported 
diagnosis or hospital record of schizophrenia (as defined in Chapter 4) were excluded from 
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the exposed and unexposed groups. Participants who did not meet the above criteria for 
either the exposed or unexposed groups were not further analysed.  
8.1.1.3 Outcome measures and covariates 
The cognitive measures were as described previously; reasoning, reaction time, numeric 
memory and visuospatial memory were analysed as z-scores (higher scores represent better 
performance), and prospective memory was analysed as a dichotomous variable (correct 
response at the first attempt or not). Other sociodemographic, local environment, lifestyle, 
physical, medical and family history, mental health and psychotropic medication measures 
were as described in Chapter 7, and the same education/cognition GPS was used. A GPS 
was created for major depression, using summary statistics from the most recent 
Psychiatric Genomics Consortium GWAS (Wray et al., 2017); the GWAS authors 
provided reanalysed statistics that excluded UK Biobank participants (participants from the 
23andMe data resource were also omitted due to data-sharing restrictions). The major 
depression GPS was generated for unrelated UK Biobank participants of white British 
genetic ancestry, using the same quality control criteria as described previously, and the 
model residuals after adjustment for genotyping array and batch, UK Biobank assessment 
centre, and the first 20 genetic principal components were used in the analyses. Appendix 
W shows the R2 at each p threshold, and the odds ratio for the association between deciles 
of the optimum GPS and the major depression phenotype in the UK Biobank cohort. The 
R2 for the optimum GPS was 0.005. This is similar to that reported by the GWAS authors 
when using their core “anchor” cohort results alone to predict into independent samples, 
although R2 values of up to 0.02 were obtained when additional cohort results (including 
UK Biobank and 23andMe) were included in GWAS meta-analyses (Wray et al., 2017). 
8.1.1.4 Data analysis 
The DAG used in the major depression analyses was based on the final DAG used in the 
mania/BD study, with the exception that an arrow was added from gender to major 
depression; studies have consistently shown higher prevalence of depression in women 
(e.g. Parker & Brotchie, 2010; Piccinelli & Wilkinson, 2000), and it was assumed in the 
DAG that this relationship was at least partly causal. No arrows were removed compared 
with the mania/BD DAG, on the assumption that similar causal relationships might be 
operating to explain cognitive impairment in both disorders. Two versions of the DAG 
were evaluated: the first depicted a causal influence of educational attainment on major 
depression and other psychiatric/neurological conditions, and the second depicted these 
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relationships in reverse. The testable implied independencies were analysed as per Chapter 
7. 
The total causal effect of major depression on cognitive performance was identified using 
the back-door criterion in DAGitty, and a series of regression and matching-based models 
were then conducted for each cognitive outcome, as described in Chapter 7. The propensity 
score model was again specified in three ways, and the score that resulted in the best 
covariate balance was taken forward into the analyses. G-computation was used to estimate 
the natural direct and indirect effects via intermediate nodes, adjusting for the minimum 
sufficient covariate sets to block all back-door paths.  
8.1.1.5 Sensitivity analyses 
These followed the same procedure as described in Chapter 7. The sensitivity of the total 
effects results to different potential magnitudes of departure from exchangeability were 
evaluated using Rosenbaum bounds. To investigate the impact of missing covariate data on 
the results, the multiple linear regression models were repeated using multiply-imputed 
datasets, and the chained equations imputation option was also implemented in the G-
computation models. The effect of different hypothetical levels of major depression 
exposure misclassification on cognitive outcome (dichotomous impaired status) was 
assessed using a trapezoidal probability function, assuming differential misclassification. 
The final DAG was analysed structurally to determine its equivalence class.  
8.1.2 Results 
8.1.2.1 Characteristics of the sample 
Figure 8.1 shows a flowchart of exclusions leading to the final analysis sample, which 
comprised 50,975 participants with major depression and 102,931 comparison participants.  
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Figure 8.1 - Major depression analysis sample flowchart 
 
Table 8.1 indicates slightly lower scores, on average, in the major depression group (all 
available data) for reaction time, numeric memory and visuospatial memory, but not for 
reasoning or prospective memory. Scores appeared higher overall among the participants 
with complete covariate data. Missingness was most common on the visuospatial memory 
test (3.2% and 2.8% in the major depression and comparison groups, respectively). 
Reliability (Cronbach’s alpha) was higher for reaction time than for reasoning, and was 
largely similar between the major depression and comparison groups.  
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Table 8.1 - Summary of cognitive outcome measures in the major depression and 
comparison groups 
 
 All available data Complete covariate dataa 
 Major depression Comparison Major depression Comparison 
n  50,975 102,931 11,662 26,392 
Reasoning z-score 
n (%) missingb 
Mean (SD) 
Cronbach’s α 
 
421 (1.3) 
-0.20 (0.96) 
0.69 
 
1,584 (1.6) 
-0.20 (0.97) 
0.70 
 
25 (0.3) 
0.10 (0.90) 
0.66 
 
84 (0.3) 
0.13 (0.92) 
0.68 
Reaction time z-score  
n (%) missing 
Mean (SD)  
Cronbach’s α 
 
534 (1.1) 
-0.08 (0.98) 
0.82 
 
1,139 (1.1) 
-0.03 (0.98) 
0.82 
 
34 (0.3) 
0.04 (0.94) 
0.82 
 
68 (0.3) 
0.07 (0.95) 
0.82 
Numeric memory z-score 
n (%) missingb 
Mean (SD) 
 
252 (2.6) 
-0.39 (0.93) 
 
733 (2.4) 
-0.35 (0.94) 
 
18 (0.8) 
-0.24 (0.90) 
 
49 (0.7) 
-0.17 (0.93) 
Visuospatial memory z-score 
n (%) missing 
Mean (SD) 
 
1,653 (3.2) 
0.19 (1.05) 
 
2,843 (2.8) 
0.26 (1.05) 
 
106 (0.9) 
0.30 (1.04) 
 
206 (0.8) 
0.37 (1.03) 
Prospective memoryb,c 
n (%) correct 
 
25,006 (78.0) 
 
78,673 (76.8) 
 
7,003 (85.6) 
 
22,591 (85.7) 
GPS, genome-wide polygenic score; SD, standard deviation. 
a. Participants with complete data on all the covariates that were entered into the maximally-adjusted total effects models 
(age, gender, white British genetic ancestry, English-speaking country of birth, degree, comorbid neurological/psychiatric 
condition, family history of dementia, family history of Parkinson’s disease, family history of severe depression, maternal 
smoking around birth, childhood trauma, education/cognition GPS, major depression GPS). 
b. Missing data refers only to the period when this measure was included in the battery. 
c. No missing data. 
 
Table 8.2 describes the covariate data in both groups. As was found in Chapter 7, the 
proportion of missing data was highest, by far, on the childhood trauma variable, and was 
also relatively high on the family history, current depressive symptoms and physical 
activity measures. The descriptive information indicated that the major depression group 
was younger, on average, than the comparison group, had a substantially higher proportion 
of women, and had higher proportions of current smokers, former drinkers, and 
participants living in deprived areas. The major depression group had higher proportions 
with frequent sleeplessness, obesity, cardiometabolic disease, comorbid 
neurological/psychiatric conditions, family history of severe depression, current 
psychotropic medication and history of childhood trauma, and they reported more 
depressed episodes and higher current depressive symptoms on average. The distribution 
of the major depression GPS score was skewed towards higher values in the major 
depression group. The subset of participants with complete covariate data appeared 
different from the full analysis sample across multiple measures, e.g. having a greater 
proportion of degree-holders and a smaller proportion from the most deprived areas.  
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Table 8.2 - Summary of covariates in the major depression and comparison groups 
 
 All available data Complete covariate dataa 
 Major depression Comparison Major depression Comparison 
n  50,975 102,931 11,662 26,392 
Sociodemographic      
Age (years)b 
Mean (SD) 
 
55.6 (7.9) 
 
57.0 (8.2) 
 
54.9 (7.6) 
 
56.3 (7.9) 
Genderb 
n (%) female 
 
33,090 (64.9) 
 
51,463 (50.0) 
 
7,996 (68.6) 
 
14,072 (53.3) 
Ethnic group 
n (%) missing 
White, n (%)c 
Asian/Asian British 
Black/Black British 
Chinese 
Mixed & other background 
 
220 (0.4) 
48,345 (95.3) 
814 (1.6 ) 
641 (1.3) 
69 (0.1) 
886 (1.8) 
 
401 (0.4) 
93,194 (90.9) 
3,663 (3.6) 
3,159 (3.1) 
473 (0.5) 
2,041 (2.0) 
 
32 (0.3) 
11,347 (97.6) 
77 (0.7) 
67 (0.6) 
11 (0.1) 
128 (1.1) 
 
71 (0.3) 
25,123 (95.5) 
451 (1.7) 
319 (1.2) 
97 (0.4) 
331 (1.3) 
White British genetic ancestry 
n (%) missing 
n (%)c 
 
1,518 (3.0) 
41,509 (83.9) 
 
3,419 (3.3) 
79,097 (79.5) 
 
0 (0.0) 
10,029 (86.0) 
 
0 (0.0) 
22,075 (83.6) 
English-speaking country of birth 
n (%) missing 
n (%)c 
 
85 (0.2) 
47,741 (93.8) 
 
149 (0.2) 
91,524 (89.1) 
 
0 (0.0) 
11,068 (94.9) 
 
0 (0.0) 
24,407 (92.5) 
Has a degree  
n (%) missing 
n (%)c 
 
493 (1.0) 
16,713 (33.1) 
 
1,012 (1.0) 
36,211 (35.5) 
 
0 (0.0) 
5,570 (47.8) 
 
0 (0.0) 
12,977 (49.2) 
Townsend quintiled 
n (%) missing 
Qu1 (least deprived), n (%)c 
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
93 (0.2) 
8,109 (15.9) 
9,124 (17.9) 
9,793 (19.3) 
11,261 (22.1) 
12,595 (24.8) 
 
159 (0.2) 
17,672 (17.2) 
20,807 (20.3) 
21,291 (20.7) 
23,193 (22.6) 
19,809 (19.3) 
 
25 (0.2) 
2,207 (19.0) 
2,291 (19.7) 
2,359 (20.3) 
2,620 (22.5) 
2,160 (18.6) 
 
33 (0.1) 
5,019 (19.0) 
5,704 (21.6) 
5,767 (21.9) 
5,989 (22.7) 
3,880 (14.7) 
Local environment     
Home area population densitye 
n (%) missing 
England/Wales urban, n (%)c 
England/Wales town 
England/Wales village 
England/Wales hamlet/isolated 
Scotland large urban 
Scotland other urban 
Scotland small town 
Scotland rural 
 
596 (1.2) 
42,462 (84.3) 
3,239 (6.4) 
2,031 (4.0) 
842 (1.7) 
1,376 (2.7) 
300 (0.6) 
66 (0.1) 
63 (0.1) 
 
951 (0.9) 
88,651 (86.9) 
6,392 (6.3) 
4,853 (4.8) 
2,084 (2.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
160 (1.4) 
9,617 (83.6) 
793 (6.9) 
555 (4.8) 
223 (1.9) 
253 (2.2) 
41 (0.4) 
9 (0.1) 
11 (0.1) 
 
265 (1.0) 
22,259 (85.2) 
1,727 (6.6) 
1,493 (5.7) 
648 (2.5) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
Proximity to major road (1/m) 
n (%) missing 
Mean (SD) 
 
772 (1.5) 
0.006 (0.014) 
 
1,290 (1.3) 
0.006 (0.013) 
 
166 (1.4) 
0.005 (0.012) 
 
344 (1.3) 
0.006 (0.010) 
Particulate matter ≤10μm (μg/m3) 
n (%) missing 
Mean (SD) 
 
938 (1.8) 
22.4 (2.9) 
 
1,668 (1.6) 
22.8 (3.1) 
 
205 (1.8) 
22.5 (3.1) 
 
430 (1.6) 
22.8 (3.2) 
Nitrogen dioxide (μg/m3) 
n (%) missing 
Mean (SD) 
 
772 (1.5) 
30.9 (10.1) 
 
1,290 (1.3) 
31.9 (10.6) 
 
166 (1.4) 
30.9 (10.6) 
 
344 (1.3) 
31.9 (1.1) 
Lifestyle and physical      
Smoking status 
n (%) missing 
Never, n (%)c 
Former 
Current 
 
170 (0.3) 
25,008 (49.2) 
18,320 (36.1) 
7,477 (14.7) 
 
368 (0.4) 
58,955 (57.5) 
34,658 (33.8) 
8,950 (8.7) 
 
8 (0.1) 
6,222 (53.4) 
4,361 (37.4) 
1,071 (9.2) 
 
47 (0.2) 
16,066 (61.0) 
8,682 (33.0) 
1,597 (6.1) 
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 All available data Complete covariate dataa 
 Major depression Comparison Major depression Comparison 
Alcohol frequency 
n (%) missing 
Daily/almost daily, n (%)c 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
100 (0.2) 
9,839 (19.3) 
10,085 (19.8) 
11,765 (23.1) 
6,344 (12.5) 
7,333 (14.4) 
3,189 (6.3) 
2,320 (4.6) 
 
80 (0.1) 
21,729 (21.1) 
24,196 (23.5) 
26,111 (25.4) 
11,118 (10.8) 
11,536 (11.2) 
3,096 (3.0) 
5,065 (4.9) 
 
5 (0.1) 
2,562 (22.0) 
2,773 (23.8) 
2,660 (22.8) 
1,410 (12.1) 
1,378 (11.8) 
536 (4.6) 
338 (2.9) 
 
5 (0.1) 
6,399 (24.3) 
7,045 (26.7) 
6,450 (24.4) 
2,812 (10.7) 
2,299 (8.7) 
599 (2.3) 
783 (3.0) 
Sleeplessness 
n (%) missing 
Never/rarely, n (%)c 
Sometimes 
Usually 
 
58 (0.1) 
8,438 (16.6) 
23,090 (45.4) 
19,389 (38.1) 
 
79 (0.1) 
28,617 (27.8) 
49,193 (47.8) 
25,042 (24.4) 
 
5 (0.1) 
2,236 (19.2) 
5,381 (46.2) 
4,040 (34.7) 
 
14 (0.1) 
7,855 (29.8) 
12,485 (47.3) 
6,038 (22.9) 
Physical activity (MET h/week) 
n (%) missing 
Median (Q1, Q3)  
 
4,617 (9.1) 
26.2 (11.6, 55.9) 
 
6,690 (6.5) 
29.9 (13.8, 60.2) 
 
583 (5.0) 
25.6 (12.1, 51.5) 
 
1,031 (3.9) 
29.2 (14.2, 55.8) 
Body mass index 
n (%) missing 
Underweight, n (%)c 
Normal 
Overweight 
Obese class I 
Obese class II 
Obese class III 
 
354 (0.7) 
270 (0.5) 
15,166 (30.0) 
20,289 (40.1) 
9,781 (19.3) 
3,443 (6.8) 
1,672 (3.3) 
 
732 (0.7) 
496 (0.5) 
34,192 (33.5) 
43,942 (43.0) 
17,374 (17.0) 
4,588 (4.5) 
1,607 (1.6) 
 
26 (0.2) 
62 (0.5) 
4,152 (35.7) 
4,660 (40.1) 
1,897 (16.3) 
601 (5.2) 
264 (2.3) 
 
89 (0.3) 
145 (0.6) 
10,534 (40.1) 
10,842 (41.2) 
3,660 (13.9) 
836 (3.2) 
286 (1.1) 
Medical and family history     
Cardiometabolic disease 
n (%) missing 
n (%)c 
 
121 (0.2) 
17,459 (34.3) 
 
177 (0.2) 
31,361 (30.5) 
 
7 (0.1) 
2,961 (25.4) 
 
21 (0.1) 
6,185 (23.5) 
Comorbid neurological or 
psychiatric conditionf 
n (%) 
 
 
11,542 (22.6) 
 
 
9,155 (8.9) 
 
 
2,242 (19.2) 
 
 
2,035 (7.7) 
Family history of dementia 
n (%) missing 
n (%)c 
 
7,815 (15.3) 
7,032 (16.3) 
 
14,476 (14.1) 
15,330 (17.3) 
 
0 (0.0) 
1,880 (16.1) 
 
0 (0.0) 
4,546 (17.2) 
Family history of Parkinson’s 
disease 
n (%) missing 
n (%)c 
 
 
9,456 (18.6) 
2,064 (5.0) 
 
 
16,090 (15.6) 
4,161 (4.8) 
 
 
0 (0.0) 
510 (4.4) 
 
 
0 (0.0) 
1,253 (4.8) 
Family history of severe 
depression 
n (%) missing 
n (%)c 
 
 
7,871 (15.4) 
12,370 (28.7) 
 
 
15,347 (14.9) 
10,201 (11.7) 
 
 
0 (0.0) 
3,014 (25.8) 
 
 
0 (0.0) 
3,000 (11.4) 
Maternal smoking around birth 
n (%) missing 
n (%)c 
 
6,933 (13.6) 
14,521 (33.0) 
 
13,107 (12.7) 
24,125 (26.9) 
 
0 (0.0) 
3,595 (30.8) 
 
0 (0.0) 
6,894 (26.1) 
Mental health      
Current depressive symptoms 
n (%) missing 
Mean (SD)  
 
5,028 (9.9) 
3.1 (3.0) 
 
8,556 (8.3) 
1.2 (1.7) 
 
672 (5.8) 
2.5 (2.6) 
 
270 (1.0) 
1.0 (1.4) 
Any psychotropic medication 
n (%) missing 
n (%)c 
 
860 (1.7) 
20,898 (41.7) 
 
1,194 (1.2) 
2,577 (2.5) 
 
182 (1.6) 
3,902 (34.0) 
 
1,189 (4.5) 
490 (1.9) 
Number of depressed episodes 
n (%) missing 
Median (Q1, Q3) 
 
1,495 (2.9) 
1 (0, 4) 
 
6,451 (6.3) 
0 (0, 1) 
 
354 (3.0) 
3 (1, 6) 
 
1,418 (5.4) 
0 (0, 1) 
Any childhood traumag 
n (%) missing 
n (%)c 
 
34,801 (68.3) 
9,455 (58.5) 
 
67,160 (65.3) 
15,651 (43.8) 
 
0 (0.0) 
6,515 (55.9) 
 
0 (0.0) 
10,968 (41.6) 
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 All available data Complete covariate dataa 
 Major depression Comparison Major depression Comparison 
Genome-wide polygenic scores     
Education/cognition GPS deciled 
n (%) missing 
D1 (lowest), n (%)c 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
1,518 (3.0) 
5,169 (10.5) 
5,089 (10.3) 
5,002 (10.1) 
4,931 (10.0) 
4,960 (10.0) 
4,890 (9.9) 
4,914 (9.9) 
4,830 (9.8) 
4,815 (9.7) 
4,857 (9.8) 
 
3,419 (3.3) 
9,728 (9.8) 
9,808 (9.9) 
9,895 (9.9) 
9,966 (10.0) 
9,937 (10.0) 
10,007 (10.1) 
9,983 (10.0) 
10,067 (10.1) 
10,082 (10.1) 
10,039 (10.1) 
 
0 (0.0) 
982 (8.4) 
1,089 (9.3) 
1,096 (9.4) 
1,130 (9.7) 
1,142 (9.8) 
1,157 (9.9) 
1,244 (10.7) 
1,185 (10.2) 
1,285 (11.0) 
1,352 (11.6) 
 
0 (0.0) 
2,163 (8.2) 
2,350 (8.9) 
2,423 (9.2) 
2,572 (9.8) 
2,515 (9.5) 
2,641 (10.0) 
2,753 (10.4) 
2,877 (10.9) 
2,950 (11.2) 
3,148 (11.9) 
Bipolar disorder GPS deciled 
n (%) missing 
D1 (lowest), n (%)c 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
1,518 (3.0) 
4,271 (8.6) 
4,645 (9.4) 
4,690 (9.5) 
4,693 (9.5) 
4,890 (9.9) 
4,887 (9.9) 
5,057 (10.2) 
5,247 (10.6) 
5,313 (10.7) 
5,764 (11.7) 
 
3,419 (3.3) 
10,626 (10.7) 
10,252 (10.3) 
10,207 (10.3) 
10,204 (10.3) 
10,007 (10.1) 
10,010 (10.1) 
9,840 (9.9) 
9,650 (9.7) 
9,584 (9.6) 
9,162 (9.2) 
 
0 (0.0) 
1,038 (8.9) 
1,124 (9.6) 
1,136 (9.7) 
1,070 (9.2) 
1,144 (9.8) 
1,142 (9.8) 
1,198 (10.3) 
1,228 (10.5) 
1,249 (10.7) 
1,333 (11.4) 
 
0 (0.0) 
2,998 (11.4) 
2,826 (10.7) 
2,791 (10.6) 
2,784 (10.6) 
2,699 (10.2) 
2,551 (9.7) 
2,517 (9.5) 
2,460 (9.3) 
2,460 (9.3) 
2,306 (8.7) 
D, decile; GPS, genome-wide polygenic score; MET, metabolic equivalent of task; Q, quartile; Qu, quintile; SD, standard 
deviation. 
a. Participants with complete data on all the covariates that were entered into the maximally-adjusted total effects models 
(age, gender, white British genetic ancestry, English-speaking country of birth, degree, comorbid neurological/psychiatric 
condition, family history of dementia, family history of Parkinson’s disease, family history of severe depression, maternal 
smoking around birth, childhood trauma, education/cognition GPS, major depression GPS). 
b. No missing data. 
c. Missing excluded from denominator. 
d. Based on data distribution in the whole UK Biobank cohort. 
e. Scottish psychiatric hospital records were unavailable, which meant no Scotland-based participants could be classified 
in the comparison group; therefore all locations for comparison participants are in England/Wales.  
f. Apart from mood disorder or schizophrenia; not possible to distinguish between missing data and self-report of no 
condition, therefore both classified as No. 
g. From the web-based questionnaire, which was completed by 157,366 (31.3%) of the cohort.  
 
8.1.2.2 Evaluation of the graphical model 
The different predicted independencies implied by the two specifications of the DAG 
(educational attainment as an antecedent, or a consequence, of major depression and other 
psychiatric/neurological conditions) were tested, and better fit was evident in the first 
specification (see Appendix BB). Fifteen percent (21 of 137) of the partial correlation 
coefficients were above |0.1|, but most of these were below |0.2| and the largest coefficient 
was |0.22|. This model, depicted in Figure 8.2, was used to plan the causal effect models 
reported below.  
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Figure 8.2 - Directed acyclic graph for the effect of major depression on cognitive outcome 
 
Cardiomet, cardiometabolic disease; cog, cognitive; curr, current; edu, educational; eng_speak, English speaking birth country; famhx, family history; 
geno, genotype; hx, history; majordep, major depression; other_neupsy, other neurological/psychiatric condition; par, parental; PD, Parkinson’s disease; 
phys, physical; pre_IQ, premorbid intelligence; psych_meds, psychotropic medications; SES, socioeconomic status. Green node is the exposure and blue 
node is the outcome. Light nodes represent unmeasured constructs and darker nodes represent measured constructs. This graph and the underlying code 
are publicly available online at dagitty.net/mqiL72i
179 
 
8.1.2.3 Total causal effects 
Applying d-separation criteria to the DAG indicated that the minimum sufficient 
adjustment set for the total effect of major depression on cognitive performance comprised 
gender, educational attainment, English-speaking birth country, ethnicity, 
education/cognition GPS, major depression GPS, family history of dementia, family 
history of PD, maternal smoking around birth, childhood trauma, and other 
psychiatric/neurological conditions. The extended adjustment set encompassed additional 
measured nodes that were antecedents of the exposure, namely age and family history of 
depression. This extended adjustment set was also used as the predictor set for the 
propensity score model. Ethnicity was accounted for in all the multivariable analyses and 
in the propensity score estimation by restricting these to participants of white British 
genetic ancestry. The GPS score residuals were entered as deciles, based on the 
distribution in the full analysis sample.  
The best covariate balance was obtained using the first propensity score model with no 
interaction terms, as illustrated in Table 8.3. This was used in all the outcome models that 
involved propensity score adjustment or matching, or inverse probability weighting.  
Figures 8.3 to 8.7 show the results of all the total effects models. Only the visuospatial 
memory test indicated a detrimental effect of major depression that remained evident in the 
multivariable models. The effect size was very small, with the major depression group 
scoring approximately 0.07 SD lower than the comparison group. The visuospatial 
memory estimates showed little change between the unadjusted and adjusted/matched 
models, whereas the estimates for the other cognitive measures generally showed 
attenuation towards the null.  
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Table 8.3 - Summary of covariates in matched major depression and comparison groups 
 
 Major depression Comparison 
 Mean (SD) 
Age (years) 55.1 (7.5) 55.2 (7.5) 
 % 
Female gender 68.4 69.5 
English-speaking country of birth 98.3 98.2 
Has a degree  46.0 46.5 
Comorbid neurological or psychiatric condition 19.3 19.3 
Family history of dementia 16.4 16.4 
Family history of Parkinson’s disease 4.4 4.3 
Family history of severe depression 25.2 24.7 
Maternal smoking around birth 31.2 30.7 
Any childhood trauma 54.8 54.7 
Education/cognition GPS 
D1 (lowest) 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
8.6 
9.4 
9.5 
9.7 
9.7 
9.8 
10.6 
10.1 
11.1 
11.5 
 
8.2 
9.4 
9.5 
9.5 
9.8 
9.8 
10.9 
10.1 
11.1 
11.7 
Major depression GPS 
D1 (lowest) 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
D9 
D10 (highest) 
 
8.6 
9.6 
9.9 
9.0 
9.8 
9.8 
10.2 
10.6 
10.8 
11.7 
 
8.8 
9.7 
9.8 
8.8 
10.0 
9.3 
10.6 
10.7 
10.9 
11.4 
D, decile; GPS, genome-wide polygenic score; SD, standard deviation. 
These results are from the matched samples used in the 1:3 matched model for the total effect of major depression on 
reaction time (major depression n = 9,381; comparison n = 13,538). 
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Figure 8.3 - Total causal effect of major depression on reasoning 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 8.4 - Total causal effect of major depression on reaction time 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 8.5 - Total causal effect of major depression on numeric memory 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 8.6 - Total causal effect of major depression on visuospatial memory 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are in z-
score units and can be interpreted as standardised mean differences. 
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Figure 8.7 - Total causal effect of major depression on prospective memory 
 
CI, confidence interval; IPW, inverse probability weighting; IPWRA, inverse probability 
weighting with regression adjustment; teffects, Stata teffects package. Estimates are 
proportions and can be interpreted as risk differences. No estimates are provided from 
propensity-score matched models as it was not possible to express these as risk 
differences. 
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8.1.2.4 Direct and indirect effects 
As with the mania/BD study, structural analysis of the DAG indicated that direct and 
indirect effects could be decomposed for cardiometabolic disease and psychotropic 
medication. In both sets of analyses, the indirect pathways were affected by intermediate 
confounding, and so an identifying assumption was firstly made of no interaction between 
major depression and either cardiometabolic disease or psychotropic medication (Robins & 
Greenland, 1992). This assumption was checked by conducting a regression model of each 
cognitive outcome on major depression exposure status, the mediator and all the 
covariates, including a product term for major depression * mediator. There was no 
evidence of interaction in the cardiometabolic disease mediation models, but some 
evidence of interaction in the psychotropic medication models (see Table CC.1 in 
Appendix CC). The alternative identifying assumption proposed by Petersen et al. (2006) 
was therefore made for the psychotropic medication models; following De Stavola et al. 
(2015), this was checked by testing for interactions between major depression and each of 
the intermediate confounders (deprivation, and lifetime number of episodes of depressed 
mood/anhedonia), in regression models that included major depression, psychotropic 
medication and their product, along with all the other model covariates. There was little 
evidence of interaction between major depression and the intermediate confounders (Table 
CC.2 in Appendix CC), and so the Petersen et al. (2006) identifying assumption was 
deemed reasonable and these mediation models were estimated with a product term 
included between major depression and psychotropic medication.  
Table 8.4 shows the direct and indirect effect estimates via cardiometabolic disease. The 
model covariates were age, gender, educational attainment, English-speaking birth country, 
education/cognition GPS, major depression GPS, family history of dementia, family 
history of PD, maternal smoking around birth, childhood trauma, other 
psychiatric/neurological conditions, deprivation, population density, road proximity, air 
pollution (PM10 and NO2), BMI, alcohol frequency, smoking status, physical activity, and 
psychotropic medication. The analyses were restricted to participants of white British 
genetic ancestry, and the residualised GPS scores were entered as deciles. There was no 
evidence of substantive indirect effects via cardiometabolic disease in any of the models.  
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Table 8.4 - Mediation of the effect of major depression on cognitive outcome via 
cardiometabolic disease 
 
 n Estimate 95% CIa 
Reasoningb  26,679   
TCE  -0.009 -0.038, 0.019 
CDE  -0.029 -0.056, -0.001 
NDE  0.005 -0.023, 0.033 
NIE  -0.014 -0.028, 0.000 
Reaction timeb  29,422   
TCE  -0.015 -0.042, 0.013 
CDE  -0.006 -0.036, 0.024 
NDE  -0.009 -0.037, 0.020 
NIE  -0.006 -0.021, 0.009 
Numeric memoryb  8,085   
TCE  -0.034 -0.087, 0.019 
CDE  -0.032 -0.085, 0.021 
NDE  -0.035 -0.089, 0.018 
NIE  0.001 -0.027, 0.029 
Visuospatial memoryb  29,284   
TCE  -0.074 -0.107, -0.042 
CDE  -0.077 -0.109, -0.046 
NDE  -0.079 -0.111, -0.047 
NIE  0.005 -0.012, 0.022 
Prospective memoryc  26,789   
TCE  -0.010 -0.022, 0.001 
CDE  -0.001 -0.012, 0.010 
NDE  -0.011 -0.022, 0.000 
NIE  0.001 -0.012, 0.010 
CDE, controlled direct effect when cardiometabolic disease = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; NO2, nitrogen dioxide; PM10, particulate matter of up to 
10μm diameter; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for age, gender, educational 
attainment, English-speaking birth country, education/cognition GPS, major depression GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, population density, road proximity, air pollution (PM10 and NO2), body mass index, alcohol 
frequency, smoking status, physical activity, and psychotropic medication. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
 
Table 8.5 shows the direct and indirect effect estimates via psychotropic medication. The 
model covariates were gender, educational attainment, English-speaking birth country, 
education/cognition GPS, major depression GPS, family history of dementia, family 
history of PD, maternal smoking around birth, childhood trauma, other 
psychiatric/neurological conditions, deprivation, and lifetime number of episodes of 
depressed mood/anhedonia. The analyses were restricted to participants of white British 
genetic ancestry, and the residualised GPS scores were entered as deciles. There was little 
evidence of mediation via psychotropic medication: approximately one third of the total 
effect on visuospatial memory (itself of very small magnitude, at -0.058) was estimated to 
be indirect, but the confidence interval included the null (-0.019; 95% CI -0.040, 0.003). 
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Table 8.5 - Mediation of the effect of major depression on cognitive outcome via 
psychotropic medication 
 
 n Estimate 95% CIa 
Reasoningb  27,263   
TCE  -0.009 -0.037, 0.019 
CDE  -0.011 -0.040, 0.018 
NDE  -0.010 -0.039, 0.020 
NIE  0.001 -0.016, 0.017 
Reaction timeb  30,189   
TCE  0.002 -0.026, 0.029 
CDE  0.005 -0.025, 0.036 
NDE  0.026 -0.004, 0.055 
NIE  -0.024 -0.042, -0.005 
Numeric memoryb  8,338   
TCE  -0.023 -0.078, 0.032 
CDE  -0.021 -0.077, 0.035 
NDE  -0.019 -0.076, 0.038 
NIE  -0.004 -0.035, 0.028 
Visuospatial memoryb  30,038   
TCE  -0.058 -0.088, -0.028 
CDE  -0.066 -0.100, -0.031 
NDE  -0.039 -0.073, -0.006 
NIE  -0.019 -0.040, 0.003 
Prospective memoryc  27,381   
TCE  0.001 -0.011, 0.012 
CDE  0.001 -0.010, 0.013 
NDE  0.001 -0.011, 0.012 
NIE  0.000 -0.006, 0.006 
CDE, controlled direct effect when psychotropic medication = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for gender, educational 
attainment, English-speaking birth country, education/cognition GPS, major depression GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, and lifetime number of episodes of depressed mood/anhedonia. All models included a product 
term for major depression * psychotropic medication. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
 
8.1.2.5 Sensitivity analyses 
Rosenbaum bounds were calculated to check the sensitivity of the visuospatial memory 
total effect result to departures from exchangeability. The estimated effect crossed the null 
at a gamma value of 1.07, i.e. the point where the probability of being in the exposed group 
is approximately 0.48 or 0.52. The results would therefore not be robust to an unmeasured 
confounder with even a very weak association with group membership.   
There was evidence of missing data bias, in that the unadjusted total effects estimates 
shifted (towards or away from the null) when the sample was restricted to participants with 
complete covariate data. When the multiple linear regression models for total causal effects 
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were repeated using imputed covariate values, the estimates for reaction time indicated a 
very small detrimental effect (point estimate approximately -0.02 to -0.03) in the major 
depression group (Figure 8.8(b) below), which was not evident in the complete case 
analyses. The estimates for the other cognitive outcomes were similar between the 
complete case analyses and those using multiple imputation.   
 
 
 
Figure 8.8 - Comparison of missing data approaches in major depression total effects 
analyses 
 
CI, confidence interval; MICE, multiple imputation with chained equations. Panels show: (a) 
reasoning, (b) reaction time, (c) numeric memory and (d) visuospatial memory. Prospective 
memory not shown as it was not possible to calculate risk differences. 
  
When the mediation models were repeated with imputation of missing mediator and 
covariate values, there remained no evidence of indirect effects via cardiometabolic disease 
(Table CC.3 in Appendix CC). There was evidence of an indirect effect via psychotropic 
medication on visuospatial memory performance (Table CC.4 in Appendix CC), 
accounting for approximately 18% of the total effect. 
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The results of the probabilistic analysis using episens indicated that the total effects 
estimate for visuospatial memory would be biased away from the null if there were 
differential misclassification of the exposure. When dichotomised into impaired and 
unimpaired outcome categories, and assuming no exposure misclassification, the 
unadjusted relative risk of impairment was 1.14 in the major depression group (95% CI 
1.07, 1.20). Assuming lower sensitivity to true major depression status among the 
cognitively impaired (sensitivity range 0.6 to 0.9) versus unimpaired participants 
(sensitivity range 0.7 to 1.0), the relative risk was estimated as 1.37 (1.06, 1.75).  
DAGitty determined that there were six other DAGs that were equivalent to the DAG 
shown in Figure 8.2 above. In each of these, path directions involving the ancestral history 
or parental genotype nodes were reversed (see Appendix DD). None of these alternative 
configurations was causally plausible, owing to temporal order constraints. The same 
minimum adjustment set was valid for the analysed DAG and for the six equivalent DAGs, 
for estimating the total effect of major depression on cognitive outcome. 
8.2 Schizophrenia 
8.2.1 Methods 
8.2.1.1 Participants and exposure status 
Participants were retained for analysis if they had sufficient data to classify their exposure 
status and had data on at least one cognitive outcome measure. The illness exposure was 
schizophrenia, classified using the broad definition given in Chapter 4 (i.e. met criteria 
according to self-reported diagnosis or pre-baseline hospital records; participants were 
classified as exposed if they met the criteria in at least one information source, even if the 
other information source was missing). The unexposed comparison group included 
participants who had complete self-reported data indicating no diagnosis of schizophrenia, 
and whose pre-baseline hospital records had no primary or secondary diagnosis of 
schizophrenia. Participants meeting the criteria for mania/BD or major depression (as 
defined earlier), according to the self-reported data, touchscreen mood questionnaire 
algorithm or hospital records, were excluded from the exposed and unexposed groups. 
Participants who did not meet the above criteria for either the exposed or unexposed 
groups were not further analysed.  
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8.2.1.2 Outcome measures and covariates 
The cognitive outcome measures and covariates were as described in section 8.1.1.3 above, 
with the exception of the past mental state data: in addition to the information regarding 
past depressive episodes collected at baseline or in the subsequent web-based questionnaire 
(as described in Chapter 7), data were also collected in the web-based questionnaire 
regarding past “unusual experiences”. Participants were asked “Did you ever”: “…see 
something that wasn’t really there, that other people could not see?”; “…hear things that 
other people said did not exist, like strange voices coming from inside your head talking to 
you or about you, or voices coming out of the air when there was no one around?”; 
“…believe that a strange force was trying to communicate directly with you by sending 
special signs or signals that you could understand but that no one else could understand 
(for example through the radio or television)?”; or “…believe that that there was an unjust 
plot going on to harm you or to have people follow you, and which your family and friends 
did not believe existed?”. If they answered affirmatively, they were asked to state how 
many times each type of experience had occurred, when they were “not dreaming, not half-
asleep, and not under the influence of alcohol or drugs”, and this was recorded ordinally as 
0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, >10 and ‘too many to count’. For the present analyses, the 
item (seeing things; hearing things; signs; plot) that had the highest reported frequency was 
used as a single index of the number of past unusual experiences; frequencies were not 
summed across the four items, on the assumption that these experiences may have 
happened concurrently. It was not possible to distinguish between experiences that 
occurred before or after the baseline assessment date. This variable was then summed with 
the variable coding the number of past episodes of depressed mood or anhedonia 
(described in Chapter 7), to produce a single ordinal variable representing the number of 
past episodes of depressed or psychotic-like experiences.  
A GPS was created for schizophrenia, using summary statistics from the most recent 
GWAS (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). 
The GPS was generated for unrelated UK Biobank participants of white British genetic 
ancestry, using the same quality control criteria as described previously, and the model 
residuals after adjustment for genotyping array and batch, UK Biobank assessment centre, 
and the first 20 genetic principal components were used in the analyses. Appendix W 
shows the R2 at each p threshold, and the odds ratio for the association between deciles of 
the optimum GPS and the schizophrenia phenotype in the UK Biobank cohort. The R2 for 
the optimum GPS was 0.023. This is notably lower than the R2 of 0.184 reported by the 
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GWAS authors when predicting into an independent sample (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, 2014). 
8.2.1.3 Data analysis 
The DAG used in the schizophrenia analyses was the same as the final DAG used in the 
major depression analyses reported above (with the exposure and genotype nodes re-
named as appropriate). Two versions of the DAG were evaluated: the first depicted a 
causal influence of educational attainment on schizophrenia and other 
psychiatric/neurological conditions, and the second depicted these relationships in reverse. 
The testable implied independencies were analysed as before. Total effects and mediation 
analyses were planned using the back-door criterion in DAGitty, as before.   
8.2.2 Results 
8.2.2.1 Analysis sample and evaluation of the graphical model 
Figure 8.9 shows a flowchart of exclusions leading to the final analysis sample, which 
comprised 351 participants with schizophrenia and 360,122 comparison participants.  
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Figure 8.9 - Schizophrenia analysis sample flowchart 
 
The different predicted independencies implied by the two specifications of the DAG were 
tested (see Appendix EE). Twenty percent (28 of 137) of the predicted independencies 
were above |0.10| in the better fitting model (educational attainment as an antecedent of 
schizophrenia and other psychiatric/neurological conditions), with two being above |0.40|. 
More detailed evaluation of these results confirmed that most of the highest correlations 
were reliably different from the null. Modifications to the DAG were therefore considered. 
Given the strong evidence of a relationship between cannabis use and schizophrenia (Gage 
et al., 2017), cannabis use (measured dichotomously as an indicator for ever having taken 
cannabis, using the web-based questionnaire data) was incorporated into the DAG 
(Appendix EE). The conditional independencies were tested again twice, with cannabis 
depicted as either an antecedent or a consequence of schizophrenia and other 
psychiatric/neurological conditions. The fit in both modified DAGs was worse than the 
original DAG that did not include cannabis (Appendix EE).  
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8.2.2.2 Causal estimation 
Based on structural analysis of the best-fitting DAG, the covariate adjustment set for the 
total effect of schizophrenia on cognitive outcome was the same as that used in the major 
depression analyses described above (substituting the schizophrenia GPS and the expanded 
measure of depressive and psychotic-like episodes). An attempt was made to estimate a 
propensity score model for these covariates, but this could not proceed because only 24 
participants in the schizophrenia group had complete covariate data, and only 15 of these 
were of white British genetic ancestry (a necessary model restriction). In light of the poor 
fit of the graphical model and the predominance of missing data, it was concluded that 
estimation of the causal effect of schizophrenia on cognitive outcome was not feasible in 
this dataset, and no further analyses were undertaken.   
8.3 Discussion 
The total causal effect of major depression on cognitive performance in the UK Biobank 
cohort followed a similar pattern to that of mania/BD, though with an effect size of around 
one-third the magnitude. This echoes previous evidence of a ‘dose-response’-type 
relationship between mood disorders and cognitive function, with major depression groups 
showing an intermediate level of impairment on average, between BD groups and those 
with no psychiatric history (Bora et al., 2013; Szmulewicz et al., 2017). There was 
equivocal evidence of an indirect causal pathway through psychotropic medication, but no 
evidence of mediation via cardiometabolic disease. The effect estimates are likely to be 
sensitive to even very low levels of residual confounding. As with the mania/BD analyses, 
widespread missingness in the covariates limited the interpretation of the results. 
The finding of a robust—though very small—deficit in visuospatial memory but not on 
other cognitive tests was at odds with previous studies, which have reported deficits in a 
range of cognitive domains. The meta-analysis of Bora et al. (2013) found worse 
performance compared with healthy participants in every cognitive domain, with effect 
sizes in the medium range (-0.4 to -0.6), far exceeding the very small group difference 
observed here (-0.07). After multiple imputation of missing covariate data, additional 
evidence emerged of a very small group difference in reaction time (-0.02), although the 
validity of this result rests on the plausibility of the missing-at-random assumption, which 
may not be justifiable.  
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As with the mania/BD results reported in Chapter 7, the lack of evidence of a mediating 
effect via cardiometabolic disease was somewhat surprising, and may be explained by 
measurement error, adjustment for closely related risk factors, or the age of the sample, as 
noted previously. The evidence of mediation through psychotropic medication that was 
found in the mania/BD analyses was not so clearly apparent here: the point estimate of the 
proportion of the total effect transmitted through this path was similar to that in the 
mania/BD group (for the visuospatial memory outcome), but the confidence interval was 
wide and the estimate was reliably different from the null only after missing data 
imputation. A further issue to be considered here is the evidence for interaction between 
major depression and psychotropic medication; this indicates that any causal effect of 
major depression on cognitive outcome that is transmitted through psychotropic 
medication is non-linear. In other words, if non-depressed participants who are not on 
psychotropic medication were the reference group, the observed effect of both having 
depression and being on psychotropic medication would be different from the linear 
combination of the two separate effects of having depression but not being on psychotropic 
medication, and not having depression but being on psychotropic medication (Richiardi, 
Bellocco, & Zugna, 2013). This means that the mediation model results reported in this 
chapter represent a population average effect over both levels of the mediator, but these 
results will be sensitive to the population prevalence of being on psychotropic medication.  
The strengths of the major depression analyses reported here include the sample size—
exceeding 50,000 participants with depression, more than 50 times as large as the most 
recent meta-analysis of cognitive function in euthymic depression (Bora et al., 2013)—and 
the consideration of multiple consistently-measured covariates. The statistical analyses 
were informed by the graphical model and took account of interaction effects. As 
previously outlined in earlier chapters, there are a number of limitations in using the UK 
Biobank resource for this type of research, including assumptions regarding temporal 
order, measurement error and misclassification, and the possibility of collider bias arising 
from patterns of participation and missingness that may be related to mental health and 
cognitive status.  
Extensive missing data in the schizophrenia group precluded any causal estimation 
analyses. The proportion with complete data on all the measures required for the 
multivariable analyses was only 7%, compared with 23% in the comparison group (and 
19% and 23% in the mania/BD and major depression groups, respectively). Aside from the 
impact on study power, this pattern calls into question the validity of attempting inferential 
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analyses, given the non-representativeness of the sub-group with complete data, and the 
likelihood that the missingness mechanism was non-random and not amenable to statistical 
approaches such as multiple imputation. This illustrates the limitation of a general 
population cohort such as UK Biobank for conducting this type of research in a group with 
severe mental illness; accurate and representative assessment in this area may be better 
accomplished through smaller-scale clinic-based studies or whole population registries, 
although such studies are typically limited in statistical power (in the former case) and in 
depth of phenotyping (in the latter). 
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Chapter 9 Discussion 
This chapter presents an overall summary and discussion of the findings of this thesis, in 
light of the research questions addressed, the methods chosen, and the strengths and 
limitations of the work undertaken. Implications for the clinical understanding of cognitive 
impairment in psychiatric and neurological conditions are considered, and future research 
directions are outlined. 
9.1 Summary of findings 
9.1.1 Prevalence of cognitive impairment in bipolar disorder and 
other psychiatric and neurological conditions 
The aim of the systematic review presented in Chapter 2 was to determine the prevalence 
of cognitive impairment in euthymic adults with BD, and to ascertain which clinical, 
sociodemographic or other factors were associated with cognitive impairment in this 
population. Fifteen articles provided prevalence data, using a wide variety of cognitive 
tests and impairment thresholds. Taking the 5th percentile threshold as the reference, 
impairment prevalence ranges were: executive function 5.3% to 57.7%; attention/working 
memory 9.6% to 51.9%; speed/reaction time 23.3% to 44.2%; verbal memory 8.2% to 
42.1%; visual memory 11.5% to 32.9%. Sample sizes were generally small, and the 
individual study estimates were consequently imprecise. There was some evidence that the 
prevalence or severity of cognitive impairment was associated with illness severity or 
duration. Associations were also reported with antipsychotic medication use, although 
these must be interpreted with caution, given the complex interplay between treatment 
indication, adherence and responsiveness. 
In Chapter 5, baseline data from the UK Biobank cohort were analysed to quantify the 
prevalence of cognitive impairment in adults with a history of mania or BD, and to 
compare these results with estimates from adults with a history of major depression, 
schizophrenia, MS and PD. Using the 4th-5th percentile performance level in a single 
unexposed comparison group as the reference, the age- and gender-standardised prevalence 
of impairment across four cognitive tests ranged from 6.6% (95% CI 5.7, 7.5) to 10.4% 
(95% CI 7.7, 13.1) in the (broadly-defined) mania/BD group. Estimates were lower in the 
major depression group, ranging from 4.3% (95% CI 4.1, 4.5) to 5.7% (95% CI 5.3, 6.2), 
and were higher in schizophrenia, at 9.7% (95% CI 7.7, 11.7) to 20.6% (95% CI 10.6, 
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30.6). In MS, prevalence ranged from 3.2% (95% CI 1.8, 4.7) to 15.2% (95% CI 13.6, 
16.8), and in PD, the range was 5.9% (95% CI 3.2, 8.7) to 12.7% (95% CI 6.0, 19.4). The 
prevalence of impairment was also elevated in most groups on a pass/fail test of 
prospective memory: compared with a failure prevalence of 22.8% in the unexposed 
comparison group, the standardised prevalence was 29.7% (95% CI 27.6, 31.7) in 
mania/BD, 22.8% (95% CI 22.4, 23.3) in major depression, 45.9% (95% CI 40.5, 51.3) in 
schizophrenia, 26.2% (95% CI 22.8, 29.7) in MS and 27.8% (95% CI 22.8, 32.9) in PD.  
The relative pattern of impairment by clinical group and cognitive domain was in 
accordance with previous research, e.g. the schizophrenia group showed the highest 
prevalence on all tests (Bortolato et al., 2015) except reaction time, on which the MS group 
had the highest proportion with impairment (Rao et al., 2014). The absolute prevalence 
was lower than expected in each clinical group, however, compared with estimates from 
previous clinic-based studies. This may reflect truly lower cognitive impairment 
prevalence in general population-based illness groups than in those attending specialist 
clinics, or it may indicate collider bias arising from non-representative patterns of cohort 
participation and data completion among the more cognitively able people with these 
conditions. Collider bias is discussed in more detail in section 9.3.2 below. 
Although the difference in prevalence (compared with the unexposed group) of cognitive 
impairment in major depression was relatively small, lifetime prevalence of major 
depression is approximately ten times that of BD and schizophrenia and fifty times that of 
MS and PD, which meant that the population attributable prevalence of cognitive 
impairment was highest overall for this group. 
9.1.2 Explaining variation in cognitive function in bipolar disorder 
and other conditions 
Chapter 7 presented the results of causal analyses to estimate the total effect of mania/BD 
on baseline cognitive performance in the UK Biobank cohort, and to estimate the 
proportion of any such effect that was transmitted indirectly through potentially modifiable 
intermediate factors. Analysis of the independencies implied by the structural causal graph 
indicated moderate fit to the data, once modifications had been made to take account of the 
influence of other psychiatric/neurological comorbidities. When background confounders 
were incorporated into the matched or adjusted analyses, a total causal effect of mania/BD 
was only evident on a test of short-term visuospatial memory. The magnitude of this effect 
was small, with the point estimates across the various matched/adjusted models being in 
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the range -0.23 to -0.17 standard deviation units (95% CI range across all estimates -0.39, -
0.03). The small effect size relative to previous published research may reflect the larger 
sample size or less severe clinical status of the mania/BD group in UK Biobank, compared 
with clinic-based samples in other studies. There was evidence of an indirect causal 
pathway through psychotropic medication (accounting for approximately one-quarter of 
the total effect: -0.05; 95% CI -0.09, -0.01), but (perhaps surprisingly) not through 
cardiometabolic disease. The effect estimates are likely to be sensitive to residual 
confounding and misclassification, and they may be biased toward the null as a result of 
missing covariate data.  
This work was extended to other psychiatric conditions in Chapter 8. For major depression, 
the graphical model was adapted to take account of gender differences in depression 
propensity, and the fit of the model in terms of implied independencies was deemed 
reasonable. The total causal effect of major depression on baseline cognitive performance 
in UK Biobank followed a similar pattern to that of mania/BD, though with an effect size 
of around one-third the magnitude: the point estimate across the various models was 
approximately -0.07 (95% CI range across all estimates -0.10, -0.03). The point estimate of 
the proportion of the total effect transmitted through psychotropic medication was similar 
to that in mania/BD, but the confidence interval was wide and the estimate was reliably 
different from the null only after imputation of missing data. Again, potential biases from 
residual confounding, misclassification and collider stratification are likely. 
Similar models for cognitive performance in UK Biobank participants with schizophrenia 
were planned as part of the work reported in Chapter 8. The fit of the structural model was 
poorer in this study population, and problems were encountered as a result of widespread 
missing data. In light of this, multivariable causal models could not be conducted for the 
effect of schizophrenia on cognitive performance.  
9.2 Contribution of this work to the literature 
This thesis presents the first systematic review of the prevalence of cognitive impairment 
in euthymic BD. It complements and extends the findings of previous systematic reviews 
and meta-analyses (Arts et al., 2008; Bortolato et al., 2015; Bostock et al., 2017; Bourne et 
al., 2013; Dickinson et al., 2017; Mann-Wrobel et al., 2011; Raucher-Chene et al., 2017; 
Robinson et al., 2006), which have focused on the magnitude of between-group differences 
in cognitive test scores. Although mean score differences are important for understanding 
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the nature and extent of cognitive performance variation associated with BD, quantifying 
the number who have clinically relevant levels of cognitive impairment is essential in order 
to measure and understand the ‘cognitive footprint’ of this disorder, and to target clinical 
resources towards interventions and support for those who need it most. This work is also 
relevant to recent efforts to identify distinct clusters of people with BD on the basis of their 
cognitive performance patterns (Burdick et al., 2014; Sparding et al., 2017; Sparding et al., 
2015), which have also highlighted the existence of heterogeneous sub-groups with 
different difficulties and needs.  
This contribution was further extended by examining the prevalence of cognitive 
impairment in adults with mania/BD within a large population cohort, and comparing this 
with impairment prevalence in cohort sub-groups with a history of other psychiatric and 
neurological conditions. This is the first study to directly compare across these conditions, 
using consistent assessment methods and a common unexposed comparison group. 
Multiple sources of information were used to classify exposure status, and direct 
standardisation permitted like-for-like comparisons across conditions. This also enabled 
direct comparisons of population attributable prevalence, highlighting the contribution of 
both exposure prevalence and cognitive impairment prevalence to the overall ‘cognitive 
footprint’ of behavioural and brain disorders. The findings underscore the importance of 
making cognitive impairment a key focus of research and treatment in mood disorders, as 
is already the case in less prevalent neurological conditions such as MS and PD.  
This thesis makes a novel contribution to the literature by applying, for the first time, a 
formal causal inference framework to identify and estimate total and indirect effects of 
mood disorders on cognitive performance. The complexity inherent in this area was 
acknowledged and addressed as far as possible, by developing and evaluating 
comprehensive graphical models and incorporating a broad range of genetic, 
sociodemographic, environmental, lifestyle and clinical measures in the analyses. Model 
estimation was conducted in multiple ways, and a series of quantitative and graphical 
sensitivity analyses were carried out to investigate the robustness of the results to various 
assumptions. The sample sizes were substantially larger than those used in previous studies 
in the field, allowing small effect sizes to be estimated with precision.   
The results of the causal analyses indicated a reliable decrement, of small magnitude, in 
visuospatial memory in adults with a history of mania/BD, and a very small decrement on 
the same task in those with major depression. This is congruent with previous reports of a 
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gradation of severity of cognitive impairment in mood disorders (Szmulewicz et al., 2017). 
Any group differences seen in other cognitive functions such as reasoning and reaction 
time attenuated towards the null when background confounders were included in the 
analyses. The absence of differences on these tasks was surprising, in light of previous 
research showing multi-domain impairments, and it remains unclear to what extent this 
reflects insufficient adjustment for confounding in previous studies, the characteristics of 
the UK Biobank cohort, or the possibility that episodic memory is a particularly sensitive 
marker of cognitive function in mood disorders.  
The results also contribute to the evidence base on the relationship between psychotropic 
medication and cognitive impairment, which has been repeatedly highlighted in previous 
observational studies (Balanzá-Martínez et al., 2010). Mediation analyses, taking account 
of intermediate confounders such as past depressive episodes, indicated that an appreciable 
proportion of the detrimental effect of mania/BD on visuospatial memory performance was 
carried via this pathway. The interplay between reasons for prescribing—especially of 
antipsychotic medications—and affective remission in understanding this relationship is 
not yet understood, but the present results appear to confirm that psychotropic medications 
warrant closer study as potential contributors to cognitive impairment in mood disorders.  
9.3 Critical appraisal 
9.3.1 Limitations of the prevalence studies 
The issue of burden of cognitive impairment is complex and cannot be fully addressed by 
investigating the prevalence of sub-threshold test performance alone. Furthermore, there is 
no clear consensus regarding the best threshold to define impairment. It is likely that the 
disabling impact of cognitive impairment varies substantially even among those who score 
below a certain threshold (for example, depending on individual circumstances and levels 
of social support), and it is also possible that individuals can score above a threshold and 
yet experience functional disability related to cognitive difficulties. It was not possible to 
address these issues within the scope of this thesis. Also beyond the scope, and deserving 
of further study, is the identification and understanding of superior cognitive function in 
some people with psychiatric conditions, as previously highlighted in BD (Burdick et al., 
2014). 
The UK Biobank prevalence study was limited by the information sources available to 
identify the exposed and unexposed groups, which relied largely on self-reported data. 
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Large population registry-based studies have the advantage of access to a range of 
routinely recorded healthcare data; only hospital in-patient and day case records are 
currently available in UK Biobank, although primary care records will be incorporated into 
the resource in the coming years. Registry-based studies of whole populations remain 
ideally placed to investigate clinical outcomes such as dementia diagnoses in exposure 
groups that have also been identified through clinical records, but direct cognitive testing is 
not undertaken routinely in adulthood, and so prevalence studies of cognitive impairment 
still rely on research cohorts.  
9.3.2 Limitations of the causal inference studies 
The analyses were necessarily limited by the variables measured in the UK Biobank 
resource. A broad range of background and intermediate variables were available, but 
many of the measures were brief (e.g. four items to measure current mood state), and very 
little information was available regarding early life factors. Assumptions were made here 
about the temporal order of the variables, but these could not be verified empirically. For 
example, it was not possible to tell when a participant’s cognitive performance reached the 
level at which it was measured at the UK Biobank baseline assessment, or whether this 
represented a change from a previous level of ability. The introduction of a premorbid 
ability estimate (vocabulary test) at the imaging follow-up visit will go some way to 
addressing this, for at least a subset of the cohort. The overall range of cognitive domains 
assessed has also been increased at the imaging visit, which will offer an improvement 
over the limited and idiosyncratic baseline assessments that were available for analysis in 
this thesis.  
Assumptions were also made regarding the conditional exchangeability of the exposed and 
unexposed groups in the causal models, but sensitivity analyses using Rosenbaum bounds 
indicated that plausibly small levels of residual confounding would alter the findings. The 
SUTVA assumption may be deemed questionable, given the lack of a clear definition of 
what would constitute a well-defined contrast between having and not having a psychiatric 
condition, and how a hypothetical intervention on this could be conceptualised. This opens 
up criticisms regarding the true applicability of the analyses in the real world (Hernán, 
2005).  
The issue of collider stratification bias was noted throughout the thesis, and the problems 
this poses for causal inference in a cohort such as UK Biobank should not be 
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underestimated (Munafò et al., 2017). It is likely that people with less severe psychiatric 
and neurological phenotypes and better cognitive function will have joined the cohort, and 
this will have been amplified further in the patterns of missingness across the cognitive 
outcome measures and the covariates. The missing-at-random assumption that is required 
for multiple imputation is arguably not valid for some of the measures in these analyses, 
given the probability that, for example, missingness on mental health-related measures will 
be influenced by true mental health status. What is unknown, however, is the magnitude of 
the bias arising from collider stratification, and how this compares with similar or opposing 
biases from residual confounding.  
Difficulties arising from measurement error and misclassification were also noted in earlier 
chapters. Quantitative sensitivity analysis methods are still being developed in this area, to 
encompass the range of issues arising from differential and non-differential 
misclassification of exposures, outcomes, mediators and covariates. SEM estimation 
approaches have a major advantage over other modelling methods here, in that they 
incorporate latent measures as an intrinsic part of model estimation. This does require 
additional data in the form of multiple indicators for each latent variable, or reliability 
coefficients which can be used to constrain error variances, but unfortunately there is little 
scope for applying these methods in UK Biobank, owing to the limited number of 
measures of each construct and the lack of reliability data.  
A further advantage of SEM in causal modelling more generally is that the role of multiple 
mediators, and the inter-relationships between these and both background and intermediate 
confounders, are naturally accommodated in a single estimation model. This requires every 
path to be identified, however, which is not realistic in complex models with unmeasured 
nodes, such as those depicted in the DAGs in Chapters 7 and 8 here. Estimation can instead 
be approached on a localised basis, as was the case in this thesis, but this is not optimal 
when multiple mediators are of interest and would ideally be considered simultaneously in 
one model. Conducting estimation one mediator at a time may lead to erroneous 
conclusions about the contribution of each mediator to the overall effect, if the sum of the 
individual mediated effects does not equal the joint mediated effect (as will be the case 
when mediators cause, or interact with, each other) (VanderWeele & Vansteelandt, 2014; 
Vansteelandt & Daniel, 2017).  
A final issue to note concerns the external validity of the results, including generalisability 
to the population from which the sample was drawn, and transportability to different 
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populations (Westreich et al., 2017). Weighting and imputation-based methods can be used 
to estimate the magnitude of bias in study estimates compared with a reference population, 
provided that data are available for comparison. Limited sociodemographic data regarding 
non-participating UK Biobank invitees have been retained (Fry et al., 2017), but these are 
not generally available to researchers. There is potential to use routine healthcare records 
from the same sampling frame as the study sample, to construct synthetic datasets via 
imputation within strata defined by combinations of outcome and confounder 
characteristics (Gray et al., 2013), but data on cognitive function are not captured in 
routine records. A further consideration is that the external validity of the estimates 
reported here is influenced by the population prevalence of variables that act in an 
interactive manner to produce outcomes, as noted in Chapter 8 with regard to the 
interaction between major depression exposure and psychotropic medication.  
9.4 Clinical and public health implications 
This thesis emphasises the importance of cognitive impairment as a persistent problem for 
a substantial proportion of adults with mood disorders, as was already recognised to be the 
case for those with schizophrenia and neurological conditions. Whether arising from the 
general background vulnerability and inequalities that affect these populations, or intrinsic 
to the nature of the disorders themselves, cognitive impairment may contribute to the 
overall picture of clinical need and should be recognised by practitioners and service 
managers as part of routine follow-up and service planning.  
Even the crude prevalence estimates and test score differences reported here may be of 
interest to clinicians and service planners because, although they may have arisen in part 
from non-causal pathways (e.g. shared antecedents of both mood disorder and cognitive 
impairment), this has a real impact on the needs of the patients who attend clinics, and 
therefore shapes the services that should be provided in response. A different perspective 
may be taken by public health professionals, who will be more concerned with identifying 
modifiable causal pathways, on which interventions may be implemented to prevent or 
ameliorate adverse outcomes. These are conceptualised at the population level rather than 
the individual level, in that intervening on a certain causal pathway may be predicted to 
alter average outcomes in the population, even if the specific individuals who will benefit 
cannot be predicted in advance. Causal modelling and understanding of intermediate 
pathways are, of course, also important to professionals and patients alike, if they shed 
light on the fundamental mechanisms that explain the illness experience. 
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A greater understanding of the causes and consequences of cognitive impairment in mood 
disorders will have potentially widespread implications. There is scope to educate 
individuals with mood disorders and their families about the nature and impact of cognitive 
difficulties, as part of the broader picture of symptom recognition and self-management, 
and this in turn would have beneficial effects in dealing with the challenges of employment 
support and social participation. Clinical psychologists, occupational therapists, 
community mental health nurses and social care staff should be aware of the influence of 
cognitive impairment on day to day functioning, and take this into account when planning 
rehabilitation and support. The possible adverse effects of psychotropic medications should 
be of concern to psychiatrists and general practitioners; getting the balance right in terms 
of adequate symptom remission and minimal adverse consequences is difficult, and 
cognitive impairment should be recognised as part of that. Finally, consideration should be 
given to incorporating indicators of cognitive impairment and associated disability within 
routine outcome measurements, for the purposes of service evaluation and informing 
policy development.  
9.5 Future directions 
More work needs to be done to develop a meaningful measure of the ‘cognitive footprint’, 
including analysis of a wide range of health, social, educational and economic data to build 
a comprehensive picture of the population burden of chronic cognitive disability (Rossor & 
Knapp, 2015). Clinical researchers can aid these efforts by focusing on representative 
samples and by reporting numbers of participants falling below impairment thresholds of 
varying strictness, in addition to reporting between-group score differences.  
Our understanding of causal pathways towards cognitive impairment in psychiatric and 
neurological conditions will improve as the UK Biobank cohort is followed up over time, 
and other prospective cohorts such as the Avon Longitudinal Study of Parents and 
Children (ALSPAC; Boyd et al., 2013; Golding, 1990) and the US National Longitudinal 
Study of Adolescent to Adult Health (Add Health; Klein, 1997) mature into adulthood. The 
availability of a fuller range of background and intermediate data, including early life 
factors, premorbid cognitive ability measures and brain imaging, will expand the kinds of 
causal effects that can be identified in models such as those proposed here. Linkage with 
prescribing data will permit more detailed investigation of the role of different classes of 
psychotropic medication, and combinations thereof, in explaining adverse cognitive 
outcomes.  
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A current barrier to progress in this area is that research cohorts often lack 
representativeness but offer deep and broad measurement of key data, while routine 
records offer population coverage but lack information about context, behavioural and 
psychosocial factors, and clinical data beyond that which can be captured in standardised 
coding systems. Significant investment is required to bridge this gap. It is essential that 
research cohorts are adequately resourced to achieve more representative recruitment and 
to maintain follow-up rates over time. This, in turn, requires research investment to 
improve our understanding of the determinants of participation and the optimal strategies 
which should be implemented in research cohorts. These efforts can be supplemented by 
improving approaches to sample weighting, and understanding and dealing with missing 
data. This is especially important for cognitive research, because cognitive function is 
likely to be a key driver of non-random missingness mechanisms. Improving linkage 
between research cohorts and routine administrative records should also be a priority, 
including taking advantage of the wealth of data contained in text-based records (e.g. 
clinical notes and correspondence; radiology reports). The coming years are likely to see 
continuing advances in text analytics and machine learning, and healthcare researchers 
must be ready to use these methods to enrich research capabilities. In the meantime, efforts 
to validate centrally-held code-based records against detailed local data will provide 
essential evidence regarding the quality and accuracy of the mental health data currently 
available to the research community (Davis et al., 2016; McIntosh et al., 2016; Stewart & 
Davis, 2016).  
Even if the full potential of routine data for mental health research could be realised, 
however, investment in dedicated cohort studies will remain crucial. This is because 
research of the type undertaken in this thesis will always require detailed, dimensional 
measures of psychological traits and states, and multi-domain cognitive abilities, at 
multiple points in time. Furthermore, cheaper and more easily accessible MRI scanning 
means that neuroimaging assessments are no longer constrained to small studies, and 
should be viewed as a core component of large-scale observational research in mental 
health. Genomic data will also increasingly be seen as essential rather than optional; the 
recent step-change in GWAS discoveries and the growing appreciation of pleiotropy 
between psychological and physical traits means that no study can hope to provide a 
comprehensive causal account of cognitive function in mental health without incorporating 
genomic data.  
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Cognitive function is a fundamental phenotype in psychiatric and epidemiological 
research. As an outcome in its own right, as a transdiagnostic dimensional construct in 
ongoing efforts to improve psychiatric nosology (Insel et al., 2010), and as a determinant 
of health behaviours, morbidity and mortality (Deary, 2009), it deserves increased research 
attention. 
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B – Search strategy for systematic review 
Search strategy implemented in Web of Science 
 
Search set-up: English; publication year 1994 to date 
 
1 TS=((bipolar NEAR/3 depress*) OR (bipolar NEAR/3 disorder*) OR (manic NEAR/0 
depress*)) 
2 TS=(cogniti* OR neuro-cogniti* OR neurocogniti* OR neuro-psycholog* OR 
neuropsycholog* OR speed OR reaction OR attention OR memory OR learning OR *spatial 
OR executive OR reasoning OR IQ OR intelligence) 
3 TS=(impair* OR dysfunction* OR declin* OR deteriorat* OR defici*) 
4 (#1 AND #2 AND #3) 
5 TI=(therapy OR CBT OR cognitive-behavio* OR (cognitive NEAR/0 behavio*)) 
6 #4 NOT #5 
7 TS=((nursing NEAR/0 home*) OR (care NEAR/0 home*)) 
8 #6 NOT #7 
9 TS=(dement*) 
10 #8 NOT #9 
 
Results limits: Refined by: Databases: (WOS OR SCIELO OR MEDLINE OR CCC OR 
DRCI) AND DOCUMENT TYPES: (ARTICLE OR CLINICAL TRIAL OR DATA SET 
OR UNSPECIFIED OR OTHER OR DATA STUDY) AND LANGUAGES: (ENGLISH) 
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C – Eligibility checklist for systematic review 
Eligibility checklist used when screening titles, abstracts and full text 
 
No. Criteria and definitions 
1 Original research published in peer-reviewed journals, from 1994 until date of search 
 Not editorials, opinion papers, reviews, meta-analyses (but ‘individual patient data 
meta/mega-analyses’ that involve re-analysis of raw data [rather than group effect sizes] are 
acceptable) 
 Not conference proceedings, books, book chapters, academic theses 
 Not single case studies or case series (must be group studies) 
 If unsure whether journal is peer-reviewed, check the journal website or look up the title at 
https://ulrichsweb.serialssolutions.com/ and look for the ‘refereed’ symbol:  
 Publication year is 1994 or later 
2 Articles published in English 
 Full text of the article must be available in English 
3 Studies of community-dwelling adults aged 18 to 70 years inclusive 
 Out-patient service or general population setting (this refers to the setting in which 
participants were recruited and/or the study took place) 
 BD participants may be recruited from clinic attendees, or from a population study (e.g. large-
scale population registry) 
 Participants must have been living in the community at time of assessment 
 Not currently a hospital in-patient (but hospital/clinic out-patient is acceptable) 
 Not living in a nursing/care home 
 Participants are adults of minimum age 18 years and maximum age 70 years (abstracts 
describing samples as ‘adolescent’ or ‘elderly’ are presumed to be ineligible unless they also 
mention a separate sample of ‘adults’ in the study) 
 There may be a healthy comparison group in the study, but this is not a requirement 
4 Cross-sectional study design 
 The key criterion is that the assessment of mood disorder status (whether the person has 
euthymic BD – the ‘exposure’) and the assessment of cognitive performance (the ‘outcome’) 
took place at the same time (maximum allowable time gap between establishing euthymic 
status and carrying out cognitive assessment = 2 weeks) 
 The mood disorder may have been diagnosed in the past; this is acceptable (as long as the 
confirmation of current euthymic status took place at the same time as the cognitive 
assessment – see section 8 below) 
 A cross-sectional study of this type may be part of a prospective/longitudinal/cohort study or 
a treatment trial; this is acceptable as long as separate (standalone) results are presented for 
the cross-sectional component that we are interested in 
 Studies investigating whether cognitive status predicts future remission of mood disorder are 
not eligible 
5 If clinical out-patient service setting, samples must be consecutively recruited 
 Where BD participants have been recruited via a clinical service, recruitment must have been 
consecutive and representative of the target group 
 This means participants should not have been selectively approached (e.g. on the basis of their 
cognitive function or some other characteristic) in a way that might bias the results of the 
study 
 All eligible patients in the target group should have had an equal chance of being approached 
 For example, if the target group was patients with euthymic BD, and the researchers 
considered all such patients attending the clinic between time X and time Y (or a randomly 
chosen subset of these), then that would be acceptable 
6 Primary diagnosis of bipolar disorder (BD) 
 Primary means the disorder has been diagnosed in its own right, not secondary to another 
illness 
 BD = History of bipolar disorder (type I or II or unspecified), meeting DSM or ICD criteria 
 Evidence for meeting diagnostic criteria may come from direct assessment as part of the study 
(often including a semi-structured interview schedule), or from a doctor’s diagnosis recorded 
in the medical notes 
 Questionnaire measures of mood state alone (without reference to a diagnostic reference 
system) are not acceptable 
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 The diagnosis may have been made at any time in the person’s life up until the time of the 
study 
7 Euthymic at time of assessment 
 Not meeting DSM or ICD criteria for a depressive or manic episode at time of cognitive 
assessment; or as otherwise defined by the study authors based on an appropriate clinical 
measure 
 For example, the authors may define euthymia as being below X threshold on a depression or 
mania rating scale 
 The concept of euthymia may be referred to as remitted/remission, or recovery, or stable on 
treatment, or treatment-responsive (or other similar phrase) 
 Non-euthymic patients may be described as acutely manic/unwell, or treatment-resistant (or 
other similar phrase) 
 Baseline samples within treatment trial studies are presumed to be NOT euthymic unless the 
abstract says otherwise 
8 Assessed using at least one standardised cognitive measure 
 The measure should be an objective test, on which the participant’s performance is assessed 
directly 
 Self-report questionnaires are not acceptable (e.g. the participant rates how good they think 
their cognition is) 
 Informant-rated questionnaires are not acceptable (e.g. the participant’s spouse rates how 
good they think the participant’s cognition is) 
 Informal behavioural observations are not acceptable (e.g. researcher observes participant 
without using any standardised rating scale) 
 The cognitive test may cover one or more of the following abilities/domains: 
 Global/overall function (cognitive/neuropsychological)  
 Processing speed/psychomotor speed/reaction time 
 Attention/vigilance/alertness/concentration 
 Working memory/memory/learning/encoding/recall/recognition/retrieval 
 Spatial/visuospatial ability 
 Language/naming/comprehension  
 Executive function (including planning, strategy-formation, problem-solving, 
decision-making, initiation, self-monitoring, self-regulation, mental control, goal 
management, goal neglect, inhibition, response suppression, fluency, word 
generation, perseveration, set-shifting, rule-shifting, flexibility, impulsivity, 
sequencing, dual-tasking, multi-tasking) 
 Reasoning/abstraction/concept formation/IQ/intelligence 
 Social cognition (including theory of mind, meta-cognition – e.g. judgement of other 
people’s thoughts/behaviours) 
 Studies of non-conscious learning (e.g. classical conditioning and extinction) are not eligible 
 Studies using only experimental neuroimaging tasks (e.g. oddball/continuous performance 
tasks that are not interpretable in their own right) are not eligible 
 Studies of basic emotional processing only, without an explicit social cognition aspect, (e.g. 
reaction times to emotional faces) are not eligible 
 The test should yield a numeric score, or a rating (e.g. pass/fail, or poor/fair/good, or 
impaired/unimpaired) 
 NOTE: The mood disorder literature also contains many studies about cognitive 
distortions/biases. For example, a study may look at biased thinking patterns, attitudes, or 
rumination. This can be thought of as cognitive style, which is not the same as cognitive 
function in the neuropsychological sense outlined above. Therefore studies which are solely 
about these cognitive distortions, including treatments such as CBT aimed at changing these 
distortions, are not relevant to this review.  
 Similarly, some studies may focus on formal thought disorder (e.g. tangentiality, flight of 
ideas); these are not eligible unless a cognitive assessment of the type outlined above is also 
conducted. 
9 Samples NOT selected on the basis of presence of cognitive impairment (known or suspected) 
 Participants (BD participants, or healthy comparison participants) should have been recruited 
(approached/selected) based on their exposure status (having or not having BD), and NOT 
based on their outcome status (having or not having cognitive impairment) 
 It is possible that potential participants who were approached to take part might have been 
more or less likely to agree depending on their cognitive status; this is outside the researcher’s 
control and so is not the focus here. Rather, the issue is that the initial approach/selection by 
the researcher should not be based on cognitive status 
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D – Data extraction form for systematic review 
Instructions for data extraction  
 
Spreadsheet 
field no. 
Description Entry format 
1  Publication ID  Number 
2  Sub-ID (use if study contains separate results 
for >1 BD sample) 
Number-letter 
3  Authors (e.g. Bloggs, A.B., Jones, C.D. & 
Smith, E.F.)  
Free text 
4  Year  XXXX 
5  Journal Free text 
6  Volume  Free text 
7  Pages   XX-YY 
8  Title Free text 
9  Corresponding author’s name and email  Free text 
10  Study funding source  Free text or Not stated 
11  Any other conflicts of interest declared  Free text or Not stated 
12  Study setting: type 1=general community (e.g. population 
cohort) 
2=clinical service 
3=other 
4=not stated 
13  Study setting: details Free text or Not stated 
14  Population from which BD sample was drawn 
(e.g. all BD patients known to clinical service 
between date X and date Y; all families with 2 
or more BD patients, etc)  
Free text or Not stated 
15  Healthy comparison group included 1=none (no healthy controls) 
2=internal (from same population e.g. BD 
and controls taken from same general pop 
cohort) 
3=external (from different population e.g. 
BD from clinic and controls from posters 
in community) 
16  Comparison group matching  
(NB this refers to planned matching during 
recruitment – i.e. matched study design - not 
whether some characteristics happened to be 
similar after analysis) 
1=not matched 
2=matched to BD at group level only 
(unpaired design) 
3=matched to BD individually (paired 
design) 
4=NA 
5=not stated 
17  Comparison group: characteristics matched by  Free text or NA or Not stated 
18  Recruitment procedure for BD group Free text or Not stated 
19  Recruitment procedure for comparison group  Free text or NA or Not stated 
20  Inclusion criteria for BD group Free text or Not stated 
21  Exclusion criteria for BD group Free text or Not stated 
22  Inclusion criteria for comparison group Free text or NA or Not stated 
23  Exclusion criteria for comparison group Free text or NA or Not stated 
24  Informed consent obtained from all 
participants  
1=yes 
2=no 
3=not stated 
25  Power/sample size calculation reported for the 
study  
1=yes 
2=no 
26  Country where study took place Free text or Not stated 
27  Language in which cognitive test was 
administered (assume English if test name and 
citation are for English version AND study is 
from English-speaking country) 
Free text or Not stated 
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28  BD sample: sample size n or Not stated 
29  BD sample: age (mean and SD, or median and 
IQR, or range) 
Free text or Not stated 
30  BD sample: sex (n and % male) Free text or Not stated 
31  BD sample: ethnicity (n and % in each 
category) 
Free text or Not stated 
32  BD sample: education (info re years or 
qualifications) 
Free text or Not stated 
33  BD sample: socioeconomic status (how 
measured, and status of sample) 
Free text or Not stated 
34  Comparison sample: sample size n or NA or Not stated 
35  Comparison sample: age (mean and SD, or 
median and IQR, or range) 
Free text or NA or Not stated 
36  Comparison sample: sex (n and % male) Free text or NA or Not stated 
37  Comparison sample: ethnicity (n and % in 
each category) 
Free text or NA or Not stated 
38  Comparison sample: education (info re years 
or qualifications)  
Free text or NA or Not stated 
39  Comparison sample: socioeconomic status 
(how measured, and status of sample) 
Free text or NA or Not stated 
40  Qualifications/training of person who made 
BD diagnosis  
Free text or Not stated 
41  Qualifications/training of person who did 
cognitive assessment  
Free text or Not stated 
42  BD definition (e.g. DSM IV/ICD-10 criteria) Free text or Not stated 
43  Euthymia definition (e.g. score less than X on 
named questionnaire, or clinician judgement 
of remission, etc)  
Free text or Not stated 
44  Euthymia confirmed at time of cognitive 
assessment 
1=yes 
2=no 
3=not stated 
45  Age at onset of BD (mean and SD, or median 
and IQR, or range)  
Free text or Not stated 
46  Duration since onset of BD (mean and SD, or 
median and IQR, or range) 
Free text or Not stated 
47  Number of previous illness episodes, all types 
combined (mean and SD, or median and IQR, 
or range)  
Free text or Not stated 
48  Number of previous depressive episodes 
(mean and SD, or median and IQR, or range)  
Free text or Not stated 
49  Number of previous manic/hypomanic 
episodes (mean and SD, or median and IQR, 
or range)  
Free text or Not stated 
50  Number of previous mixed episodes (mean 
and SD, or median and IQR, or range)  
Free text or Not stated 
51  BD sample: n and % currently taking any 
psychotropic medication 
Free text or Not stated 
52  BD sample: further details of medication type 
and dosage 
Free text or Not stated 
53  Comparison sample: n and % currently taking 
any psychotropic medication 
Free text or NA or Not stated 
54  Comparison sample: further details of 
medication type and dosage 
Free text or NA or Not stated 
55  Cognitive assessment: name of test   Free text 
56  Cognitive assessment: source reference 
(journal citation; or name of publishing 
company)   
Free text or Not stated 
57  Cognitive assessment: domain covered (e.g. 
verbal memory)  
Free text or Not stated 
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* Optional fields – only complete these for papers for which information is available regarding prevalence of 
impairment (fields 59 and 60), otherwise enter NA 
 
58  Cognitive assessment: definition of 
impairment threshold (e.g. 2SD below control 
mean score on one test; or 2SD below control 
mean score on at least two tests; or 1.5SD 
below published norms; or scores less than X; 
etc) 
Free text or Not stated 
59  Prevalence of cognitive impairment in BD 
sample (n and % who meet the stated 
definition of impairment given in field 58) 
Free text or Not stated 
60  Prevalence of cognitive impairment in 
comparison sample (n and % who meet the 
stated definition of impairment given in field 
58) 
Free text or NA or Not stated 
61  Source of prevalence info (or explanation for 
missing info) 
1=provided in paper 
2=author provided on request 
3=info missing: author replied but did not 
provide 
4=info missing: author did not reply 
62  Statistical analysis method to test/adjust for 
confounders/covariates (e.g. multiple 
regression)  
Free text or NA or Not stated 
63  Confounders/covariates (apart from other 
cognitive measures) that were significantly 
associated with cognitive performance in the 
analysis (e.g. higher age was a significant 
independent predictor of worse performance)  
Free text or NA or Not stated 
64  Missing data: brief description of level of 
missing data in the analysis (e.g. 10% of BD 
patients were missing a memory score)  
Free text or Not stated 
65  Missing data: brief description of how authors 
dealt with missing data (e.g. complete case 
analysis, or all available data, or imputation)  
Free text or Not stated 
66  Any other comments  Free text 
67 * Group cognitive score: BD sample 
(unadjusted group average) (mean and SD, or 
median and IQR, or range) 
Free text or NA or Not stated 
68 * Group cognitive score: comparison sample 
(unadjusted group average) (mean and SD, or 
median and IQR, or range) 
Free text or NA or Not stated 
69 * Cohen’s d (if M and SD available in fields 67 
and 68). Minus sign = BD worse; calculate 
using http://www.uccs.edu/~lbecker/  
Free text or NA or Not stated 
70  Full list of all confounders/covariates tested 
(apart from other cognitive measures), 
whether significant or not (additional info for 
field 63) 
Free text or NA or Not stated 
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synthesis 
Supplementary references for eligible articles not included in synthesis 
 
Antila, M., Partonen, T., Kieseppa, T., Suvisaari, J., Eerola, M., Lonnqvist, J., & Tuulio-
Henriksson, A. (2009). Cognitive functioning of bipolar I patients and relatives 
from families with or without schizophrenia or schizoaffective disorder. Journal of 
Affective Disorders, 116(1-2), 70-79. doi:10.1016/j.jad.2008.11.006 
Antila, M., Tuulio-Henriksson, A., Kieseppa, T., Eerola, M., Partonen, T., & Lonnqvist, J. 
(2007). Cognitive functioning in patients with familial bipolar I disorder and their 
unaffected relatives. Psychological Medicine, 37(5), 679-687. 
doi:10.1017/s0033291706009627 
Braw, Y., Sitman, R., Sela, T., Erez, G., Bloch, Y., & Levkovitz, Y. (2012). Comparison of 
insight among schizophrenia and bipolar disorder patients in remission of affective 
and positive symptoms: Analysis and critique. European Psychiatry, 27(8), 612-
618. doi:10.1016/j.eurpsy.2011.02.002 
Donaldson, S., Goldstein, L. H., Landau, S., Raymont, V., & Frangou, S. (2003). The 
Maudsley Bipolar Disorder Project: The effect of medication, family history, and 
duration of illness on IQ and memory in bipolar I disorder. Journal of Clinical 
Psychiatry, 64(1), 86-93.  
Frangou, S. (2005). The Maudsley Bipolar Disorder Project. Epilepsia, 46, 19-25.  
Goswami, U., Sharma, A., Khastigir, U., Ferrier, I. N., Young, A. H., Gallagher, P., . . . 
Moore, P. B. (2006). Neuropsychological dysfunction, soft neurological signs and 
social disability in euthymic patients with bipolar disorder. British Journal of 
Psychiatry, 188, 366-373. doi:10.1192/bjp.188.4.366 
Haldane, M., & Frangou, S. (2005). The Maudsley Bipolar Disorder Project: Insights into 
the role of the prefrontal cortex in bipolar disorder I. Revista de Psiquiatria do Rio 
Grande do Sul, 27(3), 1-20.  
Kauer-Sant'Anna, M., Yatham, L. N., Tramontina, J., Weyne, F., Cereser, K. M., Gazalle, 
F. K., . . . Kapczinski, F. (2008). Emotional memory in bipolar disorder. British 
Journal of Psychiatry, 192(6), 458-463. doi:10.1192/bjp.bp.107.040295 
Martinez-Aran, A., Penades, R., Vieta, E., Colom, F., Reinares, M., Benabarre, A., . . . 
Gasto, C. (2002). Executive function in patients with remitted bipolar disorder and 
schizophrenia and its relationship with functional outcome. Psychotherapy and 
Psychosomatics, 71(1), 39-46. doi:10.1159/000049342 
Mur, M., Portella, M. J., Martinez-Aran, A., Pifarre, J., & Vieta, E. (2009). Influence of 
Clinical and Neuropsychological Variables on the Psychosocial and Occupational 
Outcome of Remitted Bipolar Patients. Psychopathology, 42(3), 148-156. 
doi:10.1159/000207456 
Palsson, E., Figueras, C., Johansson, A. G. M., Ekman, C.-J., Hultman, B., Ostlind, J., & 
Landen, M. (2013). Neurocognitive function in bipolar disorder: a comparison 
between bipolar I and II disorder and matched controls. BMC Psychiatry, 13, 165. 
doi:10.1186/1471-244x-13-165 
Strejilevich, S. A., & Martino, D. J. (2013). Cognitive function in adulthood and elderly 
euthymic bipolar patients: A comparison to test models of cognitive evolution. 
Journal of Affective Disorders, 150(3), 1188-1191. doi:10.1016/j.jad.2013.05.012 
Torralva, T., Gleichgerrcht, E., Torrente, F., Roca, M., Strejilevich, S. A., Cetkovich, M., . 
. . Manes, F. (2011). Neuropsychological functioning in adult bipolar disorder and 
ADHD patients: A comparative study. Psychiatry Research, 186(2-3), 261-266. 
doi:10.1016/j.psychres.2010.08.007 
221 
 
Trivedi, J. K., Goel, D., Sharma, S., Singh, A. P., Sinha, P. K., & Tandon, R. (2007). 
Cognitive functions in stable schizophrenia & euthymic state of bipolar disorder. 
Indian Journal of Medical Research, 126(5), 433-439.  
van Gorp, W. G., Altshuler, L., Theberge, D. C., & Mintz, J. (1999). Declarative and 
procedural memory in bipolar disorder. Biological Psychiatry, 46(4), 525-531. 
doi:10.1016/s0006-3223(98)00336-9 
van Gorp, W. G., Altshuler, L., Theberge, D. C., Wilkins, J., & Dixon, W. (1998). 
Cognitive impairment in euthymic bipolar patients with and without prior alcohol 
dependence - A preliminary study. Archives of General Psychiatry, 55(1), 41-46. 
doi:10.1001/archpsyc.55.1.41 
 
 
222 
 
 
 
F – Critical appraisal ratings for systematic review 
 1
. 
R
ep
re
se
n
ta
ti
v
e 
sa
m
p
le
 
2
. 
A
p
p
ro
p
ri
a
te
 
re
cr
u
it
m
en
t 
3
. 
S
a
m
p
le
 s
iz
e 
4
. 
S
u
b
je
ct
s 
&
 s
et
ti
n
g
 
d
es
cr
ib
ed
 
5
. 
A
n
a
ly
si
s 
co
v
er
a
g
e 
6
. 
O
b
je
ct
iv
e 
m
ea
su
re
 
7
. 
R
el
ia
b
le
 m
ea
su
re
 
8
. 
S
ta
ti
st
ic
a
l 
a
n
a
ly
si
s 
9
. 
C
o
n
fo
u
n
d
in
g
 
fa
ct
o
rs
 
1
0
. 
O
b
je
ct
iv
e 
su
b
g
ro
u
p
in
g
s 
Altshuler 
2004 
N Y N Y ? Y ? Y Y Y 
Arslan 
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Barrera 
2013 
N Y N N ? Y ? ? Y NA 
Cavanagh 
2002 
Y Y N Y Y Y Y ? Y NA 
Cheung 
2013 
N Y Y Y ? Y Y Y Y Y 
Daban 
2012 
Y Y Y N ? Y ? Y Y Y 
Doganavsargil-Baysal 
2013 
N Y N N ? Y ? Y Y Y 
Elshahawi 
2011 
Y Y Y Y ? Y ? Y Y Y 
Fakhry 
2013 
Y Y N Y ? Y ? Y Y Y 
Ferrier 
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Frangou 
2005 
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Martinoc 
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Martinoc 
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Y Y N Y ? Y Y Y Y Y 
Martinoc 
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Y Y N Y ? Y Y Y Y Y 
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Y Y N Y ? Y Y Y Y Y 
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N Y Y Y ? Y Y Y Y Y 
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Y Y N Y ? Y Y Y Y Y 
Normalaa 
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Y Y N Y ? Y Y Y Y Y 
Osher 
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Y Y Y Y ? Y Y Y Y Y 
Pirkolab 
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N Y N Y ? Y Y Y Y NA 
223 
 
 
 
 1
. 
R
ep
re
se
n
ta
ti
v
e 
sa
m
p
le
 
2
. 
A
p
p
ro
p
ri
a
te
 
re
cr
u
it
m
en
t 
3
. 
S
a
m
p
le
 s
iz
e 
4
. 
S
u
b
je
ct
s 
&
 s
et
ti
n
g
 
d
es
cr
ib
ed
 
5
. 
A
n
a
ly
si
s 
co
v
er
a
g
e 
6
. 
O
b
je
ct
iv
e 
m
ea
su
re
 
7
. 
R
el
ia
b
le
 m
ea
su
re
 
8
. 
S
ta
ti
st
ic
a
l 
a
n
a
ly
si
s 
9
. 
C
o
n
fo
u
n
d
in
g
 
fa
ct
o
rs
 
1
0
. 
O
b
je
ct
iv
e 
su
b
g
ro
u
p
in
g
s 
Sánchez-Morla 
2009 
Y Y Y Y Y Y Y Y Y NA 
Sparding 
2015 
Y Y Y Y ? Y ? Y Y Y 
van der Werf-Eldering 
2010 
? Y N Y Y Y Y Y Y Y 
 
a. Studies contain overlapping samples. 
b. Studies contain overlapping samples. 
c. Studies contain overlapping samples. 
 
 
 
 
 
Y Yes 
N No 
? Unclear/unsure 
NA Not applicable 
 
224 
 
G – STROBE ratings for systematic review 
 1
a
. 
D
e
si
g
n
 i
n
 a
b
st
r
a
c
t/
ti
tl
e
 
1
b
. 
A
b
st
r
a
c
t 
2
. 
B
a
c
k
g
r
o
u
n
d
 
3
. 
O
b
je
c
ti
v
es
 
4
. 
D
e
si
g
n
 
5
. 
S
e
tt
in
g
 
6
a
. 
P
a
r
ti
ci
p
a
n
ts
 
7
. 
V
a
r
ia
b
le
s 
8
. 
D
a
ta
 s
o
u
r
c
e
s/
m
e
a
su
r
e
m
e
n
t 
9
. 
B
ia
s 
1
0
. 
S
tu
d
y
 s
iz
e
 
1
1
. 
Q
u
a
n
ti
ta
ti
v
e 
v
a
r
ia
b
le
s 
1
2
a
. 
D
e
sc
r
ib
e
 s
ta
ti
st
ic
s 
1
2
b
. 
S
u
b
g
r
o
u
p
s/
in
te
r
a
c
ti
o
n
s 
1
2
c
. 
M
is
si
n
g
 d
a
ta
 
1
2
d
. 
A
c
c
o
u
n
t 
fo
r
 s
a
m
p
li
n
g
 
1
2
e
. 
S
e
n
si
ti
v
it
y
 a
n
a
ly
se
s 
1
3
a
. 
P
a
r
ti
ci
p
a
n
t 
n
u
m
b
e
r
s 
a
t 
e
a
c
h
 
st
a
g
e
a
 
1
3
b
. 
N
o
n
-p
a
r
ti
ci
p
a
ti
o
n
 r
e
a
so
n
sa
 
1
3
c
. 
F
lo
w
 d
ia
g
r
a
m
 
1
4
a
. 
S
a
m
p
le
 c
h
a
r
a
c
te
r
is
ti
cs
 
1
4
b
. 
N
u
m
b
e
r
 m
is
si
n
g
 d
a
ta
 
1
5
. 
O
u
tc
o
m
e
 d
a
ta
 
1
6
a
. 
E
st
im
a
te
s 
&
 p
r
e
c
is
io
n
 
1
6
b
. 
C
a
te
g
o
r
y
 b
o
u
n
d
a
r
ie
s 
1
6
c
. 
A
b
so
lu
te
 r
is
k
 
1
7
. 
O
th
e
r
 a
n
a
ly
se
s 
1
8
. 
K
ey
 r
e
su
lt
s 
1
9
. 
L
im
it
a
ti
o
n
s 
2
0
. 
In
te
r
p
r
e
ta
ti
o
n
 
2
1
. 
G
en
er
a
li
sa
b
il
it
y
 
2
2
. 
F
u
n
d
e
r
 a
n
d
 r
o
le
 
Altshuler 
2004 
N Y Y Y N N Y Y Y Y N Y Y Y N NA NA N N N Y N Y N Y NA Y N Y Y Y N 
Arslan 
2014 
N N Y Y N Y N Y Y Y Y Y Y NA N NA NA Y Y N Y N Y N Y NA Y Y Y Y N N 
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2013 
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Cavanagh 
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Y N Y Y Y N Y Y Y N Y Y Y NA N N Y Y Y N Y N Y Y NA NA Y Y Y Y Y N 
Cheung 
2013 
N Y Y Y N N N Y Y N N N Y NA N NA NA N N N Y N Y N Y NA Y Y N Y Y Y 
Daban 
2012 
N Y Y Y N N N Y Y N N Y Y NA N NA NA N N N Y N Y N Y NA Y Y N N N N 
Doganavsargil-
Baysal 2013 
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Elshahawi 
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N N Y Y Y N Y Y Y N Y Y Y Y N NA NA N N N Y N Y N NA NA Y N N N Y Y 
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2013 
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1999 
N N Y Y N N Y Y Y N N N Y NA N NA NA N N N Y N Y N NA NA NA Y N Y N N 
Frangou 
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N N Y Y N N Y Y Y Y Y N Y Y N Y NA N Y N Y N Y Y NA NA Y N Y Y Y N 
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N N Y Y N N N Y N N N Y Y NA N NA NA N N N N N Y N NA NA NA Y N N N N 
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2008 
N Y Y Y N N N Y Y N N Y Y Y N NA NA N N N Y N Y N Y NA Y N Y Y Y N 
Martinod 
2011a 
N N Y Y N N N Y Y N N Y Y Y N NA NA N N N Y N Y N NA NA Y N Y Y N N 
Martinod 
2011b 
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Martinod 
2011c 
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2015 
N N Y Y N N Y Y Y N N Y Y Y N NA NA N N N Y N Y Y NA NA Y Y Y N Y Y 
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Eldering 2010 
N Y Y Y N Y Y Y Y N Y Y Y Y N NA Y Y Y N Y N Y Y Y NA Y Y N Y Y Y 
 
 
a. Rated Yes if information reported for bipolar disorder sample, at a minimum. 
b. Studies contain overlapping samples. 
c. Studies contain overlapping samples. 
d. Studies contain overlapping samples. 
 
 
Y Yes 
N No 
NA Not applicable 
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H – Characteristics of the study samples in the 
systematic review 
Table H.1 Characteristics of the BD-I samples 
 
Author 
Year 
Age (years),  
M (SD) 
Male gender,  
n (%) 
Education (years),  
M (SD) 
BD onset 
age and/or 
duration 
(years),  
M (SD) 
BD past 
illness 
episodes,  
M (SD) 
Psychotropic 
medication in BD 
sample 
 BD HC BD HC BD HC    
Altshuler 
2004  
49.9 
(13.9) 
51.8 
(12.6) 
40 
(100%) 
22 
(100%) 
15.5 (2.4) 14.9 (2.0) Onset  
26.7 (9.2) 
Duration  
24.9 (11.1) 
Not stated Lithium 63%, 
anticonvulsant 30%, 
antidepressant 10%, 
benzodiazepine 8%, 
typical antipsychotic 
15%, anticholinergic 
5% 
Cavanagh 
2002  
43.6 
(14.2) 
42.2 
(14.7) 
10 
(50%) 
10 
(50%) 
Not stated Not stated Duration  
16 (12.5) 
Depressive  
6 (6) 
Manic  
6 (7) 
SSRI 35%, typical 
antipsychotic 40%, 
lithium 40%, 
carbamazepine 25% 
Cheung 
2013  
38.57 
(10.70) 
37.76 
(10.27) 
19 
(36.5%) 
19 
(36.5%) 
12.0 (2.94) 14.04 (3.11) Onset  
24.63 (7.6) 
Duration  
13.3 (8.3) 
Depressive 
5.1 (5.2) 
Manic  
5.2 (5.0) 
Monotherapy (sodium 
valproate, lithium, 
antipsychotic, 
carbamazepine or 
lamotrigine) 48.1%, 
combination therapy 
48.1% (inc. 
anticholinergic 15.3%); 
Two patients received 
short-acting low-dose 
benzodiazepine 12h 
before assessment 
Fakhry 
2013  
S1: recent 
manic 
episode 
32.27 
(7.43) 
31.47 
(5.93) 
17 
(56.7%) 
15 
(50%) 
Middle 
3 (10%)  
Secondary 
12 (40%) 
University 
15 (50%) 
Middle  
3 (10%) 
Secondary 
12 (40%) 
University 
15 (50%) 
Not stated Not stated Antipsychotic n=30, 
mood stabiliser other 
than lithium n=28 
Fakhry 
2013  
S2: recent 
depressive 
episode 
31.60 
(6.43) 
As 
above 
13 
(43.3%) 
As 
above 
Middle 
3 (10%) 
Secondary 
15 (50%) 
University 
12 (40%) 
As above Not stated Not stated Antipsychotic n=28, 
mood stabiliser other 
than lithium n=26, 
antidepressant n=22 
Ibrahim 
2009a & 
Normala 
2010a  
Mdn 
37.5 
IQR 
20.0 
Mdn 
27.0 
IQR 
15.0 
19 
(47.5%) 
10 
(25%) 
Not stated Not stated Onset  
Mdn 21 
IQR 13 
Duration  
10.95 (9.04) 
All types  
3.83 (3.07) 
Mood stabiliser only 
27.5%, mood stabiliser 
+ antipsychotic 55%, 
mood stabiliser + 
antidepressant 2.5%, 
antipsychotic only 15% 
Juselius 
2009b  
 
44.2 
(1.6) 
47.8 
(0.6) 
15 
(57.7%) 
55 
(48.2%) 
Level 
attainedc 4.1 
(0.5) 
Level 
attainedc  
4.1 (0.2)  
Duration  
20.5 (5.8) 
Manic  
3.8 (0.45) 
Not stated 
Osher 
2011  
41.3 
(13.2) 
53.7 
(18.9) 
25 
(49%) 
181 
(37%) 
12.8 (2.0) 15.3 (3.2) Onset 
24.0 (8.0) 
Not stated Mood stabiliser 
monotherapy n=12, 
neuroleptic 
monotherapy n=8, 
polytherapy n=31 
BD, bipolar disorder; BD-I, bipolar disorder type I; HC, healthy comparison; M, mean; Mdn, median; IQR, interquartile range; SD, standard deviation; 
SSRI, selective serotonin reuptake inhibitor.  
a. Same sample. 
b. All participants were twins. BD sample (n = 26) included 20 individuals whose co-twin did not have BD plus 3 pairs (6 individuals) concordant for BD. 
HC sample included n = 114 twins (46 pairs + 22 individuals) with no history of BD in the participant or their co-twin. 
c. Level 4 is "vocation school or equivalent", after graduating high school. 
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Table H.2 Characteristics of the mixed BD samples 
 
Author  
Year 
% 
with 
BD-I 
Age (years),  
M (SD) 
Male gender,  
n (%) 
Education (years),  
M (SD) 
BD onset 
age and/or 
duration 
(years),  
M (SD) 
BD past 
illness 
episodes,  
M (SD) 
Psychotropic 
medication in BD 
sample 
  BD HC BD HC BD HC    
Barrera 
2013  
58% 48.21 
(11.24) 
46.04 
(12.30) 
12 
(100%) 
12 
(100%) 
12.33 
(2.67) 
12.50 
(2.71) 
Onset  
25 (7.93) 
Depressive  
10.63 (13.5) 
Manic  
5 (3.8) 
Mood stabiliser 
83.3%, 
antipsychotic 
50%, anxiolytic 
30% 
Daban 
2012  
Not 
stated 
41.12 
(10.87) 
46.53 
(13.99) 
23 
(43.4%) 
20 
(33.3%) 
14.21 
(3.05) 
12.49 
(2.75) 
Not stated Not stated Not stated 
Martino 
2014  
51% 39.55 
(10.83) 
40.28 
(12.03) 
36 
(36%) 
12 
(30%) 
14.36 
(2.36) 
13.88 
(2.77) 
Onset  
27.65 (9.49) 
Duration  
11.18 (6.67) 
Depressive  
3.46 (2.01) 
Manic  
3.18 (2.09) 
Mood stabiliser 
100%, 
antidepressant 
38%, 
benzodiazepine 
55%, 
antipsychotic 55%  
Mur 
2007  
Not 
stated 
42.6 
(13.0) 
42.2 
(12.4) 
22 
(50%) 
23 
(50%) 
10.5 
(3.2) 
12.5 (3.4) Onset 
25.6 (11.5) 
Duration 
16.9 (11.67) 
Manic 
2.45 (2.5) 
Lithium 
monotherapy 
n=20, lithium plus 
other n=24 
Sánchez-
Morla 
2009  
75% 43.5 
(10.4) 
43.8 
(11.2) 
30 
(41.1%) 
31 
(46.3%) 
12.5  
(3.9) 
14.1  
(3.5) 
Onset  
26.2 (9.3) 
Duration  
17.3 (10.5) 
All types  
13.3 (11.2) 
Manic  
6.0 (5.6) 
Lithium 39.8%, 
anticonvulsant 
26.0%, lithium + 
anticonvulsant 
30.1%, SSRI 
30.1%, 
benzodiazepine 
23.3%, typical 
antipsychotic 
8.2%, atypical 
antipsychotic 
26.0% 
van der 
Werf-
Eldering 
2010  
83% Not 
stateda 
40.8 
(14.4) 
Not 
stateda 
27 
(36%) 
Not 
stateda 
Level 
attainedb 
3.7 (1.1)  
Not stateda Not stateda Not stateda 
BD, bipolar disorder; HC, healthy comparison; M, mean; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor.  
a. This information not reported in article for euthymic group separately. 
b. Ranging from 1 = primary school to 6 = PhD or higher degree obtained. 
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I – Cognitive impairment in BD-I vs BD-II 
Prevalence of cognitive impairment in BD-I versus BD-II samples, from Sparding et al. 
(2015) 
 
Cognitive measure Impairment 
prevalencea,b 
 BD-Ic BD-IId 
D-KEFS TMT 2 number sequencing (executive/speed) 34% 19% 
D-KEFS TMT 3 letter sequencing (executive/speed) 22% 14% 
D-KEFS TMT 4 number-letter switching (executive) 48% 43% 
D-KEFS Verbal Fluency 2 category (executive/language) 38% 39% 
D-KEFS Verbal Fluency 3 category switching total (executive/language) 34% 27% 
D-KEFS Verbal Fluency 3-v category switching accuracy (executive) 18% 11% 
D-KEFS Color-Word 3 inhibition (executive) 29% 29% 
D-KEFS Color-Word 4 inhibition/switching (executive) 27% 15% 
D-KEFS Design Fluency 3 switching (executive) 32% 17% 
D-KEFS Tower rule violations (executive) 34% Not stated 
WAIS-III Matrix Reasoning (abstract reasoning) 21% 30% 
WAIS-III Similarities (abstract reasoning) 13% 11% 
WAIS-III Letter-Number Sequencing (working memory) 22% 28% 
WAIS-III Arithmetic (working memory) 37% 31% 
WAIS-III Symbol Search (speed) 28% 19% 
WAIS-III Digit-Symbol Coding (speed) 19% 11% 
WAIS-III Digit Symbol Coding copy (speed) 35% 19% 
WAIS-III Block Design (speed/visuospatial) 40% 44% 
RCFT time to copy (speed/visuospatial) 23% 24% 
RCFT 3-minute recall (visual memory) 23% 21% 
RCFT recognition (visual memory) 22% 21% 
WAIS-III Digit Symbol Coding free recall (visual memory) 25% 16% 
WAIS-III Digit Symbol Coding pairing (visual memory) 26% 27% 
WAIS-III Picture Completion (visuospatial) 14% 16% 
BD-I, bipolar disorder type I; BD-II, bipolar disorder type II; D-KEFS, Delis-Kaplan Executive Function System; HC, 
healthy comparison; RCFT, Rey Complex Figure Test; SD, standard deviation; TMT, Trailmaking Test; WAIS-III, 
Wechsler Adult Intelligence Scale third edition. 
a. Impairment threshold is 1.25 SD from HC mean; HC impairment prevalence is 10.57% by definition. HC sample (n = 
86) was frequency matched to BD samples based on age, gender and years of education; details not reported in article. 
b. Standardised mean difference between BD and HC groups is not given in table because SD was not reported in article. 
c. BD-I (n = 64) sample characteristics: age M = 38 (SD = 14); 48% male; education level M = 3.7 (SD = 1.1) (where 3 = 
12 years, 4 = 13–15 years); age of onset M = 19 (SD = 9); past illness episodes (all types) M = 19 (SD = 26); 
medications: lithium 68%, antipsychotic 32%, antidepressant 31%, anticonvulsant 32%. 
d. BD-II (n = 44) sample characteristics: age M = 35 (SD = 12); 45% male; education level M = 3.9 (SD = 1.2) (where 3 
= 12 years, 4 = 13–15 years); age of onset M = 18 (SD = 11); past illness episodes (all types) M = 18 (SD = 18); 
medications: lithium 48%, antipsychotic 11%, antidepressant 41%, anticonvulsant 32%. 
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J – Factors associated with cognitive impairment in the systematic review 
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ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; F, female; M, male. 
a. Analysis based on number of recent episodes as well as time to recovery. 
b. Studies contain overlapping samples. 
c. Positive association with cognitive performance on some scores. 
d. Studies contain overlapping samples. 
e. Studies contain overlapping samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Significantly associated with impairment 
 Not significantly associated with impairment 
 Not analysed/measured 
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K – UK Biobank project approval 
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L – NHS Research Ethics Committee approval 
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M – University Research Ethics Committee approval 
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N – NHS R&D acknowledgement 
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O – Touchscreen mood questionnaire classifications in 
UK Biobank 
Criteria for lifetime experience of features of bipolar disorder 
 
Bipolar disorder, type I 
Ever ‘manic or hyper’ for 2 days OR ever ‘irritable/argumentative’ for 2 days; plus at least 
3 features from ‘more active’, ‘more talkative’, ‘needed less sleep’ and ‘more 
creative/more ideas’; plus duration of a week or more; plus ‘needed treatment or caused 
problems at work’. 
 
Bipolar disorder, type II 
Ever ‘manic or hyper’ for 2 days OR ever ‘irritable/argumentative’ for 2 days; plus at least 
3 features from ‘more active’, ‘more talkative’, ‘needed less sleep’ and ‘more 
creative/more ideas’; plus duration of a week or more. 
 
 
Criteria for lifetime experience of features of major depression 
 
Probable recurrent major depression (severe) 
Ever depressed/down for a whole week; plus at least two weeks duration; plus at least two 
episodes; plus ever seen a psychiatrist for ‘nerves, anxiety, tension, depression’ OR ever 
anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; 
plus at least two episodes; plus ever seen a psychiatrist for ‘nerves, anxiety, tension, 
depression’. 
 
Probable recurrent major depression (mild-moderate) 
Ever depressed/down for a whole week; plus at least two weeks duration; plus at least two 
episodes; plus ever seen a GP (but not a psychiatrist) for ‘nerves, anxiety, tension, 
depression’ OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least 
two weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) 
for ‘nerves, anxiety, tension, depression’. 
 
Single probable episode of major depression 
Ever depressed/down for a whole week; plus at least two weeks duration; plus only one 
episode; plus ever seen a GP or a psychiatrist for ‘nerves, anxiety, tension, depression’ OR 
ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks 
duration; plus only one episode; plus ever seen a GP or a psychiatrist for ‘nerves, anxiety, 
tension, depression’. 
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P – Psychiatric and neurological diagnoses in linked 
hospital records 
ICD-10 code ICD-10 description 
A8x.x Viral infections of the central nervous system 
B22.0 HIV disease resulting in encephalopathy 
B90.0 Sequelae of central nervous system tuberculosis 
B94.1 Sequelae of viral encephalitis 
C70.0 Malignant neoplasm of meninges (cerebral) 
C71.x Malignant neoplasm of brain 
C72.8  Overlapping lesion of brain and other parts of central nervous system 
C75.1 Malignant neoplasm of pituitary gland 
C75.3 Malignant neoplasm of pineal gland 
C79.3 Secondary malignant neoplasm of brain and cerebral meninges 
D32.0 Benign neoplasm of meninges (cerebral) 
D33.0 Benign neoplasm of brain, supratentorial 
D33.1 Benign neoplasm of brain, infratentorial 
D33.2 Benign neoplasm of brain, unspecified 
D35.2  Benign neoplasm of pituitary gland 
D35.4 Benign neoplasm of pineal gland 
D42.0 Neoplasm of uncertain or unknown behaviour of meninges (cerebral) 
D43.0 Neoplasm of uncertain or unknown behaviour of brain, supratentorial 
D43.1  Neoplasm of uncertain or unknown behaviour of brain, infratentorial 
D43.2 Neoplasm of uncertain or unknown behaviour of brain, unspecified 
D44.3 Neoplasm of uncertain or unknown behaviour of pituitary gland 
D44.5 Neoplasm of uncertain or unknown behaviour of pineal gland 
Fxx.x Mental and behavioural disorders 
G0x.x Inflammatory diseases of the central nervous system 
G10 Huntington disease 
G11.x Hereditary ataxia 
G12.2  Motor neuron disease 
G13.1 Other systemic atrophy primarily affecting central nervous system in 
neoplastic disease (Paraneoplastic limbic encephalopathy) 
G2x.x Extrapyramidal and movement disorders 
G30.x Alzheimer disease 
G31.x Other degenerative diseases of nervous system, not elsewhere classified 
G32.8 Other specified degenerative disorders of nervous system in diseases 
classified elsewhere 
G35 Multiple sclerosis 
G36.x Other acute disseminated demyelination 
G37.x Other demyelinating diseases of central nervous system 
G4x.x Episodic and paroxysmal disorders 
G8x.x Cerebral palsy and other paralytic syndromes 
G90.3 Multi-system degeneration 
G91.x Hydrocephalus 
G92 Toxic encephalopathy 
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ICD-10 code ICD-10 description 
G93.x Other disorders of brain 
G94.x Other disorders of brain in diseases classified elsewhere 
G96.x Other disorders of central nervous system 
G97.x Postprocedural disorders of nervous system, not elsewhere classified 
G98 Other disorders of nervous system, not elsewhere classified 
H47.6 Disorders of visual cortex 
I6x.x Cerebrovascular diseases 
Q0x.x Congenital malformations of the nervous system 
Q28.2 Arteriovenous malformation of cerebral vessels 
Q28.3 Other malformations of cerebral vessels 
Q9x.x Chromosomal abnormalities, not elsewhere classified 
R41.x Other symptoms and signs involving cognitive functions and awareness 
R90.0 Intracranial space-occupying lesion 
R94.0 Abnormal results of function studies of central nervous system 
S02.0x Fracture of vault of skull 
S02.1x Fracture of base of skull 
S06.x Intracranial injury 
S07.1 Crushing injury of skull 
S09.7 Multiple injuries of head 
T02.0x Fractures involving head with neck 
T04.0 Crushing injuries involving head with neck 
T06.0 Injuries of brain and cranial nerves with injuries of nerves and spinal cord 
at neck level 
T40.x Poisoning by narcotics and psychodysleptics [hallucinogens] 
T42.x Poisoning by antiepileptic, sedative-hypnotic and antiparkinsonism drugs 
T43.x Poisoning by psychotropic drugs, not elsewhere classified 
T51.x Toxic effect of alcohol 
T58 Toxic effect of carbon monoxide 
T90.2  Sequelae of fracture of skull and facial bones 
T90.5 Sequelae of intracranial injury 
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Q – Self-reported psychiatric and neurological diagnoses 
in UK Biobank 
UK Biobank data field Diagnosis 
6150 (touchscreen - vascular) Stroke 
20001 (interview - cancer) Brain cancer/primary malignant tumour 
“ Meningeal cancer/malignant meningioma 
20002 (interview - non-cancer) Alcohol dependency 
“ Anorexia/bulimia/other eating disorder 
“ Anxiety/panic attacks 
“ Benign/essential tremor 
“ Brain haemorrhage 
“ Brain/intracranial abscess 
“ Cerebral aneurysm 
“ Cerebral palsy 
“ Chronic/degenerative neurological problem 
“ Deliberate self-harm/suicide attempt 
“ Dementia/Alzheimer's/cognitive impairment 
“ Encephalitis 
“ Epilepsy 
“ Fracture skull/head 
“ Head injury 
“ Headaches (not migraine) 
“ Infection of nervous system 
“ Insomnia 
“ Ischaemic stroke 
“ Meningioma benign 
“ Meningitis 
“ Migraine 
“ Motor neurone disease 
“ Nervous breakdown 
“ Neurological injury/trauma 
“ Neuroma benign 
“ Obsessive compulsive disorder (OCD) 
“ Opioid dependency 
“ Other demyelinating condition 
“ Other neurological problem 
“ Other substance abuse/dependency 
“ Post-traumatic stress disorder 
“ Psychological/psychiatric problem 
“ Spina bifida 
“ Stress 
“ Stroke 
“ Subarachnoid haemorrhage 
“ Subdural haematoma 
“ Transient ischaemic attack 
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R – Self-reported medications in UK Biobank 
Table R.1 Psychotropic medications from UK Biobank field 20003 
 
Mood stabilisers Selective serotonin reuptake 
inhibitors 
Other antidepressants Traditional antipsychotics Second generation 
antipsychotics 
Sedatives & 
hypnotics 
lithium product paroxetine mirtazapine chlorpromazine quetiapine diazepam 
Priadel (lithium) Seroxat (paroxetine) Zispin (mirtazapine) cpz - chlorpromazine Seroquel (quetiapine)  diazepam product 
Camcolit (lithium) fluoxetine duloxetine Largactil (chlorpromazine)  risperidone Valium tablet 
(diazepam) 
sodium valproate Prozac (fluoxetine) Cymbalta (duloxetine) haloperidol Risperdal (risperidone)  Valium syrup 
(diazepam) 
Epilim (sodium valproate) citalopram Yentreve (duloxetine)  Haldol (haloperidol) olanzapine Valium supp 
(diazepam) 
Depakote (semisodium 
valproate) 
Cipramil (citalopram)  venlafaxine Serenace (haloperidol)  Zyprexa (olanzapine) temazepam 
valproic acid  escitalopram Efexor (venlafaxine) fluphenazine decanoate aripiprazole Normison 
(temazepam) 
carbamazepine product Cipralex (escitalopram) amitriptyline fluphenazine Abilify (aripiprazole)  Euhypnos 
(temazepam) 
carbamazepine sertraline Elavil (amitriptyline)  Modecate (fluphenazine)  amisulpride zopiclone 
Tegretol (carbamazepine) Lustral (sertraline)  Tryptizol (amitriptyline) Moditen tablet 
(fluphenazine)  
Solian (amisulpride) Zimovane (zopiclone)  
Teril (carbamazepine) fluvoxamine Lentizol (amitriptyline)  Moditen enanthate 
(fluphenazine) 
clozapine  zaleplon 
Teril retard (carbamazepine)  amitriptyline+perphenazine flupentixol Clozaril (clozapine)  Sonata (zaleplon) 
Timonil retard 
(carbamazepine) 
 Triptafen (amitriptyline+perphenazine) Flupenthixol (flupentixol)  zolpidem 
Epimaz (carbamazepine)  amitriptyline+chlordiazepoxide Depixol (flupentixol)  Stilnoct (zolpidem)  
lamotrigine  Limbitrol 10 
(amitriptyline+chlordiazepoxide) 
Fluanxol (flupentixol)  nitrazepam 
Lamictal (lamotrigine)  Limbitrol-5 
(amitriptyline+chlordiazepoxide) 
zuclopenthixol  Mogadon 
(nitrazepam) 
  phenelzine Clopixol (zuclopenthixol)   Nitrados (nitrazepam) 
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Mood stabilisers Selective serotonin reuptake 
inhibitors 
Other antidepressants Traditional antipsychotics Second generation 
antipsychotics 
Sedatives & 
hypnotics 
  maoi - phenelzine loxapine  Remnos (nitrazepam) 
  Nardil (phenelzine) Loxapac (loxapine)  Somnite (nitrazepam) 
  moclobemide droperidol   Noctesed (nitrazepam) 
  Manerix (moclobemide) Droleptan (droperidol)  Surem (nitrazepam) 
  imipramine trifluoperazine  Unisomnia 
(nitrazepam) 
  Tofranil (imipramine) Stelazine (trifluoperazine)   flunitrazepam 
  trimipramine thioridazine  Rohypnol 
(flunitrazepam) 
  Surmontil (trimipramine) Melleril (thioridazine)  triazolam 
  dothiepin   Halcion (triazolam) 
  dosulepin    
  Prothiaden (dosulepin)    
  Thaden (dosulepin)    
  clomipramine    
  Anafranil (clomipramine)    
  lofepramine    
  Gamanil (lofepramine)    
  Lomont (lofepramine)    
  mianserin    
  Bolvidon (mianserin)    
  Norval (mianserin)    
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Table R.2 Multiple sclerosis and Parkinson’s disease medications from UK Biobank field 20003 
 
Multiple sclerosis disease modifying medications Parkinson's disease medications 
interferon beta apomorphine 
interferon beta-1a Uprima (apomorphine) 
Rebif 12million iu/0.5ml prefilled syringe (interferon beta-1a) bromocriptine 
Rebif 6million iu/0.5ml prefilled syringe (interferon beta-1a) Parlodel (bromocriptine) 
Rebif 22micrograms/0.5ml prefilled syringe (interferon beta-1a) cabergoline 
Rebif 44micrograms/0.5ml prefilled syringe (interferon beta-1a) Cabaser (cabergoline) 
interferon beta-1b pergolide 
interferon beta-1b product pramipexole 
Avonex 6million iu injection (pdr for recon)+solvent (interferon beta-1b) Mirapexin (pramipexole) 
Avonex 6million iu/0.5ml prefilled syringe (interferon beta-1b) ropinirole 
Avonex 30micrograms/0.5ml prefilled syringe (interferon beta-1b) Requip (ropinirole) 
Betaferon 9.6 million iu injection (pdr for recon)+diluent (interferon beta-1b) levodopa 
Betaferon 300micrograms injection (pdr for recon)+diluent (interferon beta-1b) l-dopa - levodopa 
glatiramer levodopa+careldopa+entacapone 
Copaxone 20mg injection (pdr for recon) (glatiramer acetate) Stalevo (carbidopa/levodopa/entacapone) 
 co-careldopa 
 Sinemet (co-careldopa) 
 half-sinemet (co-careldopa) 
 Sinemet-62.5 (co-careldopa) 
 co-beneldopa 
 co-beneldopa product 
 Madopar (co-beneldopa) 
 co-careldopa 
 selegiline 
 Eldepryl (selegiline) 
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Multiple sclerosis disease modifying medications Parkinson's disease medications 
 Zelapar(selegiline) 
 entacapone 
 tolcapone 
 Tasmar (tolcapone) 
 amantadine 
 Symmetrel (amantadine) 
 orphenadrine 
 Norgesic (orphenadrine) 
 Norflex (orphenadrine) 
 procyclidine 
 Kemadrin (procyclidine) 
 Arpicolin (procyclidine) 
 trihexyphenidyl 
 Artane (trihexyphenidyl) 
 benzhexol 
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S – Characteristics of the depression sub-groups in UK 
Biobank 
Table S.1 Severe recurrent depression group characteristics 
 
 Information source Definition 
 NHS hospital 
records 
Touchscreen mood 
questionnaire 
Broad Narrow 
n 137 8,905 9,016 26 
Age, M (SD) 56.8 (8.6) 55.6 (8.1) 55.6 (8.1) 54.8 (8.2) 
Female, n (%)a 96 (70.1) 5,144 (57.8) 5,225 (58.0) 15 (57.7) 
Ethnic group, n (%)a 
White 
Asian/Asian British 
Black/black British 
Other 
 
130 (95.6) 
4 (2.9) 
0 (0.0) 
2 (1.5) 
 
8,231 (92.8) 
242 (2.7) 
189 (2.1) 
208 (2.3) 
 
8,337 (92.8) 
245 (2.7) 
189 (2.1) 
209 (2.3) 
 
24 (92.3) 
1 (3.9) 
0 (0.0) 
1 (3.9) 
Townsend quintileb, n (%)a 
Qu1 (least deprived) 
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
18 (13.2) 
18 (13.2) 
32 (23.5) 
30 (22.1) 
38 (27.9) 
 
1,159 (13.0) 
1,417 (15.9) 
1,668 (18.8) 
2,086 (23.5) 
2,558 (28.8) 
 
1,175 (13.1) 
1,433 (15.9) 
1,694 (18.8) 
2,110 (23.5) 
2,586 (28.7) 
 
2 (7.7) 
2 (7.7) 
6 (23.1) 
6 (23.1) 
10 (38.5) 
Has a degree, n (%)a 41 (30.4) 3,204 (36.2) 3,235 (36.2) 10 (38.5) 
Smoking status, n (%)a 
Never 
Former 
Current 
 
75 (55.6) 
38 (28.2) 
22 (16.3) 
 
4,065 (45.8) 
3,314 (37.3) 
1,501 (16.9) 
 
4,127 (45.9) 
3,345 (37.2) 
1,517 (16.9) 
 
13 (50.0) 
7 (26.9) 
6 (23.1) 
Alcohol frequency, n (%)a 
Daily/almost daily 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
25 (18.4) 
19 (14.0) 
26 (19.1) 
13 (9.6) 
27 (19.9) 
18 (13.2) 
8 (5.9) 
 
1,773 (19.9) 
1,660 (18.7) 
1,916 (21.5) 
1,108 (12.5) 
1,308 (14.7) 
689 (7.7) 
443 (5.0) 
 
1,795 (19.9) 
1,676 (18.6) 
1,937 (21.5) 
1,121 (12.5) 
1,330 (14.8) 
699 (7.8) 
449 (5.0) 
 
3 (11.5) 
3 (11.5) 
5 (19.2) 
0 (0.0) 
5 (19.2) 
8 (30.8) 
2 (7.7) 
Any psychotropic medication, n (%)a 107 (80.5) 3,072 (34.9) 3,154 (35.4) 25 (96.2) 
Lithium, n (%)a 13 (10.2) 95 (1.1) 105 (1.2) 3 (12.0) 
Other mood stabiliser, n (%)a 10 (7.8) 189 (2.2) 195 (2.2) 4 (16.0) 
SSRI antidepressant, n (%)a 42 (32.3) 1,741 (19.9) 1,770 (20.0) 13 (52.0) 
Other antidepressant, n (%)a 59 (45.0) 1,095 (12.5) 1,142 (12.9) 12 (48.0) 
Neuroticism score, M (SD) 7.2 (3.6) 6.8 (3.4) 6.8 (3.4) 7.3 (3.8) 
Current depressive symptom score, 
M (SD) 
 
4.2 (4.2) 
 
3.3 (3.0) 
 
3.3 (3.1) 
 
4.0 (4.3) 
M, mean; Qu, quintile; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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Table S.2 Mild-moderate recurrent depression group characteristics 
 
 Information source Definition 
 NHS hospital 
records 
Touchscreen mood 
questionnaire 
Broad Narrow 
n 312 15,012 15,320 4 
Age, M (SD) 54.7 (8.1) 55.4 (7.9) 55.4 (7.9) 55.3 (2.8) 
Female, n (%)a 178 (57.1) 10,324 (68.8) 10,499 (68.5) 3 (75.0) 
Ethnic group, n (%)a 
White 
Asian/Asian British 
Black/black British 
Other 
 
298 (96.8) 
2 (0.7) 
4 (1.3) 
4 (1.3) 
 
14,175 (94.7) 
247 (1.7) 
244 (1.6) 
302 (2.0) 
 
14,470 (94.8) 
249 (1.6) 
247 (1.6) 
306 (2.0) 
 
3 (75.0) 
0 (0.0) 
1 (25.0) 
0 (0.0) 
Townsend quintileb, n (%)a 
Qu1 (least deprived) 
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
27 (8.7) 
33 (10.6) 
51 (16.4) 
69 (22.2) 
131 (42.1) 
 
2,384 (15.9) 
2,873 (19.2) 
3,091 (20.6) 
3,425 (22.9) 
3,210 (21.4) 
 
2,411 (15.8) 
2,906 (19.0) 
3,141 (20.5) 
3,493 (22.8) 
3,339 (21.8) 
 
0 (0.0) 
0 (0.0) 
1 (25.0) 
1 (25.0) 
2 (50.0) 
Has a degree, n (%)a 82 (27.1) 5,211 (34.9) 5,293 (34.8) 0 (0.0) 
Smoking status, n (%)a 
Never 
Former 
Current 
 
131 (42.3) 
95 (30.7) 
84 (27.1) 
 
7,785 (52.0) 
5,450 (36.4) 
1,748 (11.7) 
 
7,915 (51.8) 
5,543 (36.3) 
1,831 (12.0) 
 
1 (25.0) 
2 (50.0) 
1 (25.0) 
Alcohol frequency, n (%)a 
Daily/almost daily 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
55 (18.0) 
38 (12.4) 
71 (23.2) 
28 (9.2) 
57 (18.6) 
43 (14.1) 
14 (4.6) 
 
2,896 (19.3) 
3,204 (21.4) 
3,734 (24.9) 
1,992 (13.3) 
2,001 (13.3) 
640 (4.3) 
538 (3.6) 
 
2,951 (19.3) 
3,241 (21.2) 
3,804 (24.9) 
2,019 (13.2) 
2,058 (13.4) 
682 (4.5) 
552 (3.6) 
 
0 (0.0) 
1 (25.0) 
1 (25.0) 
1 (25.0) 
0 (0.0) 
1 (25.0) 
0 (0.0) 
Any psychotropic medication, n (%)a 231 (74.0) 2,772 (18.7) 3,001 (19.9) 2 (50.0) 
Lithium, n (%)a 27 (9.0) 1 (0.01) 28 (0.2) 0 (0.0) 
Other mood stabiliser, n (%)a 42 (14.0) 73 (0.5) 115 (0.8) 0 (0.0) 
SSRI antidepressant, n (%)a 87 (28.6) 1,835 (12.4) 1,922 (12.8) 0 (0.0) 
Other antidepressant, n (%)a 117 (38.1) 842 (5.7) 957 (6.4) 2 (50.0) 
Neuroticism score, M (SD) 8.2 (3.3) 5.8 (3.2) 5.8 (3.2) 6.3 (3.5) 
Current depressive symptom score, 
M (SD) 
 
5.4 (3.6) 
 
2.5 (2.4) 
 
2.5 (2.5) 
 
- 
M, mean; Qu, quintile; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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Table S.3 Single episode depression group characteristics 
 
 Information source Definition 
 NHS hospital 
records 
Touchscreen mood 
questionnaire 
Broad Narrow 
n 3830 7,927 11,686 71 
Age, M (SD) 55.6 (8.0) 56.3 (8.0) 56.1 (8.0) 55.3 (8.5) 
Female, n (%)a 2,246 (58.6) 5,042 (63.6) 7,246 (62.0) 42 (59.2) 
Ethnic group, n (%)a 
White 
Asian/Asian British 
Black/black British 
Other 
 
3,593 (94.5) 
74 (2.0) 
54 (1.4) 
81 (2.1) 
 
7,575 (96.0) 
97 (1.2) 
109 (1.4) 
114 (1.5) 
 
11,106 (95.5) 
169 (1.5) 
159 (1.4) 
192 (1.7) 
 
62 (87.3) 
2 (2.8) 
4 (5.6) 
3 (4.2) 
Townsend quintileb, n (%)a 
Qu1 (least deprived) 
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
430 (11.2) 
545 (14.3) 
560 (14.6) 
811 (21.2) 
1,479 (38.7) 
 
1,353 (17.1) 
1,621 (20.5) 
1,681 (21.3) 
1,846 (23.3) 
1,407 (17.8) 
 
1,778 (15.3) 
2,161 (18.5) 
2,224 (19.1) 
2,639 (22.6) 
2,860 (24.5) 
 
5 (7.0) 
5 (7.0) 
17 (23.9) 
18 (25.4) 
26 (36.6) 
Has a degree, n (%)a 805 (21.6) 2,893 (36.7) 3,681 (31.9) 17 (23.9) 
Smoking status, n (%)a 
Never 
Former 
Current 
 
1,605 (42.3) 
1,251 (33.0) 
941 (24.8) 
 
4,125 (52.2) 
2,957 (37.4) 
825 (10.4) 
 
5,697 (49.0) 
4,188 (36.0) 
1,748 (15.0) 
 
33 (46.5) 
20 (28.2) 
18 (25.4) 
Alcohol frequency, n (%)a 
Daily/almost daily 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
607 (16.0) 
514 (13.6) 
765 (20.2) 
441 (11.6) 
689 (18.2) 
508 (13.4) 
269 (7.1) 
 
1,616 (20.4) 
1,862 (23.5) 
2,010 (25.4) 
957 (12.1) 
911 (11.5) 
302 (3.8) 
261 (3.3) 
 
2,211 (19.0) 
2,359 (20.3) 
2,764 (23.7) 
1,387 (11.9) 
1,592 (13.7) 
807 (6.9) 
522 (4.5) 
 
12 (17.1) 
17 (24.3) 
11 (15.7) 
11 (15.7) 
8 (11.4) 
3 (4.3) 
8 (11.4) 
Any psychotropic medication, n (%)a 2,325 (61.9) 658 (8.4) 2,949 (25.7) 34 (48.6) 
Lithium, n (%)a 76 (2.1) 4 (0.05) 79 (0.7) 1 (1.5) 
Other mood stabiliser, n (%)a 182 (5.0) 43 (0.6) 221 (2.0) 4 (5.8) 
SSRI antidepressant, n (%)a 1,294 (34.9) 343 (4.4) 1,617 (14.2) 20 (29.0) 
Other antidepressant, n (%)a 922 (25.1) 240 (3.1) 1,150 (10.1) 12 (17.1) 
Neuroticism score, M (SD) 7.5 (3.3) 4.2 (3.0) 5.2 (3.5) 5.3 (3.1) 
Current depressive symptom score, 
M (SD) 
 
4.4 (3.5) 
 
1.3 (1.7) 
 
2.3 (2.8) 
 
2.1 (2.2) 
M, mean; Qu, quintile; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole cohort. 
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T – Additional characteristics of the exposed and unexposed groups in UK Biobank 
Additional characteristics of the exposed and unexposed groups analysed in the prevalence study in Chapter 5 
 
 Unexposed 
comparison 
Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
n  104,410 3,020 607 56,425 7,583 850 259 1,905 931 916 323 
Ethnic group 
n (%) missing 
White, n (%)a 
Asian/Asian British 
Black/black British 
Other 
 
398 (0.4) 
94,798 (91.1) 
3,643 (3.5) 
3,121 (3.0) 
2,450 (2.4) 
 
31 (1.0) 
2,727 (91.2) 
84 (2.8) 
84 (2.8) 
94 (3.1) 
 
4 (0.7) 
563 (93.4) 
6 (1.0) 
13 (2.2) 
21 (3.5) 
 
279 (0.5) 
53,515 (95.3) 
887 (1.6) 
718 (1.3) 
1,026 (1.8) 
 
20 (0.3) 
7,171 (94.8) 
144 (1.9) 
108 (1.4) 
140 (1.9) 
 
21 (2.5) 
719 (86.7) 
24 (2.9) 
49 (5.9) 
37 (4.5) 
 
4 (1.5) 
221 (86.7) 
8 (3.1) 
17 (6.7) 
9 (3.5) 
 
11 (0.6) 
1,859 (98.2) 
5 (0.3) 
11 (0.6) 
19 (1.0) 
 
8 (0.9) 
899 (97.4) 
4 (0.4) 
5 (0.5) 
15 (1.6) 
 
6 (0.7) 
876 (96.3) 
15 (1.7) 
8 (0.9) 
11 (1.2) 
 
1 (0.3) 
310 (96.3) 
6 (1.9) 
1 (0.3) 
5 (1.6) 
Townsend quintileb 
n (%) missing 
Qu1 (least deprived), n (%)a 
Qu2 
Qu3 
Qu4 
Qu5 (most deprived) 
 
157 (0.2) 
18,130 (17.4) 
21,340 (20.5) 
21,782 (20.9) 
23,337 (22.4) 
19,664 (18.9) 
 
3 (0.1) 
356 (11.8) 
405 (13.4) 
492 (16.3) 
676 (22.4) 
1,088 (36.1) 
 
1 (0.2) 
71 (11.7) 
78 (12.9) 
99 (16.3) 
133 (22.0) 
225 (37.1) 
 
101 (0.2) 
8,872 (15.8) 
10,071 (17.9) 
10,836 (19.2) 
12,380 (22.0) 
14,165 (25.2) 
 
19 (0.3) 
1,015 (13.4) 
1,304 (17.2) 
1,388 (18.4) 
1,663 (22.0) 
2,194 (29.0) 
 
3 (0.4) 
33 (3.9) 
48 (5.7) 
75 (8.9) 
165 (19.5) 
526 (62.1) 
 
1 (0.4) 
8 (3.1) 
11 (4.3) 
19 (7.4) 
44 (17.1) 
176 (68.2) 
 
4 (0.2) 
382 (20.1) 
382 (20.1) 
389 (20.5) 
373 (19.6) 
375 (19.7) 
 
2 (0.2) 
181 (19.5) 
173 (18.6) 
190 (20.5) 
187 (20.1) 
198 (21.3) 
 
2 (0.2) 
222 (24.3) 
188 (20.6) 
177 (19.4) 
167 (18.3) 
160 (17.5) 
 
1 (0.3) 
80 (24.8) 
66 (20.5) 
59 (18.3) 
53 (16.5) 
64 (19.9) 
Smoking status 
n (%) missing 
Never, n (%)a 
Former 
Current 
 
372 (0.4) 
60,061 (57.7) 
35,126 (33.8) 
8,851 (8.5) 
 
26 (0.9) 
1,281 (42.8) 
1,024 (34.2) 
689 (23.0) 
 
5 (0.8) 
262 (43.5) 
196 (32.6) 
144 (23.9) 
 
236 (0.4) 
27,577 (49.1) 
20,210 (36.0) 
8,402 (15.0) 
 
21 (0.3) 
3,611 (47.8) 
2,559 (33.8) 
1,392 (18.4) 
 
16 (1.9) 
299 (35.9) 
237 (28.4) 
298 (35.7) 
 
4 (1.5) 
89 (34.9) 
74 (29.0) 
92 (36.1) 
 
17 (0.9) 
897 (47.5) 
690 (36.6) 
301 (15.9) 
 
11 (1.2) 
419 (45.5) 
337 (36.6) 
164 (17.8) 
 
10 (1.1) 
555 (61.3) 
293 (32.3) 
58 (6.4) 
 
5 (1.6) 
201 (63.2) 
98 (30.8) 
19 (6.0) 
Alcohol frequency 
n (%) missing 
Daily/almost daily, n (%)a 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions only 
Never (former drinker) 
Never (not former drinker) 
 
75 (0.1) 
22,026 (21.1) 
24,920 (23.9) 
26,928 (25.8) 
11,266 (10.8) 
11,449 (11.0) 
2,783 (2.7) 
4,963 (4.8) 
 
22 (0.7) 
561 (18.7) 
492 (16.4) 
641 (21.4) 
355 (11.8) 
473 (15.8) 
296 (9.9) 
180 (6.0) 
 
4 (0.7) 
99 (16.4) 
92 (15.3) 
126 (20.9) 
75 (12.4) 
99 (16.4) 
74 (12.3) 
38 (6.3) 
 
157 (0.3) 
10,801 (19.2) 
11,020 (19.6) 
13,097 (23.3) 
7,031 (12.5) 
8,153 (14.5) 
3,609 (6.4) 
2,557 (4.5) 
 
28 (0.4) 
1,361 (18.0) 
1,281 (17.0) 
1,634 (21.6) 
938 (12.4) 
1,207 (16.0) 
699 (9.3) 
435 (5.8) 
 
13 (1.5) 
125 (14.9) 
84 (10.0) 
161 (19.2) 
79 (9.4) 
157 (18.8) 
151 (18.0) 
80 (9.6) 
 
2 (0.8) 
34 (13.2) 
24 (9.3) 
53 (20.6) 
22 (8.6) 
51 (19.8) 
46 (17.9) 
27 (10.5) 
 
5 (0.3) 
368 (19.4) 
342 (18.0) 
447 (23.5) 
232 (12.2) 
295 (15.5) 
128 (6.7) 
88 (4.6) 
 
4 (0.4) 
169 (18.2) 
149 (16.1) 
214 (23.1) 
120 (12.9) 
158 (17.0) 
71 (7.7) 
46 (5.0) 
 
4 (0.4) 
178 (19.5) 
167 (18.3) 
221 (24.2) 
86 (9.4) 
124 (13.6) 
79 (8.7) 
57 (6.3) 
 
1 (0.3) 
62 (19.3) 
50 (15.5) 
75 (23.3) 
32 (9.9) 
55 (17.1) 
27 (8.4) 
21 (6.5) 
Any psychotropic medication 
n (%) missing 
n (%)a 
 
1,180 (1.1) 
1,424 (1.4) 
 
40 (1.3) 
1,663 (55.8) 
 
3 (0.5) 
542 (89.7) 
 
949 (1.7) 
23,280 (42.0) 
 
58 (0.8) 
5,530 (73.5) 
 
23 (2.7) 
688 (83.2) 
 
7 (2.7) 
231 (91.7) 
- - - - 
Lithium 
n (%) missing 
n (%)a 
-  
90 (3.0) 
501 (17.1) 
 
15 (2.5) 
209 (35.3) 
 
1,965 (3.5) 
373 (0.7) 
 
245 (3.2) 
117 (1.6) 
- - - - - - 
Other mood stabiliser 
n (%) missing 
n (%)a 
-  
75 (2.5) 
531 (18.0) 
 
10 (1.7) 
267 (44.7) 
 
1,930 (3.4) 
768 (1.4) 
 
237 (3.1) 
196 (2.7) 
- - - - - - 
SSRI antidepressant 
n (%) missing 
n (%)a 
-  
81 (2.7) 
508 (17.3) 
 
15 (2.5) 
102 (17.2) 
 
1,316 (2.3) 
15,529 (28.2) 
 
123 (1.6) 
3,792 (50.8) 
- - - - - - 
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 Unexposed 
comparison 
Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
Other antidepressant 
n (%) missing 
n (%)a 
-  
90 (3.0) 
428 (14.6) 
 
16 (2.6) 
128 (21.7) 
 
1,625 (2.9) 
7,239 (13.2) 
 
180 (2.4) 
1,737 (23.5) 
- - - - - - 
Traditional antipsychotic 
n (%) missing 
n (%)a 
-  
97 (3.2) 
131 (4.5) 
 
18 (3.0) 
39 (6.6) 
- -  
57 (6.7) 
174 (21.9) 
 
17 (6.6) 
62 (25.6) 
- - - - 
Second generation antipsychotic 
n (%)  missing 
n (%)a 
-  
82 (2.7) 
470 (16.0) 
 
12 (2.0) 
205 (34.5) 
- -  
43 (5.1) 
439 (54.4) 
 
10 (3.9) 
169 (67.9) 
- - - - 
Multiple sclerosis disease-modifying 
medication 
n (%) missing 
n (%)a 
- - - - - - -  
 
153 (8.0) 
175 (10.0) 
 
 
94 (10.1) 
120 (14.3) 
- - 
Parkinson’s disease medication 
n (%) missing 
n (%)a 
- - - - - - - - -  
58 (6.3) 
721 (84.0) 
 
11 (3.4) 
300 (96.2) 
Neuroticism score 
n (%) missing 
Mean (SD) 
 
17,114 (16.4) 
3.3 (2.9) 
 
665 (22.0) 
6.8 (3.6) 
 
130 (21.4) 
7.1 (3.6) 
 
11,146 (19.8) 
6.4 (3.4) 
 
1,392 (18.4) 
7.4 (3.2) 
 
223 (26.2) 
6.8 (3.6) 
 
67 (25.9) 
6.9 (3.5) 
 
442 (23.2) 
4.6 (3.4) 
 
219 (23.5) 
4.5 (3.3) 
 
200 (21.8) 
4.1 (3.3) 
 
72 (22.3) 
4.4 (3.4) 
Current depressive 
symptom score 
n (%) missing 
Mean (SD) 
 
 
8,543 (8.2) 
1.1 (1.6) 
 
 
311 (10.3) 
3.6 (3.3) 
 
 
53 (8.7) 
3.4 (3.2) 
 
 
5,585 (9.9) 
3.1 (3.0) 
 
 
666 (8.8) 
4.0 (3.4) 
 
 
155 (18.2) 
3.7 (3.3) 
 
 
45 (17.4) 
3.9 (3.3) 
 
 
243 (12.8) 
2.6 (2.4) 
 
 
149 (16.0) 
2.9 (2.5) 
 
 
113 (12.3) 
2.3 (2.4) 
 
 
39 (12.1) 
2.6 (2.5) 
Qu, quintile; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor. 
a. Missing excluded from denominator. 
b. Quintiles generated from the whole UK Biobank cohort. 
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U – Population attributable prevalence results in UK 
Biobank 
Highest population attributable prevalence in each exposed group 
 
 Impaired n Unimpaired n Total n Prevalencea Population 
attributable 
fraction 
Population 
attributable 
prevalence 
per 100,000 
Mania/BD       
Point estimate       
Exposed n 89 911 1,000 0.0890b 0.0102 45.2 
Unexposed n 4,336 94,664 99,000 0.0438   
Total n 4,425 95,575 100,000 0.0443   
CI lower       
Exposed n 67 933 1,000 0.0670 0.0053 23.2 
Unexposed n 4,336 94,664 99,000 0.0438   
Total n 4,403 95,597 100,000 0.0440   
CI upper       
Exposed n 112 888 1,000 0.1120 0.0153 68.2 
Unexposed n 4,336 94,664 99,000 0.0438   
Total n 4,448 95,552 100,000 0.0445   
Major depression      
Point estimate       
Exposed n 778 9,222 10,000 0.0778c 0.0468 256.0 
Unexposed n 4,698 85,302 90,000 0.0522   
Total n 5,476 94,524 100,000 0.0548   
CI lower       
Exposed n 652 9,348 10,000 0.0652 0.0243 130.0 
Unexposed n 4,698 85,302 90,000 0.0522   
Total n 5,350 94,650 100,000 0.0535   
CI upper       
Exposed n 903 9,097 10,000 0.0903 0.0680 381.0 
Unexposed n 4,698 85,302 90,000 0.0522   
Total n 5,601 94,399 100,000 0.0560   
Schizophrenia       
Point estimate       
Exposed n 204 796 1,000 0.2040d 0.0283 151.8 
Unexposed n 5,167 93,833 99,000 0.0522   
Total n 5,371 94,629 100,000 0.0537   
CI lower       
Exposed n 105 895 1,000 0.1050 0.0100 52.8 
Unexposed n 5,167 93,833 99,000 0.0522   
Total n 5,272 94,728 100,000 0.0527   
CI upper       
Exposed n 304 696 1,000 0.3040 0.0460 251.8 
Unexposed n 5,167 93,833 99,000 0.0522   
Total n 5,471 94,529 100,000 0.0547   
Multiple sclerosis      
Point estimate       
Exposed n 37.64 162.36 200 0.1882e 0.0055 27.7 
Unexposed n 4,970.00 94,830.00 99,800 0.0498   
Total n 5,007.64 94,992.36 100,000 0.0501   
CI lower       
Exposed n 32.56 167.44 200 0.1628 0.0045 22.6 
Unexposed n 4,970.00 94,830.00 99,800 0.0498   
Total n 5,002.56 94,997.44 100,000 0.0500   
CI upper       
Exposed n 42.74 157.26 200 0.2137 0.0065 32.8 
Unexposed n 4,970.00 94,830.00 99,800 0.0498   
Total n 5,012.74 94,987.26 100,000 0.0501   
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 Impaired n Unimpaired n Total n Prevalencea Population 
attributable 
fraction 
Population 
attributable 
prevalence 
per 100,000 
Parkinson's disease      
Point estimate       
Exposed n 37.38 162.62 200 0.1869f 0.0051 26.9 
Unexposed n 5,209.56 94,590.44 99,800 0.0522   
Total n 5,246.94 94,753.06 100,000 0.0525   
CI lower       
Exposed n 11.54 188.46 200 0.0577 0.0002 1.1 
Unexposed n 5,209.56 94,590.44 99,800 0.0522   
Total n 5,221.10 94,753.06 100,000 0.0522   
CI upper       
Exposed n 63.20 136.80 200 0.3160 0.0100 52.8 
Unexposed n 5,209.56 94,590.44 99,800 0.0522   
Total n 5,272.76 94,727.24 100,000 0.0527   
BD, bipolar disorder; CI, confidence interval. 
a. All standardised prevalence estimates taken from Table 5.2 in Chapter 5. 
b. Visuospatial memory estimates in narrowly-defined group. 
c. Numeric memory estimates in narrowly-defined group. 
d. Numeric memory estimates in broadly-defined group. 
e. Reaction time estimates in narrowly-defined group. 
f. Numeric memory estimates in narrowly-defined group. 
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V – Sensitivity analysis results for prevalence study in UK Biobank 
Table V.1 Crude prevalence results, excluding exposed participants with comorbid psychiatric or neurological conditions 
 
Impairment threshold  Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
Reasoning 
≤ unexposed 4th percentile 
score 
(Unexposed prevalence 
4.16%) 
n 1,343 191 28,271 4,163 26 7 268 108 159 60 
Crude P %  
95% CI 
Crude PR  
95% CI 
6.78 
5.44, 8.12 
1.63* 
1.33, 1.99 
3.66 
1.00, 6.32 
0.88 
0.43, 1.83 
3.76 
3.54, 3.98 
0.90* 
0.85, 0.97 
4.32 
3.70, 4.94 
1.04 
0.90, 1.20 
7.69 
0.00, 17.93 
1.85 
0.49, 7.01 
0 
- 
- 
- 
1.49 
0.04, 2.94 
0.36* 
0.14, 0.95 
0.93 
0.00, 2.74 
0.22 
0.03, 1.57 
6.29 
2.52, 10.06 
1.51 
0.83, 2.76 
10.0 
2.41, 17.59 
2.40* 
1.13, 5.14 
Reaction time 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.98%) 
n 1,974 342 42,791 4,840 28 8 276 114 169 64 
Crude P %  
95% CI 
Crude PR  
95% CI 
5.98 
4.93, 7.03 
1.20* 
1.01, 1.43 
6.73 
4.07, 9.39 
1.35 
0.91, 2.01 
4.72 
4.52, 4.92 
0.95* 
0.90, 0.99 
5.64 
4.99, 6.29 
1.13* 
1.01, 1.28 
17.86 
3.67, 32.05 
3.59* 
1.62, 7.94 
12.50 
0.00, 35.42 
2.51 
0.40, 15.71 
10.14 
6.58, 13.70 
2.04* 
1.43, 2.90 
12.28 
6.26, 18.30 
2.47* 
1.51, 4.03 
6.51 
2.79, 10.23 
1.31 
0.74, 2.32 
6.25 
0.32, 12.18 
1.26 
0.49, 3.24 
Numeric memory 
≤ unexposed 5th percentile 
score 
(Unexposed prevalence 
5.22%) 
n 370 50 8,602 1,196 7 3 82 36 48 17 
Crude P %  
95% CI 
Crude PR  
95% CI 
8.65 
5.79, 11.51 
1.66* 
1.19, 2.32 
6.00 
0.00, 12.58 
1.15 
0.38, 3.45 
5.16 
4.69, 5.63 
0.99 
0.89, 1.10 
7.11 
5.65, 8.57 
1.36* 
1.10, 1.68 
0 
- 
- 
- 
0 
- 
- 
- 
7.32 
1.68, 12.96 
1.40 
0.65, 3.03 
11.11 
0.84, 21.38 
2.13 
0.84, 5.37 
6.25 
0.00, 13.10 
1.20 
0.40, 3.59 
11.76 
0.00, 27.07 
2.25 
0.61, 8.29 
Visuospatial memory 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.38%) 
n 1,996 346 43,128 4,875 30 8 279 116 172 65 
Crude P %  
95% CI 
Crude PR  
95% CI 
5.91 
4.88, 6.94 
1.35* 
1.13, 1.61 
6.65 
4.02, 9.28 
1.52* 
1.02, 2.26 
4.55 
4.35, 4.75 
1.04 
0.99, 1.10 
4.45 
3.87, 5.03 
1.02 
0.89, 1.16 
3.33 
0.00, 9.75 
0.76 
0.11, 5.23 
0 
- 
- 
- 
3.23 
1.15, 5.30 
0.74 
0.39, 1.40 
3.45 
0.13, 6.77 
0.79 
0.30, 2.06 
7.56 
3.61, 11.51 
1.73* 
1.02, 2.91 
7.69 
1.21, 14.17 
1.76 
0.76, 4.08 
Prospective memory 
Incorrect score 
(Unexposed prevalence 
22.82%) 
n 1,390 199 28,976 4,286 29 8 277 114 169 64 
Crude P %  
95% CI 
Crude PR  
95% CI 
26.12 
23.81, 28.43 
1.14* 
1.05, 1.25 
32.16 
25.67, 38.65 
1.41* 
1.15, 1.72 
21.26 
20.79, 21.73 
0.93* 
0.91, 0.95 
22.84 
21.58, 24.10 
1.00 
0.95, 1.06 
48.28 
30.09, 66.47 
2.12* 
1.45, 3.08 
62.50 
28.95, 96.05 
2.74* 
1.60, 4.68 
23.83 
18.81, 28.85 
1.04 
0.85, 1.29 
28.07 
19.82, 36.32 
1.23 
0.92, 1.65 
25.44 
18.87, 32.01 
1.11 
0.86, 1.44 
34.38 
22.74, 46.02 
1.51* 
1.07, 2.11 
CI, confidence interval; P, prevalence; PR, prevalence ratio. 
* p < 0.05 
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Table V.2 Prevalence of cognitive impairment across groups, standardised for age group, gender and educational attainment 
 
Impairment threshold  Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
Reasoning 
≤ unexposed 4th percentile 
score 
(Unexposed prevalence 
4.16%) 
n 1,866 318 35,211 6,052 274 86 572 272 283 115 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
7.32 
6.14, 8.50 
1.76* 
1.48, 2.11 
7.24 
4.39, 10.09 
1.74* 
1.13, 2.70 
4.33 
4.11, 4.54 
1.04a 
0.98, 1.10 
5.45 
4.88, 6.02 
1.31* 
1.16, 1.48 
10.86 
7.17, 14.54 
2.61* 
1.78, 3.82 
-b 
- 
- 
- 
3.29 
1.83, 4.75 
0.79 
0.44, 1.42 
-b 
- 
- 
- 
5.95 
3.19, 8.70 
1.43 
0.73, 2.81 
9.07 
3.82, 14.32 
2.18* 
1.01, 4.69 
Reaction time 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.98%) 
n 2,955 593 55,773 7,484 798 243 1,866 906 897 316 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
7.22 
6.29, 8.15 
1.45* 
1.26, 1.68 
8.72 
6.44, 10.99 
1.75* 
1.30, 2.35 
5.53 
5.34, 5.72 
1.11*c 
1.06, 1.17 
7.02 
6.44, 7.60 
1.41*d 
1.28, 1.55 
13.50 
11.13, 15.87 
2.71* 
2.21, 3.32 
11.45 
7.45, 15.46 
2.30* 
1.52, 3.49 
15.34 
13.70, 16.97 
3.08*e 
2.70, 3.52 
19.27 
16.70, 21.84 
3.87*f 
3.30, 4.54 
6.27 
4.69, 7.86 
1.26 
0.92, 1.71 
5.98 
3.36, 8.59 
1.20 
0.73, 1.98 
Numeric memory 
≤ unexposed 5th percentile 
score 
(Unexposed prevalence 
5.22%) 
n 505 75 10,808 1,746 63 20 193 103 94 35 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
10.07 
7.45, 12.70 
1.93* 
1.45, 2.58 
-b 
- 
- 
- 
5.85 
5.40, 6.29 
1.12* 
1.01, 1.23 
7.88 
6.62, 9.15 
1.51* 
1.26, 1.82 
19.42 
9.65, 29.19 
3.72* 
2.20, 6.28 
-b 
- 
- 
- 
7.20 
3.56, 10.85 
1.38 
0.69, 2.75 
-b 
- 
- 
- 
-b 
- 
- 
- 
-b 
- 
- 
- 
Visuospatial memory 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.38%) 
n 3,006 606 56,308 7,571 833 256 1,887 920 907 321 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
6.48 
5.60, 7.36 
1.48* 
1.28, 1.72 
9.15 
6.86, 11.45 
2.09* 
1.59, 2.76 
5.12 
4.94, 5.31 
1.17* 
1.12, 1.23 
5.65 
5.13, 6.17 
1.29* 
1.16, 1.44 
9.68 
7.67, 11.69 
2.21* 
1.74, 2.82 
9.72 
6.09, 13.35 
2.22*g 
1.38, 3.58 
6.53 
5.41, 7.64 
1.49* 
1.21, 1.83 
7.97 
6.22, 9.72 
1.82* 
1.39, 2.37 
6.57 
4.96, 8.18 
1.50* 
1.14, 1.98 
7.05 
4.25, 9.85 
1.61 
0.98, 2.65 
Prospective memory 
Incorrect score 
(Unexposed prevalence 
22.82%) 
n 1,959 335 36,237 6,267 325 103 608 291 306 124 
Standardised P %  
95% CI 
Standardised PR  
95% CI 
29.89 
27.87, 31.92 
1.31*h 
1.22, 1.41 
36.74 
31.58, 41.90 
1.61* 
1.38, 1.86 
22.82 
22.39, 23.25 
1.00i 
0.98, 1.03 
25.56 
24.48, 26.64 
1.12*j 
1.07, 1.17 
44.50 
39.10, 49.90 
1.95* 
1.71, 2.23 
42.22 
32.68, 51.76 
1.85* 
1.44, 2.37 
26.24 
22.75, 29.74 
1.15 
0.99, 1.34 
29.89 
24.63, 35.15 
1.31* 
1.07, 1.60 
27.84 
22.82, 32.86 
1.22 
0.98, 1.53 
35.60 
27.17, 44.03 
1.56* 
1.16, 2.09 
CI, confidence interval; P, prevalence; PR, prevalence ratio. 
Standardised estimates are directly standardised by age, gender and education with reference to the unexposed comparison group. 
* p < 0.05 
a. Significant interaction with gender: women PR = 0.95 (CI 0.88, 1.03); men PR = 1.13 (CI 1.03, 1.24). 
b. Estimates not reported because more than 3 of 8 strata contained no exposed participants with impairment. 
c. Significant interaction with gender: women PR = 1.04 (CI 0.98, 1.10); men PR = 1.21 (CI 1.12, 1.30). 
d. Significant interaction with gender: women PR = 1.28 (CI 1.14, 1.44); men PR = 1.57 (CI 1.34, 1.83). 
e. Significant interaction with age and gender: <60 years PR = 4.29 (CI 3.63, 5.09); ≥60 years PR = 2.43 (CI 1.99, 2.97); women PR = 2.53 (CI 2.20, 2.92); men PR = 3.78 (CI 3.06, 4.66). 
f. Significant interaction with age and gender: <60 years PR = 5.96 (CI 4.91, 7.24); ≥60 years PR = 2.75 (CI 2.12, 3.56); women PR = 2.96 (CI 2.46, 3.57); men PR = 5.01 (CI 3.94, 6.37). 
g. Significant interaction with education: no degree PR = 1.46 (CI 0.76, 2.82); has degree PR = 3.88 (CI 1.96, 7.68). 
h. Significant interaction with age: <60 years PR = 1.41 (CI 1.28, 1.54); ≥60 years PR = 1.24 (CI 1.11, 1.28). 
i. Significant interaction with gender and education: women PR = 0.97 (CI 0.94, 0.99); men PR = 1.04 (CI 1.01, 1.08); no degree PR = 1.03 (CI 0.99, 1.05); has degree = PR 0.94 (CI 0.89, 0.98). 
j. Significant interaction with gender: women PR = 1.06 (CI 0.99, 1.12); men PR = 1.19 (CI 1.10, 1.28). 
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Table V.3 Crude prevalence results, excluding participants with missing educational attainment data 
 
Impairment threshold  Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
  Broad Narrow Broad Narrow Broad Narrow Broad Narrow Broad Narrow 
Reasoning 
≤ unexposed 4th percentile 
score 
(Unexposed prevalence 
4.05%) 
n 1,855 318 35,011 6,029 272 86 569 270 282 115 
Crude P %  
95% CI 
Crude PR  
95% CI 
6.90 
5.74, 8.05 
1.70* 
1.44, 2.02 
6.29 
3.62, 8.96 
1.55* 
1.02, 2.38 
4.14 
3.93, 4.35 
1.02 
0.96, 1.08 
5.19 
4.63, 5.75 
1.28* 
1.15, 1.43 
11.03 
7.31, 14.75 
2.72* 
1.94, 3.82 
6.98 
1.59, 12.37 
1.72 
0.80, 3.73 
2.81 
1.45, 4.17 
0.69 
0.43, 1.13 
1.85 
0.24, 3.46 
0.46 
0.19, 1.09 
4.96 
2.43, 7.49 
1.23 
0.74, 2.05 
6.69 
2.12, 11.26 
1.72 
0.88, 3.36 
Reaction time 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.95%) 
n 2,925 589 55,263 7,433 778 236 1,831 883 881 311 
Crude P %  
95% CI 
Crude PR  
95% CI 
6.63 
5.73, 7.53 
1.34* 
1.17, 1.54 
7.64 
5.49, 9.79 
1.54* 
1.16, 2.05 
5.28 
5.09, 5.47 
1.07* 
1.02, 1.12 
6.54 
5.98, 7.10 
1.32* 
1.21, 1.45 
12.72 
10.38, 15.06 
2.57* 
2.14, 3.10 
10.17 
6.31, 14.03 
2.06* 
1.41, 3.01 
14.2 
12.60, 15.80 
2.87* 
2.56, 3.22 
17.78 
15.26, 20.30 
3.59* 
3.11, 4.15 
6.81 
5.15, 8.47 
1.38* 
1.08, 1.76 
7.40 
4.49, 10.31 
1.49* 
1.01, 2.22 
Numeric memory 
≤ unexposed 5th percentile 
score 
(Unexposed prevalence 
5.12%) 
n 501 74 10,748 1,735 63 20 192 103 93 35 
Crude P %  
95% CI 
Crude PR  
95% CI 
9.98 
7.36, 12.60 
1.95* 
1.49, 2.55 
5.41 
0.26, 10.56 
1.06 
0.41, 2.74 
5.59 
5.16, 6.02 
1.09 
0.99, 1.20 
7.55 
6.31, 8.79 
1.48* 
1.24, 1.75 
20.63 
10.64, 30.62 
4.03* 
2.48, 6.56 
15.00 
0.00, 30.65 
2.93* 
1.03, 8.33 
6.25 
2.83, 9.67 
1.22 
0.70, 2.12 
8.74 
3.29, 14.19 
1.71 
0.91, 3.19 
8.6 
2.90, 14.30 
1.68 
0.86, 3.27 
14.29 
2.70, 25.88 
2.79* 
1.24, 6.29 
Visuospatial memory 
> unexposed 95th 
percentile score 
(Unexposed prevalence 
4.35%) 
n 2,980 603 55,843 7,524 819 249 1,866 905 896 317 
Crude P %  
95% CI 
Crude PR  
95% CI 
6.24 
5.37, 7.11 
1.44* 
1.25, 1.65 
8.46 
6.24, 10.68 
1.95* 
1.49, 2.53 
4.74 
4.56, 4.92 
1.09* 
1.04, 1.14 
5.14 
4.64, 5.64 
1.18* 
1.07, 1.31 
9.04 
7.08, 11.00 
2.08* 
1.67, 2.59 
8.03 
4.65, 11.41 
1.85* 
1.21, 2.81 
6.06 
4.98, 7.14 
1.39* 
1.16, 1.67 
7.07 
5.40, 8.74 
1.63* 
1.28, 2.06 
8.04 
6.26, 9.82 
1.85* 
1.48, 2.31 
7.57 
4.66, 10.48 
1.74* 
1.18, 2.56 
Prospective memory 
Incorrect score 
(Unexposed prevalence 
22.58%) 
n 1,944 334 35,988 6,232 323 103 602 287 304 124 
Crude P %  
95% CI 
Crude PR  
95% CI 
28.81 
26.80, 30.82 
1.28* 
1.19, 1.37 
34.73 
29.62, 39.84 
1.54* 
1.33, 1.78 
22.16 
21.73, 22.59 
0.98 
0.96, 1.00 
24.49 
23.42, 25.26 
1.08* 
1.04, 1.13 
44.58 
39.16, 50.00 
1.97* 
1.75, 2.23 
43.69 
34.11, 53.27 
1.93* 
1.55, 2.41 
26.25 
22.74, 29.76 
1.16* 
1.02, 1.33 
28.92 
23.67, 34.17 
1.28* 
1.07, 1.54 
28.95 
23.85, 34.05 
1.28* 
1.07, 1.53 
36.29 
27.83, 44.75 
1.61* 
1.27, 2.03 
CI, confidence interval; P, prevalence; PR, prevalence ratio. 
* p < 0.05 
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Table V.4 Prevalence of cognitive impairment in alternative versions of mood disorder 
groupsa 
 
Impairment threshold  Mania/bipolar Major depression 
  Broad Narrow Broad Narrow 
Reasoning 
≤ unexposed 4th percentile score 
(Unexposed prevalence 4.16%) 
n 572 152 9,925 816 
Crude prevalence %  
95% CI 
Crude prevalence ratio  
95% CI 
7.69 
5.51, 9.87 
1.85* 
1.39, 2.46 
10.53 
5.65, 15.41 
2.53* 
1.59, 4.03 
5.95 
5.48, 6.42 
1.43* 
1.32, 1.56 
8.82 
6.87, 10.77 
2.12* 
1.70, 2.65 
Standardised prevalence %  
95% CI 
Standardised prevalence ratio 
95% CI 
7.61 
5.44, 9.79 
1.83* 
1.37, 2.45 
11.15 
6.15, 16.15 
2.68* 
1.64, 4.37 
6.07 
5.60, 6.54 
1.46*b 
1.34, 1.60 
9.24 
7.25, 11.22 
2.22*c 
1.75, 2.80 
Reaction time 
> unexposed 95th percentile score 
(Unexposed prevalence 4.98%) 
n 1,621 424 30,051 2,123 
Crude prevalence %  
95% CI 
Crude prevalence ratio  
95% CI 
8.27 
6.93, 9.61 
1.66* 
1.41, 1.96 
8.25 
5.63, 10.87 
1.66* 
1.21, 2.28 
5.80 
5.54, 6.06 
1.16* 
1.10, 1.23 
7.68 
6.55, 8.81 
1.54* 
1.33, 1.79 
Standardised prevalence %  
95% CI 
Standardised prevalence ratio 
95% CI 
8.62 
7.25, 9.98 
1.73* 
1.46, 2.05 
9.51 
6.72, 12.30 
1.91* 
1.37, 2.66 
6.13 
5.85, 6.40 
1.23*d 
1.17, 1.30 
8.12 
6.96, 9.28 
1.63* 
1.40, 1.91 
Numeric memory 
≤ unexposed 5th percentile score 
(Unexposed prevalence 5.22%) 
n 152 37 2,910 233 
Crude prevalence %  
95% CI 
Crude prevalence ratio  
95% CI 
12.50 
7.24, 17.76 
2.40* 
1.57, 3.66 
0.00 
- 
- 
- 
7.49 
6.53, 8.45 
1.44* 
1.25, 1.65 
11.16 
7.12, 15.20 
2.14* 
1.48, 3.08 
Standardised prevalence %  
95% CI 
Standardised prevalence ratio 
95% CI 
12.95 
7.61, 18.28 
2.48* 
1.61, 3.81 
- 
- 
- 
- 
7.51 
6.56, 8.47 
1.44* 
1.24, 1.66 
11.07 
7.04, 15.09 
2.12* 
1.40, 3.21 
Visuospatial memory 
> unexposed 95th percentile score 
(Unexposed prevalence 4.38%) 
n 1,651 434 30,365 2,151 
Crude prevalence %  
95% CI 
Crude prevalence ratio  
95% CI 
7.63 
6.35, 8.91 
1.74* 
1.47, 2.07 
7.37 
4.91, 9.83 
1.68* 
1.20, 2.35 
5.37 
5.12, 5.62 
1.23* 
1.16, 1.30 
6.51 
5.47, 7.55 
1.49* 
1.26, 1.75 
Standardised prevalence %  
95% CI 
Standardised prevalence ratio 
95% CI 
7.80 
6.50, 9.09 
1.78*e 
1.50, 2.12 
8.23 
5.65, 10.82 
1.88* 
1.33, 2.67 
5.87 
5.60, 6.13 
1.34* 
1.26, 1.42 
7.05 
5.97, 8.13 
1.61* 
1.36, 1.90 
Prospective memory 
Incorrect score 
(Unexposed prevalence 22.82%) 
n 614 165 10,395 877 
Crude prevalence %  
95% CI 
Crude prevalence ratio  
95% CI 
36.64 
32.83, 40.45 
1.61* 
1.45, 1.78 
41.21 
33.70, 48.72 
1.81* 
1.50, 2.17 
26.35 
25.50, 27.20 
1.15* 
1.12, 1.19 
31.58 
28.50, 34.66 
1.38* 
1.25, 1.53 
Standardised prevalence %  
95% CI 
Standardised prevalence ratio 
95% CI 
36.74 
32.93, 40.55 
1.61*f 
1.45, 1.79 
42.67 
35.13, 50.22 
1.87* 
1.54, 2.26 
27.16 
26.30, 28.01 
1.19*g 
1.15, 1.23 
33.09 
29.97, 36.20 
1.45*h 
1.32, 1.61 
CI, confidence interval. 
Standardised estimates are directly standardised by age and gender with reference to the unexposed comparison group. 
* p < 0.05 
a. Exposure groups formed without reference to the touchscreen mood questionnaire data. 
b. Significant interaction with gender: women ratio = 1.31 (CI 1.18, 1.46); men ratio = 1.62 (CI 1.41, 1.87). 
c. Significant interaction with gender: women ratio = 1.65 (CI 1.20, 2.29); men ratio = 2.84 (CI 2.05, 3.92). 
d. Significant interaction with age and gender: <60 years ratio = 1.42 (CI 1.31, 1.54); ≥60 years ratio = 1.13 (CI 1.05, 1.22); women ratio 
= 1.13 (CI 1.05, 1.21); men ratio = 1.36 (CI 1.25, 1.49). 
e. Significant interaction with age: <60 years ratio = 2.17 (CI 1.74, 2.72); ≥60 years ratio = 1.52 (CI 1.16, 1.98). 
f. Significant interaction with age: <60 years ratio = 1.79 (CI 1.55, 2.07); ≥60 years ratio = 1.46 (CI 1.25, 1.71). 
g. Significant interaction with age and gender: <60 years ratio = 1.25 (CI 1.19, 1.32); ≥60 years ratio = 1.13 (CI 1.08, 1.19); women ratio 
= 1.12 (CI 1.07, 1.17); men ratio = 1.26 (CI 1.19, 1.34). 
h. Significant interaction with gender: women ratio = 1.31 (CI 1.15, 1.49); men ratio = 1.61 (CI 1.39, 1.88). 
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Table V.5 Comparison of multiple sclerosis and Parkinson’s disease groups identified 
via linked hospital records, including and excluding data from Scotland 
 
 Multiple sclerosis Parkinson’s disease 
 Including Scotland Excluding Scotland Including Scotland Excluding Scotland 
n 1,059 981 381 362 
Age (years) 
Mean (SD) 
 
55.3 (7.5) 
 
55.4 (7.4) 
 
62.3 (5.6) 
 
62.2 (5.6) 
Female 
% 
 
72.2 
 
72.3 
 
41.7 
 
40.6 
Has a degree 
% 
 
30.8 
 
29.6 
 
25.5 
 
26.6 
On medicationa 
% 
 
13.0 
 
13.6 
 
84.9 
 
85.0 
Reasoning score 
Mean (SD) 
 
5.7 (2.0) 
 
5.7 (2.0) 
 
5.7 (2.1) 
 
5.7 (2.1) 
Reaction time (ms) 
Median (Q1, Q3) 
 
598 (518, 715) 
 
598 (520, 719) 
 
578 (516, 653) 
 
575 (512, 653) 
Numeric memory score 
Mean (SD) 
 
6.4 (1.3) 
 
6.4 (1.3) 
 
6.5 (1.4) 
 
6.5 (1.4) 
Visuospatial memory errors 
Median (Q1, Q3) 
 
3 (2, 6) 
 
3 (2, 6) 
 
4 (2, 6) 
 
4 (2, 6) 
Prospective memory 
% correct 
 
71.1 
 
71.1 
 
65.5 
 
65.5 
Q, quartile; SD, standard deviation. 
a. Multiple sclerosis disease modifying medication or Parkinson’s disease medication, respectively. 
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Table V.6a Characteristics of exposed and unexposed groupsa, with or without reasoning data 
 
 Unexposed comparison Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
 Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data 
n 100,927 1,595 1,866 40 35,211 485 274 17 572 17 283 6 
Age (years) 
Mean (SD) 
 
56.9 (8.2) 
 
59.6 (7.8) 
 
54.7 (8.1) 
 
58.6 (7.5) 
 
55.7 (8.0) 
 
58.8 (7.7) 
 
54.4 (8.0) 
 
54.6 (8.8) 
 
55.7 (7.7) 
 
59.8 (6.8) 
 
62.1 (5.7) 
 
60.7 (3.1) 
Female 
% 
 
50.0 
 
51.0 
 
49.8 
 
50.0 
 
65.0 
 
56.9 
 
33.9 
 
35.3 
 
74.5 
 
52.9 
 
37.5 
 
50.0 
Has a degree 
% 
 
35.5 
 
15.5 
 
37.0 
 
21.6 
 
34.9 
 
14.0 
 
31.3 
 
11.8 
 
36.2 
 
6.3 
 
34.4 
 
0.0 
No known comorbidity 
% 
 
- 
 
- 
 
72.0 
 
50.0 
 
80.3 
 
19.7 
 
9.5 
 
5.9 
 
46.9 
 
29.4 
 
56.2 
 
50.0 
SD, standard deviation. 
a. Broad group definitions. 
 
 
 
Table V.6b Characteristics of exposed and unexposed groupsa, with or without reaction time data 
 
 Unexposed comparison Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
 Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data 
n 103,303 1,107 2,955 65 55,773 652 798 52 1,866 39 897 19 
Age (years) 
Mean (SD) 
 
57.0 (8.2) 
 
57.2 (8.7) 
 
54.9 (8.0) 
 
55.2 (8.1) 
 
55.6 (7.9) 
 
57.1 (8.2) 
 
53.7 (8.0) 
 
56.8 (8.1) 
 
55.3 (7.5) 
 
57.4 (6.2) 
 
62.2 (5.6) 
 
63.8 (4.3) 
Female 
% 
 
50.0 
 
50.5 
 
52.5 
 
58.5 
 
64.9 
 
58.0 
 
34.0 
 
42.3 
 
73.4 
 
76.9 
 
37.8 
 
36.8 
Has a degree 
% 
 
35.0 
 
22.9 
 
37.9 
 
14.6 
 
32.7 
 
16.2 
 
26.9 
 
7.3 
 
34.9 
 
8.6 
 
31.0 
 
20.0 
No known comorbidity 
% 
 
- 
 
- 
 
67.3 
 
46.2 
 
76.9 
 
63.2 
 
3.5 
 
3.9 
 
14.8 
 
7.7 
 
18.8 
 
15.8 
SD, standard deviation. 
a. Broad group definitions. 
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Table V.6c Characteristics of exposed and unexposed groupsa, with or without numeric memory data 
 
 Unexposed comparison Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
 Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data 
n 30,351 749 505 22 10,808 301 63 9 193 9 94 3 
Age (years) 
Mean (SD) 
 
56.8 (8.3) 
 
56.7 (8.7) 
 
54.7 (8.1) 
 
55.2 (7.6) 
 
55.3 (8.1) 
 
55.2 (8.6) 
 
54.3 (8.9) 
 
52.9 (5.9) 
 
56.1 (7.8) 
 
54.4 (8.8) 
 
61.2 (6.2) 
 
66.7 (2.1) 
Female 
% 
 
49.8 
 
43.8 
 
48.9 
 
59.1 
 
65.5 
 
53.8 
 
39.7 
 
22.2 
 
75.7 
 
55.6 
 
39.4 
 
33.3 
Has a degree 
% 
 
32.4 
 
16.1 
 
35.5 
 
23.8 
 
33.0 
 
13.4 
 
27.0 
 
11.1 
 
31.3 
 
37.5 
 
30.1 
 
0.0 
No known comorbidity 
% 
 
- 
 
- 
 
73.3 
 
50.0 
 
79.6 
 
76.1 
 
11.1 
 
11.1 
 
42.5 
 
33.3 
 
51.1 
 
100.0 
SD, standard deviation. 
a. Broad group definitions. 
 
 
 
Table V.6d Characteristics of exposed and unexposed groupsa, with or without visuospatial memory data 
 
 Unexposed comparison Mania/bipolar Major depression Schizophrenia Multiple sclerosis Parkinson’s disease 
 Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data Has data Missing data 
n 104,410 0 3,006 14 56,308 117 833 17 1,887 18 907 9 
Age (years) 
Mean (SD) 
 
57.0 (8.2) 
 
- 
 
54.9 (8.0) 
 
51.5 (8.4) 
 
55.6 (7.9) 
 
55.9 (7.9) 
 
53.9 (8.1) 
 
54.5 (7.5) 
 
55.4 (7.5) 
 
55.8 (5.8) 
 
62.2 (5.5) 
 
58.3 (7.3) 
Female 
% 
 
50.0 
 
- 
 
52.5 
 
71.4 
 
64.9 
 
47.9 
 
34.8 
 
17.7 
 
73.6 
 
66.7 
 
37.6 
 
55.6 
Has a degree 
% 
 
34.9 
 
- 
 
37.5 
 
- 
 
32.6 
 
- 
 
25.9 
 
- 
 
34.4 
 
- 
 
30.8 
 
- 
No known comorbidity 
% 
 
- 
 
- 
 
66.9 
 
57.1 
 
76.8 
 
64.1 
 
3.6 
 
0.0 
 
14.8 
 
0.0 
 
19.0 
 
0.0 
SD, standard deviation. 
a. Broad group definitions.  
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W – Genome-wide polygenic score results 
GPS were created at a range of p value thresholds using summary statistics from previous 
GWAS of education, bipolar disorder, major depression and schizophrenia, as described in 
Chapters 7 and 8. The results below show the model R2 at each p threshold for the target 
phenotype in UK Biobank, and the association between deciles of the optimum GPS and 
the target phenotype. Analyses were restricted to unrelated participants of white British 
genetic ancestry, and the GPS were residualised for genotyping array and batch, UK 
Biobank assessment centre, and the first 20 genetic principal components.  
Education 
Using continuous GPS to predict UK Biobank reasoning score: 
 
0.0011
0.0098
0.0117 0.0126
0.0132 0.013 0.0129 0.0129 0.0129
0
0.01
0.02
0.03
0.04
0.05
p 5e-08 p 0.01 p 0.05 p 0.1 p 0.5 p 0.6 p 0.7 p 0.8 p 0.9
R2 for UK Biobank reasoning score (n = 134,110)
 
Using deciles of GPS as predictor, at p 0.5 (highest R2 in graph above): 
 
Decile Coefficient 95% CI lower 95% CI upper 
D1 (reference) 
D2 .1529  .1010     .2049 
D3 .2585  .2067      .3104 
D4 .3130  .2613     .3647 
D5 .3963  .3446     .4480 
D6 .4513  .3996     .5030 
D7 .5101  .4585     .5617 
D8 .5817  .5301     .6332 
D9 .6819  .6303     .7336 
D10 .8866  .8349     .9382 
 
 
 
 
268 
 
Using continuous GPS to predict UK Biobank educational attainment: 
 
0.001
0.011
0.015
0.017 0.018 0.017 0.017 0.017 0.017
0
0.01
0.02
0.03
0.04
0.05
p 5e-08 p 0.01 p 0.05 p 0.1 p 0.5 p 0.6 p 0.7 p 0.8 p 0.9
McFadden R2 for UK Biobank educational attainment 
(has a degree) (n = 395,644)
 
Using deciles of GPS as predictor, at p 0.5 (highest R2 in graph above): 
 
Decile Odds ratio 95% CI lower 95% CI upper 
D1 (reference) 
D2 1.2340    1.1946     1.2747 
D3 1.3952    1.3512     1.4406 
D4 1.4956    1.4488     1.5440 
D5 1.6369     1.5860     1.6893 
D6 1.7798    1.7248     1.8366 
D7 1.9698     1.9093     2.0323 
D8 2.1644    2.0983      2.2327 
D9 2.4101    2.3368     2.4858 
D10 3.0417    2.9497     3.1366 
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Bipolar disorder 
Using continuous GPS to predict UK Biobank mania/bipolar disorder (broad): 
 
0
0.005
0.008 0.009
0.01 0.01 0.01 0.01 0.01
0
0.01
0.02
0.03
0.04
0.05
p 5e-08 p 0.01 p 0.05 p 0.1 p 0.5 p 0.6 p 0.7 p 0.8 p 0.9
McFadden R2 for UK Biobank mania/bipolar (n = 94,435)
 
Using deciles of GPS as predictor, at p 0.5 (highest R2 in graph above): 
 
Decile Odds ratio 95% CI lower 95% CI upper 
D1 (reference) 
D2    1.2430    .9936     1.5549 
D3     1.3469    1.0807     1.6787 
D4    1.4606    1.1754     1.8150 
D5    1.5537    1.2547     1.9239 
D6    1.5615    1.2605     1.9343 
D7    1.6603    1.3427     2.0529 
D8    1.9207    1.5622     2.3615 
D9      2.2258    1.8181     2.7249 
D10    2.8981    2.3829     3.5247 
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Major depression 
Using continuous GPS to predict UK Biobank major depression (broad): 
 
0
0.002 0.003
0.004 0.005 0.005 0.005 0.005 0.005
0
0.01
0.02
0.03
0.04
0.05
p 5e-08 p 0.01 p 0.05 p 0.1 p 0.5 p 0.6 p 0.7 p 0.8 p 0.9
McFadden R2 for UK Biobank major depression (n = 136,772)
 
Using deciles of GPS as predictor, at p 0.5 (highest R2 in graph above): 
 
Decile Odds ratio 95% CI lower 95% CI upper 
D1 (reference) 
D2    1.1760    1.1148     1.2406 
D3    1.2209    1.1578     1.2875 
D4    1.2407    1.1769     1.3080 
D5    1.3218    1.2539     1.3933 
D6    1.3621    1.2923     1.4357 
D7    1.4215    1.3491     1.4977 
D8     1.5444    1.4663     1.6266 
D9    1.5965    1.5159     1.6814 
D10    1.8576    1.7645     1.9556 
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Schizophrenia 
Using continuous GPS to predict UK Biobank schizophrenia (broad): 
 
0.001
0.016
0.02 0.021
0.023 0.023 0.023 0.023 0.023
0
0.01
0.02
0.03
0.04
0.05
p 5e-08 p 0.01 p 0.05 p 0.1 p 0.5 p 0.6 p 0.7 p 0.8 p 0.9
McFadden R2 for UK Biobank schizophrenia (n = 339,869)
 
Using deciles of GPS as predictor, at p 0.5 (highest R2 in graph above): 
 
Decile Odds ratio 95% CI lower 95% CI upper 
D1 (reference) 
D2    1.4074    .6251        3.1690 
D3    1.4114    .6268     3.1779 
D4    2.2286     1.0552     4.7069 
D5    1.8212    .8406     3.9458 
D6    3.6847    1.8284     7.4258 
D7    3.6812    1.8266     7.4188 
D8    4.3097    2.1620     8.5906 
D9    5.3652    2.7264      10.5579 
D10  7.4185    3.8259      14.3846 
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X – Testable independency results for mania/bipolar DAG 
Summary of residual partial correlations from alternative versions of the mania/bipolar DAG: 
 
DAG description Number of 
implied 
independencies 
n (%) of results in each correlation coefficient range Largest correlation coefficient 
|0.00| to 
|0.09| 
|0.10| to 
|0.19| 
|0.20| to 
|0.29| 
|0.30| to 
|0.39| 
|0.40| to 
|0.49| 
|0.50| to 
|0.59| 
|0.60| to 
|0.69| 
 
Original DAG (edu→bipolar) 142 105 (73.9) 19 (13.4) 3 (2.1) 7 (4.9) 2 (1.4) 3 (2.1) 3 (2.1) -0.67 
curr_psych_meds ⊥ famhx_pd | 
adult_SES bipolar bipolar_geno 
past_mental_state 
Original DAG with education 
arrow reversed (edu←bipolar) 
142 102 (71.8) 18 (12.7) 5 (3.5) 8 (5.6) 3 (2.1) 3 (2.1) 3 (2.1) -0.67 
curr_psych_meds ⊥ famhx_pd | 
adult_SES bipolar bipolar_geno 
past_mental_state 
Modified DAG with new 
node representing other 
neuro/psy conditions 
(edu→bipolar) 
(edu→other_neupsy) 
138 110 (79.7) 19 (13.8) 4 (2.9) 4 (2.9) 1 (0.7) 0 (0) 0 (0) 0.43 
curr_psych_meds ⊥ famhx_pd |  
adult_SES age bipolar 
bipolar_geno child_adversity 
edu_attain gender other_neupsy 
Modified DAG with new node 
representing other neuro/psy 
conditions 
(edu←bipolar) 
(edu←other_neupsy) 
138 109 (79.0) 19 (13.8) 4 (2.9) 5 (3.6) 1 (0.7) 0 (0) 0 (0) 0.43 
curr_psych_meds ⊥ famhx_pd | 
adult_SES bipolar bipolar_geno 
edu_attain gender other_neupsy 
past_mental_state 
Optimal model fit is indicated by smaller correlation coefficients. Coefficients ≥ |0.10| may indicate model misspecification, measurement error, selection bias etc. 
The third DAG above was taken forward into the causal analyses. 
 
Results of additional regression models to obtain more details on the highest residual correlations indicated above (≥ |0.30|): 
(1) curr_psych_meds ⊥ famhx_pd | adult_SES age bipolar bipolar_geno child_adversity edu_attain gender other_neupsy 
Odds ratio 0.89 (95% CI 0.62, 1.28) 
(2) curr_psych_meds ⊥ famhx_depression | adult_SES bipolar bipolar_geno edu_attain gender other_neupsy past_mental_state 
Odds ratio 1.25 (95% CI 1.11, 1.40) 
(3) curr_psych_meds ⊥ famhx_pd | adult_SES bipolar bipolar_geno edu_attain gender other_neupsy past_mental_state 
Odds ratio 1.02 (95% CI 0.83, 1.25) 
(4) famhx_dementia ⊥ phys_environ | bipolar bipolar_geno child_adversity cog_geno edu_attain eng_speak ethnicity gender maternal_smoking other_neupsy 
Odds ratio 0.94 (95% CI 0.86, 1.02) 
(5) famhx_pd ⊥ phys_environ | bipolar bipolar_geno child_adversity cog_geno edu_attain eng_speak ethnicity gender maternal_smoking other_neupsy 
Odds ratio 1.09 (95% CI 0.94, 1.27) 
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Y – Explanation of DAG used in causal analyses 
 
 
 
Original DAG used in the mania/bipolar disorder analyses reported in Chapter 7 
 
The above DAG (shown as Fig. 7.2 in Chapter 7) represents the original assumptions made 
about the causal relationship between mania/BD and cognitive function. As explained in 
Chapter 6 (Box 6.1), the presence of an arrow represents the weak assumption of a causal 
relationship for at least one member of the population, and the absence of an arrow 
represents the strong assumption of no causal relationship for any member of the 
population. All nodes that are causally antecedent to a given node are known as ancestors; 
shared ancestors of the exposure and outcome are potential confounders, because they lie 
on back-door paths. Intermediate nodes were included in the DAG where these were of 
interest in the mediation analyses or were required as common parents of other pairs of 
nodes; these were not exhaustive, and so each individual arrow could in principle be shown 
in more detail as a chain of intermediate nodes that, for the purposes of the present 
research, are omitted or unknown. The node names, the constructs they are intended to 
represent, and the corresponding measures in UK Biobank, are listed in the table below. 
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Node name Construct represented Measurement in UK Biobank 
Exposure 
bipolar Lifetime history of mania or bipolar disorder 
(prior to cognitive assessment) 
 
Disorder exposure status (versus 
comparison group)  
Outcome 
cog_score Performance on cognitive assessment • Reasoning 
• Reaction time  
• Numeric memory 
• Visuospatial memory 
• Prospective memory 
Shared ancestors of exposure and outcome 
age  Age Age in years 
ancestral_hx  Various ancestral/migration factors that 
determine ethnicity, country of origin and 
family history (genetic and non-genetic) 
Unmeasured 
bipolar_geno Genotype associated with bipolar disorder Genome-wide polygenic score 
child_adversity  Adverse experiences in childhood Childhood abuse and neglect (self-
reported as ‘never true’ to ‘very often 
true’): 
When I was growing up… 
a) I felt loved 
b) People in my family hit me so hard 
that it left me with bruises or marks 
c) I felt that someone in my family 
hated me 
d) Someone molested me (sexually) 
e) There was someone to take me to 
the doctor if I needed it 
cog_geno  Genotype associated with cognitive function Genome-wide polygenic score (using 
education GWAS as proxy) 
edu_attain  Educational attainment Has a degree or not (self-reported) 
eng_speak  Born in an English-speaking country Born in an English-speaking country 
(self-reported) 
ethnicity  Ethnic background • Ethnic category (self-reported)  
• Genetically-identified white British 
ancestry 
famhx_depression  Parent/sibling with depression Self-report of biological parent or 
sibling with ‘severe depression’ 
gender  Gender Self-reported male or female 
maternal_smoking  Mother smoked around time of participant’s 
birth 
Participant’s response to “Did your 
mother smoke regularly around the 
time when you were born?" 
other_famhx  Other aspects of family history (non-genetic) 
and circumstances/environment 
Unmeasured 
par_geno  Genotype of parents Unmeasured 
pre_IQ Premorbid intellectual ability Unmeasured 
Intermediates between exposure and outcome 
adiposity  Body fat Body mass index 
adult_SES  Socioeconomic status or deprivation in 
adulthood 
Townsend index score 
air_pollution  Airborne toxic particles/gases Neighbourhood measures of: 
• Particulate matter 
• Nitrogen dioxide 
alcohol Frequency/amount of alcohol consumption Self-reported frequency of intake 
brain_health  Structural/functional brain state Unmeasured (except for small 
subgroup) 
cardiomet History of cardiometabolic disease • Self-reported history of angina, 
hypertension or diabetes (non-
gestational) 
• Adjudicated history of myocardial 
infarction or stroke 
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Node name Construct represented Measurement in UK Biobank 
curr_mood Mood state at time of cognitive assessment Patient Health Questionnaire (four 
self-reported items) 
curr_psych_meds  Psychotropic medication at time of cognitive 
assessment 
On any psychotropic medication (self-
reported) 
past_mental_state  Past psychiatric symptoms/illness 
course/duration/severity, over and above 
history of simply having exposure of interest 
or not  
Number of depressed/unenthusiastic 
episodes (self-reported on touchscreen 
or web) 
phys_activity  Level of physical activity International Physical Activity 
Questionnaire (self-reported) 
phys_environ  Physical aspects of the local environment • Inverse distance to nearest major 
road 
• Home area population density 
sleep  Sleep pattern/quality/duration Self-reported sleeplessness/insomnia 
(never/rarely; sometimes; usually) 
smoking  Tobacco smoking history Self-reported smoking status (never; 
former; current) 
Other ancestors of outcome (not descended from exposure) 
famhx_dementia  Parent/sibling with dementia Self-report of biological parent or 
sibling with ‘Alzheimer’s/dementia’ 
famhx_pd Parent/sibling with Parkinson’s disease Self-report of biological parent or 
sibling with ‘Parkinson’s disease’ 
 
Shared ancestors of exposure and outcome 
Older age increases the risk of cognitive impairment, although the trajectory and 
mechanisms are not fully understood (Deary et al., 2009). Age was also assumed to have 
an indirect effect on mania/BD status, via educational attainment. Gender differences in 
average cognitive performance have often been reported, although again the causal 
mechanisms are not well understood (Miller & Halpern, 2014). Gender was assumed not to 
affect mania/BD status (Blanco et al., 2017; Lloyd et al., 2005), except through educational 
attainment. As described in Chapter 7, the direction of the relationship between educational 
attainment and mania/BD was uncertain, and the model was tested with the arrow as 
shown above and with it reversed. Given the temporal order of the measures in UK 
Biobank, educational attainment (past) was assumed to influence cognitive performance 
(current). Premorbid intellectual ability was not measured in UK Biobank, but was 
depicted as an antecedent of current cognitive performance and of other nodes such as 
educational attainment, socioeconomic status and health-related behaviours (e.g. smoking). 
No arrow was drawn between premorbid ability and mania/BD status, because it was 
assumed that any statistical association between them would be accounted for by their 
shared genetic and early life antecedents (see below), or by the indirect causal path through 
educational attainment.  
276 
 
Genotypes associated with bipolar disorder and with cognitive function were assumed to 
have shared effects on those respective phenotypes and on other outcomes (Hagenaars et 
al., 2016; Hill, Davies, et al., 2016). These genotypes were depicted as descending from 
parental genotype (unmeasured). Parental genotype and other aspects of family history 
(unmeasured) were also assumed to affect parental behaviour (maternal smoking measure), 
childhood adversity, and family history of psychiatric and neurological conditions. A distal 
node representing ancestral history was conceptualised as giving rise to parental genotype 
and other aspects of family history, as well as ethnicity and English-speaking status. 
Ethnicity was assumed to be a possible antecedent of mania/BD (Lloyd et al., 2005), and 
(through other nodes such as socioeconomic status) of cognitive performance. Being from 
a non-English-speaking country was assumed to influence educational attainment and 
childhood adversity (e.g. among individuals who had migrated at a young age), in turn 
influencing mania/BD status, and it was also assumed to affect cognitive performance.  
Maternal smoking was assumed to affect mania/BD (Talati et al., 2013), and to affect 
cognitive function indirectly through other nodes (e.g. brain health). Childhood adversity 
(conceptualised broadly when constructing the graph, although measured in UK Biobank 
solely as abuse and neglect history) was assumed to be a possible cause of mania/BD (Aas 
et al., 2016), and of cognitive function via nodes such as educational attainment, 
socioeconomic status and health-related behaviours. Finally, family history of depression 
was depicted as a cause of mania/BD (Mortensen, Pedersen, Melbye, Mors, & Ewald, 
2003), and of cognitive function via childhood adversity.  
Intermediates between exposure and outcome 
Lifetime history of mania/BD was assumed to affect multiple behaviour-related measures, 
namely physical activity, adiposity, alcohol consumption and smoking (Scott et al., 2015), 
and these in turn were assumed to influence cognitive function (Baumgart et al., 2015), 
including via their effects on brain structure. Cardiometabolic disease was also assumed to 
be influenced by mania/BD status (Fiedorowicz et al., 2011; Kemp & Fan, 2012) and to 
affect cognitive outcome (Knopman et al., 2001; Qiu & Fratiglioni, 2015). It was assumed 
that mania/BD might affect socioeconomic status in adulthood (e.g. via impact on 
occupational functioning) (Gitlin & Miklowitz, 2017); this in turn might influence 
performance on cognitive tests (Lyu & Burr, 2016), although this relationship is 
complicated by shared genetic factors (Marioni et al., 2014), as shown in the graph. Note 
that early life socioeconomic status was not measured in UK Biobank, but this can be 
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conceptualised as part of the childhood adversity node, and can thus be assumed to 
influence both mania/BD and adult socioeconomic status. With regard to local 
environment variables, mania/BD was assumed to influence exposure to air pollution, 
including via socioeconomic status, smoking and physical activity; the relationship 
between mania/BD and other aspects of the physical environment was assumed to arise 
indirectly via socioeconomic status. Physical environment exposures, including pollution, 
were assumed to affect cognitive function (Killin, Starr, Shiue, & Russ, 2016; Power, 
Adar, Yanosky, & Weuve, 2016).  
It was assumed that mood state around the time of the cognitive assessment would be 
influenced by mania/BD status, and would in turn affect cognitive performance (Bourne et 
al., 2013; Ganguli, Du, Dodge, Ratcliff, & Chang, 2006). Mood state was here measured 
by items assessing current depressive symptoms only; manic mood state (unmeasured in 
UK Biobank) was not included as a separate node in the graph, as previous research had 
reported no association between residual mania and cognitive performance (Bourne et al., 
2013). Sleeplessness was also depicted as an intermediate between mania/BD status and 
cognitive performance. Although sleep disturbance can be a trigger for relapse in BD, it 
was placed temporally downstream of mania/BD status in this graph because it represented 
recent sleep patterns (in the four-week period preceding the UK Biobank cognitive 
assessment), whereas the mania/BD node represented lifetime status. Sleeplessness is an 
ongoing problem for many people with BD (A. G. Harvey, Schmidt, Scarna, Semler, & 
Goodwin, 2005), and it may affect cognitive performance (Fortier-Brochu & Morin, 2014; 
Goldman-Mellor et al., 2015). 
A node representing past mental state was included as an intermediate between mania/BD 
status and cognitive score. Although the past mental state node and the mania/BD exposure 
node both represent past states (i.e. lifetime experiences up to the time of the cognitive 
assessment), mania/BD was placed first in the temporal order depicted in the graph, on the 
grounds that having mania/BD influences the severity of the illness experience over time 
(measured here as number of depressed episodes). It was not a requirement in the exposure 
definition used here that a participant had to have experienced more than one affective 
episode to be classified in the mania/BD group, and so it was deemed more plausible that 
mania/BD status would influence the number of episodes, rather than the reverse. 
Similarly, current psychotropic medications at the time of the cognitive assessment were 
assumed to be a consequence of lifetime mania/BD status, and being on such medications 
did not contribute to the exposure classification used here. The temporal order of the past 
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mental state and current psychotropic medication nodes was depicted such that the former 
influenced the latter, although it is likely that there is a reciprocal relationship between 
these variables over time (i.e. a graph for a longitudinal analysis might show mental state 
at time 1 influencing medication at time 2, and medication at time 2 influencing mental 
state at time 3). Given the nature of the present cross-sectional analysis, however, it was 
considered plausible that cumulative lifetime affective episodes (past mental state) would 
be an antecedent of current medication status. Both past mental state and current 
psychotropic medications were assumed to affect cognitive performance (Balanzá-
Martínez et al., 2010; Bourne et al., 2013; Robinson & Ferrier, 2006).  
A node representing brain health (i.e. as potentially measured by structural volume and 
integrity, and functional activation and connectivity) was depicted as intermediate between 
mania/BD status and cognitive performance. This assumes that changes occur in the brain 
as a consequence of mania/BD, as shown in longitudinal studies (Lim et al., 2013), 
although it may also be the case that some brain changes (e.g. reduced white matter tract 
integrity) are a marker of BD vulnerability that precedes illness onset, given that similar 
findings are evident in unaffected relatives of people with BD (Miskowiak et al., 2017). 
Structural and functional brain changes were assumed to cause cognitive impairment, 
although—as shown in the graph—premorbid cognitive ability and shared genetic 
antecedents likely contribute to this relationship (Deary et al., 2009). It was not assumed 
that every causal path leading to cognitive outcome went through brain health, however, as 
other factors may be at play (such as confidence or test experience) that would affect 
performance on cognitive tests but are not necessarily mediated by brain structure or 
function. Since neuroimaging data were available only for a relatively small and non-
representative sub-group (~2%) of the UK Biobank cohort, this node was tagged as 
unmeasured when planning the analyses in this thesis.  
Other ancestors of outcome 
Family history of neurodegenerative disease was assumed to be a potential additional cause 
of cognitive impairment, given that participants with this background may be at higher risk 
of cognitive decline arising from disease processes not necessarily captured by their own 
medical history data (e.g. individuals with unrecognised early-stage disease). This was 
represented in the graph by separate nodes for family history of dementia and of 
Parkinson’s disease, although this could have been depicted equivalently using one node, 
because they were considered to share the same antecedents and consequences (separate 
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nodes were included originally because PD-specific analyses were undertaken for 
prevalence elsewhere in the thesis, although causal analyses were not attempted for PD 
owing to insufficient background clinical data). Family history of neurodegenerative 
disease was assumed not to be a causal antecedent of mania/BD status.  
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Z – Supplementary results for mania/bipolar mediation 
analyses 
Table Z.1 Tests of interactions between exposure and mediators 
 
 Coefficient for 
mania/BD * mediator 
95% CI p 
Mediator: Cardiometabolic disease    
Reasoninga 0.029 -0.207, 0.264 0.812 
Reaction timea 0.149 -0.047, 0.345 0.137 
Numeric memorya -0.124 -0.652, 0.403 0.644 
Visuospatial memorya 0.239 -0.019, 0.497 0.070 
Prospective memoryb 0.991 0.475, 2.071 0.982 
Mediator: Psychotropic medication    
Reasoninga 0.005 -0.255, 0.264 0.973 
Reaction timea 0.095 -0.110, 0.301 0.364 
Numeric memorya 0.311 -0.294, 0.916 0.313 
Visuospatial memorya -0.045 -0.295, 0.205 0.725 
Prospective memoryb 0.883 0.435, 1.796 0.732 
BD, bipolar disorder; CI, confidence interval. 
All models included mania/BD, the mediator and their product, as well as all the covariates entered into the gformula 
mediation models. 
a. Linear regression model with outcome measured in z-score units. 
b. Logistic regression model with outcome measured as correct or not; estimate expressed as odds ratio. 
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Table Z.2 Mediation of the effect of mania/bipolar disorder on cognitive outcome via 
cardiometabolic disease, with missing data imputation 
 
 n Estimate 95% CIa 
Reasoningb  80,698   
TCE  -0.092 -0.158, -0.026 
CDE  -0.087 -0.152, -0.022 
NDE  -0.085 -0.151, -0.019 
NIE  -0.007 -0.017, 0.003 
Reaction timeb  82,648   
TCE  -0.094 -0.150, -0.037 
CDE  -0.091 -0.148, -0.034 
NDE  -0.091 -0.148, -0.033 
NIE  -0.003 -0.014, 0.008 
Numeric memoryb  26,248   
TCE  -0.142 -0.275, -0.008 
CDE  -0.158 -0.291, -0.024 
NDE  -0.150 -0.283, -0.018 
NIE  0.008 -0.011, 0.027 
Visuospatial memoryb  81,773   
TCE  -0.206 -0.267, -0.145 
CDE  -0.200 -0.261, -0.139 
NDE  -0.210 -0.272, -0.149 
NIE  0.005 -0.007, 0.016 
Prospective memoryc  82,194   
TCE  -0.041 -0.062, -0.021 
CDE  -0.037 -0.057, -0.017 
NDE  -0.039 -0.059, -0.018 
NIE  -0.003 -0.006, 0.001 
CDE, controlled direct effect when cardiometabolic disease = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; NO2, nitrogen dioxide; PM10, particulate matter of up to 
10μm diameter; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for age, gender, educational 
attainment, English-speaking birth country, education/cognition GPS, bipolar disorder GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, population density, road proximity, air pollution (PM10 and NO2), body mass index, alcohol 
frequency, smoking status, physical activity, and psychotropic medication. Missing mediator and covariate data were 
imputed via a single stochastic imputation using chained equations. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
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Table Z.3 Mediation of the effect of mania/bipolar disorder on cognitive outcome via 
psychotropic medication, with missing data imputation 
 
 n Estimate 95% CIa 
Reasoningb  80,698   
TCE  -0.095 -0.162, -0.027 
CDE  -0.034 -0.103, 0.035 
NDE  -0.034 -0.103, 0.035 
NIE  -0.061 -0.078, -0.044 
Reaction timeb  82,648   
TCE  -0.080 -0.136, -0.024 
CDE  -0.034 -0.095, 0.028 
NDE  -0.024 -0.085, 0.037 
NIE  -0.056 -0.078, -0.033 
Numeric memoryb  26,248   
TCE  -0.147 -0.276, -0.018 
CDE  -0.079 -0.210, 0.051 
NDE  -0.082 -0.212, 0.049 
NIE  -0.065 -0.098, -0.033 
Visuospatial memoryb  81,773   
TCE  -0.196 -0.255, -0.137 
CDE  -0.147 -0.210, -0.084 
NDE  -0.146 -0.209, -0.083 
NIE  -0.050 -0.076, -0.024 
Prospective memoryc  82,194   
TCE  -0.025 -0.045, -0.005 
CDE  -0.010 -0.029, 0.010 
NDE  -0.012 -0.031, 0.007 
NIE  -0.014 -0.019, -0.008 
CDE, controlled direct effect when psychotropic medication = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for gender, educational 
attainment, English-speaking birth country, education/cognition GPS, bipolar disorder GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, and lifetime number of episodes of depressed mood/anhedonia. Missing mediator and covariate 
data were imputed via a single stochastic imputation using chained equations. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
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AA – Equivalence class for mania/bipolar DAG 
 
 
Summary diagram for all DAGs that are structurally equivalent to the DAG used in the analyses 
Bold lines indicate paths that can be reversed while still maintaining the same predicted independencies. 
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BB – Testable independency results for major depression DAG 
Summary of residual partial correlations from alternative versions of the major depression DAG: 
 
DAG description Number of 
implied 
independencies 
n (%) of results in each correlation coefficient range Largest correlation coefficient 
|0.00| to 
|0.09| 
|0.10| to 
|0.19| 
|0.20| to 
|0.29| 
|0.30| to 
|0.39| 
|0.40| to 
|0.49| 
|0.50| to 
|0.59| 
|0.60| to 
|0.69| 
 
DAG with education as 
antecedent 
(edu→major_depression) 
(edu→other_neupsy) 
137 116 (84.7) 16 (11.7) 5 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.2248 
curr_psych_meds ⊥ 
famhx_depression |  
adult_SES age child_adversity 
edu_attain gender 
major_depression majordep_geno 
other_neupsy 
DAG with education as 
consequence 
(edu←major_depression) 
(edu←other_neupsy) 
137 115 (83.9) 17 (12.4) 5 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.2663 
curr_psych_meds ⊥ 
famhx_depression | 
child_adversity cog_geno 
eng_speak ethnicity gender 
major_depression majordep_geno 
maternal_smoking other_neupsy 
Optimal model fit is indicated by smaller correlation coefficients. Coefficients ≥ |0.10| may indicate model misspecification, measurement error, selection bias etc. 
The first DAG above was taken forward into the causal analyses. 
 
Results of additional regression models to obtain more details on the highest residual correlations indicated above (≥ |0.20|): 
(1) curr_psych_meds ⊥ famhx_depression | adult_SES age child_adversity edu_attain gender major_depression majordep_geno other_neupsy 
Odds ratio 1.45 (95% CI 1.34, 1.56) 
(2) famhx_depression ⊥ sleep | child_adversity cog_geno edu_attain eng_speak ethnicity gender major_depression majordep_geno maternal_smoking other_neupsy 
Odds ratio 1.20 (95% CI 1.13, 1.27) 
(3) curr_psych_meds ⊥ famhx_depression | child_adversity cog_geno edu_attain eng_speak ethnicity gender major_depression majordep_geno maternal_smoking other_neupsy 
Odds ratio 1.48 (95% CI 1.37, 1.60) 
(4) edu_attain ⊥ famhx_pd | child_adversity cog_geno eng_speak ethnicity majordep_geno maternal_smoking 
Odds ratio 0.99 (95% CI 0.90, 1.09) 
(5) famhx_pd ⊥ phys_environ | child_adversity cog_geno edu_attain eng_speak ethnicity gender major_depression majordep_geno maternal_smoking other_neupsy 
Odds ratio 1.09 (95% CI 0.95, 1.24) 
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CC – Supplementary results for major depression 
mediation analyses 
Table CC.1 Tests of interactions between exposure and mediators 
 
 Coefficient for major 
depression * mediator 
95% CI p 
Mediator: Cardiometabolic disease    
Reasoninga 0.029 -0.027, 0.085 0.304 
Reaction timea 0.053 -0.001, 0.107 0.056 
Numeric memorya 0.057 -0.052, 0.166 0.306 
Visuospatial memorya 0.036 -0.024, 0.095 0.241 
Prospective memoryb 1.157 0.952, 1.407 0.142 
Mediator: Psychotropic medication    
Reasoninga 0.244 0.135, 0.354 <0.001 
Reaction timea 0.080 -0.025, 0.185 0.134 
Numeric memorya 0.203 0.013, 0.393 0.036 
Visuospatial memorya 0.082 -0.037, 0.200 0.176 
Prospective memoryb 1.454 1.057, 2.000 0.021 
CI, confidence interval. 
All models included major depression, the mediator and their product, as well as all the covariates entered into the 
gformula mediation models. 
a. Linear regression model with outcome measured in z-score units. 
b. Logistic regression model with outcome measured as correct or not; estimate expressed as odds ratio. 
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Table CC.2 Tests of interactions between exposure and intermediate confounders 
 
 Coefficient 
for major 
depression * 
deprivation 
95% CI p Coefficient for major 
depression * lifetime 
number of episodes of 
depressed 
mood/anhedonia 
95% CI p 
Reasoninga 0.018 -0.030, 0.066 0.458 -0.020 -0.074, 0.035 0.481 
Reaction timea -0.017 -0.064, 0.030 0.475 0.033 -0.020, 0.085 0.224 
Numeric memorya 0.041 -0.057, 0.138 0.413 -0.002 -0.106, 0.103 0.974 
Visuospatial memorya 0.056 0.005, 0.108 0.033 -0.023 -0.081, 0.035 0.433 
Prospective memoryb 0.989 0.836, 1.171 0.900 1.000 0.834, 1.212 0.996 
CI, confidence interval. 
Deprivation was entered as a dichotomous indicator for the two most deprived Townsend quintiles versus the three least 
deprived quintiles. Lifetime number of episodes of depressed mood/anhedonia was entered as a dichotomous indicator 
for ≥2 episodes versus <2 episodes. All models included the product terms indicated in the table above, as well as major 
depression, deprivation, lifetime number of episodes of depressed mood/anhedonia, psychotropic medication, major 
depression * psychotropic medication, and all the other covariates entered into the gformula mediation models. 
a. Linear regression model with outcome measured in z-score units. 
b. Logistic regression model with outcome measured as correct or not; estimate expressed as odds ratio. 
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Table CC.3 Mediation of the effect of major depression on cognitive outcome via 
cardiometabolic disease, with missing data imputation 
 
 n Estimate 95% CIa 
Reasoningb  102,643   
TCE  0.001 -0.017, 0.019 
CDE  -0.005 -0.023, 0.013 
NDE  -0.009 -0.026, 0.009 
NIE  0.009 -0.023, 0.013 
Reaction timeb  119,830   
TCE  -0.024 -0.042, -0.006 
CDE  -0.022 -0.039, -0.004 
NDE  -0.032 -0.050, -0.014 
NIE  0.008 -0.002, 0.019 
Numeric memoryb  33,250   
TCE  -0.006 -0.039, 0.027 
CDE  -0.013 -0.047, 0.020 
NDE  -0.006 -0.039, 0.027 
NIE  0.000 -0.016, 0.017 
Visuospatial memoryb  118,363   
TCE  -0.072 -0.091, -0.054 
CDE  -0.074 -0.093, -0.056 
NDE  -0.072 -0.091 -0.053 
NIE  -0.001 -0.011, 0.010 
Prospective memoryc  104,509   
TCE  -0.004 -0.009, 0.001 
CDE  -0.002 -0.007, 0.003 
NDE  -0.004 -0.009, 0.002 
NIE  -0.000 -0.003, 0.002 
CDE, controlled direct effect when cardiometabolic disease = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; NO2, nitrogen dioxide; PM10, particulate matter of up to 
10μm diameter; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for age, gender, educational 
attainment, English-speaking birth country, education/cognition GPS, major depression GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, population density, road proximity, air pollution (PM10 and NO2), body mass index, alcohol 
frequency, smoking status, physical activity, and psychotropic medication. Missing mediator and covariate data were 
imputed via a single stochastic imputation using chained equations. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
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Table CC.4 Mediation of the effect of major depression on cognitive outcome via 
psychotropic medication, with missing data imputation 
 
 n Estimate 95% CIa 
Reasoningb  102,643   
TCE  -0.004 -0.022, 0.014 
CDE  0.003 -0.016, 0.021 
NDE  -0.010 -0.028, 0.008 
NIE  0.006 -0.003, 0.015 
Reaction timeb  119,830   
TCE  -0.009 -0.026, 0.008 
CDE  0.011 -0.009, 0.030 
NDE  -0.008 -0.026, 0.009 
NIE  -0.001 -0.011, 0.010 
Numeric memoryb  33,250   
TCE  -0.022 -0.056, 0.011 
CDE  -0.001 -0.035, 0.034 
NDE  -0.005 -0.040, 0.030 
NIE  -0.017 -0.036, 0.002 
Visuospatial memoryb  118,363   
TCE  -0.068 -0.087, -0.049 
CDE  -0.035 -0.057, -0.014 
NDE  -0.056 -0.074, -0.037 
NIE  -0.012 -0.023, -0.001 
Prospective memoryc  104,509   
TCE  0.002 -0.003, 0.008 
CDE  0.007 0.001, 0.013 
NDE  0.001 -0.004, 0.006 
NIE  0.001 -0.002, 0.004 
CDE, controlled direct effect when psychotropic medication = 0; CI, confidence interval; GPS, genome-wide polygenic 
score; NDE, natural direct effect; NIE, natural indirect effect; TCE, total causal effect. 
Models were restricted to participants of white British genetic ancestry, and were adjusted for gender, educational 
attainment, English-speaking birth country, education/cognition GPS, major depression GPS, family history of dementia, 
family history of Parkinson’s disease, maternal smoking around birth, childhood trauma, other psychiatric/neurological 
conditions, deprivation, and lifetime number of episodes of depressed mood/anhedonia. All models included a product 
term for major depression * psychotropic medication. Missing mediator and covariate data were imputed via a single 
stochastic imputation using chained equations. 
a. Normal-based, from bootstrapped standard error (1000 replicates).  
b. Estimate expressed as a standardised mean difference. 
c. Estimate expressed as a risk difference for the probability of being correct. 
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DD – Equivalence class for major depression DAG 
 
 
Summary diagram for all DAGs that are structurally equivalent to the DAG used in the analyses 
Bold lines indicate paths that can be reversed while still maintaining the same predicted independencies. 
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EE – Testable independency results for schizophrenia DAG 
Summary of residual partial correlations from alternative versions of the schizophrenia DAG: 
 
DAG description Number of 
implied 
independencies 
n (%) of results in each correlation coefficient range Largest correlation coefficient 
|0.00| to 
|0.09| 
|0.10| to 
|0.19| 
|0.20| to 
|0.29| 
|0.30| to 
|0.39| 
|0.40| to 
|0.49| 
|0.50| to 
|0.59| 
|0.60| to 
|0.69| 
 
Original DAG with education 
as antecedent 
(edu→schizophrenia) 
(edu→other_neupsy) 
137 109 (79.6) 18 (13.1) 4 (2.9) 4 (2.9) 2 (1.5) 0 (0.0) 0 (0.0) 0.4743 
curr_psych_meds ⊥ famhx_pd | 
child_adversity cog_geno 
edu_attain eng_speak ethnicity 
gender schizophrenia scz_geno 
maternal_smoking other_neupsy 
Original DAG with education 
as consequence 
(edu←schizophrenia) 
(edu←other_neupsy) 
137 106 (77.4) 18 (13.1) 7 (5.1) 3 (2.2) 3 (2.2) 0 (0.0) 0 (0.0) 0.4743 
curr_psych_meds ⊥ famhx_pd | 
child_adversity cog_geno 
eng_speak ethnicity gender 
schizophrenia scz_geno 
maternal_smoking other_neupsy 
Modified DAG including 
cannabis node (education as 
per row 1 above)a 
(cannabis→schizophrenia) 
(cannabis→other_neupsy) 
141 107 (75.9) 20 (14.2) 6 (4.3) 7 (5.0) 0 (0.0) 1 (0.7) 0 (0.0) 0.5511 
curr_psych_meds ⊥ famhx_pd | 
adult_SES cannabis edu_attain 
gender other_neupsy 
past_mental_state schizophrenia 
scz_geno 
Modified DAG including 
cannabis node (education as 
per row 1 above) 
(cannabis←schizophrenia) 
(cannabis←other_neupsy) 
141 109 (77.3) 22 (15.6) 4 (2.8) 5 (3.5) 0 (0.0) 1 (0.7) 0 (0.0) 0.5511 
curr_psych_meds ⊥ famhx_pd | 
adult_SES cannabis edu_attain 
gender other_neupsy 
past_mental_state schizophrenia 
scz_geno 
Optimal model fit is indicated by smaller correlation coefficients. Coefficients ≥ |0.10| may indicate model misspecification, measurement error, selection bias etc. 
The first DAG above was taken forward into the causal analyses. 
a. Graph with cannabis added is shown overleaf. 
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Results of additional regression models to obtain more details on the highest residual correlations indicated above (≥ |0.30|): 
(1) curr_psych_meds ⊥ famhx_pd | child_adversity cog_geno edu_attain eng_speak ethnicity gender schizophrenia scz_geno maternal_smoking other_neupsy 
Odds ratio 1.17 (95% CI 0.97, 1.40) 
(2) curr_psych_meds ⊥ famhx_depression | child_adversity cog_geno edu_attain eng_speak ethnicity gender schizophrenia scz_geno maternal_smoking other_neupsy 
Odds ratio 1.33 (95% CI 1.20, 1.48) 
(3) curr_psych_meds ⊥ famhx_dementia | child_adversity cog_geno edu_attain eng_speak ethnicity gender schizophrenia scz_geno maternal_smoking other_neupsy 
Odds ratio 1.17 (95% CI 1.05, 1.32) 
(4) curr_psych_meds ⊥ famhx_depression | adult_SES age child_adversity edu_attain gender schizophrenia scz_geno other_neupsy 
Odds ratio 1.37 (95% CI 1.24, 1.51) 
(5) curr_psych_meds ⊥ famhx_depression | adult_SES edu_attain gender schizophrenia scz_geno other_neupsy past_mental_state 
Odds ratio 1.26 (95% CI 1.13, 1.39) 
(6) curr_psych_meds ⊥ famhx_pd | adult_SES edu_attain gender schizophrenia scz_geno other_neupsy past_mental_state 
Odds ratio 1.15 (95% CI 0.97, 1.38) 
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